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Introduction: Acute respiratory infections (ARI) are a major global cause of morbidity and mortality. 
Vitamin D deficiency has been reported to associate with susceptibility to ARI and with greater severity 
and poorer control of asthma and chronic obstructive pulmonary disease (COPD). Clinical trials of 
vitamin D for the prevention of ARI have yielded heterogeneous results, with some showing protection 
and others not. This may reflect variation in the frequency of genetic variants influencing response to 
vitamin D supplementation in different populations. The impact that genetic variation in the vitamin 
D pathway has on vitamin D status, disease phenotype and response to vitamin D supplementation in 
prevention of ARI has not been comprehensively investigated. 
Methods: I conducted: 
1. A systematic review and meta-analysis of clinical studies which have investigated vitamin D as a 
potential therapy for ARI;  
2. Three cross-sectional studies (in n=297 adult asthma patients, n=278 COPD patients, and n=272 
older adults) to investigate potential environmental determinants (lifestyle and anthropometric) and 
genetic determinants (35 single nucleotide polymorphisms [SNP] in 11 vitamin D related genes) of 
serum 25-hydroxyvitamin D concentration (25[OH]D) and clinical phenotype;  
3. Three prospective studies investigating the influence of genetic variation in the vitamin D pathway 
on a) susceptibility to ARI (main effects analysis) and b) efficacy of vitamin D supplementation for the 
prevention of ARI (interaction analysis). 
Results: My systematic review identified consistent reports of an inverse association between vitamin 
D status and risk of ARI in observational studies, and heterogeneous reports from clinical trials. My 
cross-sectional studies identified a range of classical environmental factors which predict vitamin D 
status in the three study populations, but did not identify any genetic variants in the vitamin D 
pathway that associate with vitamin D status. I identified an association between vitamin D deficiency 
and decreased lung function in COPD patients, but no associations between vitamin D deficiency and 
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asthma phenotype. Finally, my analysis identified a haplotype of 5 single nucleotide polymorphisms 
in the vitamin D receptor (VDR) gene which significantly modify the effect of vitamin D 
supplementation on risk of upper respiratory infection in COPD patients.  
Conclusions: I identified environmental determinants that predict 25(OH)D concentrations in all three 
study populations, but only found an association between vitamin D deficiency and disease severity 
in COPD patients. Furthermore, I identified a haplotype in VDR which modifies the effect of vitamin D 
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This introductory chapter offers an overview of the epidemiology of acute respiratory infection (ARI); 
a summary of the vitamin D metabolic pathway and mechanisms by which vitamin D may prevent ARI; 
and a review of genetic variation in the vitamin D pathway, and how this may influence susceptibility 
















1.1.  Acute Respiratory Infection. 
 
 
1.1.1. Definition, Classification and Aetiology of ARI. 
Acute respiratory infections (ARI) are defined as infections of one or more sites along the respiratory 
tract, comprising the paranasal sinuses, nasal cavity, pharynx, larynx, epiglottis, trachea, bronchioles 
and lungs, with symptoms lasting for 30 days or less. ARI are classified as either upper respiratory 
infection (URI), or lower respiratory infection (LRI) according to their localisation above or below the 
vocal cords, respectively. 
 
Upper respiratory infection. 
URI are the most common infections in humans. The most typical clinical manifestation of URI is the 
common cold, which is often referred to as a “symptom-complex” as multiple sites along the upper 
respiratory tract become infected, while other common syndromes (laryngitis, pharyngitis, tonsillitis 
and otitis media) occur at a single site and like the common cold are considered mild, self-limiting 
infections that are predominantly viral in origin. Rhinoviruses are the commonest causative agent of 
viral URI, accountable for roughly 30% of infections; respiratory syncytial virus (RSV), human 
parainfluenza & influenza viruses, human meta-pneumovirus, and adenoviruses together are believed 
to cause up to 30%; coronaviruses are responsible for 10%, whilst the remaining ~30% of URI are 
thought to be of unknown viral aetiology (1). URI are less frequently caused by bacteria: severe cases 
of laryngotracheitis and epiglottitis are typically caused by Haemophilus influenzae type B. 
Furthermore, the previously mentioned viral syndromes of URI (laryngitis, pharyngitis, tonsillitis and 
otitis media) can also to a lesser extent be caused by a range of bacteria: Group A streptococci, 
Mycoplasma pneumonia, Neisseria gonorrhoeae, Staphylococcus aureus and Streptococcus 
pneumonia are the most frequently identified agents (2). 
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Lower respiratory infection. 
Syndromes of acute lower respiratory infection (influenza-like illness [which also affects the upper 
respiratory tract], bronchitis, bronchiolitis and pneumonia) are less frequent than URI, though they 
have more severe health implications and as such are one of the leading causes of mortality 
worldwide. LRI syndromes may also have a viral, bacterial or fungal aetiology, and in some instances 
e.g. community acquired pneumonia, there occurs a dual viral, dual bacterial, or mixed viral-bacterial 
aetiology (3). Influenza-like illness is caused by the influenza virus (types A, B and C) which belong the 
Orthomyxoviridae family. Influenza A and B are largely responsible for seasonal influenza epidemics, 
whilst species of type A influenza virus have been responsible for past human pandemics (4). 
Bronchitis and bronchiolitis have both bacterial and viral aetiologies. Bronchitis often occurs as a 
secondary complication of a viral URI; the most commonly detected viruses are RSV, human 
parainfluenza virus and coronavirus (5), though the bacteria Mycoplasma pneumonia, Chlamydia 
pneumoniae and Bordetella pertussis have also been identified (6). Bronchiolitis is generally 
considered a paediatric syndrome and as with bronchitis, the most commonly isolated pathogen (in 
up to 90% of cases) is RSV. Rhinovirus and human meta-pneumovirus have also been implicated, and 
in rare cases, Mycoplasma pneumonia (7). Pneumonia is responsible for a large proportion of LRI-
related deaths. It can be caused by a wide variety of respiratory pathogens, though unlike the majority 
of the previously mentioned syndromes, it typically has a bacterial aetiology: Streptococcus 
pneumoniae is the most common causative agent in children, followed by Haemophilus influenzae 
type B (8). Other isolated bacteria include Staphylococcus aureus, Klebsiella pneumonia, Escherichia 
coli, Mycoplasma Pneumoniae, Pseudomonas aeruginosa and Moraxella catarrhalis. In terms of viral 
pneumonia, RSV is the most common causative agent, though influenza, rhinovirus and parainfluenza 
viruses can also be responsible (9). In addition to these pathogens, fungal species can cause endemic 
pneumonia outbreaks in environmental niches with conditions that favour fungal growth (10), as well 
as being dangerous opportunist pathogens for the immunocompromised. The species: Aspergillus, 
Candida, Cryptococcus, Histoplasma capsulatum and Coccidioides are common agents, and in HIV-
20 
 
infected infants, Pneumocystis jiroveci is responsible for one quarter of pneumonia-related deaths (8, 
11). 
 
1.1.2. Pathogenesis of ARI 
The respiratory tract is the route of access most commonly exploited by invading pathogens owed to 
it being constantly exposed to our external environment. For example, an individual living in the 
Midwest of the United States has been estimated to inhale 860,000 bacteria per day (12), which does 
not include respiratory viruses that are responsible for the majority of ARI. Most pathogens which 
invade the respiratory tract are adequately combated by host innate and adaptive immune responses. 
However, in some cases an invading pathogen is able to effectively circumvent or impede an immune 
response. The specific strategies employed by respiratory pathogens are numerous. Some examples 
include: hiding from immune surveillance, generating antigenic hyper-variability, inhibiting the 
complement pathway, directly inhibiting the release of cytokines, chemokines, and interferons from 
effector immune cells, modulation of apoptosis, and the interference of toll-like receptor proteins 
(13). These tactics often allow the pathogen to colonise the respiratory tract and directly inflict 
damage to pulmonary architecture. A degree of indirect damage is also caused by the immune 
response to the pathogen (immunopathology). Which source of damage most significantly contributes 
to the precipitation of clinical sequelae is not well understood because their effects are difficult to 
differentiate, and they vary by pathogen (14). To use RSV as an example: it causes direct viral damage 
by inhibition of ciliated epithelium movement to cause airway blockade (15). Indirectly, RSV affects 
immune-mediated pathology by causing a hyper-inflammatory state that arises due to a large influx 
of leukocytes. Neutrophils are often the most commonly found leukocyte at the site of infection and 
cause overstimulation of inflammatory factors and cytotoxic enzymes which result in airway tissue 
damage (16). Both of these forms of damage combine to cause increased mucus production, cell 
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apoptosis, tissue necrosis, and sloughing of epithelial cells (17), often resulting in symptoms of 
increased mucus secretion, difficulty in breathing, nasal congestion, fever, and coughing. 
 
The different forms of direct pathogenic damage and immunopathology are vast due to the wide range 
of pathogens that cause ARI, but in general, the degree of infection reflects the level of structural 
damage and functional compromise caused to pulmonary architecture, which is mostly dependent on 
the amount of pathogen dissemination along the respiratory tract. 
 
 
1.1.3. The Burden of ARI: Economics & Mortality. 
As previously mentioned, LRI carry a far greater risk of death than do URI. The recently published 
‘Global Burden of Disease Study 2013’ attributed 3.9 thousand deaths globally to URI in 2013, and 2.7 
million deaths to LRI (18). URI generally impose a large burden on the economy through healthcare 
related costs and loss of productivity due to work and school absenteeism. In many developed 
countries there has been a burgeoning health economics issue surrounding the over-prescription of 
antibiotics in primary care settings, for the treatment of URI which are predominantly self-limiting 
viral infections (19). Between 1980 and 1991, there was an estimated 46% increase in the number of 
antibiotic prescriptions issued in England (20); a 65% increase in France; and a 78% increase in West 
Germany (21). Between 1994 and 2000, in the UK, antibiotic prescription incidence reportedly 
decreased significantly (22), though a recently published survey found the median general practice (of 
568 providing electronic medical records) prescribed antibiotics for 54% of URI consultations in 2010 
and 2011 (23). It has been estimated that £15 million per year is spent in the UK on antibiotics 
prescribed in primary care settings for patients presenting only with acute coughs (24), furthermore, 
work absence due to coughs and colds during 2011 were estimated at a total of 27.5 million days (25). 
A similar story has been observed in the US: in 1998, 55% (22.6 million) of antibiotic prescriptions were 
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made for URI, at a cost of roughly $726 million (26). In 1996 upper respiratory infections were 
estimated to cause 20 million days of work absence, and 22 million days of school absence (27). The 
overprescription of antibiotics to treat viral URI, which occurs in many parts of the world, also 
contributes to the economic burden imposed by ARI. This is not only due to the immediate cost of 
prescribed antibiotics, but also due to the investment in solutions to combat the resulting problem 
which has arisen from overprescription: the widespread use of antibiotics has generated a strong 
selective pressure for strains of bacteria that can adapt, and as such antibiotics which were once very 
effective in the management of ARI have had to be replaced by, or combined with other forms of 
antibiotic. Penicillin in the treatment of Streptococcus pneumoniae infection is a classic example. S. 
pneumoniae is one of the most frequent causes of pneumonia which until the mid-1960s was 
universally sensitive to penicillin treatment. The first case of penicillin-resistant S.pneumoniae was 
identified in 1967, in Australia, and 10 years later within an infectious disease hospital in South Africa 
where patients were routinely prescribed antibiotics as prophylaxis for viral infection, strains of 
S.pneumoniae with additional resistance to erythromycin, tetracycline, streptomycin and clindamycin 
were reported (28). By 1997 an estimated 14% of S.pneumoniae isolates had achieved penicillin 
resistance, globally (29), which had increased to 22% of isolates in the US by 2004 (30), and as much 
as 50% in other parts of the world (31). Due to the development of drug-resistant pathogens it has 
been estimated that from 1991 to 2012, in the UK, there has been a 12% increase in failure rates for 
first line antibiotic treatment of upper and lower respiratory infections, and soft tissue infections (32).  
 
The burden of ARI mortality is predominantly due to pneumonia, and is particularly high in people on 
either end of the age scale – the very young and the very old. Between 2000 and 2003, pneumonia 
was estimated to be the single largest cause of child mortality globally in those aged <5 years; 
responsible for 19% of deaths (2.01 million) each year (33), and as figure.1 shows, mortality rates were 
highest in sub-Saharan Africa and South Asia. 
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Figure 1.1 shows the WHO’s estimations for global pneumococcal mortality in 2000, for children aged 




Mortality rates in children aged <5 years have decreased significantly in the last decade, which may 
be due to increased vaccination efforts or more effective treatment strategies, and perhaps other 
factors such as improvements in socioeconomic status and nutrition, or the decreasing prevalence of 
smoking have contributed to the effect. Despite this decline, according to the WHO, in 2013 
pneumonia was still the global leading cause of infectious mortality in this age-group; responsible for 
an estimated 0.94 million deaths (8). In older adults, impaired response to influenza vaccines have 
been reported (35) and controversy surrounds the efficacy of the 23-valent polysaccharide 
pneumococcal vaccine (PPV) introduced in Europe in 1998 for vaccination against pneumococcal 
pneumonia in those aged >65 years: while some clinical trials have reported a reduced incidence of 
infection and mortality and sustained immunogenicity (36, 37), survey data still reports that 90% of 




The burden of ARI is also particularly high in those with chronic respiratory diseases such as asthma 
and chronic obstructive pulmonary disease (COPD). URI have been reported to be the major 
precipitant of symptom exacerbations in children and adults with asthma (39); a chronic respiratory 
disease which causes roughly 250,000 deaths globally each year (40) and significant morbidity in the 
estimated 235 million worldwide sufferers (41). In the UK, there are approximately 5.1 million 
sufferers and an estimated 12.7 million lost work days per year; costing the economy £2.3 billion in 
lost productivity, welfare benefits, and NHS costs (42). COPD represents an even larger global health 
problem which is expected to worsen in the coming decade. The disease was responsible for over 3 
million deaths in 2012 (43), and an estimated $32.1 billion in medical care costs during 2010, for the 
US alone (44). It is estimated that 50% of COPD exacerbations are precipitated by URI (45), therefore 
more effective interventions to prevent ARI could have significant, positive health and economic 











1.2. Vitamin D. 
In the early 20th century it was discovered that increased sun exposure and the administration of cod-
liver oil could be used to treat rickets (46). Although it was not known at the time that improvement 
of vitamin D status was the feature these two treatments had in common, it has since become well 
known that vitamin D is essential for the regulation of calcium and phosphate homeostasis to maintain 
skeletal bone health. More recently vitamin D’s potential ‘non-classical’ roles have begun to emerge, 
one of them being its immunomodulatory activity. 
 
1.2.1. Biochemistry and metabolism. 
In 1914 a team of biochemists in the US lead by Elmer V. McCollum isolated a substance from butterfat 
they termed ‘fat-soluble factor A’ (47). Through further experimentation with heat oxidised cod-liver 
oil, in 1922 McCollum reported the discovery of a distinct compound in fat-soluble factor A, which was 
later named ‘vitamin D’ (48). The name belies its chemical nature however: due to a broken carbon-
carbon bond in its B ring and the requirement of a change in the compound’s structure before it can 
become metabolically active, it is more accurate to regard vitamin D as a secosteroid pre-prohormone. 
This has not prompted a change in nomenclature however; the term vitamin D is still generally used 
to refer to the two known forms of the compound - vitamin D2, (ergocalciferol) which is derived from 
ergosterol, a cell wall component found in fungi, or vitamin D3 (cholecalciferol), which is derived from 




Figure 1.2. A diagram depicting the intake of dietary vitamin D (1) from two common oral sources, 
fortified milk and oily fish; the cutaneous synthesis of vitamin D (2) via photoactivation of 7-
dehydrocholesterol by ultra-violet radiation which occurs in the skin; the 25-hydroxylation of 
cholecalciferol (3) by cytochrome P450 enzymes in the liver to produce the intermediate metabolite of 
vitamin D, 25(OH)D; the 1α-hydroxylation of 25(OH)D in the kidneys (4) by CYP27B1 enzyme to produce 
the active metabolite of vitamin D, 1,25(OH)2D3; the extra-renal 1α-hydroxylation of 25(OH)D (5) which 
occurs in a variety of cells, but of particular interest to immune responses to respiratory pathogens, this 
occurs in monocytes, respiratory epithelial cells, dendritic cells (DC) and macrophages (Mφ) via intra-






Humans synthesize cholecalciferol in the skin following exposure to ultra-violet B (UV-B) radiation, 
though we also receive some from our diet (primarily from oily fish [pathway.1 in Figure 1.2]). The 
cutaneous production of cholecalciferol is achieved by photo-activation of 7-DHC when UV-B rays with 
a wavelength of 290 to 315 nm penetrate the epidermal and dermal layers: a photon of radiation is 
absorbed by 7-DHC which cleaves the B ring’s C9-C10 bond to create a seco-sterol, called pre-vitamin 
D3 (50). Pre-vitamin D3 then undergoes spontaneous thermal isomerisation to become vitamin D3 
(cholecalciferol) (pathway.2 in Figure 1.2) (51). Vitamin D3 is then hydroxylated twice by cytochrome 
P450 enzymes to produce an active metabolite. The first reaction primarily occurs in the liver 
(pathway.3, Figure 1.2), predominantly by CYP2R1, though CYP27A1 and CP3A4 have also been 
reported to show 25-hydroxylation activity (52, 53). This reaction produces 25-hydroxyvitamin D3  
(25[OH]D3, also referred to as ‘calcidiol’) - the intermediate, major circulating vitamin D metabolite 
and widely accepted measure of vitamin D status due to its longer half-life than the metabolically 
active form of vitamin D (ca.15 days vs. 15 hours) (54). The second reaction occurs in the kidneys and 
a variety of extra-renal tissues around the body, including certain innate immune cells (pathways 4 & 
5, Figure 1.2). The enzyme CYP27B1 1α-hydroxylates 25(OH)D3 to produce 1α,25-dihydroxyvitamin D3 
(1,25[OH]2D3, also referred to as ‘calcitriol’) (55). This is the active metabolite of vitamin D which 
ligates vitamin D receptor (VDR) with high affinity to mediate the secosteroid hormone’s actions. To 
avoid excess concentration of the active metabolite, 1,25(OH)2D3 down-regulates its own production 
by VDR-mediated negative regulation of CYP27B1 gene (56, 57) and catabolism of vitamin D also 
occurs by the enzyme CYP24A1, which can 24R-hydroxylate 25(OH)D3 and 1,25(OH)2D3 to produce the 
relatively inactive metabolites 24,25(OH)2D3 and 1,24,25(OH)3D3, respectively; either indirectly, or 
directly decreasing the amount of active substrate available for reaction (58). Excessive 
supplementation of vitamin D can result in toxicity (hypervitaminosis D), the major symptoms of which 
arise from elevated calcium levels: nausea, constipation, dehydration, excessive thirst and vomiting, 
and in some cases, nocturia, muscle weakness, itching and renal stones (59). If left untreated, 
hypervitaminosis D can result in renal failure, however, due to vitamin D’s wide therapeutic index, 
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toxicity in general is relatively rare. There are currently no population-level statistics on the incidence 
of vitamin D toxicity; existing data comes from case studies (60) (61) (62) and reports of adverse events 
from clinical trials of vitamin D supplementation: to illustrate, a recently completed individual patient 
data meta-analysis conducted by my group reports a total of 3 cases of hypercalcaemia, and 2 cases 
of renal stones in 5,703 members of the intervention arms, of 24 clinical trials. Hypervitaminosis D has 
been suggested to arise when serum 25(OH)D3 concentrations rise above 375 nmol/L (63). However 
to achieve this would require an estimated sustained supplementation of 40,000 IU per day (64), 
which is far in excess of safe upper dosing limits for clinical trials, currently set at 2,500 IU per day for 
1-3 year olds; 3,000 IU per day for 4-8 year olds; and 4,000 IU per day for those aged ≥9 years (65). 
 
1.2.2. Vitamin D deficiency & susceptibility to Acute Respiratory Infections. 
The association of sunlight with well-being long predates modern medicine - throughout human 
history ancient cultures have worshiped solar deities, whom they credited with powers of healing, 
such as the Mesopotamian God, Shamash; the Celtic God, Belenus; and the Greek God, Apollo. Whilst 
unempirical, it is interesting to speculate that humans made a connection between sunlight and 
improved health more than two millennia before the work of Niels Ryberg Finsen, a Faroese born 
physician who in the late 1880’s devoted his research to deciphering the clinical benefits of the sun 
after observing an improvement in the symptoms of his own condition (Pick's disease) with increased 
sun exposure. Finsen was awarded the Nobel Prize in Physiology or Medicine in 1903 for 
demonstrating that ultra-violet light therapy is effective in the treatment of cutaneous tuberculosis 
(66). Roughly 80 years later the British physician-turned-epidemiologist, Robert Edgar Hope-Simpson 
proposed a theory to explain the seasonal cycle of epidemic influenza we see in temperate latitudes. 
His ‘seasonal stimulus’ theory attributed the fluctuating incidence of influenza across seasons to be “a 
rather direct effect of some component of solar radiation acting positively or negatively upon the virus, 
the human host, or their interaction”(67). Hope-Simpson’s work paved the way for the investigation 
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of this component of solar radiation which may modulate immune responses to respiratory 
pathogens. 
 
1.2.3. Immunomodulatory actions of vitamin D. 
Over the past 10 years a wide range of primarily in vitro data has been published reporting the actions 
of 1,25(OH)2D3 on both the innate and adaptive arms of the immune system. These have been 
summarised in a simplified diagram (figure.3) below. 
 
Effect of vitamin D on innate immune responses. 
In the innate immune system 1,25(OH)2D3 has been found to: induce expression of antimicrobial 
peptides (AMPs, e.g. cathelicidin LL-37 and beta-defensins) in monocytes, macrophages and 
respiratory epithelial cells, providing them with increased bactericidal, virucidal and fungicidal 
properties (68-71); enhance monocyte and macrophage antimicrobial effector function through 
induction of reactive oxygen and nitrogen intermediate production (72-74); promote chemotaxis in 
neutrophils, macrophages, monocytes and T Cells via induction of cathelicidin LL-37 (75); and 
strengthen barriers to infection by inducing synthesis of structural proteins which form tight-, 
adherens- and gap-junctions between epithelial cells (76-78) (depicted by the green area in Figure 
1.3). 
 
1,25(OH)2D3 also directly affects dendritic cells (DC) by inhibiting synthesis of their surface receptor 
(major histocompatibility complex II [MHC-II]) and co-stimulatory proteins (CD40, CD80, CD86) 
resulting in suppression of maturation and proliferation (79, 80). Immature dendritic cells (iDC) then 
present antigen to naïve CD4+ T cells to promote tolerance via differentiation to T-regulatory cells 
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(Tregs) (81) resulting in greater production of anti-inflammatory interleukin-10 (IL-10), thus bridging 

















Figure 1.3. An overview of the main actions of 1,25(OH)2D3 on myeloid (green) and lymphoid (red) 
immune cells in innate and adaptive immune systems. In the innate immune system 1,25(OH)2D3 
stimulates the proliferation of more pathogenicidal macrophages ([Mφ] which produce reactive oxygen 
and nitrogen species; cathelicidin and beta-defensin; and show enhanced chemotaxis) and suppresses 
the maturation of dendritic cells which favours the differentiation of naïve CD4+ T Cells to anti-
inflammatory T-regulatory Cells (Treg). In the adaptive immune system 1,25(OH)2D3 affects naïve CD4+ 
T Cell differentiation to down-regulate release of pro-inflammatory mediators from type 1 and type 17 
T helper cells (Th1 and Th17) and upregulate release of anti-inflammatory mediators from type 2 T 







Effect of vitamin D on adaptive immune responses. 
In the adaptive immune system, 1,25(OH)2D3 has been found to potentiate T cell activation via the 
classical T cell receptor signalling pathway (82), and skew the phenotype of CD4+ T helper cell 
populations from pro-inflammatory mediator releasing Th1/Th17 cells towards anti-inflammatory 
mediator releasing Treg/Th2 cells (depicted by the orange area in Table 1.3), thus decreasing the 
production of pro-inflammatory cytokines IL-2, IFN-γ, IL-21 and IL-17 (83). By down-regulating the pro-
inflammatory Th1/Th17 response and up-regulating an anti-inflammatory Th2/Treg response via 
induction of IL-10 secretion, vitamin D’s actions may prevent inflammatory damage during an 
overzealous response to respiratory pathogens. It can be argued, however, that this action may 
represent a double-edged sword, as it may hinder adaptive immunity and increase susceptibility to 
infection. A clinical trial of vitamin D supplementation for the prevention of congestive heart failure 
offers in vivo findings in human subjects that support the aforementioned work conducted in vitro and 
in murine models which suggest vitamin D stimulates anti-inflammatory conditions: this study found 
that members of the intervention arm who received 2,000 IU per day of cholecalciferol for nine 
months had significantly higher serum concentrations of the anti-inflammatory cytokine, IL-10, than 
members of the placebo arm, and significantly lower serum concentrations of the pro-inflammatory 
cytokine, TNF-α (84).   
 
1.2.4. Immune dysregulation in older adults. 
Older adults are at increased risk of ARI than younger people. Through laboratory work, 
predominantly in murine models, the following effects of aging on the innate immune response have 
been discovered: macrophages of aged animals have been shown to experience a 75% decrease in the 
production of superoxide anions (85-87) and similar reductions have been found in neutrophils (88). 
Decreasing production of reactive nitrogen species with age has also been documented in 
macrophages and neutrophils (89, 90). Ageing is also associated with impairment of neutrophil 
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chemotaxis (91, 92) and antigen presentation by macrophages; the latter phenomenon is associated 
with a progressive increase in prostaglandin E2 secretion with age, resulting in the inhibition of 
interleukin-12 (IL-12) secretion and decreased cell surface expression of major histocompatibility 
complex class II proteins (93). A progressive increase in the production of pro-inflammatory cytokines 
(“inflammaging”) is another characteristic of the ageing immune system, and is believed to be a major 
contributor to age-related immunopathology (94). Ageing is also associated with attenuation of 
adaptive immune responses, which may arise due to reduced dendritic cell-mediated stimulation of T 
and B cells (95). T cell activation has also been found to be impaired by dysregulation of signal 
transduction proteins in older adults (96, 97).  Immunosenescence is also associated with a marked 
decrease in the population of naïve lymphocytes, caused by reduced T cell thymic output as a 
consequence of thymic involution (98), decreased progenitor B cell production in bone marrow (99) 
and accumulation of anergic effector memory CD8+ T cells (100).  These defects in adaptive immune 
responses are associated with decreased protective efficacy of vaccines against respiratory pathogens 
such as influenza virus (101). 
 
1.2.5. Immune dysregulation in Asthma & COPD patients. 
Asthma and COPD sufferers are two further at-risk groups for ARI. The immunopathology of these two 
respiratory diseases share several similar features, but they differ in their pathogeneses: both diseases 
are characterised by inflammation of the lower airways and airflow obstruction due to excessive 
mucus secretion, though airway obstruction in asthma is classically reversible and due to variable 
inflammation of allergic origin, whereas in COPD inflammation is chronic due to smoking/pollutant-
related airway damage and thus the obstruction is non-reversible. Both conditions involve acute 
episodes marked by a worsening of symptoms, referred to as disease ‘exacerbations’. Vitamin D’s 
antimicrobial-stimulating effects in the innate immune system and anti-inflammatory effects in the 




In asthma, the cytokines IL-4, IL-5 and IL-13 are implicated in disease immunopathology, and are 
believed to predominantly arise from allergen-specific Th2 responses, which lead to B cell proliferation 
and high levels of IgE antibody production, as well as eosinophil activation and concomitant mucus 
over-production (102). The ‘hygiene hypothesis’ was proposed to explain the higher observed 
incidence of asthma in children who grow up in urban, compared to rural settings, and states this to 
be due to more sanitary conditions in urban areas causing reduced exposure to pathogens and 
decreased development of immune regulatory controls at an early age (103). Whilst only in a murine 
model, recent lab work has shown that perinatal vitamin D deficiency skews the profile of naïve T 
helper cells towards a Th2 phenotype, along with reduced T reg cell proliferation, and concomitant 
atopy. Subsequent vitamin D supplementation was found to significantly reduce IgE levels and airway 
eosinophilia (104). The role of Th17 cells in asthma pathogenesis is also beginning to emerge, 
challenging the classical view of the disease being predominantly Th2-driven. Non-Th2 cytokine (IL-9, 
IL-22 and IL-17) expression has been demonstrated in asthma patients (105);increased Th17 cell 
proliferation has been reported to be characteristic of neutrophilic asthma (106); and ex vivoTh17 cell 
proliferation from 1,25(OH)2D3 –restricted naïve CD4+ T cells has been found to be significantly greater 
in young asthmatic children compared to healthy controls, and conversely, the inhibition of Th17 cell 
proliferation was observed when naïve CD4+ T cells were stimulated with 1,25(OH)2D3 (107). 
 
The immunopathology of COPD features an abundance of pulmonary neutrophils and macrophages 
(108), though despite high levels of these important pathogen-killing innate immune cells, COPD 
patients remain at high risk of ARI. This has been suggested to be due to defects in immune cell 
function, for example macrophages of COPD patients show reduced phagocytic capability (109); 
neutrophils have been found to have impaired chemotaxis (110) and enhanced survival which is 
responsible for their accumulation (111); and respiratory epithelial cells show impaired mucociliary 
and barrier function (112), all of which contribute to an impaired innate immune response to 
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respiratory viruses. Interestingly, expression of the vitamin D receptor (VDR) and major vitamin D 
activating enzyme (CYP27B1) have been found in airway epithelial cells (113), macrophages (114) and 
neutrophils (115) which allows vitamin D to exert local autocrine or paracrine actions, and in the case 
of macrophages, CYP27B1 expression is upregulated with the activation of toll-like receptors (TLR) 
from viral ligands (116). This therefore raises the question of whether vitamin D’s ability to stimulate 
improved pathogenicity and chemotaxis within these cell types may be of particular benefit to the 
improvement of innate immune responses in COPD patients, and reduce the risk of exacerbation-
causing ARI. 
 
1.2.6. Clinical studies of vitamin D and ARI. 
The previously mentioned epidemiological observations of UVR exposure and consequent laboratory 
studies on vitamin D’s immunomodulatory actions have in the past decade prompted a significant 
number of clinical studies investigating vitamin D in relation to ARI, though no reviews of the literature 
existed when I commenced my PhD project. To analyse this large body of research I conducted a 
systematic review during my first year, which was published in the Journal of Steroid Biochemistry and 
Molecular Biology in December of 2012. I identified a total of 39 clinical studies (4 cross-sectional, 8 
case-control, 13 cohort, and 14 clinical trials). 19/25 observational studies reported a significant 
association between vitamin D deficiency and increased risk of ARI, whilst only 7/14 clinical trials 
found vitamin D to offer protection against ARI. I present the complete synthesis of these studies and 







1.3. Vitamin D Pathway Genes. 
Complex pathways of vitamin D metabolism, transport, and signaling are governed by genes encoding 
a set of enzyme, carrier, and receptor proteins which in concert achieve the activation of vitamin D 
from its inert sterol-based precursor; its delivery to target tissues; and its utilisation in a range of cell 
signaling outputs. 
 
Figure 1.4. A diagram depicting vitamin D metabolic and signalling pathways and genes encoding key 
players (in blue): DHCR7 (A) encodes the 7-dehydrocholesterol reductase enzyme, which catalyses the 
conversion of 7-dehydrocholesterol to cholesterol; CYP2R1, CYP3A4, and CYP27A1 (B) encode 25-
hydroxylating cytochrome P450 enzymes; the vitamin D binding protein gene (DBP, [C]) encodes the 
principle vitamin D transport protein; LRP2 & CUBN (D) encode the proteins megalin and cubilin, 
respectively, involved in renal re-absorption of 25(OH)D via receptor-mediated endocytosis; CYP27B1 (E) 
encodes the cytochrome P450 enzyme which 1-alpha-hydroxylates 25(OH)D to form 1,25(OH)2D; 
CYP24A1 (F) encodes the cytochrome P450 enzyme responsible for 24-hydroxylating vitamin D 
metabolites including 25(OH)D and 1,25(OH)2D; VDR (G) encodes the vitamin D receptor, which binds 
1,25(OH)2D and forms a heterodimer with the gene product of RXRA (H) – the retinoid X receptor – to 







Enzymes of the cytochrome P450 family are primarily responsible for the metabolism of vitamin D, 
however one important non-cytochrome P450 enzyme, 7-dehydrocholestrol reductase (DHCR7) is 
involved as it converts the vitamin D pre-cursor, 7-dehydrocholesterol (7DHC) to cholesterol by 
removal of the C (7-8) double bond in the sterol’s B ring (117); a reaction that removes 7DHC from the 
vitamin D synthetic pathway. Thus the balance of vitamin D or cholesterol production is determined 
to some degree by the level of photo-activation vs. reduction of 7DHC. DHCR7 gene (pathway A on 
figure.4) is located on chromosome 11q13.4, spans 24.7 kilo-base pairs (kbp), contains 9 exons and 
encodes the 475 amino acid, 54.5 kilodalton (kDa) DHCR7 protein. Over 40 single nucleotide 
polymorphisms (SNP) of DHCR7 have previously been implicated in the pathogenesis of Smith–Lemli–
Opitz Syndrome (SLOS) (118): an autosomal recessive disease which causes multiple congenital 
deformities due to impeded cholesterol synthesis (119). Interestingly, reports of recurrent ARI (otitis 
media and pneumonia) have been made in the SLOS patients (120, 121), which may arise due to 
dysregulation in the vitamin D pathway. One SNP (rs12785878) upstream of the DHCR7 gene has also 
been identified in a recent genome wide association study (GWAS) in association with vitamin D status 
(122): homozygous carriers of the rare allele were found to have lower associated serum 25(OH)D 
concentration, a finding which has been replicated in other studies (123, 124). Colleagues within our 
centre have also recently shown that an extended haplotype in DHCR7 is under positive selection in 
populations living in Northern latitudes, and suggest this to be a mechanism which offered protection 
from vitamin D deficiency to humans when we migrated away from the equator; towards conditions 
of scarcer UVB radiation (125). 
 
The first enzymatic step in vitamin D metabolism is the 25-hydroxylation of cholecalciferol (pre-
vitamin D) to 25(OH)D. At least six enzymes belonging to the cytochrome P450 superfamily of 
monoxygenases have been found to possess 25-hydroxylation activity in the human liver: CYP2D25, 
CYP2J1, CYP2C11, CYP3A4, CYP27A1, and CYP2R1, but which of these enzymes are involved in the 25-
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hydroxylation of vitamin D was unknown  until the turn of the 21st century when several studies 
reported findings that CYP27A1, CYP2R1, and CYP3A4 have vitamin D metabolic activity (126-128). 
CYP2R1 gene (pathway B on figure.4) spans 14.2 kbp on chromosome 11p15.2, contains 5 exons and 
encodes the 501 amino acid, 57.4 kDa microsomal enzyme, CYP2R1 which is now generally believed 
to be the primary enzyme for 25(OH)D synthesis (52). Several SNP in CYP2R1 have been found to 
associate with vitamin D status, both in candidate gene association (CGA) studies and GWAS (122, 124, 
129), and one promoter region SNP, rs10766197 has also been found to significantly associate with 
lung function and IgE concentration in asthmatic cohorts (130, 131), which is an interesting finding in 
the light of a laboratory study which found perinatal deficiency in 25(OH)D concentration lead to a 
Th2-skewed T cell phenotype and atopy in offspring (104). Another finding which ties CYP2R1 to 
immune-related pathology comes from a study which found 20% lower levels of CYP2R1 expression in 
patients with nonalcoholic steatohepatitis (NASH) or chronic hepatitis C (CHC), compared to healthy 
controls (132), and further reports have been made of an association between severe vitamin D 
deficiency and CHC incidence, or severity (133, 134), supporting the argument for vitamin D’s ability 
to offer protection against viral infection. Lowered expression of CYP27A1 enzyme was also reported 
to associate with CHC (45% lower in CHC patients vs. healthy controls) (132). This 531 amino acid, 60.2 
kDa mitochondrial enzyme is encoded by CYP27A1 gene (pathway B on figure.4) which spans 33.5 kbp 
on chromosome 2q35 and contains 9 exons. Over 50 SNP in CYP27A1 have been found to associate 
with cerebrotendinous xanthomatosis, a rare disease which occurs due to dysregulated cholesterol 
and bile acid metabolism (135). The level of CYP27A1-mediated 25-hydroxylation in humans is not 
currently known, however. It has been demonstrated that CYP2R1 knock-out mice show a 50% 
decrease in 25(OH)D production, which suggests there’s redundancy in the 25-hydroxylase pathway 
(136), however previous GWAS did not identify a significant association between SNP in CYP27A1 and 
circulating vitamin D metabolite concentrations (122, 124), and CYP27A1-knockout mice do not 
display the clinical features of rickets (137), therefore it has been questioned whether CYP27A1 is 
involved in the 25-hydroxylation of vitamin D at physiologically-relevant concentrations. CYP3A 
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subtypes are the most abundant hepatic cytochrome P450 enzymes and are capable of metabolising 
roughly half of all currently available prescription drugs (138). The non-specific, 57.3 kDa, microsomal 
CYP3A4 enzyme comprises503 amino acids, encoded by CYP3A4 gene (pathway B on figure4) which 
spans 27.3 kbp, containing 13 exons, located on chromosome 7q21.1. It’s expressed in both the liver 
and small intestine and has been demonstrated to be more efficient in 24- and 25-hydroxylation of 
vitamin D2, than vitamin D3 (53, 127). Interestingly, 1α,25(OH)2D3 has also been shown to stimulate 
CYP3A4 expression in vitro, in a range of cell types (139-145), thus vitamin D supplementation may be 
an effective adjunct to drug therapies which rely upon CYP3A4 for first pass metabolism. 
 
After vitamin D has been 25-hydroxylated to its intermediate metabolite it is then activated by the 
56.5 kDa,1α-hydroxylating CYP27B1 enzyme comprising 508 amino acids; encoded by CYP27B1 gene 
(pathway E, figure 4) which spans 6.7 kbp, with 9 exons, located on chromosome 12q14.1. Renal 
synthesis of 1α,25(OH)2D3 was reported over 40 years ago (146), but more recent reports of extra-
renal synthesis have emerged, and it is now widely accepted that localized expression of CYP27B1 and 
subsequent production of 1α,25(OH)2D3 allows vitamin D to act in a autocrine, or paracrine fashion to 
affect a range of important immune cell types, including monocytes (147), macrophages(148), 
dendritic cells(149), and respiratory epithelial cells (113). SNP in CYP27B1 gene have been found to 
associate with circulating 1α,25(OH)2D3 concentration and susceptibility for several immune-related 
diseases: in a cohort of chronic hepatitis C patients, CC genotype for a promoter region SNP 
(rs10877012) associated with a 12 pmol/ml lower serum 1α,25(OH)2D3 concentration and a 35% 
decrease in sustained virologic response rate, compared to those with the AA genotype(133). 
Heterozygosity for the same SNP has also been found to associate with increased incidence of 
Hashimoto’s thyroiditis and Graves’ disease (150), and another SNP (rs703842) in near complete 
linkage disequilibrium (LD) with rs10877012 has been identified by GWAS to associate with Multiple 
Sclerosis (151, 152). The regulation of CYP27B1 in the kidney is under strict control by calcium and 
phosphate homeostatic systems, whereby parathyroid hormone (PTH), and low Ca2+ and PO43-
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concentrations stimulate CYP27B1 expression, then 1α,25(OH)2D3 limits its own synthesis via VDR-
mediated down-regulation of CYP27B1, however in extrarenal cells there exists different mechanisms 
of CYP27B1 expression, for example it has recently been demonstrated that in human macrophages, 
surface toll-like receptors (TLRs) can be activated by M.tuberculosis to stimulate the expression of 
CYP27B1 and VDR and which allows activated vitamin D to stimulate production of the anti-microbial 
peptide, cathelicidin which is a potent bactericidal compound for this pathogen (116). 
 
In the kidney, the negative feedback loop which down-regulates CYP27B1 expression, seemingly to 
ensure active metabolite concentration does not rise too high, is helped by VDR-mediated up-
regulation of CYP24A1 gene (pathway F, figure 4). The gene spans 20.5 kbp, contains 12 exons, is 
located on chromosome 20q13 and encodes the major vitamin D catabolic enzyme, CYP24A1 (153) 
which is comprised of 514 amino acids, with a molecular weight of 58.9 kDa. Under normal conditions 
CYP24A1 is a highly inducible gene, capable of causing a 20,000-fold increase in local enzyme levels in 
response to conditions of high 1α,25(OH)2D3 concentration (154), thus CYP24A1 enzyme largely 
depicts the bio-availability of vitamin D: in-vitro work has shown that CYP24A1-null mice have a 10-
fold longer 1α,25(OH)2D3 half-life (roughly 60 vs. 6 hours) (155), and CYP24A1 is key to the regulation 
of vitamin D synthesis: in macrophages it has been proposed that hypercalcaemic conditions arise due 
to an alternative splicing variant of CYP24A1 that generates a catalytically dysfunctional enzyme (156), 
and in renal epithelial cells, loss of function mutations in CYP24A1 have recently been linked to the 
development of nephrolithiasis and nephrocalcinosis due to hypervitaminosis D (157). 
 
Serum 25(OH)D concentration is not only impacted by 25-hydroxylating enzymes; two important 
receptors in the vitamin D pathway are required for efficient renal re-uptake of carrier-bound vitamin 
D: low density lipoprotein receptor-related protein-2 (LRP2, also known as megalin),is a large (4655 
amino acid, 522 kDa) cell-surface receptor protein believed to be required for cell uptake of vitamin D 
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by endocytosis, and is encoded by the LRP2 gene (pathway D, figure 4) which spans 235.6 kbp on 
chromosome 2q31.1 and contains 79 exons. More than 10 mutations in LRP2 gene have been found 
to associate with Donnai-Barrow Syndrome (DBS), characterised by diaphragmatic hernia, 
developmental delays, and ocular; sensineural; and craniofacial abnormalities (158). As LRP2 is a non-
selective multi-ligand receptor expressed in the neuroepithelium, as well as renal proximal tubule 
cells, DBS most likely occurs due to the loss of cell uptake for a range of macromolecules, including 
proteases, protease inhibitors and lipoproteins (159, 160). Interestingly, whilst LRP2-knockout mice 
develop vitamin D deficiency (161) there are currently no in-vivo reports of LRP2 mutation in 
association with vitamin D status, which suggests the renal re-uptake pathway differs in humans, or 
there is simply a lack of studies which have investigated this gene in relation to vitamin D metabolism. 
The second cell-surface receptor involved in vitamin D metabolism is the 3623 amino acid, 398.7 kDa, 
intrinsic factor-cobalamin receptor (cubilin), which like megalin is expressed in renal proximal tubules 
and can facilitate the endocytosis of carrier-bound vitamin D. Cubilin is encoded by CUBN gene 
(pathway D, figure 4) which spans 305.9 kbp on chromosome 10p12.31 and has 67 exons. Unlike 
megalin, murine CUBN-knockouts do not display vitamin D deficiency, however loss of CUBN function 
has been linked to a significant increase in urine and decrease in serum 25(OH)D concentration in both 
dogs (162) and humans. The latter has been found in sufferers of Imerslund-Gräsbeck syndrome (IGS), 
a rare autosomal recessive disorder caused by vitamin B12 deficiency, which strongly associates with 
several CUBN mutations (163). 
 
1.3.2. Transport. 
To avoid excess tissue dispersion and urinary excretion, lipophilic vitamin D parent compound and 
metabolites primarily circulate in the blood bound to their carrier protein, vitamin D binding protein 
(DBP, also known as Group-specific Component [GC]). Thus DBP ensures effective delivery of vitamin 
D to target tissue for metabolism (164) and provides a reservoir for metabolised vitamin D to prevent 
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deficiency in times of reduced synthesis or dietary intake (165). The DBP gene (pathway C, figure 4) 
spans 7.4 kbp on chromosome 19q13.3, has 13 exons and encodes a 474 amino acid, 53 kDa protein. 
It is a highly polymorphic gene: over 120 variants are known to arise (166), though 2 SNP in exon 11 
(rs4588, T>G/Asp>Glu and rs7041, C>A/Thr>Lys) give rise to 3 common DBP isoforms: group-specific 
component 1 fast (Gc1-F), Gc1-slow (Gc1-S), and Gc2, the latter isoform has been reported to show 
lower affinity for 25(OH)D than the Gc-1 isoforms (167). DBP gene variants associate with vitamin D 
levels more so than other vitamin D pathway genes: GWAS and CGAS have identified at least 9 SNP 
which associate with circulating 25(OH)D concentration  (122, 124, 168-172), though they only explain 
around 5% of variation in total 25(OH)D level. The precise level of carrier binding vitamin D undergoes 
and what effect this may have on vitamin D’s actions is a topic of much debate, but it is generally 
accepted that around 85% of 25(OH)D in circulation is bound to DBP, with the remaining 15% 
comprising a ‘bioavailable’ portion which is either bound to lower affinity serum albumin proteins or 
unbound, the latter being only around 0.1% of total 25(OH)D (173). The free-hormone hypothesis 
states that only the unbound portion of a hormone is biologically active, and is maintained in dynamic 
equilibrium with the bound portion, which if true challenges the wisdom of taking total serum 
25(OH)D concentration as a measure of vitamin D status. Furthermore, it has been proposed that the 
portion of unbound 25(OH)D is of particular importance to vitamin D’s extra-renal actions as DBP 
carriage limits cell uptake and tissue-specific 1α-hydroxylation (174). DBP has also been found to form 
a dimer with macrophage activating factor (MAF), whereby DBP-MAF stimulates activation of 
macrophages with increased superoxide formation and enhanced phagocytic capacity, but this also 
drives up airway inflammation (175). Interestingly, Gc-2 genotype associates with decreased DBP-MAF 
dimerization (176), therefore DBP genotype may influence immune responses independent of vitamin 
D. Several observational studies have reported a significantly greater frequency of Gc-1f isoform in 
COPD diagnosis, suggesting high-affinity DBP genotype to be a risk factor for disease (177-180), though 
these associations were predominantly in Asian populations; a recently conducted meta-analysis of 
the 12 case-control studies which have investigated DBP genotype on the risk of COPD found there to 
43 
 
be no overall effect when controlling for ethnicity (181). Studies investigating DBP genotype in relation 
to asthma are much fewer, though one case-control study of a Chinese han cohort found Gc-2 
genotype to associate with increased risk of disease (182), and another found a mild association 
between rs7041 and total serum IgE concentration in Caucasians (131). Findings have also been 
reported in the context of other infection related conditions: Gc-2 carriage was 2-fold higher in 
rheumatoid fever patients than healthy controls in a study conducted in Kuwait (183), and 
homozygosity for Gc-2 was significantly higher in active tuberculosis patients than healthy controls in 
Brazilian Gujarati Asians, but not South African participants (184). 
 
1.3.3. Signalling. 
The vitamin D signalling pathway utilises the supply of vitamin D generated and maintained by 
metabolic and transport pathways. Signalling is mediated via the vitamin D receptor (VDR), a 427 
amino acid, 48.3 kDa nuclear phosphoprotein which binds 1α,25(OH)2D3 with high affinity. VDR is 
encoded by VDR gene (pathway G, figure 4) which spans 101.5 kbp on chromosome 12q13.11, and 
contains 11 exons. VDR-mediated control of gene expression is global: VDR is basally expressed in 
almost every cell type in the body; highly expressed in metabolic tissues such as the skin, kidneys, 
intestine and thyroid glands (185, 186), and there are an estimated 100-500 1α,25(OH)2D3 target genes 
per tissue type throughout the body (187). Over 600 polymorphisms in VDR have been identified (188), 
and owed to the gene’s two promoter regions and six untranslated exons (189) a large quantity of 
tissue-specific VDR transcripts are expressed. However 4 SNP, named after the restriction 
endonuclease used to identify them, have been suggested to give rise to 4 functionally distinct VDR 
isoforms, and have been the focus of research in a wide range of disease contexts: FokI is a non-
synonymous mutation (rs10735810/rs2228570, C[F]>T[f]) that alters the gene’s 5’ start codon position 
in exon 2, creating a VDR protein 3 amino acids longer in homozygotes for T allele, which has been 
proposed to alter VDR transactivation (190, 191). TaqI (rs731236, T>C) occurs at codon 352 of exon 9 
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and is a synonymous mutation; ApaI (rs7975232, A>C) and BsmI (rs1544410, A>G) are silent mutations 
which occur in intron 8. TaqI, ApaI and BsmI are in high LD with a poly(A) microsatellite length 
polymorphism located in the gene’s 3’ untranslated region (UTR) which has a variable number of 
tandem repeats (VNTR), resulting in alleles with long, or short poly(A) stretches (192). As the poly(A) 
length polymorphism occurs in a gene region which exerts a strong influence on mRNA half-life (193), 
and due to its high LD relationship with TaqI, ApaI and BsmI, it has not yet been established which loci, 
if any, has a functional effect. There have however been many studies which report findings that link 
VDR gene function with asthma and COPD: laboratory studies have shown that VDR wild-type mice 
can be induced to develop experimental allergic asthma, with characteristic airway 
hyperresponsiveness, high IgE levels, eosinophilia and heighted Th2 cytokine levels, however VDR-
knockout mice do not develop the condition despite showing elevated IgE and Th2 cytokine 
concentrations (194). A case-control study on a pediatric, bronchial asthmatic cohort in Egypt found 
higher IgE levels in atopic asthmatic children with the TT (ff) genotype for foci (𝜒2 9.9, P=0.007).They 
also report a lower frequency of CC (FF) genotype in asthmatic children vs. healthy controls (OR 0.23, 
95% CI: 0.07 – 0.78, P=0.02); and a lower still frequency in atopic asthmatic children vs. healthy 
controls (OR 0.11, 95% CI: 0.02 – 0.46, P=0.002) (195). Variation in IgE levels for fokI genotype were 
also found in a case-control study of young, African Americans in the U.S (P<0.001), as was variation 
in baseline spirometry values (P<0.05), and allergen skin test results (P=0.003) (130). A case-control 
study in adult, Chinese Hans report a higher frequency of ApaIC allele in asthmatic participants vs. 
healthy controls, suggesting this allele confers increased risk of asthma (OR 1.33, 95% CI: 1.10–1.60, 
P=0.009) (196). ApaI and BsmI mutations were found to associate with asthma incidence and atopy in 
a family-based cohort of French-Canadians in Quebec, where ApaI C allele was over-transmitted to 
offspring, again suggesting an increased risk of asthma (P<0.05) (197). A higher frequency of ApaI C 
allele in asthmatics, compared to healthy controls were also observed in a nested case-control study 
of participants from the Nurses’ Health Study (NHS), however this was a validation cohort or the 
family-based Childhood Asthma Management Program (CAMP) study which found under-transmission 
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of the ApaI C allele to offspring, suggesting C allele confers protection against asthma(198). 
Homozygosity for the rare allele of ApaI was found to associate with better asthma control test score 
(Global Initiative for Asthma guidelines [GINA], P=0.001) and lower daily activity limitation (P=0.004), 
in a cohort of Greek children (199). 
 
Currently, very little research has been conducted on VDR variants in the context of COPD. One group 
has investigated them in relation to quadriceps strength (a complication of the disease), and found 
homozygosity for the C allele of FokI to associate with lower quadriceps strength in both cases and 
controls, and the b allele for BsmI to associate with increased quadriceps strength in cases, compared 
to controls (200). Another group has investigated genotype for FokI, TaqI, and BsmI polymorphisms 
on the incidence of COPD exacerbations for patients classified as frequent vs. non-frequent 
exacerbators, and found no significant relationship (201), however VDR variants have been found to 
associate with acute respiratory infection and tuberculosis (TB): a 7-fold greater adjusted relative odds 
for ff genotype in FokI for children hospitalized for LRI (predominantly RSV bronchiolitis), compared 
to healthy controls has been reported (202), as has a 2-fold greater odds of ff genotype for FokI in 
spinal TB patients, compared to healthy controls in a Chinese Han cohort (203). Transmission of the 4 
common VDR polymorphisms was investigated in a large family-based case-control study of TB 
patients in Guinea, Gambia, and Guinea-Bissau. They found significant over-transmission of FA 
haplotype for FokI-ApaI in TB cases (𝜒2 11.6, P=0.0007), but individual VDR SNP did not associate with 
the risk of TB(204).A large number of case-control studies have investigated a link between TaqI and 
TB, with conflicting results: A recent meta-analysis of 21 studies, pooling 2,960 TB cases and 3,894 
healthy controls found no overall effect of TaqI polymorphismon risk of TB. However, In a randomized 
control trial of vitamin D supplementation as an adjunctive treatment for UK adults with smear-
positive pulmonary TB, tt genotype for TaqI was found to enhance the effect of vitamin D 




The effect of mutations on vitamin D signaling may not be limited to VDR. For optimal signaling, ligated 
VDR protein binds another receptor protein, the retinoid-X receptor (RXR), to form a heterodimer 
which causes the release of co-repressor proteins. This stimulates the recruitment of co-activator 
proteins (219) and improves receptor binding to a vitamin D response element (VDRE) within a gene’s 
promoter region, therefore affecting transcription (220). There are three known isoforms of RXR: α, 
β, and γ; RXR-α has been most extensively researched in relation to VDR. RXR-α is a 462 amino acid, 
50.8 kDa nuclear receptor protein encoded by the 123.5 kbp RXRA gene (pathway H on figure 4) 
located on chromosome 9q34.3. Very little research has been conducted on RXR genes in relation to 
vitamin D and health outcomes, but one study did identify a stepwise increase in circulating 
1α,25(OH)2D3 concentration for each A allele of rs9409929 in RXRA (P=0.003 for the trend), though 
this finding became non-significant after controlling for multiple comparison testing (206). Functional 
mutations of RXRA may be of particular importance in the immunopathology of asthma and COPD: 
RXR-α has been found to regulate the transcription of macrophage cytokines (CCL6 and CCL9) which 
stimulate leukocyte recruitment to sites of inflammation, consequently impacting the efficacy of 











In summary, ARI impose a heavy toll in the form of lost productivity costs due to school and work 
absenteeism, and healthcare related costs due to GP visits, hospitalisation, and over-the-
counter/prescription medications. But most importantly, ARI are responsible for a large loss of human 
life, which is seen in both developing and developed countries and especially in at-risk groups for ARI, 
such as the elderly and those with chronic respiratory diseases. People within these at-risk groups are 
more susceptible to ARI due to defects of the immune system which arise from age-related decline or 
disease related pathology and can compromise the immune system’s capacity to stage effective 
responses to respiratory pathogens. A large and ever-growing body of in vitro research suggests that 
vitamin D modulates immune responses by stimulating enhanced bactericidal, virucidal, and fungicidal 
properties within immune cells that are active during response to respiratory pathogens. To a large 
extent in vivo research has corroborated these findings by illustrating an observational association 
between vitamin D deficiency and increased risk of ARI, and protection against ARI from vitamin D 
supplementation has been demonstrated in some clinical trials. Other clinical trials have been null 
however, and in a few instances supplementation has increased the risk of ARI. The mixed results we 
have seen may be due to important methodological inconsistencies or currently uncontrolled-for 
effect modifiers. Currently, no clinical trial of vitamin D in the prevention of ARI has investigated the 
effect of variation in genes which encode proteins involved in vitamin D metabolism, transport, and 
signalling, and specifically in at-risk populations for ARI. Mutations within these genes may result in 
aberrant or under-/over-expressed proteins which are integral to vitamin D’s immunomodulatory 
effects. Thus, genetic variation has the potential to impact an individual’s normal vitamin D status; 
their response to vitamin D supplementation; their utilisation of available active vitamin D metabolite, 





1.5. Hypothesis and Objectives of the project. 
This PhD project centred around three clinical trials of vitamin D supplementation to prevent ARI in 
asthma patients, COPD patients, or healthy older adults. The hypothesis was that in these at-risk 
populations for ARI, genetic polymorphisms affecting pathways of vitamin D metabolism, 
transportation, or signalling would:  
 
A.) Associate with serum concentrations of 25-hydroxyvitamin D; 
B.) Associate with clinical markers of asthma and COPD phenotype; 
C.) Associate with risk of acute respiratory infection, or exacerbations of asthma or COPD, 
independent of vitamin D status; 
D.) Modify the effect of vitamin D supplementation in the prevention of ARI / exacerbations of asthma 
or COPD; If true will: 
i. Associate with pro-inflammatory mediators released during immune response to 
respiratory pathogens; 
ii. Associate with the level of expression of the gene in which the SNP arises. 
 
In order to test these hypotheses I addressed the following objectives: 
 
A.) To perform a systematic review of clinical studies which have investigated a link between vitamin 
D and the incidence/prevention of ARI, or exacerbations of asthma and COPD, then to follow this up 
with a meta-analysis of randomised controlled trials in order to determine the overall protective effect 




B.) To identify from existing literature, candidate single nucleotide polymorphisms in vitamin D 
metabolism, transport, and signalling pathways which may associate with vitamin D status; clinical 
markers of asthma/COPD phenotype; ARI; and modify the effect of vitamin D supplementation. 
 
C.) To extract DNA from whole blood samples then develop and perform assays to genotype 
participants for the candidate SNPs described above, and to assay concentrations of 25-
hydroxyvitamin D and immunological parameters in serum. 
 
D.) To conduct cross-sectional analyses in three separate clinical trial cohorts to determine the level 
of variation in baseline vitamin D status explained by environmental and genetic factors, and whether 
vitamin D status and/or genetic factors associate with clinical features of asthma/COPD. 
 
E.) To conduct statistical analyses to determine whether candidate SNP:  
i. Associate with risk of ARI, or exacerbations of asthma or COPD, independent of vitamin D status. 
ii. Modify the effect of vitamin D supplementation on risk of ARI, or exacerbations of asthma or COPD.  
iii. Associate with pro-inflammatory mediators released during immune response to respiratory 
pathogens.  






2.1. Systematic review of vitamin D and ARI studies. 
This section describes the search and selection method used in a systematic review I conducted of 
clinical studies which have investigated vitamin D in prevention of ARI, which is presented in chapter 
3. 
 
2.1.1. Search method. 
The PubMed database was searched on 17th October 2012 using the terms 'vitamin D' and 'respiratory 
infection'.  No restrictions were placed on language of publication or on the age, sex, ethnic origin, 
baseline vitamin D status or presence or absence of comorbidity in populations studied.  
 
Studies were classified into one of three categories: potentially eligible primary studies, relevant 
review articles and ineligible primary studies.  Full text of potentially eligible primary studies was 
reviewed to confirm eligibility according to criteria presented below.  Relevant review articles were 
retrieved and screened for additional primary studies.  All articles were assessed for eligibility by one 
author (DAJ) then re-assessed by a second (ARM). 
 
2.1.2. Exclusion/Inclusion Criteria. 





• Cross-sectional studies, case-control studies, cohort studies or clinical trials conducted in 
human subjects, and investigating the relationship between serum concentration of vitamin D 
metabolites or clinical manifestations of vitamin D deficiency, or effect of dietary intake or 
administration of vitamin D or its analogues, on risk of acute respiratory infection or acute 
exacerbation of asthma or Chronic Obstructive Pulmonary Disease (COPD).  
 
Exclusion criterion: 
• Studies relating exclusively to tuberculosis (these are reviewed elsewhere (208)), and were 
beyond the remit of this review as tuberculosis is classically regarded as a chronic respiratory tract 
infection, with symptom duration usually exceeding 30 days). 
 
 
2.2. Clinical trials. 
All analyses conducted in support of this thesis were on data which arose from three randomised, 
double-blind, placebo-controlled trials of vitamin D supplementation in prevention of ARI or disease 
exacerbations, in patients with asthma (ViDiAs trial (209)), COPD (ViDiCO trial (210)), or healthy older 
adults and their caregivers living in sheltered accommodation (ViDiFlu trial (209)). 
  
2.2.1. Participants.  
 
ViDiAs trial. 
Adult patients with a medical record diagnosis of asthma treated with inhaled corticosteroids (ICS) 
were identified by searching medical databases at 60 general practices and asthma clinics in 2 Acute 
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National Health Service Trusts in London, UK. From this search 297 prospective participants were 
invited for screening which took place between 27th August 2009 and 25th June 2012.  
 
Patients were deemed eligible if they: 
 were between 16 and 80 years of age; 
 had a medical diagnosis of asthma treated at BTS (British Thoracic Society) Step 2 (taking 
inhaled corticosteroids daily (211)) or above; 
 showed either a ≥12% increase in forced expiratory volume in one second (FEV1) after 
inhalation of 400μg of salbutamol, or a ≥20% diurnal variability peak in expiratory flow (PEFR), 
or methacholine PC20 (concentration of methacholine causing a 20% fall in FEV1) < 8g/L.  
In addition to this, patients agreed to the required visits, were contactable by telephone, were able to 
give written informed consent to participate and, if a woman of child-bearing potential, agreed to use 
a reliable form of contraception for the duration of the study. 
 
Patients were excluded if they: 
 had a diagnosis of COPD; 
 had known sarcoidosis, hyperparathyroidism, nephrolithiasis, active tuberculosis, vitamin D 
intolerance, liver failure, renal failure or any malignancy not in remission for at least 3 years; 
 were taking dietary supplements containing >10μg per day of vitamin D; 
 had a baseline corrected serum calcium >2.65mmol/L; 
 had a baseline serum creatinine > 125μmol/L; 
 had a smoking history > 15 pack years (calculated by the number of packs of cigarettes smoked 
per day divided by 20, and multiplied by the number of years the person has smoked for); 
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 were breastfeeding, pregnant or planning a pregnancy, undergoing treatment with any other 
IMP or device up to 4 months before randomisation onto this trial;  
 were taking a cardiac glycoside (e.g. Digoxin), carbamazepine, phenobarbital, phenytoin, 
primidone or benzothiadiazine derivatives at a dose higher than recommended in the British 
National Formulary (BNF) or in combination with a calcium supplement. 
 
Of the 297 screened respondents, 37 were ineligible to participate; 10 were eligible but declined, 
leaving 250 successfully recruited and randomised patients, who were given 6 x 2-monthly doses of 
6ml of active IMP (containing 3mg of Vitamin D3, equating to 120,000 IU) or placebo over the period 
of one year. The study was approved by East London and The City Research Ethics Committee 1 (ref 
09/H0703/67) and written informed consent was obtained from all participants before enrolment. 
 
ViDiCO trial. 
Adult patients with a medical record diagnosis of COPD, emphysema or chronic bronchitis were 
identified by database searches at 60 general practices and COPD clinics in 4 Acute National Health 
Service Trusts in London, UK. From this search 320 prospective participants agreed to attend screening 
which took place between 11th September 2009 and 12th April 2012.  
 
Patients were deemed eligible if they: 
 were over 40 years old; 
 had a medical diagnosis of COPD, emphysema or bronchitis; 
 had a post-bronchodilator ratio of forced expiratory volume in one second to forced vital 
capacity (FEV1/FVC) < 70%, or post-bronchodilator FEV1/slow VC < 70%; 
 had a smoking history ≥ 15 pack years;  
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In addition to this, patients agreed to the required visits, were contactable by telephone, were able to 
give written informed consent to participate and, if a woman of child-bearing potential, agreed to use 
a reliable form of contraception for the duration of the study.  
 
Patients were excluded if they: 
 had a current diagnosis of asthma;  
 had known clinically significant bronchiectasis, sarcoidosis, hyperparathyroidism, 
nephrolithiasis, active tuberculosis, vitamin D intolerance, liver failure, renal failure or any 
malignancy not in remission for at least 3 years; 
 were taking dietary supplements containing >10μg per day of vitamin D; 
 had a baseline corrected serum calcium >2.65mmol/L; 
 had a baseline serum creatinine > 125μmol/L;  
 required long-term oxygen therapy for ≥ 12 hours per day; 
 were breastfeeding, pregnant or planning a pregnancy; 
 were undergoing treatment with any other IMP or device up to 4 months before 
randomisation onto this trial;  
 were taking a cardiac glycoside (e.g. Digoxin), carbamazepine, phenobarbital, phenytoin, 
primidone or benzothiadiazine derivatives at a dose higher than recommended in the British 
National Formulary (BNF) or in combination with a calcium supplement. 
 
Of the 320 screened respondents, 240 patients were successfully recruited and randomised to receive 
6 x 2-monthly doses of 6ml of active IMP (containing 3mg of Vitamin D3, equating to 120,000 IU) or 
placebo over a period of one year. The study was approved by East London and The City Research 
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Ethics Committee 1 (ref 09/H0703/67) and written informed consent was obtained from all 
participants before enrolment. 
 
ViDiFlu trial. 
Units, defined as sheltered accommodation schemes, residential care homes, nursing homes, day 
centres or groups for older adults, in the Greater London area were identified by searching an online 
directory (www.housingcare.org). Units offering care exclusively for residents with dementia, learning 
disability, mental health problems, and alcohol/drug dependency were deemed ineligible. The 
housing associations of eligible units were approached for permission to conduct the trial on their 
premises. Invitation letters were sent to the residents and carers of the identified units, inviting them 
to attend a screening visit. Participants were screened between 29th March 2010 to 16th March 2012 
and deemed eligible if they: 
 were a permanent resident, attendee, staff member or carer at a participating unit; 
 were aged 16 or over. 
 
In addition to this, patients agreed to the required visits, were able to give written informed consent 
to participate and, if a woman of child-bearing potential, agreed to use a reliable form of contraception 
for the duration of the study. 
 
Patients were excluded if they: 
 had a current diagnosis of asthma or COPD; 
 had a chronic respiratory infection or chronic cough; 
 had any condition requiring treatment with a vitamin D dose of > 10μg per day; 
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 had known sarcoidosis, hyperparathyroidism, nephrolithiasis, active tuberculosis, vitamin D 
intolerance, liver failure, renal failure or any malignancy not in remission other than cutaneous 
basal/squamous cell carcinoma; 
 were taking dietary supplements containing >10μg per day of vitamin D; 
 had a baseline corrected serum calcium >2.65mmol/L; 
 had a baseline serum creatinine > 125μmol/L;  
 were unable to complete the symptom diary;  
 were breastfeeding, pregnant or planning a pregnancy; 
 were undergoing treatment with any other IMP or device up to 4 months before 
randomisation onto this trial; 
 were taking a cardiac glycoside (e.g. Digoxin), carbamazepine, phenobarbital, phenytoin, 
primidone, long-term immunosuppressant therapy, or benzothiadiazine derivatives at a dose 
higher than recommended in the British National Formulary (BNF) or in combination with a 
calcium supplement. 
Two hundred and forty successfully recruited and randomised participants had various dosing 
regimens depending on their status as resident or staff/carer (Table 2.1), as it was deemed unethical 
to withhold vitamin D supplementation in individuals aged ≥ 65 with limited sunlight exposure. As 
such, staff and carers were randomised to receive 6 x 2-monthly doses of 6ml of active IMP (containing 
3mg of Vitamin D3, denoted PR1) or placebo over the period of one year (denoted PL1), while 
residents were randomised to receive low-dose vitamin D supplementation (a daily dose of 20μl of 
active IMP for 1 year, denoted PR3, as well as 6 x 2-monthly doses of 4.8ml of placebo, denoted PL2) 
or high-dose vitamin D supplementation (a daily dose of 20μl of active IMP for 1 year, denoted PR3, 
as well as 6 x 2-monthly doses of 4.8ml active IMP containing 2.4mg of Vitamin D3, denoted PR2), thus 
allowing a comparison between high-dose vitamin D3 and placebo in staff and carers, and between 
high-dose vitamin D3 and low-dose vitamin D3 in residents and attendees. The study was approved 
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by East London and The City Research Ethics Committee 1 (ref 09/H0703/112) and written informed 
consent was obtained from all participants before enrolment. 
 
Table 2.1: ViDiFlu trial dosing regimens. 




Total vitamin D3 dose in 1 
year 





PR3 + PL2 10 micrograms 
daily 
 




PR2 + PR3 10 micrograms 
daily + 6 bolus 
doses of 2.4 
milligams 
18.05 milligrams 50 micrograms 
Staff member 
and carer, control 
arm 




PR1 6 bolus doses of 3 
milligrams 
18 milligrams 50 micrograms 
 
* PR1, PR2 and PR3 are Vigantol ® regimens 
** PL1 and PL2 are Miglyol ® regimens 
………………………………………………………………………………………………………………………………………………………………………………………………………………………… 





2.2.2. Screening Procedures. 
All respondents underwent height measurement (using a Seca 220 Telescopic Measuring Rod, Seca, 
Hamburg, Germany), and weight measurement (using Marsden MMPS-250 column scales, Marsden, 
Rotherham, UK), and were asked to complete a lifestyle questionnaire detailing age, sex, ethnicity, 
self-reported Fitzpatrick skin-type (212), self-classified socio-economic position (SEP) using the NS-SEC 
method (213), daily hours spent outdoors, history of recent sunny holidays abroad (defined as a trip 
to any location within a latitude 51o North/South of the equator, during the local sunny season, 2 
months prior to blood draw, for a duration of ≥1 week), smoking behaviour and consumption of 
alcohol and supplemental vitamin D. Additionally, for ViDiFlu respondents, researchers recorded the 
extent of hair loss on the head (Norwood-Hamilton (214) scale for males; Ludwig scale (215) for 
females), if any, and skin melanin density measured using a DSM II Colormeter (Cortex Technology, 
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Hadsund, Denmark). ViDiAs and ViDiCO respondents underwent lung function tests: spirometry 
before and after inhalation of 400 μg salbutamol via a spacer device, performed using a MicroLab 
ML3500 desktop spirometer (CareFusion GmbH, Hoechberg, Germany) according to American 
Thoracic Society (ATS) / European Respiratory Society (ERS) recommendations (216), and ViDiAs 
respondents also completed the asthma control test (ACT) questionnaire (217), and underwent FeNO 
measurement, performed using a NIOX MINO 09-1100 (Aerocrine, Solna, Sweden) according to ATS / 
ERS recommendations (218).  
 
All trial respondents were requested to donate a blood sample for subsequent DNA extraction and 
determination of serum concentration of total 25[OH]D and parathyroid hormone (PTH). A sub-set of 
35 ViDiAs, and 44 ViDiCO respondents underwent sputum induction with hypertonic saline, and their 
samples were processed to make cytospin slides according to methods described by Pizzichini et al 
(219) and detailed in Methods section 2.3.3.  
 
2.2.3. Definition of respiratory outcomes. 
Successfully screened participants were given a 2 week run-in period to assess their ability/compliance 
in completing a daily study diary (Figure 2.1 shows a spread from the ViDiAs symptom diary as an 
example) to capture signs and symptoms of URI (sneezing, sore throat, headache, subjective sensation 
of fever or chilliness, malaise, nasal discharge, nasal obstruction, cough), as defined by the Jackson 
criteria (220); daily severity of asthma/COPD symptoms; daily peak flow readings in the case of ViDiAs 
trial participants; muscle pain score; use of medication; health care use; work absence; finally, out-of-





Figure 2.1. Example of the daily diary used to capture URI symptoms and related measures. 
 
 
Upper respiratory infections. 
Using the captured daily symptom diary scores, URI were defined as influenza-like illness (indicated 
by presence of cough, fever or chills, and muscle pains) (221), or a cold as defined by the Jackson 
criteria (220). This method of defining URI has been previously validated by our group using PCR 
detection of 11 respiratory viruses obtained by nasopharyngeal swabs (222). 
 
Lower respiratory infections. 
Daily symptom diary scores were also used to define LRI events in the ViDiFlu trial, according to the 
Macfarlane criteria, as follows: the five Macfarlane symptoms (cough, sputum production, dyspnoea, 
wheeze, and chest pain/discomfort) were scored 0-3 by their severity. Presence of cough and at least 
one other symptom with a score of 1 or more points greater than during the run-in period were used 




Exacerbations of Asthma & COPD. 
Disease exacerbations, rather than LRI, were defined from symptom diary data in the ViDiAs and 
ViDiCO trials, using an algorithm based on the following: for the ViDiAs trial an exacerbation was 
defined as deterioration in asthma resulting in a) treatment with oral corticosteroids, or b) hospital 
admission or emergency department treatment, or c) decrease in the morning PEFR to more than 25% 
below the mean run-in value on 2 or more consecutive days (224). For the ViDiCO trial an exacerbation 
was defined as a) the occurrence of ≥ 2 major COPD symptoms, or b) the occurrence of 1 major COPD 
symptom and ≥ 1 minor COPD symptom during ≥ 2 consecutive days. Major symptoms were defined 
as increase in dyspnoea, sputum volume or sputum purulence as compared with their usual 
symptoms; minor symptoms were defined as increase in nasal congestion or discharge, wheeze, sore 
throat, or cough (225).  
 
2.2.4. Investigational medicinal product (IMP). 
The IMP administered in all three trials was Vigantol® Oil (Merck Serono, Darmstadt, Germany) – an 
oily solution containing 0.5mg cholecalciferol (vitamin D3) per millilitre. The placebo was Miglyol® 812 
oil (Caesar and Loretz, Hilden, Germany) – an organoleptically identical mixture of palm oil and 
coconut oil widely used in pharmaceutical practice. Miglyol® 812 oil is the excipient for cholecalciferol 
in Vigantol® Oil, and is thus identical to Vigantol® Oil in every respect except for the absence of 
cholecalciferol. Nova Laboratories Ltd (Wigston, UK) produced a computer-generated randomisation 
sequence and bottled study medication, and treatment allocation was concealed from trial 






2.3.  Laboratory analyses. 
 
2.3.1. Biochemistry analysis. 
All biochemical analyses for the 3 clinical trials were carried out in the Department of Clinical 
Biochemistry at Homerton Hospital. This laboratory participates in the international vitamin D external 
quality assurance scheme (www.deqas.org/). Serum concentrations of 25(OH)D2 and 25(OH)D3 were 
determined by isotope-dilution liquid chromatography–tandem mass spectrometry (226), and 
summed to give total serum 25(OH)D concentration. Parathyroid hormone (PTH) concentrations were 
determined using an Architect ci8200 analyser (Abbott Diagnostics, Chicago, IL, USA). 
 
2.3.2. Genotyping. 
I selected a panel of 37 single nucleotide polymorphisms and contributed to the genotyping of 
participants in our three clinical trials, under the supervision of Dr Mimi Hot of Queen Mary 
University’s Genome Centre. 
 
Literature search. 
A  literature search of the PubMed database was carried out in April of 2012 (figure 2.2), using a 
combination of the following terms: ‘Vitamin D polymorphism’; ‘Vitamin D SNP’; ‘DHCR7’; ‘CYP2R1’; 
‘CYP3A4’; ‘CYP27A1’; ‘DBP’; ‘LRP2’; ‘Megalin’; ‘CUBN’; ‘Cubilin’; ‘CYP27B1’; ‘CYP24A1’; ‘VDR’; ‘RXR’. 
This search identified 56 single nucleotide polymorphisms (SNP) in 11 vitamin D pathway genes 
previously reported to associate with circulating concentrations of vitamin D metabolites and/or any 




Figure 2.2: A flow diagram depicting the SNP literature search and selection process. 
 
 
                   
 
 
Tag SNP selection. 
Twenty-four of the 54 SNP were in high linkage disequilibrium (r2 ≥ 0.8) in the HapMap database 
(release #27: Phase 1, 2 & 3 - merged genotypes & frequencies), thus for these variants, six tag SNP 
(tSNP) were selected as proxies: this was achieved by retrieving SNP location and allele frequency 
information ±10 kilo-bases upstream and downstream of all genes, from the Utah residents with 
Northern and Western European ancestry from the CEPH collection (CEU) which were chosen to 
represent the majority ethnicity of our clinical trial participants. I then ran a tagging algorithm 
developed by de Bakker et al (227) via Bioinformatics’ Haploview program (v.3.3) (228), selecting the 
‘pairwise tagging only’ option; setting the r2 threshold to > 0.8; accepting a minimum genotype 
completeness of 75%; and a MAF threshold of 0.04. Tagging reduced the number of alleles to be 
genotyped from 54 to 37 SNP, which are listed in Table 2.2. 
3,828 hits from PubMed search using a combination of terms: 
‘Vitamin D polymorphism’; ‘Vitamin D SNP’; ‘DHCR7’; 
‘CYP2R1’; ‘CYP3A4’; ‘CYP27A1’; ‘DBP’; ‘LRP2’; ‘Megalin’; 
‘CUBN’; ‘Cubilin’; ‘CYP27B1’; ‘CYP24A1’; ‘VDR’; ‘RXRA’ 
3,767 irrelevant manuscripts 
rejected primarily for 
investigating skeletal health 
outcomes or absence of SNP 
associations   
54 SNP included in our panel 
All reported to show biological significance as indicated by association:  
• with 25-hydroxyvitamin D, or 1,25-dihydroxyvitamin D concentrations   
• with any non-skeletal disease outcome 
  
2 SNP rejected for Minor 
Allele Frequency  <0.04 
  
56 SNP reported in 61 
relevant manuscripts 




Table 2.2: Single nucleotide polymorphisms (SNPs) identified as putative modifiers of the effects of 




Target SNP Tag SNP 1 R2 
CYP24A1  rs2762934 - - 
rs6127118 - - 
rs2248137 - - 
rs6013897 - - 
rs2762939 - - 
CYP27B1  rs4646536 - - 
rs10877012 rs4646536 1.00 
rs703842 rs4646536 1.00 
rs4646537 - - 
CYP2R1  rs2060793 - - 
rs10741657 rs2060793 1.00 
rs1993116 rs2060793 1.00 
rs7116978 rs2060793 0.92 
rs10500804 - - 
rs12794714 rs10500804 1.00 
rs10766197 - - 
CYP3A4  rs2740574 - - 
CYP27A1  rs17470271 - - 
VDR  rs1544410 - - 
rs731236 - - 
rs4516035 - - 
rs4334089 - - 
rs10783219 - - 
rs7976091 - - 
rs11574010 - - 
rs2853559 - - 
rs2238136 - - 
rs7975232 - - 
rs2228570 - - 
rs7970314 - - 
rs11568820 - - 
DBP  rs4588 - - 
rs2282679 rs4588 1.00 
rs3755967 rs4588 1.00 
rs17467825 rs4588 1.00 
rs1155563 rs4588 0.83 
rs2298850 rs4588 0.95 
rs7041 - - 
rs222035 rs7041 0.92 
rs842999 rs7041 0.96 
rs2298849 - - 
rs16846876 - - 
rs12512631 - - 
rs2070741 - - 
DHCR7  rs12785878 - - 
rs4944957 rs12785878 1.00 
rs4945008 rs12785878 0.95 
rs3794060 rs12785878 1.00 
rs7944926 rs12785878 1.00 
rs12800438 rs12785878 1.00 





Target SNP Tag SNP 1 R2 
CUBN  rs3740165 - - 
RXRA  rs9409929 - - 
rs7861779 - - 
LRP2  rs3755166 - - 
 
[1] Six tag SNP were selected to capture 18 SNP, due to a linkage disequilibrium r2 value of >0.8. 
………………………………………………………………………………………………………………………………………………………………………………………………………………………… 
Abbreviations: SNP: Single nucleotide polymorphism, CYP-: Cytochrome P450-, VDR: Vitamin D receptor, DBP: Vitamin D binding protein, 








Custom assay design. 
Pre-developed assays were available for 34/37 SNP. For the remaining 3 SNP, their FASTA sequences 
were retrieved from the National Centre for Biotechnology Information’s (NCBI) online dbSNP 
database (www.ncbi.nlm.nih.gov/SNP/) and entered into the Institute for Systems Biology’s online 
Repeat Masker (www.repeatmasker.org) programme, which screens the sequence for repeating bases 
that may harm the assay’s accuracy and masks them. The masked sequence was then used in Applied 
Biosystems’ File Builder application (v3.1) to generate custom assay primer and reporter sequences: 
rs2740574 in CYP3A4 (forward primer sequence CCAGGCATAGGTAAAGATCTGTAGGT, reverse primer 
sequence CTCAAGTGGAGCCATTGGCATA, reporter sequences ACAAGGGCAAGAGAG and 
ACAAGGGCAGGAGAG), rs3740165 in CUBN (forward primer sequence 
GCAATGAGATTAAATCTTCAGGAAACACA, reverse primer sequence CTGGAGGTATAGGAAGCAG-
TGAAG, reporter sequences CCGCCATATGGCCTG and CGCCATACGGCCTG) and rs7861779 in RXRA 
(forward primer sequence TGGCCCATGCACGAGTAG, reverse primer sequence 




DNA was extracted in Queen Mary University’s Genome Centre, using a modified version of Miller et 
al’s salting-out protocol (229) on a Biomek FX robot (Beckman Coulter): 400 uL whole blood was 
Table 2.2 continued. 
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pipetted into each well of a 2.4ml Elkay plate. 1600 uL water was added to each well and pipetted up 
and down five times to mix. The plate was then incubated on ice for 2 minutes then centrifuged at 
3000 rpm for 10 minutes at 4oC. After centrifugation supernatant was aspirated, then 1600 uL of 
solution 1 (for 500ml solution: 320ml of 0.5M sucrose; 5ml of 1M tris-CL pH 7.6; 2.5ml of 1M MgCl2; 
5ml of 2% sodium azide; 5ml of 100% triton X-100; 162.5ml of water) was added to each well and 
pipetted up and down 5 times to mix. The plate was then incubated on ice for 2 minutes then 
centrifuged at 3000 rpm for 10 minutes at 4oC. 1600 uL of supernatant was then aspirated and 1600 
uL of solution 1 was added to each well again. Another 2 minutes of incubation on ice and a further 
round of centrifugation at 3000 rpm, for 10 minutes at 4oC was then carried out. 1800 uL of 
supernatant was then removed from each well and discarded, then 1100 uL of solution 2 (for 500ml 
solution: 25ml of 1M tris-Cl pH 8; 40ml of 0.25M EDTA pH 8; 100ml of 10% SDS; 335ml of water) was 
added to each well, followed by 5.5 uL 20mg/ml proteinase K. The plate was then incubated overnight 
at 37oC. After overnight incubation, 400 uL of saturated NaCl was added to each well and carefully 
pipetted up and down 5 times to mix. The plate was then centrifuged at 3100 rpm for 30 minutes at 
4oC. 1 ml of supernatant from each well was then transferred to a new 2.4ml Elkay plate, and 1 ml of 
70% ethanol was added to each well. The plate was then incubated overnight at -20oC. After overnight 
incubation the plate was centrifuge cooled to 4oC – 3100 rpm, for 10 minutes. The supernatant was 
then tipped off and 1.5 ml of ice cold 70% ethanol added to each well. A final round of centrifugation 
at 3100 rpm, for 10 minutes at 4oC was carried out, and the supernatant tipped off again. The plate 
was then left to dry at room temperature for 2 hours, then 50 uL of 1x TE buffer was added to each 
well in order to re-suspend the DNA. Finally, the plate was left at room temperature overnight. 
Extracted DNA was then quantified using the Nanodrop spectrophotometer and normalised to 5ng/μl. 






Pre-developed assays were used to type 34/37 SNP; custom assays were designed for the remaining 
3 SNP. Genotyping was carried out using Applied Biosystem’s TaqMan SNP genotyping assays: 10ng of 
DNA was used as template for 2 μl assays (Applied Biosystems, Foster City, CA, USA) performed on the 
ABI 7900HT platform in 384-well format and analysed with Autocaller software. Typing for two SNP 
failed (rs6127118, CYP24A1 and rs11574010, VDR); the call rate for the remaining 35 SNP were >95%. 
Successfully genotyped SNP were tested for deviation from Hardy-Weinberg equilibrium (HWE), 
stratified by ethnicity, the results of which are presented in Table 2.3. After correction for multiple 
comparison testing using the Benjamini & Hochberg method with a 5% false discovery rate (230), all 














Table 2.3. Pearson’s Chi-squared test results for Hardy-Weinberg equilibrium in n=835 genotyped SNP. 
 








  𝜒2 P 
value 






CUBN rs3740165 0.30 0.58 0.07 0.79 0.17 0.68 0.16 0.69 
CYP24A1 rs2762939 0.34 0.56 0.35 0.55 0.13 0.72 0.13 0.72 
 rs2248137 0.20 0.65 2.44 0.12 0.19 0.66 0.02 0.90 
 rs2762934 0.53 0.47 0.01 0.91 1.47 0.23 0.62 0.43 
 rs6013897 1.14 0.29 0.14 0.71 0.09 0.77 0.78 0.38 
CYP27A1 rs17470271 0.00 0.97 0.03 0.87 0.09 0.76 1.61 0.21 
CYP27B1 rs4646537 0.91 0.34 0.01 0.93 0.24 0.63 0.30 0.58 
 rs4646536 0.07 0.79 0.01 0.92 0.19 0.66 4.50 0.03 
CYP2R1 rs10500804 0.02 0.89 3.11 0.08 0.25 0.62 0.52 0.47 
 rs2060793 0.03 0.87 0.30 0.58 0.42 0.52 0.13 0.72 
 rs10766197 0.82 0.37 1.62 0.20 0.11 0.74 0.38 0.54 
CYP3A4 rs2740574 0.00 0.98 0.18 0.67 0.11 0.74 1.05 0.31 
DBP rs7041 0.63 0.43 3.29 0.07 0.36 0.55 1.89 0.17 
 rs4588 0.97 0.32 0.28 0.60 1.11 0.29 0.72 0.40 
 rs12512631 0.22 0.64 0.01 0.94 0.25 0.62 0.00 1.00 
 rs2070741 1.66 0.20 1.09 0.30 1.27 0.26 6.84 0.01 
 rs2298849 0.33 0.57 1.12 0.29 3.08 0.08 0.00 1.00 
 rs16846876 3.88 0.05 1.42 0.23 0.36 0.55 1.13 0.29 
DHCR7 rs3829251 0.16 0.69 2.81 0.09 0.60 0.44 0.62 0.43 
 rs12785878 1.04 0.31 0.53 0.47 3.44 0.06 4.25 0.04 
LRP2 rs3755166 0.00 0.98 1.40 0.24 0.00 0.99 0.00 1.00 
RXRA rs7861779 0.04 0.85 0.53 0.47 0.76 0.38 6.38 0.01 
 rs9409929 0.84 0.36 0.16 0.69 0.86 0.35 0.00 1.00 
VDR rs4334089 3.93 0.05 0.00 1.00 1.68 0.19 0.28 0.60 
 rs10783219 0.13 0.72 2.04 0.15 3.11 0.08 0.57 0.45 
 rs4516035 0.52 0.47 0.28 0.59 0.06 0.81 0.78 0.38 
 rs11568820 2.82 0.09 1.73 0.19 4.98 0.03 0.00 0.95 
 rs7976091 2.32 0.13 1.86 0.17 4.62 0.03 0.22 0.64 
 rs2238136 1.15 0.28 0.28 0.60 0.60 0.44 0.72 0.40 
 rs1544410 0.44 0.51 0.84 0.36 0.10 0.75 5.16 0.02 
 rs2228570 0.39 0.53 4.07 0.04 0.02 0.88 0.00 1.00 
 rs2853559 0.18 0.67 0.22 0.64 0.84 0.36 1.47 0.23 
 rs7975232 0.03 0.87 0.00 0.96 0.05 0.82 2.21 0.14 
 rs7970314 1.58 0.21 0.91 0.34 6.96 0.01 0.46 0.50 
 rs731236 0.07 0.80 0.10 0.75 2.69 0.10 0.57 0.45 
 
[1] After correction for multiple comparisons testing, using Benjamini & Hochberg method with a false discovery rate of 5%, none of the p 
values for interaction remain significant. [2] Ethnicity undefined in n=4. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 
Abbreviations: SNP: Single nucleotide polymorphism, 𝜒2: Chi-squared, CYP-: Cytochrome P450 enzyme, DBP: Vitamin D binding protein, 
DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also known as megalin), RXRA: Retanoid-X 




2.3.3. Immunological analysis. 
Under the supervision of Dr. Claire Greiller (Blizard Institute, Queen Mary University of London) I 
assisted in the following immunological work. 
 
Preparation of TLR ligands. 
TLR ligands (InvivoGen, San Diego, USA) were dissolved according to product inserts to provide stock 
solutions, before being further diluted using Dulbecco’s phosphate buffered saline (D-PBS) (Sigma-
Aldrich, St Louis, USA) to produce the required working concentration (Table 2.4). Sterile 96-well 
polystyrene microplates (Corning Incorporated, Corning, USA) were prepared by adding 20μl of D-PBS 
or TLR ligand to the appropriate wells, before being stored at -80oC until use. 
 
Table 2.4. Preparation of TLR ligands used to stimulate cytokine release in whole blood samples. 
 




LPS  1 ml sterile water  5 mg/ml  1 μg/ml  0.1 μg/ml  
Pam2CSK4  1 ml endotoxin free water  100 μg/ml  0.1 μg/ml  0.01 μg/ml  
Poly I:C  2.5 ml endotoxin free water  10 mg/ml  1 mg/ml  100 μg/ml  
R848  500 μl endotoxin free water  1 mg/ml  10 μg/ml  1 μg/ml  
 






Whole blood collected from study participants was stimulated with TLR ligands and pathogens. 180μl 
of blood was incubated with 20μl of stimulant or D-PBS in a humidified incubator at 37oC and 5% CO2 
for 24 hours. Following this, plasma was aspirated and stored at -80oC until further analysis by 
multiplex ELISA. A panel of 30 inflammatory mediators were investigated (IL-1β, IL-2, IL-4, IL-5, Il-6, IL-
7, IL-8 [CXCL8], IL-10, IL-12, IL-13, IL-15, IL-17, IL-1RA, IL-2R, IFN-α, IFN-γ, TNF-α, MCP-1 [CCL2], MIP-
1α [CCL3], MIP-1β [CCL4], RANTES [CCL5], eotaxin [CCL11], MIG [CXCL9], IP-10 [CXCL10], EGF, FGF-
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basic, HGF, VEGF, G-CSF, GM-CSF). The Invitrogen Human Cytokine Magnetic 30-plex Panel was used 
(Invitrogen, Camarillo, CA, USA), following manufacturer’s instructions. 25μl of the antibody bead 
solution was added to each well of a 96-well plate, before washing two times with 200μl wash solution 
and the addition of 50μl of incubation buffer. Standards were prepared using a serial 1:2 dilution, with 
100μl standard or 50μl assay diluents + 50μl sample added to the appropriate wells. Following a 2 
hour incubation at room temperature on an orbital shaker, the plate was washed twice with 200μl 
wash solution, and 100μl of 1x biotinylated detector antibody was added to each well. After a 1 hour 
incubation at room temperature on an orbital shaker, the plate was washed twice with 200μl wash 
solution, 100μl of 1x streptavidin-RPE was added to each well, and the plate was incubated for a 
further 30 minutes. Three washes with 200μl wash solution were carried out, before 125μl wash 
solution was added to each well to re-suspend the beads. Plates were analysed using the Magpix ® 
platform (powered by Luminex xmap Technology) and the Luminex xponent ® software. 
 
 
2.3.4. Gene expression analysis. 
Under the supervision of Dr. Jennifer Roe (Division of Infection & Immunity, University College London) 
I quantified the relative level of vitamin D receptor gene expression by reverse transcription-
quantitative polymerase chain reaction (RT-qPCR), in a subset of n=55 participants from the ViDiCO 
trial for whom RNA tempus tube blood samples were available, and an association between genotype 
and the effects of vitamin D supplementation on risk of URI was observed. 
 
RNA extraction. 
RNA was extracted from blood tempus tubes following Applied Biosystems’ Tempus™ Blood RNA Tube 
and Tempus™ Spin RNA Isolation Kit protocol (workflow described in Figure 2.3), in batches of 12 
samples per run. The following description is for one sample: 3 mL of whole blood was decanted into 
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a 50 mL tube, into which 6 mL of stabilising solution and 3 mL of PBS was pipetted. The tube was then 
vortexed for 30 seconds to mix the contents, and centrifuged for 30 minutes (4oC; 3,000 rpm) to 
separate the RNA. The supernatant was then discarded to leave an RNA pellet and the tube was left 
inverted on absorbent paper for 2 minutes. 400 µL of RNA purification resuspension solution was then 
added to the tube after which it was capped and vortexed again to re-suspend the RNA pellet. The 
tube was then kept on ice whilst performing the following steps: an RNA purification filter was added 
to a 2 mL Eppendorf tube into which 100 µL of wash solution 1 was pipetted in order to pre-wet the 
filtration membrane. Roughly 400 uL of the re-suspended RNA was then pipetted into the purification 
filter and it was then centrifuged for 30 seconds (16,000 x g). After this the filter was removed, the 
waste was discarded and the filter was then re-inserted. 500 µL of wash solution 1 was then pipetted 
into the purification filter, the tube was centrifuging for 30 seconds (16,000 x g), then the purification 
filter was removed and the waste was discarded. This cycle was repeated a further 2 times, but using 
wash solution 2, then the empty Eppendorf tube was centrifuged for 30 seconds (16,000 x g) to dry 
the filtration membrane, after which the membrane was transferred to a new 2 mL Eppendorf tube. 
100 µL nucleic acid purification elution solution was pipetted into the membrane, and the tube was 
incubated for 2 minutes at 70oC, followed by another centrifuge for 30 seconds (16,000 x g). The filter 
was then removed and the eluate pipetted back through the membrane again. Following this, the 
Eppendorf tube was centrifuged one final time for 2 minutes (16,000 x g), after which the purification 
filter was discarded and the remaining ~90 uL of eluate was transferred to a new, labelled Eppendorf 








Figure 2.3: The simplified RNA extraction workflow, taken from Applied Biosystem’s Tempus™ Blood 






To remove trace DNA from extracted RNA samples I then used Applied Biosytems’ Turbo DNA-free™ 
kit (revised protocol, 4/2009): Turbo DNase buffer equivalent to 10% RNA sample volume (9 uL) was 
pipetted into the sample tube and gently mixed, then incubated for 25 minutes at 37oC. DNAse 
inactivation reagent equivalent to 10% volume of total sample volume (10 uL) was then pipetted into 
the sample, mixed, then incubated for 5 minutes at room temperature, occasionally mixing 
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In order to quantify RNA concentration and purity, 1 uL of sample was tested on a Nanodrop 
spectrophotometer. The average sample concentration was 121.2 ng/uL, and the average absorbance 
at 260:280 nm wavelength was 1.8, for n=55 samples. 
 
cDNA synthesis. 
RNA was reverse transcribed to cDNA using Quanta Biosciences’ qScriptTM cDNA Synthesis Kit. A cDNA 
master mix of sufficient volume to run PCR on samples in duplicate for quantification of the target 
gene and a housekeeping gene (Glyceraldehyde-3-Phosphate Dehydrogenase [GAPDH]) was prepared. 
The per sample reagent volumes were: 5 uL nuclease-free water, 2 uL qScript reaction mix, and 0.5 uL 
qScript RT (reverse transcriptase and ribonuclease inhibitor protein), for a total volume of 7.5 uL per 
sample. 7.5 uL of the cDNA master mix was then pipetted into individual 0.2 mL PCR tubes, then 2.5 
uL of RNA sample was added and the tubes were then vortexed gently, centrifuged for 10 seconds 
(16,000 x g), and placed in a thermal cycler and ran with the following programme parameters: 1 cycle 
of 5 minutes at 22oC, 1 cycle of 30 minutes at 42oC, 1 cycle of 5 minutes at 85oC, hold at 4oC. 
 
qPCR. 
Comparative qPCR was conducted using Applied Biosystems’ TaqMan® Gene Expression Assay for the 
vitamin D receptor gene (Cat. # 4331182), and GAPDH as a housekeeping gene. Each participant 
sample was run in duplicate for both target and control gene. The experiment was conducted in 96 
well plates, which allowed 20 participants to be analysed per run. Two master mixes (one for target 
gene, one for control gene) were prepared with the following per sample volumes: 5 uL ABI TaqMan 
MasterMix, 2.4 uL Primer Mix, 0.4 uL Probe, 1.2 uL Nuclease-free water, for a total volume of 9 uL per 
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well.  9 uL of the appropriate master mix was then pipetted into the appropriate well, to which 1 uL 
of cDNA sample was added. The plate was then sealed and lightly centrifuged for 10 seconds to mix 




















2.4.  Statistical analyses. 
All analyses were conducted by myself, using STATA (version 12.0, 2011), GraphPad Prism (version 
5.03, 2009), and RevMan (version 5.3, 2014). Data were checked for normality by visual inspection of 
histogram and q-q plots. Normally distributed data were presented as means with a standard 
deviation (SD), whilst non-normally distributed data were presented as medians with an interquartile 
range (IQR). Univariate tests were performed for all analyses: Unpaired Student’s T tests (2 groups) or 
one-way ANOVA tests (≥3 groups) were performed on normally distributed dependent variables and 
Mann-Whitney (2 groups) or Kruskal-Wallis tests (≥3 groups) were performed on non-normally 
distributed dependent variables in order to identify significantly associated environmental correlates 
of serum 25(OH)D concentration; clinical correlates of asthma and COPD phenotype; and 
environmental correlates of ARI and exacerbations of asthma and COPD (p <0.05). All dependent 
variables were continuous; non-normally distributed dependent variables were transformed to their 
natural logarithms. All independent variables were classified as categorical variables with median, 
quartile, or biologically relevant thresholds where converted from continuous data and fitted in 
multivariable models, providing they had a minimum of 5 participants per subcategory. For genetics 
analyses, SNP were analysed under an additive model and multiple comparison testing was also 
applied using the Benjamini & Hochberg method with a false discovery rate (FDR) of 5% (230). 
 
2.4.1. Cross-sectional analyses.  
Cross-sectional analyses of environmental and genetic determinants of serum 25(OH)D concentration 
and the clinical correlates of asthma/COPD phenotype were conducted on all respondents who 
attended a screening visit for participation in one of our three clinical trials and completed baseline 
screening questionnaires; underwent anthropometric and clinical measurements; and consented to 




Multivariable linear regression models were used to give adjusted coefficients, along with a 95% 
confidence interval and P value for pairwise association in variables with 2 categories, or a P value for 
trend in variables with ≥3 categories. In the case of log-transformed dependent variables, the anti-log 
of the adjusted regression coefficient is presented. Genetic analyses were adjusted for all significant 
environmental determinants of serum 25(OH)D concentration that were investigated.  
 
2.4.2. Main effects analyses. 
Analyses were performed to investigate the main effects of SNP genotype on risk of ARI and 
exacerbations of asthma/COPD, independent of vitamin D supplementation. These analyses were by 
intention to treat in all participants who took at least one dose of study medication and consented to 
donate a blood sample for quantification of serum 25(OH)D concentration and for genotyping. 
 
Cox regression was performed to give pairwise unadjusted and adjusted hazard ratios, along with a 
95% confidence interval for time to first respiratory outcome. These were presented for minor 
homozygous and heterozygous genotypes, referent to the major homozygous genotype. For adjusted 
estimates, Cox regression models were corrected for trial stratification and minimisation factors; 
significant environmental predictors of respiratory outcomes; and study allocation. Adjusted and 
unadjusted P values for trend were also presented. 
 
2.4.3. Interaction analyses. 
Analyses were performed to investigate a possible interaction between: i.) Genotype and study 
allocation, to see if SNP genotype modifies the effect of vitamin D supplementation on risk of 
respiratory outcomes. ii.) Between haplotypes and study allocation (where significant SNP in high 
linkage disequilibrium survive correction for multiple comparisons testing), to see if SNP haplotype 
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modifies the effect of vitamin D supplementation on risk on respiratory outcomes with a greater level 
of significance than individual alleles do. iii.) Between significant effect-modifying haplotypes and the 
concentration of inflammatory mediators released in response to stimulation by toll-like receptor 
ligands, to see if SNP haplotype modifies the effect of vitamin D supplementation on release of 
inflammatory mediators. 
 
For analyses i & ii, Cox regression analysis was performed to give hazard ratios along with a 95% 
confidence interval for the effect of allocation on time to first respiratory outcome within each SNP 
genotype/haplotype, and a single hazard ratio with a 95% confidence interval and P value for 
interaction between allocation and SNP genotype/haplotype. These were corrected for trial 
stratification and minimisation factors and for significant environmental predictors of respiratory 
outcomes. For analysis iii, multiple linear regression analysis was performed. As the dependent 
variables (inflammatory mediator concentrations) were non-normally distributed the exponentiated 
β-coefficient of the interaction term are presented which represents the geometric mean ratio (GMR) 
of the effect of allocation, for individuals negative or positive for the investigated haplotype. Also 
presented are P values for interaction between allocation and SNP haplotype i.e. the ratio of 
geometric mean ratios. 
 
2.4.4. Meta-analysis. 
Aggregate data meta-analysis of relevant clinical trials of vitamin D supplementation for prevention of 
ARI were conducted using a random effects model to account for study heterogeneity. There was no 
distinction made between upper or lower respiratory tract infections, but selection of trials to enter 
the meta-analysis was restricted to those which published the proportion of participants who 
experienced 1 or more ARI events by study arm, and who captured ARI data prospectively and 
analysed them as their primary outcome. Estimates of the meta-analysis were presented by odds ratio 
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3. Vitamin D in the prevention of acute respiratory infections: 
Systematic review of clinical studies. 
 
Before conducting an investigation on the impact genetic variants in the vitamin D pathway impose 
on vitamin D’s ability to prevent ARI, it was prudent to first review the large body of clinical studies 
which have investigated a direct link between either vitamin D status and risk or ARI, or vitamin D 
supplementation in the prevention of ARI. This chapter comprises a systematic review and meta-
analysis of clinical studies, which I conducted during the first year of my PhD project and was 


















Elucidation of the immunomodulatory actions of vitamin D in vitro has prompted the conduct of 
numerous observational and interventional studies investigating the influence of in vivo vitamin D 
status on susceptibility to a wide range of non-skeletal diseases. Many of these investigations have 
been distilled by systematic review and meta-analysis, and cover: Cancers (232); Multiple sclerosis 
(233); Alzheimer’s disease (234); Cardiac diseases (235, 236); Diabetes (237); Depression (238); and 
Tuberculosis (239). Previous in vitro work suggests vitamin D may also be an effective intervention for 
ARI. The 1-alpha hydroxylase enzyme, CYP27B1, that catalyses 25[OH]D to 1,25(OH)2D has been found 
to be expressed locally in extra-renal tissues, including leucocytes and pulmonary epithelium, and its 
expression is induced by both viral and bacterial ligands (113, 116). Thus, 1,25(OH)2D can be 
synthesised in the lung in response to pulmonary infection when 25(OH)D substrate is available (i.e. 
in vitamin D replete individuals). VDR is widely expressed in cells of the immune system and the 
respiratory tract, and 1,25(OH)2D ligates it to induce broad-spectrum antimicrobial responses that are 
effective against both viral and bacterial respiratory pathogens (240, 241). At the time of writing this 
review, in early 2012, a wealth of observational studies investigating an association between vitamin 
D deficiency and risk of ARI had been conducted, and so had a respectable number of clinical studies 
which administered vitamin D dosing regimens of ranging sizes and frequency for the prevention of 
ARI. A synthesis of these studies had not been previously undertaken however, therefore this chapter 
presents the first systematic review and meta-analysis of clinical studies, conducted up until 











3.2.1. Identification and Selection of Studies. 
Figure 1 depicts the study selection process. Our initial search identified 391 publications, of which 31 
were initially identified as fulfilling eligibility criteria listed in methods, section 2.1.2. A further 8 
eligible primary manuscripts were identified from the 39 relevant reviews identified in the initial 
search, bringing the total number of eligible studies for inclusion in this systematic review to 39. 
 
 















3.2.2. Study Characteristics. 
Of the 39 studies reviewed, 25 were observational studies (4 cross-sectional, 8 case-control and 13 
cohort) and 14 were intervention studies (all randomised controlled trials). The selected studies report 
data from a total of 47,360 participants whose age ranged from newly born to >80 years old.  Studies 
were conducted in USA (7 studies), UK (4), Canada (3), Japan (3), Afghanistan (2), Finland (2), India (2), 
New Zealand (2), Bangladesh, Belgium, Ethiopia, Germany, Jordan, Mongolia, the Netherlands, 
Norway, Poland, Puerto Rico, Romania, Saudi Arabia, Spain and Turkey (1 study each). Thirty-one 
studies reported serum 25(OH)D concentrations, one study reported serum 1,25(OH)2D 
concentrations, and seven studies did not report concentrations of either metabolite. 
 
3.2.3. Study Findings. 
Table 3.1 presents results of the four cross-sectional studies reviewed: all report consistent 
associations between low serum 25(OH)D concentrations and increased risk of ARI (242-245).  
 
Results of the eight case-control studies reviewed are presented in Table 3.2: five of these studies 
report associations between susceptibility to ARI and vitamin D deficiency, as evidenced by the 
presence of rickets (246, 247) or by low serum 25(OH)D concentrations (248-250); one reports an 
association between low vitamin D intake and increased risk of LRI (251), and two report no association 
between serum 25(OH)D concentration and susceptibility to LRI (252, 253).  
 
Table 3.3 presents results of the thirteen cohort studies reviewed: seven report associations between 
low serum 25(OH)D concentrations and susceptibility to ARI (254-260), two suggest that serum 
1,25(OH)2D concentrations may be protective (as evidenced by higher serum 1,25(OH)2D 
concentrations (261) or by administration of 1-alpha-hydroxylated vitamin D metabolites (262)), three 
studies were null (201, 263, 264), and one reported a positive association between high maternal 
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Table 3.1. Cross-sectional studies investigating association between vitamin D status and susceptibility 











age 38 years 
Median 29.0 ng/ml  
3.6% <10 ng/ml  
65.1% 10 – 29 ng/ml 
31.3% ≥30 ng/ml  
 
• Serum 25(OH)D concentration was inversely 
associated with risk of self-reported recent URI 
symptoms (OR 1.36, 95% CI 1.01 to 1.84, for 
participants with 25(OH)D < 10 ng/ml vs. those with 
25(OH)D ≥ 30 ng/ml). 
• Inverse associations between serum 25(OH)D 
concentration and risk of URI were stronger in 






median age 1.6 years 
Mean 27.2 ng/ml Serum 25(OH)D concentration was inversely 
associated with risk of RSV infection (OR per 4 
ng/ml increase, 0.91; 95% CI 0.83 to 0.99), 
rhinovirus (OR per 4 ng/ml increase, 0.92; 95% CI 
0.85 to 0.99) and multiple viral cause (OR per 4 




participants aged 45 
years  
Mean 29.0 ng/ml 
7.7% <10 ng/ml 
69.8% 10-29 ng/ml 
22.6% ≥30 ng/ml 
Serum 25(OH)D was inversely associated with risk 
of acute respiratory infection (after adjustment for 
adiposity, lifestyle and socio-economic factors, each 
4 ng/ml  increase in 25(OH)D  associated with a 7% 
lower risk of self-reported ARI; 95% CI, 3% to 11%; P 




287 children with 
asthma aged 6-14 
years  
Mean 32.0 ng/ml 
44% < 30 ng/ml 
56% ≥ 30 ng/ml 
Serum 25(OH)D concentration < 30 ng/ml 
associated with higher odds of ≥1 severe asthma 
exacerbation in the prior year in multivariate 
analysis (OR 2.6, 95% CI 1.5 to 4.9, P=0.001) 
 
Abbreviations: 25(OH)D: 25-hydroxyvitamin D, URI: Upper respiratory tract infection, OR: odds ratio, CI: Confidence interval, RSV: 
Respiratory syncytial virus, ARI: Acute respiratory infection, COPD: Chronic obstructive pulmonary disease, ng/ml: nanograms per millilitre. 











Table 3.2. Case-control studies investigating association between vitamin D status and susceptibility to 
ARI and/or exacerbations of asthma, or COPD.  
 
First author, Year, 
Setting 





1000 children, mean age 13 
months: 500 rickets cases vs. 
500 healthy controls. 
Not measured Diagnosis of rickets associated with 
susceptibility to pneumonia (adjusted OR 
13·37; 95% CI, 8·08 to 24·22; P<0·001).  
Najada, 2004. 
Jordan (247) 
443 acutely hospitalised 
children aged 3-24 months: 
47 cases vs. 396 controls 
without rickets. 
Not measured Diagnosis of rickets associated with risk of 
LRI (85% of children with rickets had LRI vs. 
30% of children without rickets, P<0.01) 
Wayse, 2004.            
India (248) 
150 children, mean age 23.9 
months: 80 cases with LRI 







• Serum 25(OH)D concentration was 
significantly lower in cases vs. controls 
(P<0.001).                                                                                                                 
• Serum 25(OH)D concentration > 9.0 ng/ml 
associated with decreased risk of LRI 




40 neonates: 25 cases 
admitted to neonatal 








• Mean serum 25(OH)D concentration was 
significantly lower in cases with LRI vs. 
healthy controls (P=0.01). 
• Serum 25(OH)D < 10 ng/ml associated 
with increased risk of LRI (OR 4.25; 95% CI, 
1.06 to 17.07; P=0.04 ) 
Roth, 2009. 
Canada (252) 
129 children, mean age 13 
months: 64 cases 
hospitalised with 








• No significant difference in mean serum 
25(OH)D concentration between LRI cases 
vs. controls (P=0.96).                                                                                     
• Inadequate vitamin D status was not 
associated with the risk of LRI at either 16 




197 children, mean age 14 
months: 105 cases 
hospitalised with LRI vs. 92 
controls attending hospital 








• No significant difference in mean serum 
25(OH)D concentration between cases vs. 
controls (P=0.71).                                                                                                         
• Among cases, serum 25(OH)D < 20 ng/ml 
associated with increased risk of admission 
to the intensive care unit (adjusted OR 8.23, 
95% CI, 1.4 to 48.0, P=0.02) 
Roth, 2010.   
Bangladesh 
(250) 
50 children aged 1-18 
months: 25 cases 








• Mean serum 25(OH)D concentration was 
significantly lower in LRI cases vs. healthy 
controls (p=0.015). 
• Adjusted odds for LRI was reduced 4.3-
fold for every 4 ng/ml increase in serum 
25(OH)D concentration (adjusted OR 0.23; 
95% CI, 0.06 to 0.81; P=0.02). 
Leis, 2012. 
Canada (251) 
197 children aged <5 years: 
105 cases hospitalised with 
LRI vs. 92 controls attending 
hospital with other 
diagnosis. 
Not presented Vitamin D intake <80 IU/kg/day associated 
with increased risk of LRI (adjusted OR 4.9, 
95%CI 1.5-16.4, P=0.01). 
 
Abbreviations: 25(OH)D: 25-hydroxyvitamin D, OR: Odds ratio, CI: Confidence interval, LRI: Lower respiratory tract infection, ng/ml: 
nanograms per millilitre, IU: International units, Kg: kilograms. 25(OH)D concentrations converted from nanomoles per litre (nmol/L) to ng/ml 






Table 3.3. Cohort studies investigating association between vitamin D status and susceptibility to ARI 















6 months Mean, 32.1 ng/ml; 
3.6% < 16 ng/ml 
Subjects with 25(OH)D <16 ng/ml had 
more days of absence from duty due to 
respiratory infection than those with 
25(OH)D ≥16 ng/ml (incidence rate ratio 
1.63; 95% CI, 1.15 to 2.24, P=0.004). 





(mean age not 
reported) and 
466 infants. 
9 months Mean maternal 
25(OH)D at late 
pregnancy, 20 
ng/ml; 21.2% <11 
ng/ml; 28.3% 11-20 
ng/ml; 50.4% >20 
ng/ml 
• Maternal serum 25(OH)D 
concentration in the top quartile (>30 
ng/ml) vs. bottom quartile (<12 ng/ml) 
associated with increased risk of 
pneumonia or bronchiolitis in offspring 
(OR 4.80, 95% CI 1.01-22.72). 
• ‘Overall’ maternal serum 25(OH)D 
concentration did not associate with risk 
of ARI in offspring (OR not presented). 
Asamura, 2010. 
Japan (261) 
Retrospective  32 nursing 
home 
residents, 
mean age 80.9 
years. 
2 years Not presented  • Serum 1,25(OH)2D concentration 
inversely associated with risk of febrile 
respiratory illness (64% in those with 
1,25(OH)2D <42 pg/ml vs. 22% in those 
with 1,25(OH)2D ≥42 pg/ml, P=0.03).                                                                                                               
• Serum 1,25(OH)2D concentration did 
not significantly associate with risk of 
pneumonia (21% in those with 
1,25(OH)2D <42 pg/ml vs. 6% in those 
with 1,25(OH)2D ≥42 pg/ml, P=0.30). 
Sabetta, 2010.  
USA (255) 
Prospective  198 healthy 
adults aged 20-
88 years. 
4 months Mean, 28.4 ng/ml; 
90.9% <38 ng/ml; 
9.1% ≥38 ng/ml                                               
• Serum 25(OH)D concentration 
inversely associated with risk of viral 
ARTI (45% in those with 25(OH)D <38 
ng/ml vs. 17% in those with serum 
25(OH)D ≥38 ng/ml, P=0.01). 
• Serum 25(OH)D concentration did not 
associate with median illness duration (6 
days in those with serum 25(OH)D <38 
ng/ml vs. 6 days in those with serum 
25(OH)D ≥38 ng/ml (P value not 
presented).                                                                                                
Brehm, 2010. 
USA (260) 




median age 8.9 
years 
4 years 35% ≤ 30 ng/ml; 
65% > 30 ng/ml 
Serum 25(OH)D concentration ≤ 30 
ng/ml associated with higher 
odds of any hospitalization or 
emergency department visit (OR 1.5; 






922 neonates  5 years Cord blood 
concentrations: 
Median, 17.6 ng/ml; 
19.5% <10 ng/ml; 
53.3% 10-29 ng/ml; 
27.2% ≥30 ng/ml 
• Serum 25(OH)D concentration 
inversely associated with risk of ARI by 3 
months of age (OR 1.0 for ≥30 ng/ml, 
1.39 for 10-30 ng/ml, 2.16 for 25(OH)D < 
10 ng/ml, P for trend 0.004). 
• Cord-blood 25(OH)D levels inversely 
associated with risk of wheezing by 15 





Retrospective  508 
haemodialysis 
patients, mean 
age 59.6 yrs. 
212 took 
alfacalcidol or 
5 years Not presented  Administration of alfacalcidol or calcitriol 
was associated with reduced risk of 
hospitalisation with LRI (adjusted hazard 


















156 neonates 1 year Mean, 32.9 ng/ml; 
23.1% <20 ng/ml; 
30.8% 20-29 ng/ml; 
46.1% ≥30 ng/ml 
Serum 25(OH)D concentration at birth  
inversely associated with risk of RSV LRI 
over 1st year of life (adjusted relative 
risk 6.2, 95% CI 1.6 to 24.9, P=0.01 for 
neonates with 25(OH)D <20 ng/ml vs. 
25(OH)D≥ 30 ng/ml). 
Porojnicu 2012.  
Romania (263) 
Prospective  105 healthy 
hospital 
employees, 
mean age 35.3 
years. 
2 months 35% <12 ng/ml; 
45% 12-19 ng/ml; 
17% 20-32 ng/ml; 
3% ≥32 ng/ml 
Serum 25(OH)D concentration did not 
significantly associate with self-reported 
cases of ARI (Spearman coefficient for 
correlation between 25(OH)D 
concentration and number of infectious 





1,724 infants 6 years Median maternal 
25(OH)D at 12 
weeks’ gestation, 
29.5 ng/ml 
Maternal serum 25(OH)D concentration 
at 12 weeks’ gestation inversely 
associated with risk of LRI in offspring at 
1 year (OR 0.67, 95% CI 0.50 to 0.90, 
P=0.02 for highest vs. lowest quartile of 
maternal 25(OH)D).  
Kunisaki, 2012. 
USA (264) 
Prospective 973 COPD 
patients 
1 year Mean, 25.7 ng/ml; 
8.4% < 10 ng/ml; 
23.6% 10-19 ng/ml; 
33.1% 20-29 ng/ml; 
34.9% ≥ 30 ng/ml 
Serum 25(OH)D concentration did not 
associate with time to first acute 
exacerbation of COPD (hazard ratio for a 
10 ng/ml increment in 25(OH)D,  
1.04, 95% CI 0.97 to 1.12) 
Mohamed, 
2012.          
Saudi Arabia 
(259) 
Prospective 206 infants 2 years Mean cord blood 
concentration,  
24.1 ng/ml; 12%<12 
ng/ml; 
18% 12-19 ng/ml; 
26% 20-29 ng/ml; 
44% ≥30 ng/ml 
• Mean cord blood 25(OH)D 
concentration was lower among infants 
who developed LRI in the first 2 years of 
life vs. those who did not (13.6 ng/ml vs. 
28.6 ng/ml, P<0.0001) 
• In multivariate analysis, low cord blood 
25(OH)D concentration independently 
associated with subsequent risk of LRI 
(OR 1.08; 95% CI 1.05 to 1.10; P<0.001) 
Quint, 2012.    
UK (201) 
Prospective 97 COPD 
patients 
12 months Median (IQR), 
Summer: 16.5 ng/ml 
(10.7 to 26.0 ng/ml); 
Winter: 11.1 ng/ml 
(7.8 to 17.8 ng/ml) 
Serum 25(OH)D concentration did not 
associate with risk of COPD exacerbation 
during summer or winter (median serum 
25[OH]D concentration for frequent vs. 
infrequent exacerbators in summer: 17.7 
ng/ml vs. 15.8 ng/ml; winter: 10.0 ng/ml 
vs. 10.9 ng/ml, respectively; P≥0.21). 
 
Abbreviations: 25(OH)D: 25-hydroxyvitamin D, 1,25(OH)2D: 1,25-dihydroxyvitamin D, OR: Odds ratio; CI: Confidence interval, RTI: Respiratory 
tract infection, LRI: Lower respiratory tract infection, RSV: Respirartory syncytical virus, ARI: Acute respiratory infection, COPD: Chronic 
obstructive pulmonary disease, IQR: Interquartile range, ng/ml: nanograms per millilitre. 25(OH)D concentrations converted from nmol/L to 












Results of the fourteen clinical trials reviewed are presented in Table 3.4: ARI was primary outcome in 
eleven of these studies, and a secondary outcome in three. Seven trials reported that vitamin D 
supplementation protected against ARI – six in the study population as a whole (266-271), and one in 
a sub-group with profound vitamin D deficiency (272). Six trials reported null effects for all respiratory 
outcomes investigated (273-278), and one reported a null effect of vitamin D supplementation on 
primary outcome (pneumonia incidence), with a negative effect on one secondary outcome (vitamin 




Table 3.4. Clinical trials investigating effects of vitamin D supplementation on incidence of ARI and/or exacerbations of asthma, or COPD. 
 
First author, Year, 
Setting 
Participants Duration of 
follow-up 
Dose of vitamin D3, 
intervention arm 
Mean serum 25(OH)D concentration Main findings 
Aloia, 2007. USA 
(266) 
 
208 healthy post-menopausal 
African-American women 
aged 50–75 years; 104 
allocated to intervention, 104 
to placebo. 
3 years 800 IU/day for 2 yrs, 
then 2000 IU/day for 
1 year 
Intervention: 
Baseline, 19.3 ng/ml; 
3 months, 28.4  ng/ml; 27 
months; 34.8  ng/ml 
Placebo:                                 
Baseline, 17.2  ng/ml; 
Follow-up: “no significant 
change throughout the 
study” 
Allocation to intervention arm decreased rate of self-reported URI 
symptoms (8% intervention arm vs. 25% placebo arm, P<0.002). 
Avenell, 2007.                       
UK (273) 
 
3,444 adults aged ≥ 70 years; 
1740 allocated to receive 
vitamin D3 +/- calcium, 1704 
receiving placebo +/-calcium. 
2 years 800 IU/day, 1000mg 
calcium/day, 800 




Baseline, 15.2  ng/ml         
(subset of n=60 
intervention members); 12 
months, 24.8 ng/ml  (same 
subset) 
Placebo:                                 
Not Presented 
Allocation to intervention arm did not affect incidence of self-reported 
infections (OR 0.90; 95% CI, 0.76 to 1.07; P=0.23) or antibiotic use (OR 
0.84; 95% CI, 0.64 to 1.09; P=0.18).                                                                                                             
Li-Ng, 2009. USA 
(274) 
162 healthy adults, mean age 
59 years; 84 allocated to 
intervention, 78 allocated to 
placebo. 
3 months 2,000 IU/day Intervention: 
Baseline, 25.8  ng/ml;   
3 months, 35.5 ng/ml 
Placebo:                                 
Baseline, 25.2 ng/ml;   
3 months, 24.4  ng/ml 
Allocation to intervention arm did not affect rate of self-reported URI 
(12% intervention vs. 14% placebo arm, P=0.56), URI duration (mean 
duration 5.4 days in intervention arm vs. 5.3 days in placebo arm, 
P=0.86) or URI severity (mean severity score 2.6 in intervention arm vs. 




173 patients with recent hip 
fracture, mean age 84 years; 
86 allocated to higher dose 
vitamin D3, 87 allocated to 
lower dose vitamin D3. 
1 year 2,000 IU/day vs.  
800 IU/day 
Intervention: 
Baseline, 13.1  ng/ml;                 
6 months, 45.4  ng/ml; 12 
months, 44.7  ng/ml 
Placebo:                                 
Baseline, 12.1  ng/ml;                     
6 months, 37.7  ng/ml; 
12 months, 35.4  ng/ml 
• Allocation to higher dose vitamin D3 decreased the risk of hospital 
readmission due to infection at any site (1% in higher dose group vs. 
11% in lower dose group; adjusted relative rate difference -90, 95% CI -
99 to -13). 
• Allocation to higher dose vitamin D did not influence risk of hospital 
readmission due to LRI (0% in higher dose group vs. 2% in lower dose 
group, P=0.16). 
Urashima 2010.           
Japan (268) 
 
334 school children, aged 6-15 
years; 167 allocated to 
intervention, 167 allocated to 
placebo. 
4 months  1,200 IU/day Not Presented • Allocation to intervention arm significantly reduced risk of influenza A 
infection (10.8% intervention arm vs. 18.6% placebo arm; RR: 0.58; 95% 




164 military conscripts, aged 
18-28 years; 80 allocated to 
intervention, 84 allocated to 
placebo.  
6 months 400 IU/day  Intervention:                  
Baseline, 31.5 ng/ml;                       
6 months, 28.7 ng/ml 
Placebo:                                 
Baseline, 29.8 ng/ml;                          
6 months, 20.6 ng/ml 
• Allocation to intervention arm did not affect the mean number of 
days absent from duty due to ARI (2.2 in intervention arm vs. 3.0 in 
placebo arm, P=0.10), or the rate of common cold symptoms (56% 
intervention arm vs. 52% placebo arm). 
• Proportion of participants ‘remaining healthy’ was higher in 






453 children diagnosed with 
pneumonia, aged 1-36 
months; 224 allocated to 
intervention, 229 allocated to 
placebo. 
3 months Single bolus dose of 
100,000 IU 
Not Presented • Allocation to intervention arm reduced the risk of repeat LRI episode 
within 90 days of randomisation (RR 0.78; 95% CI, 0.64 to 0.94; P=0.01). 
• Allocation to intervention arm did not affect the mean number of 
days to recovery (4.7 days in intervention arm vs. 5.0 days in placebo 




First author, Year, 
Setting 
Participants Duration of 
follow-up 
Dose of vitamin D3, 
intervention arm 




2,079 low birthweight infants 
born at >37 weeks’ gestation; 
1,039 allocated to 
intervention, 1,040 allocated 
to placebo. 
6 months 1,400 IU/week Intervention: 
Baseline, Not Presented; 
6 months, 22.0 ng/ml 
Placebo: 
Baseline, Not Presented; 
6 months, 14.4 ng/ml 
Allocation to intervention arm did not affect incidence of pneumonia or 
incidence of all-cause hospital admission or death (adjusted rate ratio 
0.98, 95% CI 0.70 to 1.38, P=0.92). 
Majak, 2011. 
Poland (270) 
48 children with budesonide-
treated asthma aged 5-18 
years; 24 allocated to 
intervention, 24 allocated to 
placebo. 
6 months 500 IU/day Intervention:                  
Baseline, 36.1 ng/ml;                   
6 months, 37.6 ng/ml   
Placebo:                               
Baseline, 35.1 ng/ml;                      
6 months, 31.9 ng/ml   
Allocation to the intervention arm significantly decreased the risk of 





182 patients with moderate 
to severe COPD, mean age 68 
years; 91 allocated to 
intervention, 91 allocated to 
placebo. 
1 year Monthly bolus dose 
of 100,000 IU 
Intervention: 
Baseline, 20.1 ng/ml; 
12 months, 52.0 ng/ml    
Placebo: 
Baseline, 19.8 ng/ml; 
12 months, 20.4  ng/ml 
• Allocation to intervention arm did not influence time to first 
exacerbation (HR 1.10; 95% CI, 0.82 to 1.56, P=0.41)                                                                                                                
• Subgroup analysis of participants with baseline 25(OH)D  <10 ng/ml (n 
= 30) showed reduced annual exacerbation rate in the intervention arm 





3,046 children diagnosed with 
pneumonia, aged 1-11 
months; 1,524 allocated to 
intervention, 1522 allocated 
to placebo. 
18 months 3-monthly bolus dose 
of 100,000 IU 
Intervention: 
Baseline, Not Presented; 
1 week, 51.9 ng/ml; 
1.5 months, 30.6 ng/ml; 
3 months, 22.2 ng/ml; 
6.5 months, 42.0 ng/ml; 
22 months, 20.8 ng/ml 
Placebo:                               
Baseline, Not Presented; 
1 week, 17.2 ng/ml; 
1.5 months, 13.2 ng/ml; 
3 months, 15.9 ng/ml; 
6.5 months, 21.2 ng/ml; 
22 months, 20.1 ng/ml 
Allocation to intervention arm did not affect the incidence of first or 
only pneumonia (incidence rate ratio 1.06, 95% CI 0.89 to 1.27, P=0.48), 
but did increase incidence of repeat episodes of radiographically –





569 participants of 10 
different clinical trials, median 
age 63 years; 289 allocated to 
intervention, 280 allocated to 
placebo. 
6 months 1111-6800 IU/day Not Presented Allocation to intervention arms did not influence risk of influenza-like 




247 schoolchildren, mean age 
10 years; 141 allocated to 
intervention, 103 to placebo. 
7 weeks  300 IU/day Intervention: (median) 
Baseline, 7 ng/ml; 
7 weeks, 18.9 ng/ml 
 
Placebo: (median) 
Baseline, 6.8 ng/ml;    
7 weeks, 7.2 ng/ml  
Allocation to intervention arm vs. placebo arm halved the rate of 
maternally reported ARI (adjusted RR: 0.50, 95% CI 0.28 to 0.88). 




322 healthy adults, mean age 
47 years; 161 allocated to 
intervention, 161 allocated to 
placebo. 
18 months Bolus dose of 
200,000 IU in months 
1 and 2, bolus dose 
of 100,000  IU/month 
thereafter. 
Intervention: 
Baseline, 29 ng/ml; 
18 months, ~50 ng/ml 
Placebo: 
Baseline, 28 ng/ml; 
18 months, ~22 ng/ml 
Allocation to intervention arm had no effect on the number of URI (RR: 




Abbreviations: URI: Upper respiratory tract infection, LRI: Lower respiratory tract infection, ARI: Acute Respiratory Infection, HR: Hazard ratio, RR: Risk ratio, COPD: Chronic obstructive pulmonary disease, IU: 
International units, CI: confidence interval, ng/ml: nanograms per millilitre. 25(OH)D concentrations converted from nanomoles per litre (nmol/L) to ng/ml by dividing by 2.496.




3.2.4. Aggregate data meta-analysis of clinical trials. 
Results from aggregate data meta-analysis are presented in Figure 3.2. This was confined to seven 
clinical trials which present data on the proportion of participants experiencing one or more ARI 
events which were prospectively captured as the primary outcome. It therefore excludes studies 
which only present data on total number of ARI events (276, 277); investigated ARI as a secondary 
outcome (267), or by post-hoc analysis (266, 273); investigated COPD/asthma exacerbations as their 
primary outcome (272, 280). The summarised estimate for the seven eligible studies indicate that 
vitamin D supplementation significantly reduces the risk of ARI (OR 0.72; 95% CI 0.53 to 0.99; P=0.04). 
Despite only including the most comparable studies, a high degree of study heterogeneity was 
observed (I2 = 68%), which justifies the use of a random effect model. 
 















This systematic review has identified broadly consistent evidence of an association between 
inadequate vitamin D status and susceptibility to ARI in observational studies conducted in large 
numbers of participants of all ages in diverse geographical settings and with a wide distribution of 
serum 25(OH)D concentrations. Evidence from intervention studies is more conflicting, with seven 
of the trials reviewed reporting protective effects of vitamin D supplementation, six reporting null 
effects, and one reporting an adverse effect of vitamin D supplementation on risk of pneumonia 
recurrence. Two interpretations of this ‘disconnect’ in the evidence from observational vs. 
intervention studies may be made. Associations seen in observational studies may be attributed to 
confounding, and inconsistent results from trials may be interpreted as providing insufficient 
evidence of effectiveness of vitamin D supplementation in preventing ARI. Alternatively, it may be 
argued that associations reported in observational studies are indeed causal, and that negative 
results in some trials have arisen as a result of high baseline vitamin D status in trial participants 
and/or ineffective vitamin D supplementation regimens employed in these studies. A consideration 
of the strengths and limitations of the studies that we have reviewed therefore follows. 
 
3.3.1. Observational Studies: Strengths and Limitations. 
Many of the observational studies reviewed here were of good quality, and potential confounders of 
the relationship between vitamin D deficiency and susceptibility to ARI such as age, sex, season, 
socioeconomic position and smoking were controlled for in the majority. Cohort studies were well 
represented, allowing confirmation that vitamin D deficiency precedes the onset of ARI, and does not 
arise as a consequence of infection, as seen with other micronutrients (281). Most studies reported 
participants’ serum 25(OH)D concentrations, the gold standard measurement of vitamin D status; 
however, two studies classified participants as vitamin D deficient on the basis of a clinical diagnosis 




(282)), and one reported serum concentrations of 1,25(OH)2D (261) (which are not generally 
considered to reflect vitamin D status (283)). Although some studies complemented symptom-based 
case definitions with physician, radiological, serological and/or molecular diagnosis, many utilised 
symptom-based definitions, which are more subjective and which cannot inform the question of 
whether protective effects of vitamin D are pathogen-specific, as suggested by some studies (243, 
268). It should also be noted that some of the outcomes classified as ARI for the purposes of this 
review, such as exacerbations of asthma and COPD, do not always have an infectious aetiology.  
 
3.3.2. Intervention Studies: Strengths and Limitations. 
All of the clinical trials reviewed here were randomised, double-blind and placebo-controlled: this 
‘gold standard’ study design effectively eliminates the potential for confounding and observer bias to 
explain any positive findings. However, some important limitations should be noted. First, some trials 
investigated effects of vitamin D supplementation on ARI as a secondary outcome (267), or in post 
hoc analyses (266, 273). Where these analyses were not pre-specified in the protocol, false positive 
results may have arisen as a result of type 1 error, and false negative results may have arisen as a 
result of type 2 error or as a result of inadequate ascertainment of ARI. In the post hoc analysis 
conducted by Aloia et al (266), for example, the number of URI reported is significantly lower than 
would be expected for a study population followed over 3 years. 
 
A second limitation relates to the dosing regimens used in some trials: in some cases, these were 
inadequate to induce prolonged, clinically significant elevations in serum 25(OH)D concentrations 
among participants in the intervention arm (275, 276). In others, the duration of administration and 
follow-up was inadequate to allow prolonged vitamin D repletion among participants in the 
intervention arm (274). A further potential issue concerns the practice of administration of large 
intermittent bolus doses of vitamin D. This results in a steep and rapid increase in circulating 25(OH)D 




peaks and troughs could have potentially deleterious effects on the immune response: 
concentrations of 25(OH)D >56 ng/ml have been associated with impaired immunity to infection 
(285), possibly reflecting the fact that vitamin D may suppress adaptive responses to infection as well 
as boost innate responses (286). Moreover, chronic exposure to falling 25(OH)D concentrations has 
been postulated to cause an imbalance between the activity of enzymes which synthesise and 
catabolise 1,25(OH)2D in extra-renal tissues, resulting in reduced concentrations of this active 
metabolite at sites of disease (287). Either or both of these phenomena could have contributed to 
the excess of recurrent pneumonia observed in the intervention arm of the second trial conducted 
by Manaseki-Holland et al (279).  Administration of lower doses of vitamin D at more frequent 
intervals induces sustained elevation of 25(OH)D concentrations into the physiological range, and this 
might have more favourable effects on immune function (288). However, if immune defects 
associated with vitamin D deficiency are mediated via effects on DNA methylation or histone 
modification, they may not be rapidly reversible by correction of deficiency. 
 
A third limitation relates to the baseline vitamin D status of trial participants: in some cases the 
minority of participants were deficient (274, 275, 278), while in others (268, 269) baseline vitamin D 
status was not measured, precluding identification of potentially important sub-group effects. 
Recently, Lehouck et al reported that protective effects of vitamin D supplementation on COPD 
exacerbation were restricted to participants with baseline 25(OH)D <10 ng/ml (272), suggesting that 
effects of vitamin D supplementation may be dependent on baseline vitamin D status, and that the 
25(OH)D threshold for protection against ARI may be low. Clinical studies conducted in patients with 
tuberculosis suggest that the influence of vitamin D status on antimicrobial immunity may be 
modified by genetic variation in the vitamin D receptor (289) and vitamin D binding protein (290); 
however, none of the studies reviewed investigated this possibility. Additionally, pathogens were not 
characterised in many of the trials reviewed here, precluding investigation of the possibility that 





3.3.3. Meta-analysis of clinical trials. 
My meta-analysis of clinical trials presenting comparable, prospectively collected event data indicates 
vitamin D is an effective intervention for prevention of ARI – offering a 28% reduction in risk to 
members of the treatment arms (OR 0.72; 95% CI 0.53 to 0.99; P=0.04). However, the extremely high 
level of study heterogeneity (I2=68%) suggests that contrasting trial characteristics significantly 
influence the effect of vitamin D, e.g. size of vitamin D dose; use of intermittent bolus dosing vs. daily 
dosing; proportion of vitamin D deficiency at baseline; and mean participant age. In order to 
effectively investigate sub-group effects which potentially influence vitamin D’s actions a meta-
analysis of individual patient data (IPD) is needed. This is a project I am currently co-ordinating 
(http://www.nets.nihr.ac.uk/projects/hta/-130325) which combines data from over ten thousand 
participants from 24 relevant clinical trials, and is sufficiently powered to detect clinically important 




This systematic review has demonstrated broadly consistent associations between vitamin D 
deficiency and susceptibility to ARI. By contrast, results of vitamin D supplementation trials did not 
demonstrate consistent protective effects against ARI, but meta-analysis of 7/14 trials with 
comparable outcomes did indicate vitamin D offers protection from ARI. It is possible that vitamin D 
is a biomarker for some unknown and un-controlled-for factor, rather than the causative agent 
responsible for protection from ARI reported in some clinical trials. However, one would expect this 
unknown factor to be equally distributed across treatment and placebo arms. Or, it may be that 
studies which report null effects have arisen as a result of sub-optimal vitamin D supplementation 




clinical trials of vitamin D supplementation for the prevention of ARI should be conducted in 
populations with a high prevalence of deficiency at baseline, using doses sufficient to induce 
sustained elevation of serum 25(OH)D concentrations, and powered to detect clinically important 


















This chapter reports the results of a cross-sectional analysis conducted on all individuals who 
attended a screening visit for participation in the ViDiAs clinical trial (described in Methods, section 
2.2.1). The analysis was conducted with a view to identify both the environmental and genetic 
determinants of vitamin D status in this population, and to test for associations between vitamin D 





Vitamin D deficiency has been reported to be common among children with asthma in diverse 
settings, and to associate with reduced forced expiratory volume in one second (FEV1), poor asthma 
control and increased requirement for inhaled corticosteroids (ICS) (245, 291-294). Despite the high 
prevalence of both asthma and vitamin D deficiency among adults in the industrialised world, cross-
sectional studies assessing the prevalence, determinants and clinical correlates of vitamin D 
deficiency in adults with asthma have not previously been performed in such settings to my 
knowledge. Moreover, despite evidence suggesting that genetic variation can influence vitamin D 
status in the general population (122), studies to quantify the relationship between single nucleotide 
polymorphisms (SNP) in the vitamin D pathway and serum 25-hydroxyvitamin D (25[OH]D) 
concentrations (the accepted biomarker of vitamin D status) have not previously been performed in 
patients with asthma. Genetic variation in the vitamin D pathway has previously been reported to 
modify the influence of vitamin D status on the risk of a diverse range of conditions in which 
deficiency is thought to play a causal role (184, 295) . However, existing studies investigating the 
potential influence of polymorphisms in the vitamin D pathway on asthma phenotype are few in 




I therefore conducted a cross-sectional study to characterise environmental and genetic 
determinants of vitamin D status in a group of adults with ICS-treated asthma in London, UK; to 
determine whether serum 25(OH)D concentration or single nucleotide polymorphisms in the vitamin 
D pathway associate with asthma phenotype as main effects; and to explore whether genetic 
























4.2.1. Study population. 
A total of 297 adults with a medical record diagnosis of asthma treated with ICS were enrolled in the 
study between 27th August 2009 and 25th June 2012. All consented to undergo clinical 
measurements and to donate blood samples for quantification of serum 25(OH)D and PTH 
concentration; all but one agreed to donate a blood sample for DNA storage and genotyping. 
Participant characteristics are presented in Table 4.1. Age range was 16-78 years, with a mean of 
48.7 years (SD 14.4). Most participants (57.2%) were female. The majority of participants (82.5%) 
classified their ethnic origin as being White; 8.5% were Black/Black British, 5.7% were Asian/Asian 
British, and 3.0% were of mixed ethnicity. 261/297 (87.9%) participants’ asthma was managed 
exclusively in primary care. Mean serum 25(OH)D concentration for all participants was 50.6 nmol/L 
(SD 24.9). Forty participants (13.5%) had serum 25(OH)D concentration <25 nmol/L; 122 (41.1%) had 
serum 25(OH)D concentration 25 - 49.9 nmol/L; 80 (26.9%) had serum 25(OH)D concentration 50 – 

















Sex, n (%) Female 170 (57.2) 
Male 127 (42.8) 
Mean age, yrs (SD)   48.7 (14.4) 
Mean BMI, kg/m2 (SD)  27.6 (5.9) 
Ethnicity, n (%) 1 White 245 (82.5) 
Asian / Asian British 17 (5.7) 
Black / Black British 25 (8.5) 
Mixed 9 (3.0) 
Fitzpatrick skin type, n (%) 2 1 19 (6.4) 
2 57 (19.2) 
3 127 (42.8) 
4 57 (19.2) 
5  25 (8.4) 
6  12 (4.0) 
Socio-economic position, n (%) 3 1 199 (67.0) 
2 29 (9.8) 
3 29 (9.8) 
4 12 (4.0) 
5 15 (5.0) 
Student 6 (2.0) 
Unemployed 7 (2.4) 
Time outdoors per day, n (%) >2hrs 103 (34.7) 
≤2hrs 194 (65.3) 
Vitamin D supplement, IU/day, n (%) 4 Any 48 (16.2) 
None 242 (81.5) 
Quarter of blood draw, n (%) Q1 (January – March) 88 (29.6) 
Q2 (April – June) 78 (26.3) 
Q3 (July – September) 60 (20.2) 
Q4 (October – December) 71 (23.9) 
Smoking status, n (%) Non-current 279 (93.9) 
Current 18 (6.1) 
Mean alcohol intake, units/week (SD) 5  10.2 (11.7) 
Tanning bed use in previous year, n (%) Yes 19 (6.4) 
No 278 (93.6) 
Recent sunny holiday, n (%) 6 Yes 52 (17.8) 
No 240 (82.2) 
BTS step of treatment, n (%) 2: Regular preventer therapy 134 (45.1) 
3: Initial add-on therapy 125 (42.1) 
4: Persistent poor control 35 (11.8) 
5: Continuous / frequent use of OCS 3 (1.0) 
Managed exclusively in primary care, n (%)  261 (87.9) 
Medication use Mean ICS dose at entry in beclometasone equivalents, µg (SD) 7 725.3 (631.2) 
Inhaled LABA use, n (%) 8 155 (52.2) 
Leukotriene antagonist use, n (%) 33 (11.1) 
Mean % predicted FEV1 (SD)  82.4 (20.3) 
Mean FeNO, ppb (SD)  36.2 (26.4) 
Mean serum corrected calcium (SD)  2.23 (0.08) 
Mean serum PTH (SD)  5.7 (3.9) 
Serum PTH >6.8 pmol/L, n (%) Yes 71 (23.9) 
No 226 (76.1) 
Serum 25(OH)D, nmol/L (%) <25 40 (13.5) 
25 – 49.9 122 (41.1) 
50 – 74.9 80 (26.9) 
≥ 75 55 (18.5) 
Mean serum 25(OH)D, nmol/L (SD)  50.6 (24.9) 
[1] Ethnicity not reported in n=1. Mixed ethnicity: n=6 White and Black Caribbean, n=1 British Mauritian, n=1 Asian Caribbean, n=1 Irish Sri Lankan. [2] Fitzpatrick skin-type 
scores:  1 = extremely fair skin; always burn, never tan, 2 = fair skin; always burn, sometimes tan, 3 = pale skin; sometimes burn, always tan, 4 = olive skin; rarely burn, 
always tan, 5 = moderately pigmented brown skin; never burn, always tan, 6 = markedly pigmented black skin; never burn, always tan. [3] SEP classes: 1 = managerial, 
administrative and professional occupations, 2 = intermediate occupations, 3 = small employers and own account workers, 4 = lower supervisory and technical occupations, 
5 = semi-routine and routine occupations, 6 = student, 7 = Never/Long-term (>5yrs) unemployed. [4] Vitamin D supplement consumption not reported in n=7. [5] One alcohol 
unit = 8g pure alcohol. [6] Recent sunny holiday not reported in n=5. [7] 1µg beclometasone assumed equivalent to 1µg budesonide, 0.5 mcg fluticasone dipropionate and 
0.75 mcg ciclesonide. [8] Includes combinations of ICS/LABA and LABA. 
………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………. 
Abbreviations: BMI: Body mass index, OCS: Oral corticosteroids, BTS: British thoracic society, PTH: Parathyroid hormone, FEV1: Forced expiratory volume in 1 second, LABA: 
Long acting beta-adrenoceptor agonists, FeNO: Fractional exhaled nitric oxide, ppb: Parts per billion, nmol/L: nanomoles per litre, pmol/L: picomoles per litre, µg: 




4.2.2. Environmental determinants of serum 25(OH)D concentration. 
Environmental determinants of vitamin D status in participants with asthma are presented in Table 
4.2 and Figure 4.1. Multiple linear regression analysis showed the following factors to independently 
associate with serum 25(OH)D concentration: BMI (adjusted mean difference of 7.2 nmol/L for BMI 
of ≥25 kg/m2vs. <25 kg/m2; 95% CI -13.0 to -1. 5; P=0.014); Ethnicity (adjusted mean difference 13.3 
nmol/L for White vs. non-White; 95% CI -25.8 to -0.9; P=0.036); SEP (greatest adjusted mean 
difference 19.6 nmol/L for SEP groups 1/2 vs. Unemployed; 95% CI -36.8 to -2.5; P for trend = 0.012); 
Vitamin D supplement consumption (adjusted mean difference 21.5 nmol/L for those taking a dose 
of any size vs. those taking no vitamin D supplement; 95% CI -28.7 to -14.2; P<0.001); Quarter of 
blood draw (greatest adjusted mean difference 18.5 nmol/L for those sampled in Q3 vs. Q1; 95% CI 
-26.2 to -10.8, P for trend <0.001); recent sunny holiday (adjusted mean difference 7.7 nmol/L for 
those who took one in the previous 2 months vs. those who did not; 95% CI -14.7 to -0.8; P=0.030); 















Table 4.2: Environmental determinants of vitamin D status in asthma patients. 
 
Factor Category N Serum 25(OH)D, nmol/L  Univariate              
P value 7 
Multivariable model -   
Beta Coefficient  
(95% CI) 
P value 8 
   Mean (SD) Mean 
difference 
   
Sex Female 170 50.7 (26.1) referent 0.96 referent 0.13 
Male 127 50.5 (23.2) -0.2  -4.4 (-10.1 to 1.4)  
Age quartiles 1 (16.0 – 37.7 yrs) 74 52.5 (25.4) referent 0.26 referent 0.54† 
2 (37.8 – 49.6 yrs) 74 48.4 (25.0) -4.1  -0.8 (-8.8 to 7.1)  
3 (49.7 – 60.5 yrs) 74 47.2 (22.2) -5.3  -0.5 (-8.5 to 7.5)  
4 (60.6 – 79.0 yrs) 75 54.3 (26.4) +1.8  +2.6 (-5.6 to 10.8)  
BMI, kg/m2 <25 113 56.8 (26.2) referent <0.001 referent 0.014 
≥25 184 46.8 (23.2) -10.0  -7.2 (-13.0 to -1.5)  
Ethnicity 1 White 245 53.3 (25.5) referent <0.001 referent 0.036 
Non-white  51 37.7 (16.8) -15.6  -13.3 (-25.8 to -0.9)  
SEP 2 1,2 228 51.0 (24.9) referent 0.099 referent 0.012† 
3,4,5 56 51.8 (24.6) +0.8  +4.9 (-2.0 to 11.8)  
6 – Student 6 49.0 (30.0) -2.0  -6.3 (-24.9 to 12.4)  
7 - Unemployed 7 27.6 (10.3) -23.4  -19.6 (-36.8 to -2.5)  
Hours spent 
outdoors/day 
>2 103 56.7 (26.9) referent 0.002 referent 0.17 
≤2 194 47.4 (23.2) -9.3  -4.1 (-9.8 to 1.7)  
Vitamin D supplement, 
IU/day 3 
Any 48 68.5 (24.8) referent <0.001 referent <0.001 
None 242 47.4 (23.5) -21.1  -21.5 (-28.7 to -14.2)  
Quarter of blood draw Q1 (Jan – Mar) 88 42.2 (23.6) -17.7 <0.001 -18.5 (-26.2 to -10.8) <0.001† 
Q2 (Apr – Jun) 78 52.5 (27.1) -7.4  -11.0 (-19.0 to -3.0)  
Q3 (Jul – Sep) 60 59.9 (24.2) referent  referent  
Q4 (Oct – Dec) 71 51.0 (21.2) -8.9  -13.5 (-21.6 to -5.4)  
Fitzpatrick skin-type 4 1,2 76 48.7 (24.4) -5.3 <0.001 -4.4 (-10.6 to 1.9) 0.81† 
3,4 184 54.0 (25.4) referent  referent  
5,6 37 37.6 (17.9) -16.4  -2.4 (-16.7 to 11.8)  
Smoking status Non-current 279 50.1 (24.6) referent 0.22 referent 0.92 
Current 18 57.5 (28.8) +7.4  -0.6 (-12.3 to 11.0)  
Alcohol consumption, 
units/wk 
0 51 45.0 (23.4) referent 0.21 referent 0.25† 
1-20 198 51.7 (24.8) +6.7  +5.7 (-1.9 to 13.2)  
>20 48 52.0 (26.2) +7.0  +5.8 (-4.1 to 15.7)  
Tanning bed use, 
previous year 
Yes 19 62.3 (17.9) referent 0.033 referent 0.19 
No 278 49.8 (25.1) -12.5  -7.4 (-18.5 to 3.8)  
Recent sunny holiday 5 Yes 52 58.6 (30.0) referent 0.012 referent 0.030 
No 240 49.0 (23.5) -9.6  -7.7 (-14.7 to -0.8)  
BTS treatment step 6 2/3 259 50.2 (24.0) -3.1 0.47 -8.1 (-16.0 to -0.3) 0.043 
4/5 38 53.3 (30.4) referent  referent  
 
[1] Ethnicity not reported in n=1. Other ethnicities: n=17 Asian, n=25 Black, n=9 Mixed ethnicity. One participant declined to report ethnicity. 
[2] Socio-economic Position (SEP) classes: 1 = managerial, administrative and professional occupations, 2 = intermediate occupations, 3 = 
small employers and own account workers, 4 = lower supervisory and technical occupations, 5 = semi-routine and routine occupations, 6 = 
student, 7 = Never/Long-term (>5yrs) unemployed. [3] Vitamin D supplement consumption not reported in n=7. [4] Fitzpatrick skin-type 
scores:  1 = extremely fair skin; always burn, never tan, 2 = fair skin; always burn, sometimes tan, 3 = pale skin; sometimes burn, always tan, 
4 = olive skin; rarely burn, always tan, 5 = moderately pigmented brown skin; never burn, always tan, 6 = markedly pigmented black skin; 
never burn, always tan. [5] Recent sunny holiday not reported in n=5. [6] BTS treatment step definitions: 2. Regular preventer therapy, 3. 
Initial add-on therapy, 4. Persistent poor control, 5. Continuous / frequent use of OCS. [7] Univariate method: Student’s T-test/One-way 
ANOVA. [8] Adjusted for all potential determinants of 25(OH)D concentration included in univariate analysis. † P-value for trend. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 










Figure 4.1. Environmental determinants of vitamin D status in adults with ICS-treated asthma. Lower 
serum 25-hydroxyvitamin D (25[OH]D) concentrations were associated with higher body mass index 
(BMI, A), non-white ethnicity (B), lower socio-economic position (C), lack of vitamin D supplement use 
(D), sampling in Winter or Spring (E) and lack of a recent sunny holiday (F). Error bars represent median 
and interquartile ranges. P values from linear regression adjusting for all potential environmental 
determinants of vitamin D status. 
 
















































































































































4.2.3. Genetic determinants of serum 25(OH)D concentration. 
 
Genetic determinants of vitamin D status are presented in Table 4.3. After adjusting for sex, age, 
BMI, ethnicity, SEP, hours outdoors, vitamin D supplement consumption, season of blood draw, 
Fitzpatrick skin-type, smoking status, alcohol consumption, tanning bed use, recent sunny holiday, 
and BTS treatment step, and correcting for multiple comparison testing, none of our 15 investigated 










Table 4.3: Genetic determinants of vitamin D status in asthma patients. 
 
Gene SNP Genotype N Serum 25(OH)D, nmol/L  Multivariable model -   

















TT 174 53.5 (26.6) referent Referent 0.13 
AT 96 47.0 (22.5) -6.5 -3.6 (-9.2 to 2.0)   




CC 97 53.4 (25.7) referent Referent 0.24 
CG 129 51.2 (26.4) -2.2 +1.1 (-4.9 to 7.1)  

















AA 138 54.9 (26.6) referent Referent 0.015 
AT 127 47.7 (23.1) -7.2 -7.8 (-13.2 to -2.4)  




TT 113 49.2 (24.9) referent Referent 0.087 
CT 137 50.3 (24.2) +1.1 +2.6 (-3.2 to 8.4)  




TT 240 50.2 (24.3) referent Referent 0.038 
TG 46 53.7 (25.3) +3.5 +6.7 (-0.4 to 13.8)  




AA 175 50.1 (25.1) referent Referent 0.47 
AG 101 51.8 (24.9) +1.7 +2.9 (-2.8 to 8.5)  




CC 160 56.0 (25.8) referent Referent 0.005 
CA 113 45.0 (23.0) -11.0 -10.5 (-15.9 to -5.2)  




GG 91 58.8 (26.7) referent Referent 0.053 
TG 132 47.9 (23.1) -10.9 -8.4 (-14.4 to -2.4)  







AA 132 50.9 (25.9) referent Referent 0.34 
AG 118 51.8 (25.2) +0.9 +0.1 (-5.6 to 5.7)  











TT 104 54.4 (24.9) referent Referent 0.77 
GT 143 46.6 (24.3) -7.8 -8.1 (-13.8 to -2.4)  




GG 107 50.3 (23.9) referent Referent 0.84 
AG 129 52.5 (26.3) +2.2 +2.5 (-3.4 to 8.3)  




GG 86 55.0 (24.9) referent Referent 0.51 
AG 143 47.4 (24.6) -7.6 -9.4 (-15.5 to -3.4)  









TT 154 52.7 (25.3) referent Referent 0.011 
GT 98 52.2 (25.1) -0.5 +1.4 (-4.5 to 7.3)  




GG 220 50.1 (23.9) referent Referent 0.96 
AG 69 52.6 (27.4) +2.5 +0.5 (-5.8 to 6.7)  
AA 2 42.0 (31.1) -8.1 +0.7 (-30.0 to 31.4)  
VDR 
  




AA 136 50.8 (24.6) referent Referent 0.28 
AT 116 50.4 (24.9) -0.4 -1.8 (-7.6 to 3.9)  
TT 34 49.3 (28.3) -1.5 -4.6 (-13.0 to 3.8)  
 
[1] Adjusted for sex, age, BMI, ethnicity, SEP, hours outdoors, vitamin D supplement consumption, quarter of sampling, Fitzpatrick skin-
type, smoking status, alcohol consumption, tanning bed use, recent sunny holiday, and BTS treatment step. After correction for multiple 
comparisons testing using the Benjamini & Hochberg method with a 5% false discovery rate, none of the above P values remained 
significant.  
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 
Abbreviations: DBP: Vitamin D binding protein, CYP-: Cytochrome P450-, DHCR7: 7-dehydrocholesterol reductase, VDR: Vitamin D 





4.2.4. Association between vitamin D status and asthma phenotype. 
After adjustment for potential confounders, I found no relationship between vitamin D status and 
asthma phenotype. Specifically, I found no statistically significant independent association between 
serum 25(OH)D concentration and asthma control test score (Table 4.4), % predicted FEV1 (Table 4.5), 
% predicted FVC (Table 4.6), inhaled corticosteroid dose (Table 4.7), FeNO (Table 4.8) or % 
eosinophils in induced sputum (Table 4.9; n=35 sub-set of participants).  
 
Multiple linear regression analysis did reveal other factors to associate with various aspects of 
asthma phenotype though. Poor asthma control, as indicated by lower ACT scores, was 
independently associated with lower alcohol consumption (P for trend = 0.003), BMI ≥25kg/m2 
(P=0.026), non-White ethnicity (P<0.001) and SEP (P for trend = 0.018; Table 4.4). Older age and non-
White ethnicity associated with decreased % predicted FEV1 (P<0.001 for both factors, Table 4.5). 
Alcohol consumption and previous pneumococcal vaccination associated independently with 
increased ICS dose (P=0.03 for both factors, Table 4.6). Decreased FeNO levels were associated with 
female sex (P<0.001) and history of current smoking (P=0.040, Table 4.7), while % eosinophils in 












Table 4.4. Environmental determinants of Asthma Control Test (ACT) score. 
 
Factor Category N Median ACT 
score (IQR) 
Univariate              
P value 1 
Multivariable 
model – antilog of 
beta coefficient 
(95% CI) 
P value 2 
Sex Female 170 19 (16 to 22) 0.031 0.95 (0.89 to 1.00) 0.064  
Male 127 20 (18 to 22)  referent  
Age quartiles 1 (16.0 – 37.7 yrs) 74 20 (18 to 22) 0.96 referent 0.65† 
2 (37.8 – 49.6 yrs) 74 20 (17 to 22)  1.05 (0.97 to 1.14)  
3 (49.7 – 60.5 yrs) 74 19 (16 to 22)  1.03 (0.95 to 1.11)  
4 (60.6 – 79.0 yrs) 75 20 (16 to 22)  1.03 (0.94 to 1.12)  
BMI, kg/m2 <25 113 20 (18 to 22) 0.065 referent 0.026 
≥25 184 20 (16 to 22)  0.94 (0.89 to 0.99)  
Ethnicity 3 White 245 20 (18 to 22) <0.001 referent <0.001 
Other / mixed 51 17 (14 to 21)  0.88 (0.81 to 0.94)  
SEP 4 1,2 228 20 (18 to 22) 0.011 referent 0.018† 
3,4,5 56 19 (15 to 21)  0.94 (0.87 to 1.00)  
Student 6 18 (16 to 20)  0.96 (0.79 to 1.16)  
Unemployed 7 14 (10 to 17)  0.79 (0.67 to 0.94)  
Smoking status Non-current 279 20 (17 to 22) 0.54 referent 0.27 
Current 18 19 (15 to 22)  0.94 (0.84 to 1.05)  
Alcohol consumption, 
units/wk 5 
0 44 17 (14 to 21)  <0.001 referent 0.003† 
1-20 198 20 (18 to 22)  1.12 (1.04 to 1.21)  
>20 48 21 (18 to 23)  1.17 (1.06 to 1.29)  
Influenza vaccination  No 40 20 (16 to 21.5) 0.36 0.97 (0.90 to 1.05) 0.48 
Yes 257 20 (17 to 22)  referent  
Pneumonia vaccination  No 201 20 (17 to 22) 0.71 1.04 (0.98 to 1.10) 0.24 
Yes 96 20 (17 to 22)  referent  
Serum 25(OH)D, 
nmol/L 
<25 40  19.5 (16.5 to 22) 0.87 1.05 (0.96 to 1.16) 0.25† 
25 – 49.9 122 20 (17 to 22)  1.02 (0.94 to 1.09)  
50 – 74.9 80 20 (17 to 22)  0.99 (0.92 to 1.07)  
≥ 75 55  20 (17 to 22)  referent  
 
[1] Univariate analysis method: Mann-Whitney/Kruskal-Wallis tests. [2] Adjusted for all potential determinants of asthma control test score 
investigated in univariate analysis. [3] Ethnicity not reported in n=1. Other ethnicities: n=17 Asian / Asian British, n=25 Black / Black British. 
Mixed ethnicity: n=9. [4] Socio-economic Position (SEP) classes: 1 = managerial, administrative and professional occupations, 2 = 
intermediate occupations, 3 = small employers and own account workers, 4 = lower supervisory and technical occupations, 5 = semi-routine 
and routine occupations. [5] Alcohol consumption not recorded in n=7.  † P value for trend. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 































Table 4.5. Environmental determinants of % predicted Forced Expiratory Volume in 1 second (FEV1). 
 
Factor Category N Mean % 
predicted 
FEV1 (SD) 
Univariate              
P value 1 
Multivariable model  
beta coefficient (95% CI) 
P value 2 
Sex Female 170 90.39 (18.37) 0.28 +4.15 (-0.38 to 8.69) 0.073 
Male 127 89.55 (19.80)  Referent  
Age quartiles 1 (16.0 – 37.7 yrs) 74 92.99 (13.64) 0.002 Referent <0.001† 
2 (37.8 – 49.6 yrs) 74 93.34 (15.26)  +1.55 (-4.55 to 7.65)  
3 (49.7 – 60.5 yrs) 74 88.04 (22.72)  -5.33 (-11.61 to 0.95)  
4 (60.6 – 79.0 yrs) 75 83.11 (21.24)  -13.16 (-19.87 to -6.44)  
BMI, kg/m2 <25 113 91.64 (16.38) 0.10 Referent 0.77 
≥25 184 87.94 (20.36)  -0.69 (-5.23 to 3.85)  
Ethnicity 3 White 245 92.23 (18.27) <0.001 Referent <0.001 
Other / mixed 51 75.36 (16.35)  -17.11 (-23.04 to -11.17)  
SEP 4 1,2 228 90.71 (18.42) 0.066 Referent 0.36† 
3,4,5 56 84.94 (21.53)  -1.27 (-6.75 to 4.21)  
Student 6 92.72 (8.84)  -1.09 (-16.00 to 13.83)  
Unemployed 7 77.33 (15.08)  -6.95 (-20.61 to 6.70)  
Smoking status Non-current 279 89.24 (19.35) 0.71 Referent 0.35 
Current 18 90.97 (12.71)  -4.22 (-13.13 to 4.69)  
Alcohol consumption, 
units/wk 5 
0 44 86.93 (20.97) 0.61 Referent 0.98† 
1-20 198 89.96 (18.91)  -0.33 (-6.32 to 5.66)  
>20 48 90.26 (17.63)  -0.11 (-7.99 to 7.78)  
Influenza vaccination No 40 89.98 (17.10) 0.82 -0.54 (-6.74 to 5.67) 0.87 
Yes 257 89.25 (19.31)  Referent  
Pneumonia vaccination  No 201 88.83 (18.99) 0.50 -4.09 (-8.99 to 0.81) 0.10 
Yes 96 90.43 (19.08)  Referent  
Serum 25(OH)D, nmol/L <25 40  85.07 (17.60) 0.48 -1.11 (-8.67 to 6.45) 0.75† 
25 – 49.9 122 89.55 (21.90)  +1.30 (-4.44 to 7.03)  
50 – 74.9 80 90.33 (15.99)  +1.74 (-4.48 to 7.96)  
≥ 75 55  90.59 (17.02)  Referent  
 
[1] Univariate analysis method: Students T-test / One-way ANOVA tests. [2] Adjusted for all potential determinants of asthma control test 
score investigated in univariate analysis. [3] Ethnicity not reported in n=1. Other ethnicities: n=17 Asian / Asian British, n=25 Black / Black 
British. Mixed ethnicity: n=9. [4] Socio-economic Position (SEP) classes: 1 = managerial, administrative and professional occupations, 2 = 
intermediate occupations, 3 = small employers and own account workers, 4 = lower supervisory and technical occupations, 5 = semi-routine 
and routine occupations. [5] Alcohol consumption not recorded in n=7. † P value for trend. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 

































Table 4.6. Environmental determinants of % predicted Forced Vital Capacity (FVC). 
 
Factor Category N Mean % 
predicted FVC 
(SD) 
Univariate              
P value 1 
Multivariable model –
beta coefficient (95% 
CI) 
P value 2 
Sex Female 170 1.04 (0.17) 0.53 +0.03 (-0.01 to 0.06) 0.14 
Male 127 1.03 (0.15)  Referent  
Age quartiles 1 (16.0 – 37.7 yrs) 74 1.03 (0.12) 0.68 Referent 0.35 
2 (37.8 – 49.6 yrs) 74 1.05 (0.15)  +0.03 (-0.02 to 0.08)  
3 (49.7 – 60.5 yrs) 74 1.02 (0.18)  -0.01 (-0.06 to 0.04)  
4 (60.6 – 79.0 yrs) 75 1.03 (0.18)  -0.01 (-0.07 to 0.04)  
BMI, kg/m2 <25 113 1.07 (0.14) 0.001 Referent 0.004 
≥25 184 1.01 (0.17)  -0.05 (-0.09 to -0.02)  
Ethnicity 3 White 245 1.07 (0.15) <0.001 Referent <0.001 
Other / mixed 51 0.88 (0.13)  -0.17 (-0.22 to -0.12)  
SEP 4 1,2 228 1.05 (0.16) 0.034 Referent 0.24 
3,4,5 56 1.00 (0.17)  -0.01 (-0.06 to 0.03)  
Student 6 0.96 (0.17)  -0.11 (-0.23 to 0.01)  
Unemployed 7 0.96 (0.13)  -0.04 (-0.15 to 0.07)  
Smoking status Non-current 279 1.03 (0.16) 0.35 Referent 0.93 
Current 18 1.07 (0.11)  -0.00 (-0.08 to 0.07)  
Alcohol consumption, 
units/wk 5 
0 44 0.97 (0.17) 0.012 Referent 0.16 
1-20 198 1.05 (0.16)  +0.04 (-0.01 to 0.09)  
>20 48 1.05 (0.14)  +0.05 (-0.06 to 0.11)  
Influenza vaccination No 40 1.02 (0.16) 0.43 -0.01 (-0.06 to 0.04) 0.63 
Yes 257 1.04 (0.16)  Referent  
Pneumonia vaccination  No 201 1.02 (0.16) 0.068 -0.02 (-0.06 to 0.02) 0.32 




<25 40  0.98 (0.13) 0.079 -0.01 (-0.07 to 0.05) 0.81 
25 – 49.9 122 1.04 (0.18)  +0.01 (-0.04 to 0.06)  
50 – 74.9 80 1.04 (0.15)  +0.00 (-0.05 to 0.05)  
≥ 75 55  1.07 (0.13)  Referent  
 
[1] Univariate analysis method: Students T-test / One-way ANOVA tests. [2] Adjusted for all potential determinants of asthma control test 
score investigated in univariate analysis. [3] Ethnicity not reported in n=1. Other ethnicities: n=17 Asian / Asian British, n=25 Black / Black 
British. Mixed ethnicity: n=9. [4] Socio-economic Position (SEP) classes: 1 = managerial, administrative and professional occupations, 2 = 
intermediate occupations, 3 = small employers and own account workers, 4 = lower supervisory and technical occupations, 5 = semi-routine 
and routine occupations. [5] Alcohol consumption not recorded in n=7. One unit defined as 8g pure alcohol. † P value for trend. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 






























Table 4.7. Environmental determinants of inhaled corticosteroid (ICS) dose. 
 
Factor Category N 6 Median ICS dose 
(IQR) 
Univariate              
P value 1 
Multivariable 




P value 2 
 
Sex Female 167 400 (200 to 800) 0.75 1.04 (0.86 to 1.25) 0.71 
Male 127 400 (200 to 800)  referent  
Age quartiles 1 (16.0 – 37.7 yrs) 74 400 (200 to 800) 0.76 referent 0.82† 
2 (37.8 – 49.6 yrs) 74 400 (200 to 800)  0.98 (0.77 to 1.26)  
3 (49.7 – 60.5 yrs) 72 400 (200 to 800)  0.96 (0.75 to 1.25)  
4 (60.6 – 79.0 yrs) 74 400 (213.3 to 800)  0.97 (0.74 to 1.28)  
BMI, kg/m2 <25 113 400 (200 to 600) 0.07 referent 0.29 
≥25 181 400 (250 to 800)  1.11 (0.92 to 1.33)  
Ethnicity 3 White 243 400 (200 to 800) 0.26 referent 0.21 
Mixed / other 50 400 (300 to 1000)  1.17 (0.92 to 1.49)  
SEP 4 1,2 225 400 (200 to 800) 0.08 referent 0.081† 
3,4,5 56 400 (400 to 700)  1.13 (0.90 to 1.42)  
Student 6 300 (200 to 800)  0.88 (0.48 to 1.62)  
Unemployed 7 800 (400 to 1600)  1.85 (1.06 to 3.24)  
Smoking status Non-current 276 400 (200 to 800) 0.13 referent 0.028 
Current 18 550 (400 to 800)  1.51 (1.05 to 2.17)  
Alcohol consumption, 
units/wk 5 
0 43 400 (300 to 800) 0.35 referent 0.95† 
1-20 197 400 (200 to 800)  0.91 (0.71 to 1.16)  
>20 48 500 (300 to 800)  1.01 (0.73 to 1.40)  
Influenza vaccination No 40 400 (200 to 500) 0.15 0.89 (0.69 to 1.15) 0.39 
Yes 254 400 (200 to 800)  referent  
Pneumonia vaccination  No 199 400 (200 to 600) 0.01 0.80 (0.65 to 0.97) 0.03 
Yes 95 500 (300 to 800)  referent  
Serum 25(OH)D, nmol/L <25 40 400 (400 to 500) 0.87 0.98 (0.72 to 1.34) 0.93† 
25 – 49.9 120 400 (200 to 800)  1.00 (0.79 to 1.27)  
50 – 74.9 80 400 (200 to 700)  1.00 (0.77 to 1.29)  
≥ 75 54 400 (200 to 800)  referent  
 
[1] Univariate analysis method: Mann-Whitney/Kruskal-Wallis tests. [2] Adjusted for all potential determinants of ICS dose investigated in 
univariate analysis. [3] Ethnicity not reported in n=1. Other ethnicities: n=17 Asian / Asian British, n=25 Black / Black British. Mixed ethnicity: 
n=9. [4] Socio-economic Position (SEP) classes: 1 = managerial, administrative and professional occupations, 2 = intermediate occupations, 
3 = small employers and own account workers, 4 = lower supervisory and technical occupations, 5 = semi-routine and routine occupations. 
[5] Alcohol consumption not recorded in n=7. [6] ICS dose not recorded in n=3.  † P value for trend. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 



























Table 4.8. Environmental determinants of fractional exhaled nitric oxide (FeNO). 
 
Factor Category N 6 Median 
FeNO, ppb 
(IQR) 
Univariate              
P value 1 
Multivariable 
model – antilog of 
beta coefficient 
(95% CI) 
P value 2 
Sex Female 168 25 (17 to 37.5) <0.001 0.71 (0.61 to 0.83) <0.001 
Male 126 35.5 (23 to 45)  referent  
Age quartiles 1 (16.0 – 37.7 yrs) 74 31 (20 to 47) 0.49 referent 0.72† 
2 (37.8 – 49.6 yrs) 73 29 (20 to 47)  1.09 (0.88 to 1.34)  
3 (49.7 – 60.5 yrs) 74 29 (19 to 41)  1.05 (0.84 to 1.30)  
4 (60.6 – 79.0 yrs) 73 28 (19 to 40)  0.97 (0.77 to 1.22)  
BMI, kg/m2 <25 113 30 (20 to 47) 0.16 referent 0.16 
≥25 181 29 (19 to 41)  0.89 (0.77 to 1.05)  
Ethnicity 3 White 243 29 (19 to 42) 0.43 referent 0.96 
Non-white  50 32 (20 to 46)  1.00 (0.81 to 1.22)  
SEP 4 1,2 226 30 (20 to 42) 0.41 referent 0.19† 
3,4,5 55 25 (17 to 42)  0.84 (0.69 to 1.01)  
Student 6 29 (14 to 96)  1.09 (0.65 to 1.82)  
Unemployed 7 39 (23 to 64)  1.28 (0.80 to 2.05)  
Smoking status Non-current 276 30 (20 to 42.5) 0.22 referent 0.040 
Current 18 24 (13 to 37)  0.72 (0.53 to 0.98)  
Alcohol consumption, 
units/wk 5 
0 44 27 (18.5 to 45) 0.58 referent 0.21† 
1-20 195 30 (20 to 43)  1.03 (0.84 to 1.27)  
>20 48 28 (20 to 40)  0.84 (0.64 to 1.10)  
Influenza vaccination No 40 29.5 (21 to 43) 0.48 1.03 (0.84 to 1.28) 0.75 
Yes 254 29.5 (19 to 42)  referent  
Pneumonia vaccination  No 200 30 (20 to 43.5) 0.34 1.02 (0.86 to 1.21) 0.80 
Yes 94 29 (18 to 41)  referent  
Serum 25(OH)D, nmol/L <25 40  30 (20.5 to 42) 0.55 1.04 (0.80 to 1.35) 0.84† 
25 – 49.9 120 29 (20 to 44.5)  1.10 (0.90 to 1.34)  
50 – 74.9 80 31 (19 to 45)  1.13 (0.91 to 1.40)  
≥ 75 54 24.5 (18 to 37)  referent  
 
[1] Univariate analysis method:Mann-Whitney/Kruskal-Wallis tests. [2] Adjusted for all potential determinants of FeNO investigated in 
univariate analysis. [3] Ethnicity not reported in n=1. Other ethnicities: n=17 Asian / Asian British, n=25 Black / Black British. Mixed ethnicity: 
n=9. [4] Socio-economic Position (SEP) classes: 1 = managerial, administrative and professional occupations, 2 = intermediate occupations, 
3 = small employers and own account workers, 4 = lower supervisory and technical occupations, 5 = semi-routine and routine occupations. 
[5] Alcohol consumption not recorded in n=7. [6] Exhaled nitric oxide levels not recorded in n=3. † P value for trend. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 






















Table 4.9. Environmental determinants of % eosinophils in sputum (subset of n=35 participants). 
 
Factor Category N Median % 
eosinophils 
(IQR) 
Univariate              
P value1 
Multivariate  




Sex Female 17 1.54 (0.75 to 3.00) 0.62 0.82 (0.50 to 1.34) 0.40 
 Male 18 1.50 (0.63 to 4.42)  referent  
Age quartiles 1 (16.0 – 37.7 yrs) 7 1.00 (0.58 to 1.50) 0.49 Referent 0.67† 
 2 (37.8 – 49.6 yrs) 6 3.09 (1.25 to 5.50)  1.53 (0.70 to 3.38)  
 3 (49.7 – 60.5 yrs) 10 1.50 (0.63 to 2.75)  1.03 (0.49 to 2.14)  
 4 (60.6 – 79.0 yrs) 12 1.71 (0.63 to 4.25)  0.96 (0.43 to 2.13)  
BMI, kg/m2 <25 11 1.50 (0.42 to 2.00) 0.21 referent 0.13 
 ≥25 24 1.54 (0.71 to 5.25)  1.54 (0.87 to 2.70)  
Blood eosinophilia  <3% 17 0.83 (0.58 to 1.50) 0.006 referent 0.013 
 ≥3% 18 2.88 (1.50 to 6.50)  2.02 (1.18 to 3.47)  
FEV1/FVC  <0.93 19 1.75 (1.17 to 5.00) 0.11 referent 0.32 
≥0.93 16 0.92 (0.50 to 1.92)  0.76 (0.44 to 1.33)  
Serum 25(OH)D, nmol/L <50 19 1.50 (0.63 to 4.42) 0.97 1.03 (0.58 to 1.84) 0.91 
 ≥ 50 16 1.50 (0.63 to 3.25)  referent  
 
[1]Univariate analysis method:Mann-Whitney/Kruskal-Wallis tests. [2] Adjusted for all potential determinants of sputum eosinophilia 
investigated in univariate analysis. † P value for trend. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 
Abbreviations: BMI: Body mass index, IQR: Interquartile range, CI: Confidence interval, nmol/L: nanomoles per litre, FEV1/FVC: Forced 


























4.2.5. Association between genetic factors and asthma phenotype. 
Finally, I investigated whether 35 SNP that had been previously been reported to associate with 
serum 25(OH)D concentrations and/or risk of non-skeletal diseases associated with % predicted FEV1 
(Table 4.10), % predicted FVC (Table 4.11), FeNO (Table 4.12), ACT score (Table 4.13), or ICS 
requirement (Table 4.14). After correcting for multiple comparisons testing (Benjamini & Hochberg 
method with a 5% false discovery rate) none of the SNP investigated were found to associate with 


















Table 4.10. Genetic determinants of Forced Expiratory Volume in 1 second (FEV1). 
 
Gene SNP Genotype N Mean FEV1 
(SD) 
Multivariable model: 








CYP3A4 rs2740574 AA 249 90.1 (19.4) referent 0.30 0.25 
AG 33 86.6 (16.2) +3.65 (-3.80 to 11.10)   
GG 10 76.1 (15.6) +6.96 (-6.18 to 20.09)   
CUBILIN rs3740165 TT 259 89.1 (19.0) referent - - 
TC 29** 90.3 (20.5) -   
CC 0* - -   
RXRA rs7861779 GG 182 90.0 (19.2) referent 0.42 0.20 
GA 86 88.4 (19.5) +1.56 (-3.26 to 6.39)   
AA 17 82.8 (17.2) +4.01 (-5.80 to 13.81)   
rs9409929 GG 125 89.3 (18.3) referent 0.68 0.89 
AG 127 89.5 (19.7) +0.39 (-4.14 to 4.91)   
AA 35 90.1 (18.4) -1.43 (-8.28 to 5.42)   
CYP24A1 rs6013897 TT 174 90.2 (19.0) referent 0.11 0.85 
AT 96 88.7 (18.8) -1.94 (-6.40 to 2.53)   
AA 14 82.0 (21.7) -8.03 (-17.83 to 1.77)   
rs2762934 GG 206 90.1 (19.6) referent 0.93 0.37 
AG 77 87.3 (17.4) -2.27 (-7.07 to 2.53)   
AA 7 88.5 (25.1) -0.57 (-14.18 to 13.03)   
rs2762939 GG 159 91.0 (19.3) referent 0.70 0.043 
CG 105 86.6 (17.9) -2.42 (-6.93 to 2.08)   
CC 22 88.0 (21.7) -1.57 (-9.68 to 6.53)   
rs2248137 CC 97 90.2 (19.3) referent 0.90 0.28 
CG 129 89.9 (18.6) -0.56 (-5.37 to 4.26)   
GG 60 86.0 (19.3) +0.38 (-5.65 to 6.41)   
DBP rs16846876 AA 138 87.4 (19.4) referent 0.019 0.47 
AT 127 89.7 (18.1) -0.14 (-4.56 – 4.28)   
TT 15 98.6 (15.7) +11.34 (1.85 to 20.83)   
rs7041 CC 91 93.3 (18.6) referent 0.32 0.86 
AC 132 88.4 (18.8) -2.94 (-7.95 to 2.08)   
AA 63 84.9 (19.9) -3.15 (-9.32 to 3.02)   
rs12512631 TT 113 89.6 (18.4) referent 0.92 0.78 
CT 137 88.0 (20.6) -1.43 (-5.98 to 3.11)   
CC 41 91.8 (15.5) +0.32 (-6.16 to 6.79)   
rs4588 GG 160 89.3 (18.3) referent 0.20 0.76 
GT 113 88.1 (20.2) -2.91 (-7.50 to 1.68)   
TT 16 96.1 (19.8) +6.22 (-3.29 to 15.73)   
rs2070741 TT 240 89.3 (19.6) referent 0.038 0.14 
TG 46 89.0 (15.7) +1.34 (-4.45 to 7.12)   
GG 1* - -   
rs2298849 AA 175 87.8 (18.8) referent 0.12 0.99 
AG 101 91.5 (19.6) +3.86 (-0.63 to 8.35)   
GG 12 93.4 (15.3) +8.37 (-2.21 to 18.96)   
CYP27A1 rs17470271 AA 113 88.3 (18.9) referent 0.97 0.46 
AT 133 89.1 (19.7) -1.46 (-6.15 to 3.23)   
TT 44 91.8 (17.6) +0.14 (-6.33 to 6.61)   
CYP27B1 rs4646536 AA 132 89.5 (18.9) referent 0.11 0.42 
AG 118 89.0 (19.3) +0.60 (-3.90 to 5.10)   
GG 30 86.9 (19.9) -5.86 (-13.01 to 1.29)   
rs4646537 TT 264 89.4 (18.8) referent 0.44 0.68 
GT 26 87.6 (22.2) +2.97 (-4.58 to 10.51)   
GG 0* - -   
CYP2R1 rs10500804 TT 104 88.6 (18.9) referent 0.64 0.90 
GT 143 89.4 (19.4) -0.53 (-5.25 to 4.19)   
GG 44 90.0 (18.7) -1.57 (-8.11 to 4.97)   




Gene SNP Genotype N Mean FEV1 
(SD) 
Multivariable model: 








AG 129 90.3 (19.4) +2.69 (-2.00 to 7.37)   
AA 41 89.9 (18.0) +3.33 (-3.21 to 9.87)   
rs10766197 GG 86 88.0 (19.7) referent 0.59 0.50 
AG 143 89.2 (19.1) -0.02 (-5.07 to 5.02)   
AA 43 89.6 (18.9) -1.85 (-8.65 to 4.95)   
LRP2 rs3755166 GG 101 87.7 (18.4) referent 0.82 0.99 
AG 151 90.2 (20.1) +0.45 (-4.31 to 5.21)   
AA 38 90.6 (16.5) -0.81 (-7.72 to 6.10)   
DHCR7 rs12785878 TT 154 93.1 (18.3) referent 0.72 0.37 
GT 98 86.6 (19.9) -3.06 (-7.87 to 1.75)   
GG 38 81.7 (16.5) -1.36 (-8.91 to 6.20)   
rs3829251 GG 220 89.3 (19.1) referent 0.41 0.067 
AG 69 89.3 (19.4) +3.13 (-1.96 to 8.22)   
AA 2 96.3 (12.0) +10.47 (-14.58 to 35.51)   
VDR rs731236 AA 113 87.8 (17.8) referent 0.60 0.37 
AG 132 90.9 (20.2) +1.78 (-2.79 to 6.36)   
GG 42 88.5 (19.2) +1.76 (-4.76 to 8.27)   
rs4334089 GG 145 89.2 (18.1) referent 0.14 0.60 
AG 104 89.6 (19.8) +1.52 (-3.07 to 6.12)   
AA 40 87.8 (21.0) +5.04 (-1.60 to 11.67)   
rs10783219 AA 136  88.7 (19.4) referent 0.44 0.39 
AT 116 89.8 (19.2) -0.58 (-5.16 to 4.01)   
TT 34 88.5 (16.5) -2.61 (-9.30 to 4.08)   
rs4516035 TT 123 88.3 (18.4) referent 0.43 0.16 
CT 112 89.3 (19.9) -2.24 (-7.12 to 2.64)   
CC 51 91.3 (19.5) -2.47 (-8.68 to 3.73)   
rs11568820 CC 158 89.4 (19.1) referent 0.21 0.51 
CT 82 91.8 (18.7) +3.96 (-0.88 to 8.81)   
TT 42 84.0 (19.1) +4.38 (-2.43 to 11.19)   
rs7976091 CC 159 89.3 (19.2) referent 0.14 0.33 
CT 83 90.7 (18.9) +3.65 (-1.18 to 8.47)   
TT 41 84.7 (18.8) +5.13 (-1.73 to 12.00)   
rs2238136 CC 172 88.6 (19.1) referent 0.64 0.53 
CT 97 90.2 (19.8) -0.50 (-5.09 to 4.09)   
TT 22 91.4 (16.1) -1.93 (-10.09 to 6.23)   
rs1544410 CC 101 89.6 (15.7) referent 0.31 0.20 
CT 134 89.1 (21.0) -0.31 (-4.96 to 4.34)   
TT 52 90.2 (19.6) +3.14 (-2.94 to 9.23)   
rs2228570 GG 114 87.9 (19.3) referent 0.25 0.090 
AG 132 88.9 (19.6) +0.36 (-4.27 to 5.00)   
AA 45 94.5 (16.4) +3.76 (-2.68 to 10.20)   
rs2853559 GG 126 88.1 (19.0) referent 0.65 0.16 
AG 122 89.5 (19.0) -1.54 (-6.20 to 3.11)   
AA 41 91.1 (19.1) -1.49 (-7.97 to 5.00)   
rs7970314 AA 153 89.6 (18.4) referent 0.20 0.80 
AG 85 90.3 (20.1) +2.87 (-1.94 to 7.67)   
GG 44 84.1 (18.6) +4.42 (-2.38 to 11.22)   
rs7975232 AA 90 90.8 (20.0) referent 0.099 0.14 
AC 129 88.4 (19.7) -2.98 (-7.78 to 1.82)   
CC 60 86.8 (14.7) -5.05 (-11.05 to 0.96)   
[1] Adjusted for potential determinants of FEV1: Sex, age, ethnicity, body mass index, socio-economic position, smoking status, alcohol consumption, influenza 
vaccination, pneumococcal vaccination, and baseline vitamin D status. * Genotype could not be analysed due to <5 participants and/or too few events within 
this sub category. ** Genotype could not be analysed due to collinearity with predictor variable. After correction for multiple comparisons testing, using 
Benjamini & Hochberg method with a false discovery rate of 5%, none of the p values for trend or interaction between baseline vitamin D status and genotype 
remain significant. 
……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………. 
Abbreviations: 25(OH)D: 25-hydroxyvitamin D, SNP: Single nucleotide polymorphism, SD: Standard deviation, CI: Confidence interval, CYP-: Cytochrome P450 
enzyme, DBP: Vitamin D binding protein, DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also known as 
megalin), RXRA: Retanoid-X receptor A, VDR: Vitamin D receptor, CUBN: Cubilin.  




Table 4.11. Genetic determinants of Forced Vital Capacity (FVC). 
 
Gene SNP Genotype N Mean FVC 
(SD) 
Multivariable model:  
beta coefficient  
(95% CI) 1 
P value 
for trend 




CYP3A4 rs2740574 AA 249 1.05 (0.16) referent 0.87 0.91 
AG 33 0.98 (0.14) +0.01 (-0.05 to 0.07)   
GG 10 0.86 (0.15) +0.01 (-0.10 to 0.11)   
CUBILIN rs3740165 TT 259 1.03 (0.16) referent - - 
TC 29** 1.03 (0.16) -   
CC 0* - -   
RXRA rs7861779 GG 182 1.06 (0.15) referent 0.21 0.012 
GA 86 1.00 (0.15) -0.03 (-0.07 to 0.01)    
AA 17 0.91 (0.19) -0.05 (-0.01 to 0.03)   
rs9409929 GG 125 1.03 (0.15) referent 0.90 0.94 
AG 127 1.04 (0.16) -0.00 (-0.04 to 0.04)   
AA 35 1.04 (0.18) -0.00 (-0.06 to 0.05)   
CYP24A1 rs6013897 TT 174 1.04 (0.16) referent 0.46 0.53 
AT 96 1.03 (0.16) -0.01 (-0.04 to 0.03)   
AA 14 1.01 (0.17) -0.03 (-0.11 to 0.05)   
rs2762934 GG 206 1.04 (0.16) referent 0.34 0.15 
AG 77 1.02 (0.16) -0.02 (-0.06 to 0.02)   
AA 7 0.98 (0.20) -0.05 (-0.16 to 0.06)   
rs2762939 GG 159 1.06 (0.15) referent 0.041 0.017 
CG 105 1.02 (0.16) -0.02 (-0.05 to 0.02)   
CC 22 0.96 (0.19) -0.07 (-0.13 to -0.00)   
rs2248137 CC 97 1.05 (0.15) referent 0.61 0.44 
CG 129 1.04 (0.16) -0.01 (-0.05 to 0.02)   
GG 60 0.99 (0.17) -0.01 (-0.06 to 0.04)   
DBP rs16846876 AA 138 1.02 (0.17) referent 0.11 0.55 
AT 127 1.04 (0.15) -0.01 (-0.05 to 0.02)   
TT 15 1.09 (0.10) 0.06 (-0.01 to 0.14)   
rs7041 CC 91 1.07 (0.14) referent 0.16 0.77 
AC 132 1.03 (0.17) -0.02 (-0.06 to 0.02)   
AA 63 0.97 (0.15) -0.04 (-0.09 to 0.01)   
rs12512631 TT 113 1.03 (0.15) referent 0.54 0.58 
CT 137 1.03 (0.17) +0.00 (-0.03 to 0.04)   
CC 41 1.06 (0.15) +0.02 (-0.04 to 0.07)   
rs4588 GG 160 1.03 (0.16) referent 0.17 0.93 
GT 113 1.03 (0.17) -0.03 (-0.06 to 0.01)   
TT 16 1.09 (0.11) -0.05 (-0.02 to 0.13)   
rs2070741 TT 240 1.04 (0.16) referent 0.13 0.76 
TG 46 1.00 (0.14) -0.02 (-0.06 to 0.03)   
GG 1* - -   
rs2298849 AA 175 1.03 (0.16) referent 0.23 0.65 
AG 101 1.04 (0.16) +0.01 (-0.03 to 0.05)   
GG 12 1.03 (0.13) +0.05 (-0.03 to 0.14)   
CYP27A1 rs17470271 AA 113 1.02 (0.16) referent 0.79 0.95 
AT 133 1.04 (0.16) -0.01 (-0.05 to 0.03)   
TT 44 1.06 (0.16) +0.01 (-0.04 to 0.06)   
CYP27B1 rs4646536 AA 132 1.03 (0.15) referent 0.11 0.57 
AG 118 1.04 (0.16) +0.02 (-0.02 to 0.05)   
GG 30 1.01 (0.17) -0.05 (-0.10 to 0.01)   
rs4646537 TT 264 1.04 (0.16) referent 0.17 0.88 
GT 26 1.02 (0.19) +0.04 (-0.02 to 0.10)   
GG 0* - -   
CYP2R1 rs10500804 TT 104 1.05 (0.16) referent 0.10 0.062 
GT 143 1.02 (0.16) -0.04 (-0.08 to -0.00)   
GG 44 1.05 (0.16) -0.04 (-0.10 to 0.01)   




Gene SNP Genotype N Mean FVC 
(SD) 
Multivariable model:  
beta coefficient  
(95% CI) 1 
P value 
for trend 




AG 129 1.04 (0.16) +0.01 (-0.03 to 0.04)   
AA 41 1.05 (0.15) +0.04 (-0.01 to 0.09)   
rs10766197 GG 86 1.04 (0.17) referent 0.033 0.24 
AG 143 1.03 (0.16) -0.04 (-0.08 to 0.00)   
AA 43 1.03 (0.15) -0.06 (-0.11 to -0.00)   
LRP2 rs3755166 GG 101 1.03 (0.16) referent 0.62 0.71 
AG 151 1.04 (0.16) -0.01 (-0.05 to 0.02)   
AA 38 1.04 (0.16 -0.01 (-0.07 to 0.04)   
DHCR7 rs12785878 TT 154 1.07 (0.15) referent 0.29 0.85 
GT 98 1.03 (0.15) -0.01 (-0.05 to 0.03)   
GG 38 0.93 (0.18) -0.03 (-0.09 to 0.03)   
rs3829251 GG 220 1.04 (0.16) referent 0.66 0.20 
AG 69 1.02 (0.17) +0.01 (-0.04 to 0.05)   
AA 2* 0.93 (0.08) -   
VDR rs731236 AA 113 1.03 (0.16) referent 0.54 0.54 
AG 132 1.04 (0.16) -0.00 (-0.04 to 0.04)   
GG 42 1.05 (0.14) +0.02 (-0.04 to 0.07)   
rs4334089 GG 145 1.05 (0.15) referent 0.22 0.90 
AG 104 1.03 (0.17) +0.01 (-0.03 to 0.04)   
AA 40 1.01 (0.17) +0.03 (-0.02 to 0.09)   
rs10783219 AA 136 1.03 (0.16) referent 0.21 0.51 
AT 116 1.04 (0.16) -0.00 (-0.04 to 0.03)   
TT 34 1.02 (0.14) -0.03 (-0.09 to 0.02)   
rs4516035 TT 123 1.00 (0.16) referent 0.92 0.96 
CT 112 1.05 (0.15) +0.01 (-0.03 to 0.04)   
CC 51 1.06 (0.16) -0.00 (-0.05 to 0.05)   
rs11568820 CC 158 1.05 (0.15) referent 0.15 0.80 
CT 82 1.04 (0.16) +0.02 (-0.02 to 0.06)   
TT 42 0.98 (0.17) +0.04 (-0.01 to 0.09)   
rs7976091 CC 159 1.04 (0.16) referent 0.11 0.72 
CT 83 1.03 (0.16) +0.02 (-0.02 to 0.06)   
TT 41 0.98 (0.18) +0.05 (-0.01 to 0.10)   
rs2238136 CC 172 1.03 (0.16) referent 0.27 0.35 
CT 97 1.04 (0.16) -0.01 (-0.04 to 0.03)   
TT 22 1.04 (0.13) -0.04 (-0.10 to 0.03)   
rs1544410 CC 101 1.05 (0.15) referent 0.81 0.35 
CT 134 1.02 (0.16) -0.02 (-0.06 to 0.02)   
TT 52 1.05 (0.18) +0.01 (-0.04 to 0.06)   
rs2228570 GG 114 1.01 (0.16) referent 0.91 0.17 
AG 132 1.06 (0.16) +0.04 (-0.00 to 0.08)   
AA 45 1.03 (0.15) -0.00 (-0.05 to 0.05)   
rs2853559 GG 126 1.01 (0.16) referent 0.58 0.76 
AG 122 1.05 (0.15) -0.00 (-0.04 to 0.04)   
AA 41 1.08 (0.17) +0.01 (-0.04 to 0.07)   
rs7970314 AA 153 1.05 (0.15) referent 0.25 0.51 
AG 85 1.04 (0.17) +0.03 (-0.01 to 0.07)   
GG 44 0.97 (0.16) +0.03 (-0.02 to 0.09)   
rs7975232 AA 90 1.04 (0.17) referent 0.59 0.39 
AC 129 1.02 (0.16) -0.02 (0.06 to 0.19)   
CC 60 1.04 (0.15) -0.01 (-0.06 to 0.04)   
[1] Adjusted for potential determinants of FVC: Sex, age, ethnicity, body mass index, socio-economic position, smoking status, alcohol consumption, influenza 
vaccination, pneumococcal vaccination, and baseline vitamin D status. * Genotype could not be analysed due to <5 participants and/or too few events within 
this sub category. ** Genotype could not be analysed due to collinearity with predictor variable. After correction for multiple comparisons testing, using 
Benjamini & Hochberg method with a false discovery rate of 5%, none of the p values for trend or interaction between baseline vitamin D status and genotype 
remain significant. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 
Abbreviations: 25(OH)D: 25-hydroxyvitamin D, SNP: Single nucleotide polymorphism, SD: Standard deviation, CI: Confidence interval, CYP-: Cytochrome P450 
enzyme, DBP: Vitamin D binding protein, DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also known as 
megalin), RXRA: Retanoid-X receptor A, VDR: Vitamin D receptor, CUBN: Cubilin.  




Table 4.12. Genetic determinants of fractional exhaled nitric oxide (FeNO). 
 
Gene SNP Genotype N 1 Median FeNO 
(IQR) 
Multivariable model: 
antilog of beta 
coefficient (95% CI) 2 
P value 
for trend 




CYP3A4 rs2740574 AA 247 30 (19 to 43) referent 0.70 0.99 
AG 33 29 (21 to 41) 1.08 (0.84 to 1.39)   
GG 9 31 (21 to 42) 1.10 (0.69 to 1.75)   
CUBILIN rs3740165 TT 256 29 (19 to 42) referent - - 
TC 29** 30 (20 to 43) -   
CC 0* - -   
RXRA rs7861779 GG 180 29 (19.5 to 41.5) referent 0.84 0.29 
GA 85 31 (20 to 42) 1.01 (0.86 to 1.19)   
AA 17 25 (19 to 42) 0.97 (0.69 to 1.35)   
rs9409929 GG 124 30 (19 to 43) referent 0.55 0.92 
AG 125 30 (20 to 42) 1.03 (0.88 to 1.20)   
AA 35 28 (20 to 41) 1.07 (0.85 to 1.35)   
CYP24A1 rs6013897 TT 171 28 (19 to 43) referent 0.46 0.30 
AT 96 30 (20 to 42) 1.04 (0.89 to 1.21)   
AA 14 34 (28 to 42) 1.13 (0.81 to 1.58)   
rs2762934 GG 204 30 (20 to 43) referent 0.54 0.93 
AG 76 28 (18 to 39.5) 0.87 (0.74 to 1.03)   
AA 7 36 (19 to 76) 1.15 (0.73 to 1.83)   
rs2762939 GG 159 30 (20 to 43) referent 0.69 0.42 
CG 102 29 (17 to 42) 0.97 (0.83 to 1.13)   
CC 22 25 (18 to 35) 0.94 (0.71 to 1.25)   
rs2248137 CC 96 30.5 (20 to 46) referent 0.80 0.75 
CG 128 28.5 (18 to 41) 0.95 (0.80 to 1.12)   
GG 59 30 (19 to 42) 1.03 (0.83 to 1.27)   
DBP rs16846876 AA 136 29 (19.5 to 41.5) referent 0.42 0.70 
AT 126 30 (20 to 45) 1.04 (0.89 to 1.21)   
TT 15 32 (18 to 58) 1.15 (0.82 to 1.59)   
rs7041 CC 90 30 (20 to 42) referent 0.53 0.54 
AC 131 29 (19 to 43) 1.03 (0.87 to 1.23)   
AA 62 29.5 (19 to 41) 0.93 (0.76 to 1.15)   
rs12512631 TT 113 30 (19 to 41) referent 0.50 0.85 
CT 134 30 (20 to 45) 1.10 (0.95 to 1.29)   
CC 41 28 (20 to 35) 0.93 (0.75 to 1.15)   
rs4588 GG 158 29 (19 to 41) referent 0.42 0.46 
GT 112 32.5 (21 to 47.5) 1.05 (0.90 to 1.23)   
TT 16 21 (16 to 39) 0.88 (0.63 to 1.21)   
rs2070741 TT 237 30 (19 to 43) referent 0.26 0.97 
TG 46 30.5 (21 to 41) 1.02 (0.84 to 1.25)   
GG 1* - -   
rs2298849 AA 172 30 (19.5 to 42) referent 0.006 0.17 
AG 101 30 (21 to 45) 1.05 (0.90 to 1.22)   
GG 12 20.5 (12.5 to 24.5) 0.61 (0.42 to 0.87)   
CYP27A1 rs17470271 AA 112 29 (19 to 38) referent 0.77 0.43 
AT 131 30 (20 to 47) 1.07 (0.91 to 1.26)   
TT 44 26 (20 to 45.5) 1.03 (0.83 to 1.29)   
CYP27B1 rs4646536 AA 131 30 (20 to 42) referent 0.30 0.38 
AG 117 31 (21 to 45) 1.13 (0.97 to 1.31)   
GG 30 21 (17 to 32) 0.88 (0.69 to 1.12)   
rs4646537 TT 262 29 (19 to 43) referent 0.75 0.54 
GT 25 31 (23 to 39) 1.04 (0.80 to 1.36)   
GG 0* - -   
CYP2R1 rs10500804 TT 103 28 (20 to 45) referent 0.091 0.14 
GT 141 30 (18 to 41) 0.96 (0.82 to 1.13)   
GG 44 31 (22 to 45) 1.21 (0.97 to 1.51)   




Gene SNP Genotype N 1 Median FeNO 
(IQR) 
Multivariable model: 
antilog of beta 
coefficient (95% CI) 2 
P value 
for trend 




AG 128 29.5 (19 to 44.5) 1.00 (0.85 to 1.18)   
AA 41 29 (20 to 42) 0.90 (0.72 to 1.13)   
rs10766197 GG 85 29 (20 to 45) referent 0.12 0.29 
AG 142 30 (18 to 37) 0.92 (0.78 to 1.09)   
AA 42 31.5 (24 to 47) 1.20 (0.95 to 1.51)   
LRP2 rs3755166 GG 100 27 (19 to 39.5) referent 0.71 0.12 
AG 149 30 (20 to 45) 1.18 (1.00 to 1.39)   
AA 38 28 (14 to 36) 1.05 (0.83 to 1.32)   
DHCR7 rs12785878 TT 154 28 (19 to 41) referent 0.14 0.27 
GT 96 31 (20 to 43) 1.07 (0.91 to 1.26)   
GG 37 30 (21 to 48) 1.21 (0.94 to 1.56)   
rs3829251 GG 219 28 (20 to 43) referent 0.76 0.88 
AG 67 30 (17 to 42) 1.01 (0.85 to 1.21)   
AA 2* - -   
VDR rs731236 AA 111 30 (20 to 40) referent 0.71 0.89 
AG 132 29 (19 to 43) 1.02 (0.87 to 1.19)   
GG 41 29 (20 to 45) 1.04 (0.83 to 1.30)   
rs4334089 GG 144 30 (20 to 44) referent 0.36 0.76 
AG 102 27 (19 to 41) 0.92 (0.78 to 1.07)   
AA 40 33.5 (20 to 42) 0.90 (0.72 to 1.13)   
rs10783219 AA 134 29.5 (20 to 42) referent 0.58 0.69 
AT 115 29 (19 to 43) 1.04 (0.89 to 1.21)   
TT 34 30 (20 to 44) 1.07 (0.85 to 1.34)   
rs4516035 TT 122 28.5 (19 to 42) referent 0.56 0.98 
CT 111 30 (20 to 42) 1.08 (0.91 to 1.27)   
CC 50 28 (18 to 44) 1.07 (0.86 to 1.32)   
rs11568820 CC 156 30 (19 to 44) referent 0.81 0.85 
CT 82 27.5 (18 to 37) 0.90 (0.77 to 1.07)   
TT 41 32 (22 to 42) 0.97 (0.77 to 1.23)   
rs7976091 CC 157 30 (20 to 44) referent 0.64 0.81 
CT 83 28 (18 to 39) 0.91 (0.77 to 1.07)   
TT 40 30.5 (20.5 to 41.5) 0.95 (0.75 to 1.20)   
rs2238136 CC 171 29 (20 to 43) referent 0.49 0.91 
CT 95 29 (18 to 44) 0.97 (0.83 to 1.14)   
TT 22 30 (22 to 36) 1.10 (0.84 to 1.46)   
rs1544410 CC 100 30 (20 to 40) referent 0.97 0.96 
CT 133 30 (20 to 44) 0.99 (0.84 to 1.16)   
TT 51 27 (19 to 45) 1.00 (0.81 to 1.24)   
rs2228570 GG 113 30 (19 to 43) referent 0.76 0.39 
AG 130 30.5 (21 to 42) 1.07 (0.91 to 1.25)   
AA 45 27 (19 to 39) 0.97 (0.78 to 1.20)   
rs2853559 GG 124 30 (20 to 41.5) referent 0.13 0.25 
AG 121 28 (19 to 42) 0.93 (0.79 to 1.09)   
AA 41 33 (21 to 47) 1.19 (0.95 to 1.48)   
rs7970314 AA 151 30 (19 to 44) referent 0.85 0.89 
AG 85 28 (18 to 37) 0.93 (0.79 to 1.10)   
GG 43 35 (22 to 42) 0.98 (0.77 to 1.24)   
rs7975232 AA 89 29 (20 to 45) referent 0.81 0.37 
AC 128 28.5 (18 to 42) 0.94 (0.80 to 1.12)   
CC 59 32 (22 to 41) 1.03 (0.83 to 1.27)   
[1] Exhaled nitric oxide levels not recorded in n=3. [2] Adjusted for potential determinants of FeNO: Sex, age, ethnicity, body mass index, socio-economic position, 
smoking status, alcohol consumption, influenza vaccination, pneumococcal vaccination, and baseline vitamin D status. * Genotype could not be analysed due to 
<5 participants and/or too few events within this sub category. ** Genotype could not be analysed due to collinearity with predictor variable. After correction for 
multiple comparisons testing, using Benjamini & Hochberg method with a false discovery rate of 5%, none of the p values for trend or interaction between baseline 
vitamin D status and genotype remain significant. 
……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………….. 
Abbreviations: 25(OH)D: 25-hydroxyvitamin D, SNP: Single nucleotide polymorphism, IQR: Inter-quartile range, CI: Confidence interval, CYP-: Cytochrome P450 
enzyme, DBP: Vitamin D binding protein, DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also known as megalin), 
RXRA: Retanoid-X receptor A, VDR: Vitamin D receptor, CUBN: Cubilin.  




Table 4.13. Genetic determinants of asthma control test score (ACT). 
 
Gene SNP Genotype N  Median ACT (IQR) Multivariable 
model: antilog of 
beta coefficient 
(95% CI) 1 
P value 
for trend 




CYP3A4 rs2740574 AA 249 20 (17 to 22) referent 0.48 0.60 
AG 33 20  (17 to 22) 1.04 (0.95 to 1.15)   
GG 10 16.5 (14 to 21) 0.94 (0.80 to 1.11)   
CUBILIN rs3740165 TT 259 20 (17 to 22) referent - - 
TC 29** 20 (15 to 21) -   
CC 0* - -   
RXRA rs7861779 GG 182 20 (17 to 22) referent 0.38 0.31 
GA 86 20 (16 to 22) 1.02 (0.96 to 1.09)   
AA 17 20 (13 to 21) 0.95 (0.84 to 1.07)   
rs9409929 GG 125 20 (17 to 22) referent 0.63 0.27 
AG 127 20 (16 to 22) 0.98 (0.93 to 1.04)   
AA 35 19 (16 to 23) 1.02 (0.94 to 1.11)   
CYP24A1 rs6013897 TT 174 20 (17 to 22) referent 0.34 0.38 
AT 96 20 (17 to 22) 1.04 (0.98 to 1.10)   
AA 14 17 (15 to 22) 0.94 (0.83 to 1.07)   
rs2762934 GG 206 20 (17 to 22) referent 0.28 0.95 
AG 77 20 (17 to 23) 1.04 (0.98 to 1.11)   
AA 7 20 (16 to 22) 1.10 (0.93 to 1.30)   
rs2762939 GG 159 20 (17 to 22) referent 0.23 0.13 
CG 105 19 (17 to 22) 1.04 (0.99 to 1.10)   
CC 22 18.5 (16 to 22) 0.94 (0.85 to 1.04)   
rs2248137 CC 97 20 (17 to 22) referent 0.29 0.88 
CG 129 19 (17 to 22) 1.00 (0.94 to 1.06)   
GG 60 21 (16.5 to 22) 1.04 (0.96 to 1.12)   
DBP rs16846876 AA 138 20 (16 to 22) referent 0.91 0.35 
AT 127 20 (17 to 22) 1.02 (0.96 to 1.08)   
TT 15 19 (16 to 23) 0.99 (0.88 to 1.12)   
rs7041 CC 91 20 (18 to 22) referent 0.30 0.66 
AC 132 20 (16 to 22) 1.01 (0.94 to 1.07)   
AA 63 20 (16 to 21) 1.04 (0.96 to 1.13)   
rs12512631 TT 113 20 (17 to 23) referent 0.52 0.34 
CT 137 20 (16 to 22) 0.95 (0.90 to 1.00)   
CC 41 20 (18 to 22) 0.97 (0.90 to 1.06)   
rs4588 GG 160 20 (17 to 22) referent 0.97 0.79 
GT 113 20 (17 to 22) 0.96 (0.91 to 1.02)   
TT 16 20 (17 to 21.5) 1.00 (0.88 to 1.13)   
rs2070741 TT 240 20 (17 to 22) referent 0.73 0.82 
TG 46 20 (17 to 22) 1.04 (0.97 to 1.12)   
GG 1* - -   
rs2298849 AA 175 20 (17 to 22) referent 0.18 0.46 
AG 101 20 (16 to 22) 1.02 (0.96 to 1.07)   
GG 12 20.5 (18 to 22) 1.10 (0.96 to 1.25)   
CYP27A1 rs17470271 AA 113 20 (16 to 21) referent 0.87 0.79 
AT 133 20 (17 to 22) 1.03 (0.97 to 1.09)   
TT 44 20 (17.5 to 23) 1.01 (0.93 to 1.09)   
CYP27B1 rs4646536 AA 132 20 (17.5 to 22) referent 0.18 0.51 
AG 118 18.5 (16 to 21) 0.94 (0.89 to 1.00)   
GG 30 20 (17 to 22) 0.94 (0.86 to 1.03)   
rs4646537 TT 264 20 (17 to 22) referent 0.19 0.50 
GT 26 20 (17 to 21) 1.06 (0.97 to 1.17)   
GG 0* - -   
CYP2R1 rs10500804 TT 104 20 (17 to 22) referent 0.97 0.49 
GT 143 19 (16 to 22) 0.94 (0.89 to 1.00)   
GG 44 21 (18.5 to 23) 1.00 (0.92 to 1.08)   




Gene SNP Genotype N  Median ACT (IQR) Multivariable 
model: antilog of 
beta coefficient 
(95% CI) 1 
P value 
for trend 




AG 129 20 (16 to 22) 1.02 (0.96 to 1.08)   
AA 41 20 (18 to 22) 1.02 (0.94 to 1.11)   
rs10766197 GG 86 20 (17 to 22) referent 0.63 0.56 
AG 143 19 (16 to 22) 0.94 (0.89 to 1.01)   
AA 43 20 (18 to 22) 0.98 (0.90 to 1.07)   
LRP2 rs3755166 GG 101 21 (17 to 22) referent 0.10 0.50 
AG 151 20 (17 to 22) 1.00 (0.95 to 1.07)   
AA 38 19.5 (15 to 20) 0.93 (0.85 to 1.01)   
DHCR7 rs12785878 TT 154 20 (18 to 22) referent 0.28 0.41 
GT 98 20 (16 to 22) 0.96 (0.90 to 1.02)   
GG 38 18 (14 to 21) 0.95 (0.87 to 1.04)   
rs3829251 GG 220 20 (17 to 22) referent 0.84 0.028 
AG 69 19 (15 to 21) 0.93 (0.87 to 0.99)   
AA 2* 19 (18 to 20) -   
VDR rs731236 AA 113 20 (18 to 22) referent 0.84 0.23 
AG 132 20 (17 to 22) 1.00 (0.95 to 1.06)   
GG 42 19.5 (15 to 22) 1.01 (0.93 to 1.09)   
rs4334089 GG 145 20 (17 to 22) referent 0.16 0.33 
AG 104 20 (16 to 22) 1.00 (0.95 to 1.06)   
AA 40 20 (18 to 22.5) 1.06 (0.98 to 1.15)   
rs10783219 AA 136 20 (17.5 to 22) referent 0.60 0.99 
AT 116 19 (16 to 22) 0.97 (0.91 to 1.02)   
TT 34 20 (17 to 22) 0.98 (0.90 to 1.06)   
rs4516035 TT 123 20 (16 to 22) referent 0.62 0.48 
CT 112 20 (17 to 22) 0.98 (0.92 to 1.04)   
CC 51 20 (18 to 22) 1.02 (0.94 to 1.10)   
rs11568820 CC 158 20 (17 to 22) referent 0.44 0.98 
CT 82 20 (16 to 22) 0.99 (0.93 to 1.05)   
TT 42 20 (16 to 22) 1.03 (0.95 to 1.12)   
rs7976091 CC 159 20 (17 to 22) referent 0.35 0.80 
CT 83 20 (17 to 22) 1.01 (0.95 to 1.07)   
TT 41 20 (16 to 22) 1.04 (0.96 to 1.14)   
rs2238136 CC 172 20 (17 to 22) referent 0.54 0.92 
CT 97 20 (17 to 22) 1.01 (0.95 to 1.07)   
TT 22 17.5 (17 to 21) 0.97 (0.87 to 1.07)   
rs1544410 CC 101 20 (18 to 22) referent 0.32 0.12 
CT 134 19.5 (16 to 22) 0.96 (0.91 to 1.02)   
TT 52 19.5 (15.5 to 22) 0.96 (0.89 to 1.04)   
rs2228570 GG 114 20 (17 to 22) referent 0.74 0.16 
AG 132 20 (16 to 22) 0.97 (0.92 to 1.03)   
AA 45 20 (18 to 22) 0.99 (0.91 to 1.07)   
rs2853559 GG 126 20 (17 to 22) referent 0.98 0.66 
AG 122 20 (16 to 22) 0.97 (0.91 to 1.03)   
AA 41 20 (18 to 22) 1.00 (0.92 to 1.09)   
rs7970314 AA 153 20 (17 to 22) referent 0.27 0.74 
AG 85 20 (17 to 22) 1.01 (0.95 to 1.07)   
GG 44 20 (16 to 21.5) 1.05 (0.96 to 1.14)   
rs7975232 AA 90 19.5 (15 to 22) referent 0.71 0.90 
AC 129 20 (17 to 22) 1.05 (0.99 to 1.12)   
CC 60 20 (18 to 22) 1.01 (0.94 to 1.10)   
[1] Adjusted for potential determinants of asthma control test score: Sex, age, ethnicity, body mass index, socio-economic position, smoking status, alcohol 
consumption, influenza vaccination, pneumococcal vaccination, and baseline vitamin D status. * Genotype could not be analysed due to <5 participants. ** 
Genotype could not be analysed due to collinearity with predictor variable. After correction for multiple comparisons testing, using Benjamini & Hochberg method 
with a false discovery rate of 5%, none of the p values for trend or interaction between baseline vitamin D status and genotype remain significant. 
……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………….. 
Abbreviations: 25(OH)D: 25-hydroxyvitamin D, SNP: Single nucleotide polymorphism, IQR: Inter-quartile range, CI: Confidence interval, CYP-: Cytochrome P450 
enzyme, DBP: Vitamin D binding protein, DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also known as megalin), 
RXRA: Retanoid-X receptor A, VDR: Vitamin D receptor, CUBN: Cubilin.  




Table 4.14. Genetic determinants of inhaled corticosteroid requirement (ICS). 
 




antilog of beta 
coefficient (95% CI) 2 
P value 
for trend 




CYP3A4 rs2740574 AA 247 400 (200 to 800) referent 0.62 0.71 
AG 32 400 (200 to 1000) 0.95 (0.70 to 1.29)   
GG 10 400 (200 to 1600) 1.15 (0.67 to 1.96)   
CUBILIN rs3740165 TT 256 400 (200 to 800) referent - - 
TC 29** 400 (400 to 1000) -   
CC 0* - -   
RXRA rs7861779 GG 180 400 (200 to 800) referent 0.86 0.90 
GA 85 400 (200 to 800) 1.02 (0.84 to 1.24)   
AA 17 400 (250 to 500) 1.03 (0.70 to 1.54)   
rs9409929 GG 123 400 (300 to 800) referent 0.33 0.81 
AG 126 400 (200 to 800) 0.97 (0.81 to 1.17)   
AA 35 400 (200 to 600) 0.87 (0.66 to 1.15)   
CYP24A1 rs6013897 TT 172 400 (200 to 800) referent 0.20 0.55 
AT 95 400 (300 to 800) 1.02 (0.85 to 1.23)   
AA 14 550 (400 to 1000) 1.30 (0.87 to 1.93)   
rs2762934 GG 204 400 (200 to 800) referent 0.64 0.32 
AG 76 400 (250 to 800) 1.02 (0.84 to 1.24)   
AA 7 400 (200 to 1000) 1.14 (0.66 to 1.99)   
rs2762939 GG 157 400 (200 to 800) referent 0.72 0.55 
CG 104 400 (300 to 1000) 1.05 (0.87 to 1.26)   
CC 22 450 (200 to 800) 0.94 (0.68 to 1.31)   
rs2248137 CC 96 400 (200 to 800) referent 0.49 0.23 
CG 127 400 (200 to 600) 0.91 (0.75 to 1.11)   
GG 60 500 (225 to 800) 1.09 (0.85 to 1.40)   
DBP rs16846876 AA 136 400 (200 to 800) referent 0.44 0.34 
AT 127 400 (250 to 600) 0.90 (0.75 to 1.08)   
TT 15 400 (200 to 500) 0.86 (0.58 to 1.27)   
rs7041 CC 91 400 (200 to 800) referent 0.66 0.25 
AC 131 400 (200 to 800) 0.90 (0.74 to 1.10)   
AA 61 400 (200 to 800) 0.95 (0.74 to 1.21)   
rs12512631 TT 112 400 (200 to 800) referent 0.92 0.94 
CT 135 400 (200 to 800) 1.06 (0.88 to 1.28)   
CC 41 400 (200 to 800 1.01 (0.78 to 1.32)   
rs4588 GG 158 400 (200 to 800) referent 0.60 0.61 
GT 112 400 (200 to 550) 0.91 (0.75 to 1.10)   
TT 16 400 (250 to 750) 0.90 (0.61 to 1.33)   
rs2070741 TT 238 400 (200 to 800) referent 0.25 0.46 
TG 46 400 (300 to 800) 1.15 (0.91 to 1.45)   
GG 0* - -   
rs2298849 AA 174 400 (250 to 800) referent 0.90 0.42 
AG 100 400 (200 to 800) 0.97 (0.81 to 1.17)   
GG 11 400 (200 to 1000) 1.03 (0.66 to 1.62)   
CYP27A1 rs17470271 AA 112 400 (200 to 800) referent 0.47 0.59 
AT 132 400 (250 to 800) 1.09 (0.90 to 1.31)   
TT 43 400 (200 to 500) 0.91 (0.70 to 1.18)   
CYP27B1 rs4646536 AA 131 400 (213.3 to 800) referent 0.57 0.13 
AG 116 400 (200 to 800) 0.94 (0.78 to 1.13)   
GG 30 400 (200 to 800) 1.09 (0.81 to 1.45)   
rs4646537 TT 261 400 (200 to 800) referent 0.30 0.26 
GT 26 400 (250 to 600) 0.85 (0.62 to 1.16)   
GG 0* - -   
CYP2R1 rs10500804 TT 102 400 (200 to 800) referent 0.29 0.75 
GT 142 400 (200 to 800) 0.89 (0.73 to 1.08)   
GG 44 400 (200 to 500) 0.87 (0.66 to 1.13)   








antilog of beta 
coefficient (95% CI) 2 
P value 
for trend 




AG 128 400 (200 to 600) 0.87 (0.72 to 1.05)   
AA 40 400 (200 to 800) 0.99 (0.76 to 1.29)   
rs10766197 GG 85 400 (200 to 800) referent 0.41 0.62 
AG 142 400 (250 to 800) 0.94 (0.77 to 1.16)   
AA 43 400 (200 to 500) 0.89 (0.68 to 1.17)   
LRP2 rs3755166 GG 98 400 (213.3 to 800) referent 0.80 0.56 
AG 151 400 (200 to 800) 0.98 (0.81 to 1.19)   
AA 38 400 (400 to 800) 1.04 (0.78 to 1.38)   
DHCR7 rs12785878 TT 153 400 (200 to 600) referent 0.81 0.056 
GT 97 400 (300 to 800) 1.06 (0.87 to 1.30)   
GG 37 400 (200 to 800) 0.96 (0.71 to 1.31)   
rs3829251 GG 219 400 (200 to 800) referent 0.95 0.42 
AG 67 500 (375 to 800) 1.15 (0.93 to 1.42)   
AA 2* 562.5 (125 to 1000) -   
VDR rs731236 AA 111 400 (200 to 800) referent 0.95 0.67 
AG 132 400 (231.7 to 800) 1.04 (0.86 to 1.25)   
GG 41 400 (400 to 800) 1.01 (0.77 to 1.31)   
rs4334089 GG 144 400 (200 to 800) referent 0.68 0.086 
AG 104 400 (200 to 800) 1.10 (0.91 to 1.33)   
AA 38 400 (400 to 800) 1.06 (0.80 to 1.39)   
rs10783219 AA 133 400 (200 to 800) referent 0.23 0.040 
AT 116 400 (275 to 800) 1.05 (0.88 to 1.27)   
TT 34 400 (200 to 500) 0.85 (0.65 to 1.11)   
rs4516035 TT 122 400 (200 to 800) referent 0.44 0.23 
CT 111 400 (300 to 800) 1.14 (0.94 to 1.39)   
CC 50 400 (200 to 800) 1.10 (0.86 to 1.41)   
rs11568820 CC 157 400 (200 to 800) referent 0.94 0.55 
CT 81 400 (200 to 800) 0.97 (0.80 to 1.19)   
TT 41 400 (250 to 800) 1.01 (0.76 to 1.34)   
rs7976091 CC 158 400 (200 to 800) referent 0.91 0.31 
CT 82 400 (200 to 600) 0.96 (0.79 to 1.17)   
TT 40 400 (200 to 900) 0.98 (0.74 to 1.30)   
rs2238136 CC 169 400 (200 to 800) referent 0.090 0.10 
CT 97 400 (250 to 800) 1.00 (0.83 to 1.20)   
TT 22 400 (200 to 400) 0.75 (0.54 to 1.04)   
rs1544410 CC 99 400 (200 to 800) referent 0.76 0.71 
CT 134 400 (200 to 800) 1.06 (0.8 to 1.28)   
TT 51 400 (250 to 800) 1.04 (0.81 to 1.33)   
rs2228570 GG 114 400 (300 to 800) referent 0.030 0.42 
AG 129 400 (200 to 800) 0.93 (0.77 to 1.12)   
AA 45 400 (200 to 500 0.75 (0.58 to 0.97)   
rs2853559 GG 124 400 (200 to 600) referent 0.96 0.18 
AG 122 400 (213.3 to 800) 1.23 (1.01 to 1.48)   
AA 40 400 (200 to 800) 0.99 (0.76 to 1.30)   
rs7970314 AA 152 400 (206.7 to 800) referent 0.47 0.46 
AG 84 400 (200 to 1000) 0.91 (0.75 to 1.10)   
GG 43 400 (200 to 1000) 1.11 (0.84 to 1.46)   
rs7975232 AA 89 400 (200 to 800) referent 0.27 0.51 
AC 129 400 (250 to 800) 1.06 (0.87 to 1.29)   
CC 58 400 (200 to 600) 0.87 (0.67 to 1.12)   
[1] ICS dose not recorded in n=3. [2] Adjusted for potential determinants of ICS requirement: Sex, age, ethnicity, body mass index, socio-economic position, 
smoking status, alcohol consumption, influenza vaccination, pneumococcal vaccination, and baseline vitamin D status. 
* Genotype could not be analysed due to <5 participants and/or too few events within this sub category. ** Genotype could not be analysed due to collinearity 
with predictor variable. After correction for multiple comparisons testing, using Benjamini & Hochberg method with a false discovery rate of 5%, none of the p 
values for trend or interaction between baseline vitamin D status and genotype remain significant. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 
Abbreviations: 25(OH)D: 25-hydroxyvitamin D, SNP: Single nucleotide polymorphism, IQR: Inter-quartile range, CI: Confidence interval, CYP-: Cytochrome P450 
enzyme, DBP: Vitamin D binding protein, DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also known as 
megalin), RXRA: Retanoid-X receptor A, VDR: Vitamin D receptor, CUBN: Cubilin. 





To my knowledge, this is the first study to investigate whether the influence of vitamin D status on 
asthma phenotype is modified by genetic variation in the vitamin D pathway. Vitamin D deficiency, 
defined using the 50 nmol/L 25(OH)D threshold, was present in the majority of participants, and it 
associated with classical environmental determinants of vitamin D status, but not with any potential 
genetic determinant investigated. No association was found between vitamin D status and a broad 
range of measures of asthma phenotype including symptom control, FEV1, FVC, ICS requirement and 
FeNO concentration. Neither did I find evidence to suggest that genetic variation in the vitamin D 
pathway influenced disease phenotype, either as a main effect, or in interaction with vitamin D 
status. 
 
My findings with respect to prevalence and environmental determinants of vitamin D status are in 
keeping with those previously reported for other UK populations (298). By contrast, my finding of a 
lack of association between serum 25(OH)D concentrations and asthma phenotype - supported by 
the lack of association between vitamin D pathway SNP and asthma phenotype I observed - conflicts 
with the other studies in the literature, which have variously reported associations between lower 
vitamin D status and worse asthma control, more severe disease, lower FEV1 and increased 
requirement for inhaled corticosteroids. 
 
Why might my findings differ? First, the majority of studies in the literature have investigated 
children with more severe asthma (245, 291-294), while our study is in adults with generally better 
symptom control. It may be that asthma phenotype is more readily modified by vitamin D in 
paediatric populations, and/or in those with more severe asthma: in keeping with the former 
hypothesis, randomised controlled trials of vitamin D supplementation to improve asthma control 
have tended to show protective effects in children (270, 299), but not in adults (209, 300). A second 




associations in other studies: I collected detailed information on potential confounders of the 
relationship between vitamin D status and asthma control and adjusted for them in multivariable 
analyses. A third possibility is that publication bias may have contributed to the dearth of null studies 
in the published literature. 
 
My analysis of other determinants of asthma phenotype identified a number of expected predictors, 
but also revealed some new information. The association between increased alcohol consumption 
and improved asthma control is intriguing: more research is needed to understand the relationship 
between alcohol intake and asthma control, and to identify potential mechanisms of protection if 
applicable. Our finding of an independent association between poorer asthma control and non-
White ethnicity chimes with other reports (301, 302); the fact that serum 25(OH)D did not associate 
with ACT score in this analysis indicates that lower vitamin D status does not account for inter-ethnic 
differences in asthma control. 
 
4.3.1. Study Strengths. 
My study has several strengths. I investigated a wide range of potential environmental and genetic 
determinants of vitamin D status and asthma control, recorded detailed information on potential 
confounders of the relationship between 25(OH)D and asthma control, and phenotyped patients in 
considerable detail: spirometry and measurement of FeNO were performed using international 
guidelines and serum 25(OH)D concentrations were measured with the gold standard assay (LC-
MS/MS) in a laboratory that participated in the international vitamin D external quality assurance 
scheme (www.deqas.org/). The study population included patients with mild, moderate and severe 
disease from both community and hospital settings, studied across all seasons: these features 





4.3.2. Study Limitations. 
My study also has some limitations. A minority of participants had serum 25(OH)D concentrations 
>75 nmol/L, so I may have been underpowered to detect effects of the highest 25(OH)D 
concentrations on asthma phenotype: our results do not therefore definitively preclude beneficial 
effects of elevating serum 25(OH)D to >75 nmol/L. However, my findings are in keeping with clinical 
trials of vitamin D supplementation to improve asthma control in adults, which have been null to 
date (209, 300): however, lack of efficacy in these trials may reflect a lack of power, low prevalence 
of profound vitamin D deficiency at baseline, and / or sub-optimal dosing regimens. Meta-analysis of 




In conclusion, I report that vitamin D deficiency is common in a UK adult population with ICS-treated 
asthma, and that this is influenced by the same classical environmental determinants of vitamin D 
status that operate in the general population. However, vitamin D status did not associate with 
genetic factors or with any one of a broad range of measures of asthma phenotype including 
symptom control, FEV1, FVC, ICS requirement and FeNO concentration. Furthermore, genetic factors 








5. Cross-sectional analysis: Environmental and genetic 
determinants of vitamin D status among older adults in London, UK. 
 
In this chapter I present a final cross-sectional analysis of factors, both environmental and genetic, 
which may associate with vitamin D status in a cohort of older adults living in sheltered housing 
(described in Methods, section 2.2.1) who attended a screening visit to participate in our ViDiFlu 
trial. This work was published online in January 2016 and is due to be published in print, in a vitamin 





The risk of vitamin D deficiency is high in older adults due to the contribution of several physiological 
and lifestyle changes which occur with advancing age, such as a decrease in epidermal capacity to 
produce pre-vitamin D (303); an increase in the prevalence of chronic kidney disease (304) and a 
decline in sun-seeking behaviour due to avoidance or reduced mobility (305, 306). Besides these 
factors relating specifically to older age, several other environmental and genetic factors can further 
increase the risk of vitamin D deficiency in older adult populations: women often display lower 25-
hydroxyvitamin D (25[OH]D) levels than men (307), possibly due to a greater adipose tissue 
component that sequesters the fat-soluble 25(OH)D compound from the circulation. Adipose 
sequestration may also be responsible for the inverse association often seen between body mass 
index (BMI) and 25(OH)D concentration (308, 309). Ethnicity and skin pigmentation affect 25(OH)D 
concentration in a number of ways: cutaneous vitamin D production depends on ultra-violet 
radiation (UVR) penetration which is limited by high skin melanin density (310), and ethnic variation 
in vitamin D pathway genes may also play a role (122). The level of cutaneous vitamin D synthesis 




outdoors, the use of tanning beds, living or holidaying in sunny locations, dress-related skin exposure, 
and the use of sunscreen. Finally, several single nucleotide polymorphisms (SNP) in vitamin D 
pathway genes have been found to associate with serum 25(OH)D concentration. The most 
commonly known are within the vitamin D binding gene (DBP); 7-dehydrocholesterol reductase gene 
(DHCR7); and two cytochrome P450 enzyme genes (CYP2R1 and CYP24A1) (122, 124). 
 
Vitamin D deficiency is associated with increased susceptibility to several major causes of morbidity 
and mortality in older adults, including fractures (311), falls (312) and acute respiratory infections 
(231). It is known to be common among populations of older adults who are unable to mobilise 
outdoors, such as those in care homes (305, 306). However, there is relatively little data relating to 
vitamin D status of older adults in the UK who have better mobility, such as those living in sheltered 
accommodation. I therefore conducted a study to determine the prevalence of vitamin D deficiency 
in a cohort of older adults living in sheltered accommodation, and to identify environmental and 
















5.4.1. Study population. 
The population for this cross-sectional study was formed from the 222 older adult, sheltered 
accommodation residents screened between 29th March 2010 to 16th March 2012 for participation 
in the ViDiFlu trial (313). All screened respondents consented to anthropometric measurements; 
complete the lifestyle questionnaire; and donate blood samples for quantification of serum 25(OH)D 
concentration and for DNA storage and genotyping. Participant characteristics are presented in Table 
6.1. Participants were aged 48-94 years at time of study induction; mean age was 72.0 years (SD 9.2). 
Females were more strongly represented in this study population (59.9%). The majority ethnic group 
was White (74.8%); 6.4% were Asian; 17.4% were Black; 1.4% had mixed ethnicity. Mean serum 
25(OH)D concentration for all participants was 42.7 nmol/L (SD 22.0). 55 participants (24.8%) had 
serum 25(OH)D concentration <25 nmol/L; 89 (40.1%) had serum 25(OH)D concentration 25-49.9 
nmol/L; 61 (27.5%) had serum 25(OH)D concentration 50-74.9 nmol/L; and 17 (7.7%) had serum 













Table 6.1. Participant Characteristics. 
 
Factor Category N=222 
 
Sex, n (%) Female 133 (59.9) 
 Male 89 (40.1) 
Mean Age, yrs (SD)   72.0 (9.2) 
Mean BMI, kg/m2 (SD)  29.3 (6.8) 
Ethnicity, n (%) 1 White 163 (74.8) 
 Asian / Asian British 14 (6.4) 
 Black / Black British 38 (17.4) 
 Mixed 3 (1.4) 
Fitzpatrick Skin-type, n (%) 2 1 19 (8.7) 
 2 44 (20.2) 
 3 72 (32.0) 
 4 37 (17.0) 
 5  26 (11.9) 
 6  20 (9.2) 
Socio-economic Position, n (%) 3 1 72 (33.5) 
 2 28 (13.0) 
 3 14 (6.5) 
 4 36 (16.7) 
 5 62 (28.8) 
 unclassified 3 (1.4) 
Time outdoors, hours per day (%)4 >2hrs 82 (37.6) 
 ≤2hrs 136 (62.4) 
Vitamin D supplement/day, n (%)5 Yes 55 (25.8) 
 No 158 (74.2) 
Quarter of blood draw, n (%)6 Q1 (Jan – Mar) 87 (39.4) 
 Q2 (Apr – Jun) 59 (26.7) 
 Q3 (Jul – Sep) 24 (10.9) 
 Q4 (Oct – Dec) 51 (23.1) 
Smoking status, n (%) Non-current 187 (84.2) 
 Current 35 (15.8) 
Mean alcohol, units/month (SD)7  5.6 (12.7) 
Recent sunny holiday, n (%) 8 Yes 11 (5.0) 
 No 208 (95.0) 
Mean melanin skin density (SD) 9  36.5 (12.8) 
Hair loss, n (%) 10 0 123 (55.4) 
 1 39 (17.6) 
 2 20 (9.0) 
 3 36 (16.2) 
 4 4 (1.8) 
Serum 25(OH)D, nmol/L (%) <25 55 (24.8) 
 25 – 49.9 89 (40.1) 
 50 – 74.9 61 (27.5) 
 ≥ 75 17 (7.6) 
Mean serum 25(OH)D, nmol/L (SD)  42.7 (22.0) 
[1] Ethnicity not reported in n=4. [2] Fitzpatrick skin-type not reported in n=4. Classification of scores:  1 = extremely fair skin; always burn, never tan, 2 = fair 
skin; always burn, sometimes tan, 3 = pale skin; sometimes burn, always tan, 4 = olive skin; rarely burn, always tan, 5 = moderately pigmented brown skin; 
never burn, always tan, 6 = markedly pigmented black skin; never burn, always tan. [3] SEP not reported in n=7. Class definitions: 1 = managerial, administrative 
and professional occupations, 2 = intermediate occupations, 3 = small employers and own account workers, 4 = lower supervisory and technical occupations, 5 
= semi-routine and routine occupations. [4] Time outdoors not reported in n=4. [5] Supplementary vitamin D consumption not reported in n=9. [6] Quarter of 
blood draw not reported in n=1. [7] 1 unit is defined as 10 millilitres of pure alcohol. [8] Recent sunny holiday not reported in n=3.Defined as a trip to any 
location within a latitude 51o North/South of the equator, during the local sunny season, 2 months prior to blood draw, for a duration of ≥1 week. †Adjusted 
for sex, ethnicity, vitamin D supplement consumption, quarter of blood draw, skin type and tanning bed use. 4 Skin melanin density: readings taken from inside 
left arm, measured in arbitrary units. [9] Skin melanin density: readings taken from inside left arm, measured in arbitrary units; range of values: 16.4 – 90.1. 
[10] Hair loss:  categories 0-4 were defined by merging Male (Norwood-Hamilton [NH]) and Female (Ludwig [LG]) scales of hair loss: 0 = No hair loss, 1 = NH 
categories II & III (minor recession of frontal hairline; significant frontal loss/significant frontal regression + early hair loss from crown) merged with LG category 
I (thinning of hair from anterior crown with minimal widening of parting), 2 = NH categories IV & V (further frontal loss and enlargement of crown; further 
enlargement of crown and bridge begins to separate) merged with LG category II (evident thinning of crown), 3 = NH categories VI & VII (bridge disappears 
leaving large bald area on front and top of scalp; only back of scalp retains significant amount of hair) merged with LG category III (crown becomes denuded 
with significant parting, but hairline remains), 4 = other. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………… 




5.4.2. Environmental determinants of vitamin D status. 
The environmental determinants of vitamin D status are presented in Table 6.2. Multivariate analysis 
identified the following factors that independently associated with serum 25(OH)D concentration: 
Non-white ethnicity associated with a 8.6 nmol/L lower serum 25(OH)D concentration (95% CI -14.9 
to -2.3, P=0.008). Lack of vitamin D supplement consumption associated with a 17.1 nmol/L lower 
serum 25(OH)D concentration (95% CI -23.3 to -10.9, P<0.001), referent to taking a daily dose. 
Referent to Q3/July-September sampling: Q1/January-March sampling associated with a 12.2 nmol/L 
lower serum 25(OH)D concentration (95% CI -21.5 to -2.9, P=0.01), and Q4/October-December 
sampling associated with a 10.3 nmol/L lower serum 25(OH)D concentration (95% CI -20.2 to -0.4, 
P=0.04). Sex, age, BMI, SEP, UVR exposure, skin-type, skin melanin density, smoking status, alcohol 
consumption, recent sunny holiday and hair loss did not independently associate with serum 















Table 6.2. Demographic & lifestyle determinants of serum 25-hydroxyvitamin D concentration.  
 





Multivariable model –  
Beta Coefficient (95% CI)   
P value† 
Sex  Female 133 46.2 (21.6) 0.002 referent   
Male 89 37.5 (21.6)  -6.95 (-14.2 to -0.33) 0.06 
Age quartiles  1 (48.0 – 64.5) 55 40.5 (21.8) 0.07 referent  
2 (64.6 – 71.8) 56 40.9 (22.5)  -1.64 (-9.24 to 5.96) 0.67 
3 (71.9 – 77.4) 55 49.7 (20.9)  +5.80 (-1.74 to 13.34) 0.13 
4 (77.5 – 94.1) 56 39.8 (21.9)  -3.96 (-11.62 to 3.69) 0.31 
BMI, kg/m2   <25 64 43.4 (22.7) 0.73 referent  
≥25 158  42.4 (21.8)  -0.42 (-6.46 to 5.61) 0.89 
Ethnicity 1 White 163 44.5 (22.3) 0.03 referent  
Other 2 55  37.4 (20.9)  -8.57 (-14.86 to -2.27) 0.008 
SEP 3  1,2 100 45.2 (21.4) 0.18 referent  
3,4,5 112 39.8 (22.3)  -2.64 (-8.37 to 3.09) 0.36 
unclassified 3 49.7 (30.9)  -3.90 (-27.25 to 19.46) 0.74 
Time outdoors, hrs/day 4 >2 82 44.2 (22.9) 0.42 referent  
≤2 136 41.8 (21.7)  -1.42 (-7.02 to 4.18) 0.62 
Vitamin D supplement 5  Yes 55 56.5 (20.3) <0.001 referent  
No 158 38.6 (20.3)  -17.09 (-23.28 to -10.91) <0.001 
Quarter of blood draw 6 Q1 (Jan – Mar) 87 37.1 (19.6) <0.001 -12.20 (-21.50 to -2.89) 0.01 
Q2 (Apr – Jun) 59 48.7 (23.6)  -2.03 (-11.65 to 7.60) 0.68 
Q3 (Jul – Sep) 24 54.4 (21.7)  referent  
Q4 (Oct – Dec) 51 39.3 (20.5)  -10.32 (-20.24 to -0.40) 0.04 
Fitzpatrick skin-type 7  1,2 63  42.5 (22.5) 0.19 -4.30 (-10.70 to -2.11) 0.19 
3,4 109 44.7 (22.2)  referent  
5,6 46 38.1 (21.0)  -0.22 (-12.30 to 11.85) 0.97 
Skin melanin density 
quartiles 8 
1 55 39.4 (22.7) 0.17 referent  
2 65 45.3 (22.0)  +3.72 (-3.78 to 11.22) 0.33 
3 48 46.6 (20.9)  +5.84 (-2.33 to 14.01) 0.16 
4 54 39.5 (21.7)  +6.39 (-4.80 to 17.58) 0.26 
Smoking status Non-current 187 43.6 (22.5) 0.21 referent  
Current 35 38.1 (18.8)  -5.14 (-12.93 to 2.65) 0.20 
Alcohol consumption, 
units/wk 
0 87 43.8 (21.5) 0.56 referent  
1-20 121 41.5 (22.2)  -1.31 (-7.25 to 4.64) 0.67 
>20 14  46.5 (23.9)  +5.42 (-6.68 to 17.53) 0.38 
Recent sunny holiday 9 Yes 11 46.8 (18.8) 0.52 referent  
No 208 42.5 (22.2)  -4.00 (-16.15 to 8.16) 0.52 
Hair loss 10  0 123 46.1 (21.2) 0.03 referent  
1 39 40.3 (25.2)  +0.14 (-9.12 to 9.40) 0.98 
2 20 38.0 (17.9)  -3.51 (-14.90 to 7.89) 0.55 
3 36 34.9 (19.7)  -2.93 (-13.74 to 7.88) 0.59 
4 4 55.5 (32.0)  +14.23 (-8.82 to 37.28) 0.23 
 
[1] Ethnicity not reported in n=4. [2] Other ethnicities: n=14 Asian, n=38 Black, n=3 Mixed ethnicity. [3] SEP not reported in n=7. Class definitions: 1 = 
managerial, administrative and professional occupations, 2 = intermediate occupations, 3 = small employers and own account workers, 4 = lower 
supervisory and technical occupations, 5 = semi-routine and routine occupations, 6 = student, 7 = Never/Long-term (>5yrs) unemployed. [4] UVR 
exposure not reported in n=4. [5] Supplementary vitamin D consumption not reported in n=9. [6] Quarter of blood draw not reported in n=1. [7] 
Fitzpatrick skin-type not reported in n=4. Classification of scores:  1 = extremely fair skin; always burn, never tan, 2 = fair skin; always burn, sometimes 
tan, 3 = pale skin; sometimes burn, always tan, 4 = olive skin; rarely burn, always tan, 5 = moderately pigmented brown skin; never burn, always tan, 
6 = markedly pigmented black skin; never burn, always tan. [8] Skin melanin density: readings taken from inside left arm, measured in arbitrary units; 
range of values: 16.4 – 90.1. [9] Recent sunny holiday not reported in n=3. Defined as a trip to any location within a latitude 51o North/South of the 
equator, during the local sunny season, 2 months prior to blood draw, for a duration of ≥1 week. †Adjusted for sex, ethnicity, vitamin D supplement 
consumption, quarter of blood draw, skin type and tanning bed use. [10] Hair loss:  categories 0-4 were defined by merging Male (Norwood-Hamilton 
[NH]) and Female (Ludwig [LG]) scales of hair loss: 0 = No hair loss, 1 = NH categories II & III (minor recession of frontal hairline; significant frontal 
loss/significant frontal regression + early hair loss from crown) merged with LG category I (thinning of hair from anterior crown with minimal 
widening of parting), 2 = NH categories IV & V (further frontal loss and enlargement of crown; further enlargement of crown and bridge begins to 
separate) merged with LG category II (evident thinning of crown), 3 = NH categories VI & VII (bridge disappears leaving large bald area on front and 
top of scalp; only back of scalp retains significant amount of hair) merged with LG category III (crown becomes denuded with significant parting, but 
hairline remains), 4 = other. † Adjusted for sex, ethnicity, vitamin D supplement consumption, quarter of blood draw, and hair loss.  
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 





5.4.3. Genetic determinants of vitamin D status. 
Genetic determinants of vitamin D status are presented in table 6.3. After adjusting for significant 
lifestyle determinants of vitamin D status (ethnicity, vitamin D supplementation and season of 
sampling), one SNP in DBP independently associated with serum 25(OH)D concentration: AA 
genotype for rs7041 associated with 10.2 nmol/L lower level (95% CI –18.7 to -1.7), referent to CC 
genotype. After correcting for multiple comparison testing (Bejamini & Hochberg; false discovery 



















Table 6.3. Genetic determinants of serum 25-hydroxyvitamin D concentration. 
 
Gene SNP   Genotype N Mean 25(OH)D, 
nmol/L (SD) 
Multivariable model –      P value  1        












TT 128 44.6 (23.3) referent 0.39 
AT 75 40.7 (19.7) -0.20 (-5.87 to 6.27)  




CC 72 44.2 (20.3) referent 0.46 
CG 94 42.3 (24.1) -1.03 (-7.46 to 5.41)  

















AA 118  43.1 (22.6) referent 0.53 
AT 88 42.9 (21.7) -3.01 (-8.79 to 2.77)  




CC 58 48.4 (25.4) referent 0.020 
AC 103 41.7 (21.2) -4.84 (-11.55 to 1.88)  




TT 94 43.0 (21.8) referent 0.69 
CT 101 41.7 (22.6) -1.05 (-6.91 to 4.82)  




GG 131 44.2 (22.5) referent 0.19 
GT 81 41.0 (21.5) -4.23 (-9.97 to 1.51)  




TT 181 43.3 (22.3) referent 0.68 
TG 29 37.3 (20.2) -6.21 (-14.34 to 1.93)  




AA 130 42.6 (21.9) referent 0.42 
AG 69 44.2 (22.0) +0.27 (-5.79 to 6.32)  







AA 103 44.9 (22.8) referent 0.24 
AG 87 41.8 (21.1) -3.09 (-8.98 to 2.80)  











TT 97 44.3 (22.3) referent 0.46 
GT 96 40.5 (21.8) -4.26 (-10.26 to 1.74)  




GG 67 41.5 (23.3) referent 0.13 
AG 114 41.9 (21.4) +1.62 (-4.73 to 7.97)  




GG 85 41.8 (21.5) referent 0.78 
AG 94 41.9 (22.8) +0.05 (-6.35 to 6.45)  









TT 106 45.0 (21.9) referent 0.52 
GT 79 42.4 (22.7) -2.32 (-8.77 to 4.12)  




GG 155 42.7 (21.7) referent 0.58 
AG 49 41.3 (23.0) -0.88 (-7.62 to 5.85)  







AA 97 40.2 (21.5) referent 0.29 
AT 90 44.1 (21.6) +3.64 (-2.61 to 9.88)  
TT 27 45.3 (26.2) +4.95 (-4.23 to 14.14)  
 
[1] Adjusted for sex, age, BMI, ethnicity, SEP, hours outdoors, vitamin D supplement consumption, season of blood draw, Fitzpatrick skin-
type, smoking status, alcohol consumption, recent sunny holiday, tanning bed use, hair loss, melanin density, and corrected for multiple 
comparisons testing, using the Benjamini & Hochberg method with a 5% false discovery rate.  
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 
Abbreviations: SNP: Single nucleotide polymorphism, SD: Standard deviation, CI: Confidence interval, CYP-: Cytochrome P450-, DBP: vitamin 







To my knowledge this is the first study to comprehensively investigate the environmental and genetic 
determinants of vitamin D status in a UK cohort of older adults residing in sheltered accommodation 
(community housing). The majority of participants (64.9%) were vitamin D deficient at the 50 nmol/L 
25(OH)D threshold; the mean serum 25(OH)D concentration for all participants was 42.7 nmol/L. 
These levels are comparable to those reported in a recent UK national survey for over 65 year olds 
living in private households (314), and higher than those reported among older adults in care home 
settings who are unable to mobilise out of doors (306, 315).  
 
Three environmental factors independently associated with lower vitamin D status: non-white 
ethnicity, lack of vitamin D supplement consumption, and sampling in Winter or Spring. Non-White 
ethnicity (25% of the cohort) associated with a 8.6 nmol/L lower vitamin D status. Of the non-White 
study participants, the largest groups were Black / Black British (38/55 non-White participants), and 
Asian / Asian British (14/55 non-White participants). My findings agree with previous reports of 
vitamin D status in elderly participants: an observational study conducted in Baltimore, U.S. found 
lower serum 25(OH)D concentrations in African American participants aged ≥65 years, compared to 
White participants of a similar age (316), and one study conducted in Birmingham, UK reported a 
higher prevalence of vitamin D deficiency (57%) in elderly Asian participants as compared to elderly 
White participants (11%) (317). Consumption of daily vitamin D supplements associated with better 
vitamin D status: those taking a daily supplement had a 17.1 nmol/L higher 25(OH)D level, compared 
to those not taking a supplement. A cross-sectional study of elderly Dutch participants reported a 
similar association: from combined dietary sources of vitamin D they calculated that consumption of 
just 6.4 µg/day (256 IU) equated to a 16.8 nmol/L higher serum 25(OH)D concentration (318). My 




This finding is consistent with reports from two cross-sectional studies in UK adults (298, 319) where 
vitamin D status was reported to peak in September and to trough from January to March.  
 
5.5.1. Study strengths. 
This study has several strengths. A wide range of potential environmental and genetic determinants 
of vitamin D status were investigated in study participants that included objective measurement of 
skin pigmentation using a colorimeter and assessment of the extent of baldness. Two further 
strengths were the measurement of serum 25(OH)D concentration by LC-MS/MS in a laboratory 
participating in the DEQAS scheme, and the fact that the study was conducted over a 1 year period 
to allow observation of serum 25(OH)D concentrations across all seasons. 
 
5.5.2. Study limitations. 
The study also has some limitations. One limitation was the estimate of UVR exposure data by self-
reported outdoor activity rather than by direct measurement of UVR exposure. Another limitation 
was the relatively small sample size used to investigate genetic determinants of vitamin D status – 
whilst the direction of association between SNP genotype and 25(OH)D concentrations in our study 
population were in agreement with those reported in previous studies, the paucity of statistically 
significant associations we identified may have arisen due to a lack of statistical power for detection,  
and the likelihood of type II error (false negatives/failure to reject the null hypothesis) was likely high 
owed to the strict false discovery rate (FDR) of 5% I set, using the Benjamini & Hochberg (BH) method. 
Setting a FDR threshold allows the researcher to control the expected proportion of type I errors 
(false positives/incorrect rejection of the null hypothesis) that exist within significant results. Whilst 
BH correction is a more forgiving, and arguably more sophisticated approach than the Bonferroni 
method that simply aims to eliminate type I error altogether by applying a cut-off threshold to all p 




type II error with BH correction (320). The likelihood of this decreases with an increasing FDR (some 
use a 10%, 20%, or 25% threshold), but this tilts the balance back towards probable type I error.  
 
There is no consensus in the field on the most appropriate FDR threshold to use, so in practice the 
compromise between acceptable levels of type I vs. type II error is often based upon the cost of 
discarding potentially true results. My approach could have been slightly less conservative by 
selecting an FDR of 10%, and this would have resulted in 3 SNP in the asthma cohort (Chapter 4) 
showing an independent association with vitamin D status after correcting for multiple comparisons, 
but that these SNP did not predict vitamin D status in the older adult and COPD study (Chapter 6) 




In conclusion, I found that vitamin D deficiency was highly prevalent in a population of UK older 
adults living in sheltered accommodation, despite their ability to mobilise independently outdoors. 
Non-white ethnicity, lack of vitamin D supplement consumption and sampling in Winter and Spring 
independently associated with decreased serum 25(OH)D concentrations in this population, but 
genetic variation in the vitamin D pathway did not. The clinical implication of these findings is that 
consumption of vitamin D supplements is protective against vitamin D deficiency in this population, 






6. Cross-sectional analysis: Prevalence, determinants and clinical 
correlates of vitamin D deficiency in Chronic Obstructive Pulmonary 
Disease. 
 
In this chapter I present a second cross-sectional analysis of lifestyle and genetic factors to associate 
with vitamin D status and the effect of vitamin D status on clinical markers of disease phenotype, on 
individuals diagnosed with COPD who attended a screening visit for participation in the ViDiCO trial 
(described in Methods, section 2.2.1).  
 
6.1. Introduction. 
Vitamin D deficiency has been reported to be more common in patients with chronic obstructive 
pulmonary disease (COPD) than in healthy controls (321-323), and has been found to associate with 
reduced forced expiratory volume in one second (FEV1) / increased global initiative for 
chronic obstructive lung disease (GOLD) stage (323-328), reduced forced vital capacity (FVC), 
reduced peak expiratory flow (PEF), lower health-related quality of life (QoL) scores (324), as well as 
increased inhaled corticosteroid (ICS) requirement, and hypoxaemia (328). Reports of the association 
between vitamin D status and exercise capacity / skeletal muscle strength are conflicting, with one 
study reporting a positive association (326) and others reporting no associations (327, 329, 330). 
 
To my knowledge, there are no previous cross-sectional investigations of serum 25(OH)D 
concentration and sputum biomarkers of COPD severity. Raised neutrophil and eosinophil levels and 
their inflammatory mediators have been identified during COPD exacerbation (331-333), and in a 
recent clinical trial we found vitamin D supplementation to significantly reduce risk of COPD 
exacerbation in those who were deficient at baseline (<50 nmol/L) (210). Furthermore, 
environmental and genetic factors which have been shown to influence vitamin D status in healthy 
populations (122, 334) have not yet been well characterised in COPD patients, nor have genetic 





I conducted a cross-sectional analysis to determine the prevalence of environmental and genetic 
determinants of serum 25(OH)D concentration in COPD patients being treated in London, UK, an 
whether associations exist between genetic variants in the vitamin D pathway and clinical correlates 
of COPD phenotype, specifically: % predicted FEV1, % predicted forced vital capacity (FVC), FEV1:FVC 
ratio, ICS requirement, Quality of Life ([Qol], as measured by the St. George’s respiratory 



























6.2.1. Study population. 
A total of 278 adult COPD patients were enrolled in the study between 11th September 2009 and 12th 
April 2012. All consented to undergo clinical measurements and to donate blood samples for 
quantification of serum 25(OH)D and PTH concentration; 277/278 consented to donate a blood 
sample for DNA storage and genotyping. Participant characteristics are presented in Table 5.1. Age 
range was 40.8 to 91.9 years, with a mean of 66.4 years (SD 9.5). Most participants (60.8%) were 
male. The majority of participants (94.2%) classified their ethnic origin as being White; 1.8% were 
Asian/Asian British; 0.7% were Black/Black British; 1.8% were of mixed ethnicity; and 1.4% preferred 
not to report their ethnicity. Participants’ COPD was managed exclusively in primary care in 202/278 
(72.7%). Mean serum 25(OH)D concentration for all participants was 45.3 nmol/L (SD 25.4). Sixtyone 
participants (21.9%) had serum 25(OH)D concentration <25 nmol/L; 110 (39.6%) had serum 25(OH)D 
concentration in the range 25-49.9 nmol/L; 74 (26.6%) had serum 25(OH)D concentration in the 

















Sex, n (%) Female 109 (39.2) 
Male 169 (60.8) 
Mean Age, yrs (range)   66.4 (40.8 -91.9) 
Mean BMI, kg/m2 (SD)  27.7 (6.8) 
Ethnicity, n (%) 1 White 262 (94.2) 
Asian / Asian British 5 (1.8) 
Black / Black British 2 (0.6) 
Mixed 5 (1.8) 
Fitzpatrick Skin-type, n (%) 2 1 35 (12.8) 
2 56 (20.5) 
3 137 (50.2) 
4 29 (10.6) 
5  15 (5.5) 
6  1 (0.4) 
Socio-economic Position, n (%) 3 1 81 (29.7) 
2 24 (8.8) 
3 42 (15.4) 
4 62 (23.7) 
5 64 (23.4) 
Time outdoors, hours/day (%) 4 >2hrs 130 (47.6) 
≤2hrs 143 (52.4) 
Daily vitamin D supplements, n (%) 5 Any 52 (19.3) 
None 217 (80.7) 
Quarter of sampling, n (%) Q1 (Jan – Mar) 82 (29.5) 
Q2 (Apr – Jun) 55 (19.8) 
Q3 (Jul – Sep) 69 (24.8) 
Q4 (Oct – Dec) 72 (25.9) 
Smoking status, n (%) Non-current 169 (60.8) 
Current 109 (39.2) 
Mean alcohol, units/week (SD) 6  10.9 (18.3) 
Managed exclusively in primary care, n (%)  202 (72.7) 
Mean serum corrected calcium (SD) 7  2.25 (0.09) 
Recent sunny holiday, n (%) 8 Yes 16 (5.9) 
No 257 (94.1) 
Tanning bed use in previous yr, n (%) 9 Yes 4 
No 269 
Mean serum PTH (SD)  5.9 (3.0) 
Serum PTH >6.8 pmol/L, n (%) Yes 68 (24.5) 
No 210 (75.5) 
Serum 25(OH)D, nmol/L (%) ≥75 33 (11.9) 
50 – 74.9 74 (26.6) 
25 – 49.9 110 (39.6) 
<25 61 (21.9) 
Mean serum 25(OH)D (SD)  45.3 (25.4) 
 
[1] Ethnicity not reported in n=4. Mixed ethnicity participants: n=3 ‘White and Black Caribbean’; n=1 ‘White and Black African’; n=1 ‘White 
and Asian’. [2] Fitzpatrick skin-type score not reported in n=5. Categories defined as:  1 = extremely fair skin; always burn, never tan, 2 = 
fair skin; always burn, sometimes tan, 3 = pale skin; sometimes burn, always tan, 4 = olive skin; rarely burn, always tan, 5 = moderately 
pigmented brown skin; never burn, always tan, 6 = markedly pigmented black skin; never burn, always tan. [3] SEP not reported in n=5. 
Classes defined as: 1 = managerial, administrative and professional occupations, 2 = intermediate occupations, 3 = small employers and 
own account workers, 4 = lower supervisory and technical occupations, 5 = semi-routine and routine occupations, 6 = student, 7 = 
Never/Long-term (>5yrs) unemployed. [4] Time outdoors not reported in n=5. [5] Vitamin D supplementation consumption not reported 
in n=9. [6] Alcohol consumption not reported in n=13. [7] Corrected calcium not measured in n=5. [8] Recent sunny holiday not reported 
in n=5. Defined as a trip to any location within a latitude 51o North/South of the equator, during the local sunny season, 2 months prior 
to blood draw, for a duration of ≥1 week. [9] Tanning bed use not reported in n=5. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………… 
Abbreviations: BMI: Body mass index, SD: Standard deviation, PTH: Parathyroid hormone, GOLD: Global initiative for chronic obstructive 









6.2.2. Environmental determinants of serum 25(OH)D concentration. 
Environmental determinants of vitamin D status are presented in Table 5.2. Multiple linear 
regression analysis showed the following factors to independently associate with lower serum 
25(OH)D concentration: higher BMI (adjusted mean difference of 9.6 nmol/L for ≥25 kg/m2 vs. <25 
kg/m2; 95% CI -15.7 to -3.4; P=0.002); lower SEP (adjusted mean difference of 6.2 nmol/L for higher 
vs. lower classes; 95% CI -12.4 to -0.0; P=0.049); lack of vitamin D supplement consumption (adjusted 
mean difference of 12.1 nmol/L for those taking any supplement vs. those taking no supplement; 
95% CI -19.4 to -4.9; P=0.001); Sampling in January – March vs. July-September (adjusted mean 
difference 14.3nmol/L; 95% CI -22.6 to -6.0; P for trend = 0.005); and lack of a recent sunny holiday 
abroad (adjusted mean difference of 20.3nmol/L for those without vs. with such a holiday; 95% CI -
















Table 5.2. Environmental determinants of serum 25-hydroxyvitamin D concentration in COPD patients. 
 
Factor Category N Serum 25(OH)D, nmol/L Univariate              
P value 1 
Multivariable model -   
Beta Coefficient  
(95% CI) 
P value 2 
   Mean (SD) Mean 
difference 
   
Sex Female 109 49.1 (29.2) referent 0.049 referent 0.52 
Male 169 42.9 (22.3) -6.2  -2.1 (-8.6 to 4.4)  
Age quartiles 1 (40.8 – 60.3 yrs) 69 45.3 (27.3) referent 0.68 referent 0.84† 
2 (60.5 – 65.3 yrs) 70 47.1 (23.8) +1.8  +1.5 (-6.9 to 9.9)  
3 (65.3 – 72.3 yrs) 69 46.6 (28.3) +1.3  0.0 (-8.5 to 8.5)  
4 (72.4 – 91.9 yrs) 70 42.3 (21.9) -3.0  -0.4 (-9.3 to 8.4)  
BMI, kg/m2 <25 109 48.9 (29.4) referent 0.058 referent 0.001 
≥25 169 43.0 (22.1) -5.9  -10.1 (-16.2 to -4.0)  
Ethnicity 3 White 262 45.9 (25.7) referent 0.29 referent 0.29 
Other  12 37.9 (17.2) -8.0  -16.4 (-46.7 to 13.9)  
SEP 4 Higher 105 50.0 (28.0) referent 0.029 referent 0.037 
Lower 168 43.1 (23.2) -6.9  -6.6 (-12.8 to -0.4)  
Time outdoors, 
hrs/day 5 
>2 130 50.5 (27.7) referent 0.003 referent 0.069 
≤2 143  41.5 (22.2) -9.0  -5.5 (-11.5 to 0.4)  
Vitamin D 
supplements 6 
Any 52 57.8 (27.8) referent <0.001 referent  <0.001 
None 217  42.8 (24.1) -15.0  -12.4 (-19.6 to -5.2)  
Quarter of sampling Q1 (Jan – Mar) 82 37.2 (23.4) -15.2 0.001 -14.0 (-22.3 to -5.7) 0.006† 
Q2 (Apr – Jun) 55 43.7 (20.0) -8.7  -8.0 (-16.9 to 0.8)  
Q3 (Jul – Sep) 69 52.4 (24.5) referent  referent  
Q4 (Oct – Dec) 72 49.0 (29.5) -3.4  -3.0 (-11.2 to 5.2)  
Fitzpatrick skin-type 7 1,2 91 44.8 (24.7) -1.9 0.73 -4.0 (-10.4 to 2.4) 0.42† 
3,4 166 46.7 (26.0) referent  referent  
5,6 16 42.3 (22.6) -4.4  +7.2 (-19.7 to 34.0)  
Smoking status Non-current 169 45.4 (22.2) referent 0.97 referent 0.15 
Current 109 45.3 (29.8) -0.1  -4.7 (-11.1 to 1.7)  
Alcohol consumption, 
units/wk 8 
0 121 47.4 (26.4) referent 0.42 referent 0.49† 
1-20 98 44.1 (22.6) -3.3  -5.3 (-12.0 to 1.4)  
>20 46 42.4 (26.4) -5.0  -2.9 (-11.2 to 5.5)  
Recent sunny holiday 
9 
Yes 16 67.4 (36.0) referent <0.001 referent 0.002 
No 257 44.4 (24.0) -23.0  -20.2 (-32.7 to -7.6)  
Tanning bed use, 
previous year 10 
Yes 4 90.8 (34.6) referent <0.001 *  
No 269 45.1 (24.7) -45.7    
GOLD Stage I 69  51.4 (29.0) referent 0.13 referent 0.015† 
II 131 43.3 (23.1) -8.1  -10.4 (-17.8 to -3.0)  
III 62  44.4 (26.2) -7.0  -8.9 (-17.6 to -0.2)  
IV 16 39.5 (20.2) -11.9  -17.8 (-31.6 to -4.1)  
 
[1] Univariate method: Student’s T-test/One-way ANOVA. [2] Adjusted for all potential determinants of 25(OH)D concentration included in 
univariate analysis. [3] Ethnicity not reported in n=4.‘Other’ ethnicity defined as: n=5 Asian/Asian British, n=2 Black/Black British, n=5 mixed 
ethnicity. [4] SEP not reported in n=5. ‘Higher’ defined as classes: 1 (managerial, administrative and professional occupations) and 2 
(intermediate occupations), ‘Lower’ defined as classes: 3 (small employers and own account workers), 4 (lower supervisory and technical 
occupations), and 5 (semi-routine and routine occupations). [5] Time outdoors not reported in n=5. [6] Vitamin D supplementation 
consumption not reported in n=9. [7] Fitzpatrick skin-type score not reported in n=5. Categories defined as:  1 = extremely fair skin; always 
burn, never tan, 2 = fair skin; always burn, sometimes tan, 3 = pale skin; sometimes burn, always tan, 4 = olive skin; rarely burn, always tan, 
5 = moderately pigmented brown skin; never burn, always tan, 6 = markedly pigmented black skin; never burn, always tan. [8] Alcohol 
consumption not reported in n=13. [9] Recent sunny holiday not reported in n=5. Defined as a trip to any location within a latitude 51o 
North/South of the equator, during the local sunny season, 2 months prior to blood draw, for a duration of ≥1 week. † P value for trend.      
* Tanning bed use omitted from multivariable analysis due to <5 participants in ‘yes’ category. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 
Abbreviations: BMI: Body mass index, SEP: Socio-economic position, GOLD: Global initiative for chronic obstructive lung disease, nmol/L: 






6.2.3. Genetic determinants of serum 25(OH)D concentration. 
Genetic determinants of vitamin D status are presented in Table 5.3. After adjusting for sex, age, 
ethnicity, BMI, SEP, time outdoors, quarter of sampling, vitamin D supplement consumption, recent 
sunny holiday and GOLD stage, and correcting for multiple comparison testing (Benjamini & 




















Table 5.3. Genetic determinants of serum 25-hydroxyvitamin D concentration in COPD patients. 
 
Gene SNP Genotype N 1 Serum 25(OH)D, nmol/L Multivariable model -   
Beta Coefficient (95% 
CI) 
P Value 
for trend 2 












TT 180 44.3 (25.5) referent referent 0.54 
AT 78 47.3 (25.2) +3.0 +3.3 (-3.1 to 9.8)  




CC 96 46.4 (29.4) referent referent 0.49 
CG 144 44.0 (23.1) -2.4 +2.5 (-4.2 to 9.1)  

















AA 124 47.2 (24.3) referent referent 0.41 
AT 126 43.3 (26.8) -3.9 -2.6 (-8.9 to 3.6)  




GG 65 50.3 (28.8) referent referent 0.010 
TG 147 44.0 (25.5) -6.3 -6.3 (-13.4 to 0.9)  




TT 113 44.2 (23.4) referent referent 0.12 
CT 130 45.3 (26.6) +1.1 +0.2 (-6.2 to 6.6)  




CC 130 48.5 (26.1) referent referent 0.099 
CA 123 42.9 (25.4) -5.6 -5.1 (-11.2 to 1.1)  




TT 237 44.7 (25.5) referent referent 0.84 
TG 31 49.8 (24.1) +5.1 +0.4 (-8.8 to 9.6)  




AA 181 44.2 (24.5) referent referent 0.38 
AG 87 47.1 (27.5) +2.9 +2.5 (-3.8 to 8.9)  







AA 111 44.0 (27.2) referent referent 0.65 
AG 128 45.7 (25.2) +1.7 +0.3 (-6.2 to 6.7)  











TT 95 46.6 (28.6) referent referent 0.49 
GT 132 45.9 (24.7) -0.7 -2.6 (-9.2 to 4.1)  




GG 95 42.9 (23.6) referent referent 0.99 
AG 129 48.1 (48.1) +5.2 +6.1 (-0.5 to 12.7)  




GG 79 45.8 (27.8) referent referent 0.53 
AG 132 46.0 (24.1) +0.2 -2.5 (-9.4 to 4.4)  









TT 171 45.5 (25.7) referent referent 0.33 
GT 87 45.4 (25.8) -0.1 -1.6 (-7.9 to 4.7)  




GG 210 45.8 (25.6) referent referent 0.22 
AG 54 45.1 (25.1) -0.7 -1.7 (-8.8 to 5.4)  
AA 7 31.9 (10.1) -13.9 -12.0 (-31.5 to 7.4)  
VDR 
  




AA 106 44.6 (24.0) referent referent 0.026 
AT 126 46.6 (25.5) +2.0 -3.4 (-9.8 to 3.1)  
TT 33 37.8 (23.5) -6.8 -10.9 (-20.4 to -1.3)  
 
[1] Genotyping not conducted in n=1. [2] Adjusted for sex, age, BMI, ethnicity, SEP, hours outdoors, vitamin D supplement consumption, 
season of blood draw, Fitzpatrick skin-type, smoking status, alcohol consumption, recent sunny holiday, tanning bed use, and GOLD stage, 
and corrected for multiple comparisons testing, using the Benjamini & Hochberg method with a 5% false discovery rate.  
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 
Abbreviations: DBP: vitamin D binding protein, CYP-: cytochrome P450-, DHCR7: 7-dehydrocholesterol reductase, VDR: vitamin D receptor, 







6.2.4. Association between vitamin D status and COPD phenotype. 
After adjustment for potential environmental confounders, profound vitamin D deficiency was found 
to associate independently with reduced % predicted FEV1 (Table 5.4, adjusted mean difference of 
9.6% for those with a serum 25(OH)D concentration of <25 nmol/L vs. those with serum 25(OH)D 
concentration ≥75 nmol/L; 95% CI -18.8 to -0.4), though the P value for trend across all 4 subgroups 
of vitamin D status was only borderline significant (P=0.060). Vitamin D status also positively 
associated with % predicted FVC (Table 5.5, adjusted mean difference of 12.5% for those with serum 
25(OH)D concentration of <25 nmol/L vs. those with serum 25(OH)D concentration ≥75 nmol/L; 95% 
CI -20.7 to -4.2; P value for trend across all 4 categories of vitamin D status = 0.003). I found no 
statistically significant association between vitamin D status and the other markers of COPD 
phenotype investigated, namely: FEV1:FVC ratio (Table 5.6), quadriceps strength (Table 5.7), St. 
George’s Respiratory Questionnaire score (Table 5.8), inhaled corticosteroid dose (Table 5.9), % 
eosinophils in induced sputum (Table 5.10), or % neutrophils in induced sputum (Table 5.11). 
Multiple linear regression analysis revealed several other factors to independently associate with 
various phenotypic features of COPD. Two measures of increased COPD severity, as indicated by 
lower % predicted FEV1 and FEV1:FVC, showed an association with a BMI <25kg/m2 (P=0.003 and 
P<0.001, respectively). Male sex also associated with lower % predicted FEV1 (P=0.018) and % 
predicted FVC (P<0.001). Older age associated with decreasing FEV1:FVC ratio (P for trend = 0.016). 
Diminished quadriceps strength associated with older age (P for trend <0.001) and non-smoking 
status (P=0.015). Poorer respiratory quality of life, as indicated by lower SGRQ scores, associated 
with older age (P for trend = 0.017), and % eosinophils in blood positively associated with % 







Table 5.4. Determinants of % predicted Forced Expiratory Volume in 1 second (FEV1). 
 
Factor Category N Mean % 
predicted 
FEV1 (SD) 
Univariate              
P value 1 
Multivariable 
model – beta 
coefficient (95% CI) 
P value 2 
Sex Female 109 68.6 (20.2) 0.001 referent 0.029 
Male 169 60.4 (20.2)  -6.1 (-11.6 to -0.6)  
Age quartiles 1 (40.8 – 60.3 yrs) 69 66.8 (19.8) 0.24 referent 0.085† 
2 (60.5 – 65.3 yrs) 70 65.3 (19.2)  -3.0 (-10.3 to 4.2)  
3 (65.3 – 72.3 yrs) 69 61.6 (22.5)  -7.2 (-14.6 to 0.2)  
4 (72.4 – 91.9 yrs) 70 60.7 (20.3)  -5.5 (-13.0 to 1.9)  
BMI, kg/m2 <25 109 59.3 (20.8) 0.005 referent 0.004 
≥25 169 66.4 (19.9)  +7.6 (2.4 to 12.8)  
Ethnicity 3 White 262 63.7 (20.7) 0.52 referent 0.57 
Other  12 59.8 (13.4)  -3.6 (-16.0 to 8.9)  
SEP 4 Higher 105 68.0 (19.7) 0.007 referent 0.089 
Lower 168 61.1 (20.6)  -4.6 (-10.0 to 0.7)  
Smoking status Non-current 169 63.3 (21.4) 0.75 referent 0.89 
Current 109 64.1 (19.1)  +0.4 (-5.1 to 5.8)  
Alcohol consumption, 
units/wk 5 
0 121 63.2 (21.0) 0.76 referent 0.26† 
1-20 98 65.2 (18.9)  +3.2 (-2.4 to 8.8)  
>20 46 64.8 (22.3)  +4.1 (-3.1 to 11.3)  
Influenza vaccination Yes 255 63.7 (20.6) 0.91 referent 0.71 
No 23 63.1 (19.9)  -1.9 (-11.7 to 7.9)  
Pneumonia vaccination  Yes 179 62.9 (20.1) 0.45 referent 0.35 
No 99 64.9 (21.4)  +2.6 (-2.9 to 8.2)  
Serum 25(OH)D, nmol/L ≥75 33  69.3 (19.4) 0.16 referent 0.060† 
74.9 – 50 74  63.6 (20.0)  -5.8 (-14.4 to 2.8)  
49.9 – 25 110 64.3 (20.2)  -4.0 (-12.2 to 4.3)  
<25 61 59.4 (21.9)  -9.6 (-18.8 to -0.4)  
 
[1] Univariate analysis method: Student’s T-test / One-way ANOVA test. [2] Adjusted for all potential determinants of FEV1 investigated in 
univariate analysis. [3] Ethnicity not reported in n=4.‘Other’ ethnicity defined as: n=5 Asian/Asian British, n=2 Black/Black British, n=5 mixed 
ethnicity.[4] SEP not reported in n=5. ‘Higher’ defined as classes: 1 (managerial, administrative and professional occupations) and 2 
(intermediate occupations), ‘Lower’ defined as classes: 3 (small employers and own account workers), 4 (lower supervisory and  technical 
occupations), and 5 (semi-routine and routine occupations). [5] Alcohol consumption not reported in n=13. † P value for trend. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 




































Table 5.5. Determinants of forced vital capacity (FVC). 
Factor Category N Mean % 
predicted FVC 
(SD) 
Univariate              
P value 1 
Multivariable model – 
beta coefficient  
(95% CI) 
P value 2 
Sex Female 109 104.0 (19.0) <0.001 referent <0.001 
Male 169 92.2 (17.8)  -11.14 (-16.07 to -6.21)  
Age quartiles 1 (40.8 – 60.3 yrs) 69 98.6 (19.3) 0.69 referent 0.52† 
2 (60.5 – 65.3 yrs) 70 97.8 (18.6)  -0.77 (-7.29 to 5.75)  
3 (65.3 – 72.3 yrs) 69 95.1 (18.7)  -3.57 (-10.21 to 3.08)  
4 (72.4 – 91.9 yrs) 70 95.9 (20.1)  -1.36 (-8.05 to 5.32)  
BMI, kg/m2 <25 109 98.3 (19.7) 0.29 referent 0.40 
≥25 169 95.8 (18.8)  -2.00 (-6.64 to 2.64)  
Ethnicity 3 White 262 97.5 (19.3) 0.009 referent 0.045 
Other  12 82.7 (9.8)  -11.41 (-22.58 to -0.24)  
SEP 4 Higher 105 101.5 (19.3) 0.002 referent 0.12 
Lower 168 94.3 (18.6)  -3.80 (-8.59 to 0.98)  
Smoking status Non-current 169 96.6 (19.4) 0.78 referent 0.60 
Current 109 97.2 (18.8)  -1.29 (-6.19 to 3.61)  
Alcohol consumption, 
units/wk 5 
0 121 97.2 (19.8) 0.89 referent 0.31† 
1-20 98 98.1 (17.5)  +3.45 (-1.56 to 8.46)  
>20 46 96.7 (20.0)  +3.30 (-3.14 to 9.73)  
Influenza vaccination Yes 255 96.8 (18.8) 0.94 referent 0.97 
No 23 96.5 (23.5)  -0.19 (-8.97 to 8.59)  
Pneumonia vaccination  Yes 179 97.1 (17.0) 0.75 referent >0.99 
No 99 96.3 (22.7)  +0.02 (-4.95 to 4.98)  
Serum 25(OH)D, 
nmol/L 
≥75 33  107.4 (18.4) 0.002 referent 0.003† 
74.9 – 50 74  98.2 (18.0)  -7.07 (-14.80 to 0.66)  
49.9 – 25 110 95.4 (18.9)  -8.00 (-15.39 to -0.59)  
<25 61 92.0 (19.5)  -12.46 (-20.70 to -4.21)  
 
[1] Univariate analysis method: Students T-test / One-way ANOVA test. [2] Adjusted for all potential determinants of FVC investigated in 
univariate analysis. [3] Ethnicity not reported in n=4, ‘Other’ ethnicity defined as: n=5 Asian/Asian British, n=2 Black/Black British, n=5 
mixed ethnicity. [4] SEP not reported in n=5. ‘Higher’ defined as classes: 1 (managerial, administrative and professional occupations) and 
2 (intermediate occupations), ‘Lower’ defined as classes: 3 (small employers and own account workers), 4 (lower supervisory and technical 
occupations), and 5 (semi-routine and routine occupations). [5] Alcohol consumption not reported in n=13. † P value for trend. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 


































Table 5.6. Determinants of forced expiratory volume in 1 second to forced vital capacity ratio 
(FEV1:FVC). 
 
Factor Category N Median FEV1:FVC 
(IQR) 
Univariate              
P value 1 
Multivariable 
model – antilog of 
beta coefficient 
(95% CI) 
P value 2 
Sex Female 109 0.57 (0.47 to 0.65) 0.003 referent 0.069 
Male 169 0.51 (0.40 to 0.62)  0.93 (0.87 to 1.01)  
Age quartiles 1 (40.8 – 60.3 yrs) 69 0.58 (0.49 to 0.65) 0.014 referent 0.019† 
2 (60.5 – 65.3 yrs) 70 0.55 (0.45 to 0.63)  0.95 (0.86 to 1.04)  
3 (65.3 – 72.3 yrs) 69 0.54 (0.39 to 0.62)  0.89 (0.80 to 0.98)  
4 (72.4 – 91.9 yrs) 70  0.49 (0.35 to 0.60)  0.90 (0.81 to 1.00)  
BMI, kg/m2 <25 109 0.48 (0.37 to 0.59) <0.001 referent <0.001 
≥25 169 0.57 (0.47 to 0.64)  1.17 (1.09 to 1.26)  
Ethnicity 3 White 262 0.53 (0.43 to 0.63) 0.33 referent 0.32 
Other  12 0.59 (0.54 to 0.59)  1.09 (0.92 to 1.29)  
SEP 4 Higher 105 0.56 (0.46 to 0.65) 0.032 referent 0.15 
Lower 168 0.52 (0.40 to 0.62)  0.95 (0.88 to 1.02)  
Smoking status Non-current 169 0.54 (0.42 to 0.63) 0.59 referent 0.31 
Current 109 0.55 (0.45 to 0.63)  1.04 (0.97 to 1.12)  
Alcohol consumption, 
units/wk 5 
0 121 0.55 (0.43 to 0.63) 0.99 referent 0.54† 
1-20 98 0.55 (0.45 to 0.63)  1.03 (0.95 to 1.11)  
>20 46 0.54 (0.42 to 0.62)  1.03 (0.94 to 1.14)  
Influenza vaccination Yes 255 0.54 (0.43 to 0.63) 0.79 referent 0.70 
No 23 0.52 (0.46 to 0.65)  0.97 (0.85 to 1.11)  
Pneumonia vaccination  Yes 179 0.53 (0.42 to 0.63) 0.16 referent 0.18 
No 99 0.56 (0.46 to 0.63)  1.05 (0.98 to 1.13)  
Serum 25(OH)D, 
nmol/L 
≥75 33 0.55 (0.43 to 0.64) 0.48 referent 0.58† 
74.9 – 50 74 0.52 (0.42 to 0.62)  0.96 (0.85 to 1.08)  
49.9 – 25 110 0.56 (0.45 to 0.64)  1.01 (0.90 to 1.13)  
<25 61 0.50 (0.42 to 0.61)  0.95 (0.84 to 1.07)  
 
[1] Univariate analysis method:Mann-Whitney / Kruskal-Wallis tests. [2] Adjusted for all potential determinants of FEV:FVC included in 
univariate analysis. [3] Ethnicity not reported in n=4.‘Other’ ethnicity defined as: n=5 Asian/Asian British, n=2 Black/Black British, n=5 mixed 
ethnicity. [4] SEP not reported in n=5. ‘Higher’ defined as classes: 1 (managerial, administrative and professional occupations) and 2 
(intermediate occupations), ‘Lower’ defined as classes: 3 (small employers and own account workers), 4 (lower supervisory and  technical 
occupations), and 5 (semi-routine and routine occupations). [5] Alcohol consumption not reported in n=13. † P value for trend. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 
















Table 5.7. Determinants of Quadriceps Strength (QS). 
 
Factor Category N 1 Mean QS, kg  
(SD) 
Univariate              
P value 2 
Multivariable model – 
beta coefficient (95% CI) 
P value 3 
Sex Female 46 25.1 (10.9) <0.001 referent <0.001 
Male 88 36.5 (11.1)  +13.63 (9.41 to 17.86)  
Age quartiles 1 (43.5 to 58.7) 33 37.2 (13.9) 0.001 referent <0.001† 
2 (58.9 to 64.4) 34 35.2 (12.3)  -5.45 (-10.35 to -0.56)  
3 (64.6 to 70.0) 32 26.2 (9.5)  -10.80 (-15.90 to -5.69)  
4 (70.2 to 91.7) 35 31.5 (10.5)  -9.25 (-14.69 to -3.81)  
BMI, kg/m2 <25 68 32.2 (13.3) 0.73 referent 0.058 
≥25 66 32.9 (11.2)  +2.91 (-0.87 to 6.68)  
SEP 4 Higher 50 31.8 (13.7) 0.60 referent 0.14 
Lower 84 33.0 (11.4)  -3.52 (-7.42 to 0.38)  
Smoking status Non-current 70 31.4 (11.3) 0.23 referent 0.015 
Current 64 33.9 (13.2)  +4.65 (0.08 to 8.47)  
Alcohol consumption, 
units/wk 5 
0 53 30.4 (11.7) 0.036 referent 0.73† 
1-20 49 36.3 (12.2)  1.99 (-2.15 to 6.13)  
>20 26 30.4 (13.3)  -1.38 (-6.23 to 3.48)  
Serum 25(OH)D, 
nmol/L 
≥ 75 24 27.8 (11.8) 0.045 referent 0.803† 
74.9 – 50 36 36.8 (13.8)  +4.52 (-1.12 to 10.17)  
49.9 – 25 51 32.0 (11.1)  +1.54 (-3.82 to 6.89)  
<25 23 32.3 (11.2)  +0.72 (-5.55 to 6.98)  
 
[1] Quadriceps strength measured in a subset of n=134. [2] Univariate analysis method: Students T-test / One-way ANOVA test. [3] Adjusted 
for all potential determinants of QS included in univariate analysis. [4] SEP not reported in n=5. ‘Higher’ defined as classes: 1 (managerial, 
administrative and professional occupations) and 2 (intermediate occupations), ‘Lower’ defined as classes: 3 (small employers and own 
account workers), 4 (lower supervisory and technical occupations), and 5 (semi-routine and routine occupations).[5] Alcohol consumption 
not reported in n=6. † P value for trend. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 




































Table 5.8. Determinants of St. George’s Respiratory Questionnaire score (SGRQ). 
 
Factor Category N 1 Mean 
SGRQ (SD) 
Univariate              
P value  2 
Multivariable model – 
beta coefficient (95% 
CI) 
P value 3 
Sex Female 108 48.6 (17.5) 0.19 referent 0.30 
 Male 167 45.6 (19.5)  -2.7 (-7.8 to 2.4)  
Age quartiles 1 (40.8 – 60.3 yrs) 69 52.5 (18.8) 0.030 referent 0.013† 
 2 (60.5 – 65.3 yrs) 70 45.5 (19.5)  -7.3 (-14.1 to -0.6)  
 3 (65.3 – 72.3 yrs) 67 43.9 (18.8)  -9.0 (-15.8 to -2.1)  
 4 (72.4 – 91.9 yrs) 69 45.1 (17.0)  -8.7 (15.6 to -1.8)  
BMI, kg/m2 <25 109 46.3 (19.2) 0.72 referent 0.66 
 ≥25 166  47.1 (18.5)  +1.1 (-3.7 to 5.9)  
Ethnicity 4 White 260 47.0 (18.9) 0.58 referent 0.53 
 Other  12 44.0 (16.0)  -3.7 (-15.2 to 7.8)  
SEP 5 Higher 105 44.1 (17.5) 0.077 referent 0.10 
 Lower 167 48.2 (19.3)  +4.1 (-0.8 to 9.0)  
Smoking status Non-current 167 47.0 (18.5) 0.83 referent 0.16 
 Current 108 46.4 (19.3)  -3.6 (-8.7 to 1.4)  
Alcohol consumption, 
units/wk 6 
0 119 49.1 (19.2) 0.034 referent 0.74† 
1-20 98 42.6 (18.3)  -6.1 (-11.2 to -0.9)  
>20 46 47.6 (17.4)  -1.1 (-7.7 to 5.5)  
Influenza vaccination Yes 254 46.6 (18.7) 0.53 referent 0.52 
No 21 49.2 (19.5)  +2.9 (-6.1 to 12.0)  
Pneumonia vaccination  Yes 177 47.8 (19.1) 0.21 referent 0.12 
No 98 44.8 (18.1)  -4.0 (-9.2 to 1.1)  
Serum 25(OH)D, 
nmol/L 
≥75 33 44.1 (18.2) 0.56 referent 0.31† 
74.9 – 50 74  45.8 (18.4)  +2.3 (-5.7 to 10.3)  
49.9 – 25 109 46.7 (18.8)  +2.5 (-5.2 to 10.1)  
<25 59 49.4 (19.7)  +4.4 (-4.1 to 12.9)  
 
[1] SGRQ completed by n=275. [2] Univariate analysis method: Students T-test / One-way ANOVA test. [3] Adjusted for all potential 
determinants of SGRQ included in univariate analysis. [4] Ethnicity not reported in n=3. ‘Other’ ethnicity defined as: n=5 Asian/Asian British, 
n=2 Black/Black British, n=5 mixed-ethnicity. [5] SEP not reported in n=3. ‘Higher’ defined as classes: 1 (managerial, administrative and 
professional occupations) and 2 (intermediate occupations), ‘Lower’ defined as classes: 3 (small employers and own account workers), 4 
(lower supervisory and technical occupations), and 5 (semi-routine and routine occupations). [6] Alcohol consumption not reported in n=12. 
† P value for trend. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 


















Table 5.9. Determinants of Inhaled Corticosteroid (ICS) dose. 
 
Factor Category N Median ICS 
dose (IQR) 
Univariate              
P value 1 
Multivariable model 
– antilog of beta 
coefficient (95% CI) 
P value 2 
Sex Female 109 500 (0 to 1000) 0.88 referent 0.84 
 Male 169 400 (0 to 1000)  1.03 (0.79 to 1.34)  
Age quartiles 1 (40.8 – 60.3 yrs) 69 400 (0 to 1000) 0.43 referent 0.33† 
 2 (60.5 – 65.3 yrs) 70  500 (0 to 1000)  1.32 (0.92 to 1.87)  
 3 (65.3 – 72.3 yrs) 69 400 (0 to 1000)  1.23 (0.86 to 1.76)  
 4 (72.4 – 91.9 yrs) 70  400 (0 to 1000)  1.24 (0.86 to 1.78)  
BMI, kg/m2 <25 109 400 (0 to 1000) 0.71 referent 0.61 
 ≥25 169 500 (0 to 1000)  0.94 (0.72 to 1.21)  
Ethnicity 3 White 262 480 (0 to 1000) 0.19 referent 0.83 
 Other  12 900 (0 to 1500)  1.07 (0.57 to 2.00)  
SEP 4 Higher 105 400 (0 to 1000) 0.57 referent 0.30 
 Lower 168  500 (0 to 1000)  1.14 (0.89 to 1.48)  
Smoking status Non-current 169 500 (0 to 1000) 0.95 referent 0.56 
 Current 109 400 (0 to 1000)  1.09 (0.83 to 1.43)  
Alcohol consumption, 
units/wk 5 
0 121 400 (0 to 1000) 0.71 referent 0.25† 
1-20 98 450 (0 to 1000)  0.90 (0.68 to 1.18)  
 >20 46 490 (0 to 1000)  0.82 (0.59 to 1.15)  
Influenza vaccination Yes 255 480 (0 to 1000) 0.65 referent 0.43 
No 23 400 (0 to 1000)  1.21 (0.75 to 1.93)  
Pneumonia vaccination  Yes 179 500 (0 to 1000) 0.83 referent 0.98 
No 99 400 (0 to 1000)  1.00 (0.77 to 1.31)  
Serum 25(OH)D, 
nmol/L 
≥75 61 500 (0 to 1000) 0.85 referent 0.95† 
74.9 – 50 110 500 (0 to 1000)  1.04 (0.67 to 1.63)  
49.9 – 25 74 450 (0 to 1000)  1.09 (0.72 to 1.67)  
<25 33 200 (0 to 1000)  0.97 (0.60 to 1.56)  
 
[1] Univariate analysis method: Mann-Whitney / Kruskal-Wallis tests. [2] Adjusted for all potential determinants of ICS score included in 
univariate analysis. [3] Other ethnicities: n=4 Asian, n=2 Black, n=5 Mixed-ethnicity, n=17 Undefined. [4] SEP not reported in n=5. ‘Higher’ 
defined as classes: 1 (managerial, administrative and professional occupations) and 2 (intermediate occupations), ‘Lower’ defined as 
classes: 3 (small employers and own account workers), 4 (lower supervisory and technical occupations), and 5 (semi-routine and routine 
occupations). [5] Alcohol consumption not reported in n=13. † P value for trend. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 



















Table 5.10. Determinants of sputum eosinophilia (subset of n=44 participants). 
 
Factor Category N Median 
eosinophilia 
(IQR) 
Univariate              
P value 1 
Multivariable model 
– antilog of beta 
coefficient (95% CI) 
P value 2 
Sex Female 16 1.5 (0.5 to 3.2) 0.97 1.12 (0.63 to 2.00) 0.69 
Male 28 1.6 (0.5 to 6.8)  referent  
Age quartiles 1 (54.0 – 62.5) 11 0.8 (0.3 to 3.6) 0.64 referent 0.082† 
2 (62.6 – 68.2) 11 1.4 (0.6 to 9.4)  1.07 (0.46 to 2.51)  
3 (68.3 – 71.6) 11 2.5 (0.4 to 3.0)  1.17 (0.52 to 2.56)  
4 (71.7 – 91.7) 11 1.8 (0.7 to 13.6)  1.95 (0.92 to 4.13)  
BMI, kg/m2 <25 9 1.6 (0.4 to 3.6) 0.87 referent 0.41 
≥25 35 1.5 (0.5 to 5.8)  0.75 (0.37 to 1.52)  
Blood eosinophilia  <3% 25 0.8 (0.3 to 2.5) 0.007 referent 0.003 
≥3% 19 3.3 (0.8 to 11.1)  2.68 (1.44 to 4.99)   
FEV1:FVC  <0.58 22 1.5 (0.5 to 3.0) 0.66 referent 0.99 
≥0.58 22 1.7 (0.4 to 10.0)  1.00 (0.55 to 1.80)  
Serum 25(OH)D, 
nmol/L 
<50 29 1.6 (0.5 to 5.8) 0.84 0.59 (0.28 to 1.25) 0.16 
≥50 15 1.5 (0.4 to 3.6)  referent  
 
[1] Univariate analysis method: Mann-Whitney/Kruskal-Wallis tests. [2] Adjusted for all potential determinants of sputum eosinophilia 
investigated in univariate analysis. † P value for trend. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 
Abbreviations: BMI: Body mass index, FEV1:FVC: Forced expiratory volume in 1 second to forced vital capacity ratio,  IQR: Interquartile range, 





















Table 5.11. Determinants of sputum neutrophilia (subset of n=44 participants). 
 
Factor Category N Median 
neutrophilia 
(IQR) 
Univariate              
P value 1 
Multivariable 
model – antilog of 
beta coefficient 
(95% CI) 
P value 2 
Sex Female 16 74.8 (66.8 to 76.8) 0.93 +0.1 (-7.5 to 7.8) 0.97 
 Male 28 72.5 (65.3 to 81.5)  referent  
Age quartiles 1 (54.0 – 62.5) 11 75.4 (60.3 to 80.6) 0.42 referent 0.61† 
 2 (62.6 – 68.2) 11 71.3 (68.1 to 74.2)  +4.5 (-7.5 to 16.4)  
 3 (68.3 – 71.6) 11 76.6 (72.3 to 83.0)  +8.9 (-2.5 to 20.3)  
 4 (71.7 – 91.7) 11 72.0 (62.3 to 82.4)  +1.5 (-9.6 to 12.5)  
Blood neutrophilia (%) <60 21 71.3 (62.3 to 76.6) 0.37 referent 0.61 
 ≥60 23 75.4 (68.3 to 83.0)  +1.9 (-5.6 to 9.4)  
Predicted FEV1(%) <67.0 22 73.8 (68.1 to 79.9) 0.42 referent 0.75 
≥67.0 22 71.8 (65.4 to 80.6)  -1.2 (-9.1 to 6.6)  
Serum 25(OH)D, 
nmol/L 
<50 29 72.4 (65.4 to 80.6) 0.66 +4.4 (-4.9 to 13.6) 0.34 
≥50 15 75.4 (70.5 to 79.9)  referent  
 
[1] Univariate analysis method: Students T-Test/One-way ANOVA. [2] Adjusted for all potential determinants of sputum eosinophilia 
investigated in univariate analysis. † P value for trend. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 
















6.2.5. Association between genetic factors and COPD phenotype. 
Genetic determinants of clinical correlates of COPD phenotype are presented in Table 5.12 (FEV1), 
Table 5.13 (FVC), Table 5.14 (FEV1:FVC), and Table 5.15 (QS). After correcting for multiple 
comparisons testing (Benjamini & Hochberg method with a 5% false discovery rate) none of the 
genetic factors which independently associated with markers of COPD phenotype as main effects, or 



















Table 5.12. Genetic determinants of % predicted forced expiratory volume in 1 second (ppFEV1). 
 




coefficient (95% CI) 1 
P value 
for trend 




CYP3A4 rs2740574 AA 247 64.1 (20.8) referent 0.64 0.51 
AG 26 59.8 (17.0) -5.36 (-14 to 3.35)   
GG 1* - 9.37 (-30.3 to 49.1)   
CUBILIN rs3740165 TT 256 64.2 (20.6) referent >0.99 0.41 
TC 16 55.2 (19.9) -6.95 (-17.52 to 3.63)   
CC 1* - -   
RXRA rs7861779 GG 198 64.1 (21.2) referent 0.49 0.18 
GA 64 63.1 (19.3) -0.86 (-6.89 to 5.17)   
AA 5 63.9 (10.7) -6.48 (-25.12 to 12.16)   
rs9409929 GG 117 66.8 (19.6) referent 0.37 0.40 
AG 135 61.5 (21.4) -4.82 (-10.14 to 0.50)   
AA 22 61.6 (19.0) -4.49 (-14.45 to 5.46)   
CYP24A1 rs6013897 TT 181 64.6 (20.7) referent 0.85 0.85 
AT 78 62.7 (20.3) -1.60 (-7.31 to 4.12)   
AA 14 59.1 (20.3) -1.22 (-13.54 to 11.10)   
rs2762934 GG 195 64.5 (21.2) referent 0.82 0.50 
AG 74 61.5 (19.0) -0.92 (-6.66 to 4.81)   
AA 6 61.8 (23.0) -1.99 (-18.93 to 14.95)   
rs2762939 GG 156 64.4 (21.0) referent 0.31 0.37 
CG 107 62.0 (20.0) -2.07 (-7.28 to 3.13)   
CC 12 68.2 (19.6) 6.71 (-6.24 to 19.65)   
rs2248137 CC 97 63.8 (21.8) referent 0.71 0.91 
CG 144 63.3 (19.9) -1.29 (-6.90 to 4.32)   
GG 33 63.8 (20.7) -1.60 (-9.93 to 6.74)   
DBP rs16846876 AA 124 64.3 (21.2) referent 0.50 0.15 
AT 127 62.8 (20.9) 0.38 (-4.97 to 5.74)   
TT 24 64.7 (15.2) 3.30 (-6.30 to 12.91)   
rs7041 CC 65 63.3 (20.8) referent 0.28 0.61 
AC 148 62.6 (20.1) -0.36 (-6.45 to 5.73)   
AA 58 64.7 (21.4) 4.24 (-3.42 to 11.90)   
rs12512631 TT 114 64.8 (20.3) referent 0.43 0.72 
CT 131 63.0 (20.6) -3.20 (-8.74 to 2.33)   
CC 28 62.0 (22.9) -3.68 (-12.76 to 5.40)   
rs4588 GG 130 65.1 (21.1) referent 0.86 0.040 
GT 124 62.5 (20.2) -0.98 (-6.29 to 4.33)   
TT 24 61.0 (18.5) 0.85 (-8.66 to 10.36)   
rs2070741 TT 238 62.3 (19.9) referent 0.017 0.25 
TG 31 70.0 (24.5) 7.35 (-0.41 to 15.11)   
GG 3* 92.4 (11.7) -   
rs2298849 AA 182 61.4 (20.5) referent 0.19 0.97 
AG 88 67.5 (19.9) 7.14 (1.70 to 12.58)   
GG 7 73.6 (23.6) 10.26 (-5.11 to 25.62)   
CYP27A1 rs17470271 AA 99 58.7 (21.1) referent 0.11 0.015 
AT 132 67.0 (19.0) 7.23 (1.82 to 12.64)   
TT 44 64.8 (21.2) 5.87 (-1.38 to 13.13)   
CYP27B1 rs4646536 AA 112 65.1 (21.1) referent 0.39 0.33 
AG 129 62.2 (20.3) -3.54 (-9.00 to 1.93)   
GG 29 63.2 (20.2) -3.84 (-12.67 to 4.99)   
rs4646537 TT 254 63.0 (20.6) referent 0.017 0.75 
GT 21 71.3 (20.2) 11.89 (2.16 to 21.62)   
GG 0* - -   
CYP2R1 rs10500804 TT 96 65.8 (21.4) referent 0.81 0.83 
GT 132 61.4 (20.8) -5.29 (-10.94 to 0.35)   
GG 48 65.3 (17.7) -0.87 (-8.12 to 6.38)   








coefficient (95% CI) 1 
P value 
for trend 




AG 130 63.0 (20.2) -2.27 (-7.97 to 3.42)   
AA 49 64.9 (22.4) 2.02 (-5.36 to 9.40)   
rs10766197 GG 80 66.8 (20.9) referent 0.62 0.98 
AG 132 61.4 (21.2) -5.40 (-11.39 to 0.59)   
AA 58 64.7 (17.4) -1.79 (-8.85 to 5.28)   
LRP2 rs3755166 GG 92 62.4 (19.3) referent 0.10 0.97 
AG 126 63.1 (20.2) 2.53 (-3.12 to 8.19)   
AA 57 67.2 (22.7) 5.64 (-1.16 to 12.45)   
DHCR7 rs12785878 TT 171 63.5 (21.4) referent 0.30 0.35 
GT 89 65.3 (19.0) 1.36 (-4.07 to 6.80)   
GG 15 56.9 (19.3) -6.67 (-19.39 to 6.05)   
rs3829251 GG 211 64.2 (21.0) referent 0.59 0.90 
AG 54 61.0 (19.3) -3.70 (-9.91 to 2.51)   
AA 7 61.8 (24.2) 4.69 (-12.25 to 21.63)   
VDR rs731236 AA 104 62.8 (20.6) referent 0.80 0.63 
AG 127 65.1 (20.6) -0.99 (-8.50 to 6.52)   
GG 43 63.1 (18.9) 1.77 (-3.87 to 7.42)   
rs4334089 GG 146 64.2 (21.2) referent 0.82 0.40 
AG 108 63.0 (20.1) -3.21 (-8.58 to 2.16)   
AA 21 64.4 (17.9) 1.11 (-8.68 to 10.90)   
rs10783219 AA 106 63.9 (19.4) referent 0.75 0.60 
AT 128 64.2 (21.1) -0.26 (-5.84 to 5.33)   
TT 33 60.1 (21.6) -1.36 (-9.79 to 7.06)   
rs4516035 TT 92 61.9 (20.2) referent 0.52 0.91 
CT 143 63.9 (21.5) 0.02 (-5.72 to 5.77)   
CC 31 66.9 (18.4) 2.80 (-5.81 to 11.42)   
rs11568820 CC 165 62.9 (21.4) referent 0.94 0.60 
CT 98 65.2 (20.0) 0.51 (-12.21 to 13.23)   
TT 11 61.8 (15.2) 1.66 (-3.71 to 7.02)   
rs7976091 CC 166 63.2 (21.2) referent 0.80 0.65 
CT 99 64.7 (20.0) 1.02 (-4.32 to 6.36)   
TT 12 60.9 (14.8) -1.63 (-14.01 to 10.75)   
rs2238136 CC 138  62.0 (18.2) referent 0.66 0.69 
CT 113 66.2 (22.5) 5.21 (-0.16 to 10.57)   
TT 19 63.1 (24.6) 2.29 (-8.02 to 12.60)   
rs1544410 CC 100 62.6 (20.7) referent 0.98 0.71 
CT 129 64.4 (21.2) 1.57 (-4.06 to 7.20)   
TT 46 63.7 (19.0) 0.09 (-7.28 to 7.47)   
rs2228570 GG 106 61.8 (21.4) referent 0.98 0.11 
AG 125 65.2 (20.7) 3.33 (-2.32 to 8.98)   
AA 41 62.6 (17.6) -0.10 (-7.78 to 7.58)   
rs2853559 GG 96 63.8 (22.1) referent 0.89 0.82 
AG 131 63.2 (20.1) -2.37 (-8.08 to 3.34)   
AA 44 65.1 (19.8) -0.54 (-8.20 to 7.13)   
rs7970314 AA 156 63.7 (20.8) referent 0.68 0.45 
AG 105 63.8 (21.2) 0.25 (-5.05 to 5.55)   
GG 14 60.7 (13.7) -2.47 (-14.28 to 9.34)   
rs7975232 AA 73 62.6 (18.7) referent 0.39 0.78 
AC 141 64.1 (21.6) 3.45 (-2.78 to 9.69)   
CC 55 63.7 (21.0) 3.24 (-4.23 to 10.71)   
[1] Adjusted for potential determinants of FEV1: Sex, age, ethnicity, body mass index, socio-economic position, smoking status, alcohol consumption, influenza 
vaccination, pneumococcal vaccination, and baseline vitamin D status. * Genotype could not be analysed due to <5 participants and/or too few events within 
this sub category. After correction for multiple comparisons testing, using Benjamini & Hochberg method with a false discovery rate of 5%, none of the p values 
for trend or interaction between baseline vitamin D status and genotype remain significant. 
……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………. 
Abbreviations: 25(OH)D: 25-hydroxyvitamin D, SNP: Single nucleotide polymorphism, IQR: Inter-quartile range, CI: Confidence interval, CYP-: Cytochrome P450 
enzyme, DBP: Vitamin D binding protein, DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also known as 
megalin), RXRA: Retanoid-X receptor A, VDR: Vitamin D receptor, CUBN: Cubilin. 




Table 5.13. Genetic determinants of forced vital capacity (FVC). 
 
Gene SNP Genotype N Mean FVC (SD) Multivariable model: 








CYP3A4 rs2740574 AA 247 97.5 (19.3) referent 0.48 0.29 
AG 26 91.7 (16.1) -7.10 (-14.85 to 0.65)   
GG 1* - -   
CUBILIN rs3740165 TT 256 97.5 (18.9) referent 0.88 0.27 
TC 16 85.5 (19.5) -9.20 (-18.54 to 0.15)   
CC 1* - -   
RXRA rs7861779 GG 198 97.8 (19.4) referent 0.33 0.11 
GA 64 94.2 (18.2) -3.54 (-8.89 to 1.81)   
AA 5 90.9 (13.8) -8.18 (-24.71 to 8.35)   
rs9409929 GG 117 97.7 (19.0) referent 0.17 0.018 
AG 135 95.3 (19.7) 0.01 (-4.74 to 4.76)   
AA 22 104.3 (15.4) 6.25 (-2.63 to 15.14)   
CYP24A1 rs6013897 TT 181 98.0 (19.5) referent 0.59 0.74 
AT 78 96.3 (18.4) -1.18 (-6.28 to 3.91)   
AA 14 88.0 (16.9) -2.97 (-13.96 to 8.02)   
rs2762934 GG 195 97.7 (19.5) referent 0.67 0.19 
AG 74 93.7 (18.0) -1.93 (-7.05 to 3.18)   
AA 6 104.5 (17.8) 3.23 (-11.87 to 18.34)   
rs2762939 GG 156 97.1 (20.1) referent 0.037 0.97 
CG 107 95.1 (17.3) -2.24 (-6.84 to 2.37)   
CC 12 108.0 (19.8) 12.19 (0.73 to 23.65)   
rs2248137 CC 97 96.4 (20.1) referent 0.91 0.74 
CG 144 96.9 (18.7) -0.55 (-5.57 to 4.46)   
GG 33 97.0 (18.4) 0.42 (-7.04 to 7.87)   
DBP rs16846876 AA 124 99.08 (20.0) referent 0.67 0.92 
AT 127 95.3 (18.7) -2.14 (-6.91 to 2.63)   
TT 24 94.2 (15.9) -1.85 (-10.40 to 6.70)   
rs7041 CC 65 98.6 (17.5) referent 0.66 0.51 
AC 148 96.9 (20.0) -0.15 (-5.65 to 5.36)   
AA 58 94.1 (19.4) -1.55 (-8.48 to 5.37)   
rs12512631 TT 114 97.6 (18.9) referent 0.56 0.28 
CT 131 96.8 (19.0) -1.46 (-6.42 to 3.50)   
CC 28 94.9 (22.2) -2.41 (-10.54 to 5.73)   
rs4588 GG 130 100.1 (19.5) referent 0.11 0.62 
GT 124 95.0 (19.0) -3.73 (-8.45 to 0.99)   
TT 24 90.4 (15.8) -6.79 (-15.25 to 1.66)   
rs2070741 TT 238 95.7 (18.7) referent 0.26 0.44 
TG 31 102.7 (20.1) 5.01 (-1.88 to 11.90)   
GG 3* 105.9 (15.3) -   
rs2298849 AA 182 95.0 (19.7) referent 0.48 0.65 
AG 88 100.4 (17.2) 6.53 (1.68 to 11.39)   
GG 7 102.8 (20.7) 4.89 (-8.83 to 18.61)   
CYP27A1 rs17470271 AA 99 95.0 (18.8) referent 0.67 0.16 
AT 132 99.0 (18.3) 2.18 (-2.69 to 7.06)   
TT 44 95.5 (20.8) -1.41 (-7.94 to 5.13)   
CYP27B1 rs4646536 AA 112 95.4 (19.9) referent 0.41 0.15 
AG 129 98.4 (19.1) 1.17 (-3.73 to 6.07)   
GG 29 95.7 (18.5) -3.33 (-11.2 to 4.58)   
rs4646537 TT 254 96.6 (19.1) referent 0.11 0.71 
GT 21 99.3 (20.3) 7.02 (-1.69 to 15.73)   
GG 0* - -   
CYP2R1 rs10500804 TT 96 96.7 (19.7) referent 0.87 0.30 
GT 132 97.1 (19.2) 0.97 (-4.13 to 6.06)   
GG 48 97.2 (18.8) 0.54 (-6.00 to 7.08)   




Gene SNP Genotype N Mean FVC (SD) Multivariable model: 








AG 130 97.2 (19.2) 0.44 (-4.65 to 5.54)   
AA 49 96.5 (20.1) -0.18 (-6.79 to 6.43)   
rs10766197 GG 80 97.1 (19.6) referent 0.53 0.20 
AG 132 96.6 (18.6) 0.84 (-4.55 to 6.23)   
AA 58 98.5 (19.5) 2.04 (-4.32 to 8.40)   
LRP2 rs3755166 GG 92 96.8 (19.8) referent 0.42 0.81 
AG 126 96.5 (19.1) 1.94 (-3.12 to 6.99)   
AA 57 98.4 (17.6) 2.47 (-3.61 to 8.55)   
DHCR7 rs12785878 TT 171 96.8 (19.4) referent 0.48 0.45 
GT 89 97.6 (17.8) 1.70 (-3.09 to 6.49)   
GG 15 91.2 (19.2) 4.03 (-7.19 to 15.24)   
rs3829251 GG 211 97.2 (19.1) referent 0.14 0.97 
AG 54 94.1 (17.1) -2.96 (-8.41 to 2.48)   
AA 7 95.4 (25.4) 11.04 (-3.80 to 25.89)   
VDR rs731236 AA 104 92.9 (19.0) referent 0.16 0.14 
AG 127 100.1 (18.3) 6.61 (1.65 to 11.58)   
GG 43 98.9 (19.1) 4.76 (-1.85 to 11.37)   
rs4334089 GG 146 98.3 (19.2) referent 0.68 0.55 
AG 108 94.9 (18.8) -4.03 (-8.82 to 0.76)   
AA 21 99.6 (19.3) 1.83 (-6.90 to 10.56)   
rs10783219 AA 106 96.6 (19.1) referent 0.68 0.32 
AT 128 97.7 (19.0) 0.34 (-4.63 to 5.32)   
TT 33 94.1 (19.0) -1.60 (-9.10 to 5.91)   
rs4516035 TT 92 95.5 (19.5) referent 0.58 0.71 
CT 143 97.9 (19.2) -0.02 (-5.18 to 5.14)   
CC 31 96.2 (18.3) -2.18 (-9.92 to 5.55)   
rs11568820 CC 165 96.6 (19.8) referent 0.11 0.46 
CT 98 96.7 (17.1) 0.58 (-4.17 to 5.33)   
TT 11 104.6 (26.0) 9.06 (-2.19 to 20.32)   
rs7976091 CC 166 96.8 (19.7) referent 0.29 0.51 
CT 99 96.4 (17.1) 0.18 (-4.57 to 4.94)   
TT 12 101.6 (26.9) 5.96 (-5.07 to 16.98)   
rs2238136 CC 138 95.9 (19.1) referent 0.74 0.32 
CT 113 98.2 (18.9) 2.59 (-2.26 to 7.44)   
TT 19 94.4 (21.6) -1.58 (-10.90 to 7.74)   
rs1544410 CC 100 93.2 (18.7) referent 0.25 0.084 
CT 129 99.4 (19.3) 5.86 (0.88 to 10.83)   
TT 46 97.2 (18.5) 3.80 (-2.72 to 10.31)   
rs2228570 GG 106 95.0 (20.2) referent 0.38 0.59 
AG 125 99.0 (18.7) 3.34 (-1.68 to 8.37)   
AA 41 94.3 (17.4) -3.03 (-9.86 to 3.80)   
rs2853559 GG 96 95.5 (19.9) referent 0.93 0.76 
AG 131 97.4 (18.7) -0.55 (-5.63 to 4.53)   
AA 44 97.6 (19.7) -0.29 (-7.12 to 6.54)   
rs7970314 AA 156 97.2 (19.6) referent 0.30 0.42 
AG 105 95.7 (17.6) -0.65 (-5.37 to 4.07)   
GG 14 101.1 (25.6) 5.53 (-4.97 to 16.04)   
rs7975232 AA 73 98.6 (18.6) referent 0.34 0.34 
AC 141 97.3 (20.1) -0.91 (-6.46 to 4.64)   
CC 55 92.7 (17.9) -3.21 (-9.86 to 3.44)   
[1] Adjusted for potential determinants of FVC: Sex, age, ethnicity, body mass index, socio-economic position, smoking status, alcohol consumption, influenza 
vaccination, pneumococcal vaccination, and baseline vitamin D status. * Genotype could not be analysed due to <5 participants and/or too few events within 
this sub category. After correction for multiple comparisons testing, using Benjamini & Hochberg method with a false discovery rate of 5%, none of the p 
values for trend or interaction between baseline vitamin D status and genotype remain significant. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………. 
Abbreviations: 25(OH)D: 25-hydroxyvitamin D, SNP: Single nucleotide polymorphism, SD: Standard deviation, CI: Confidence interval, CYP-: Cytochrome P450 
enzyme, DBP: Vitamin D binding protein, DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also known as 
megalin), RXRA: Retanoid-X receptor-A, VDR: Vitamin D receptor, CUBN: Cubilin. 




Table 5.14. Genetic determinants of FEV1:FVC. 
 












CYP3A4 rs2740574 AA 247 0.52 (0.13) referent 0.95 0.68 
AG 26 0.53 (0.10) -0.01 (-0.06 to 0.04)   
GG 1* - -   
CUBILIN rs3740165 TT 256 0.52 (0.13) referent 0.92 0.92 
TC 16 0.50 (0.13) -0.01 (-0.07 to 0.06)   
CC 1* - -   
RXRA rs7861779 GG 198 0.52 (0.13) referent 0.99 0.41 
GA 64 0.53 (0.12) 0.02 (-0.02 to 0.05)   
AA 5 0.58 (0.06) 0.00 (-0.11 to 0.11)   
rs9409929 GG 117 0.55 (0.11) referent 0.027 0.84 
AG 135 0.51 (0.13) -0.04 (-0.07 to -0.01)   
AA 22 0.47 (0.13) -0.07 (-0.13 to -0.01)   
CYP24A1 rs6013897 TT 181 0.52 (0.13) referent 0.92 0.83 
AT 78 0.51 (0.13) -0.01 (-0.04 to 0.03)   
AA 14 0.52 (0.12) 0.04 (-0.07 to 0.08)   
rs2762934 GG 195 0.52 (0.13) referent 0.36 0.87 
AG 74 0.52 (0.12) 0.01 (-0.03 to 0.04)   
AA 6 0.46 (0.11) -0.05 (-0.15 to 0.05)   
rs2762939 GG 156 0.53 (0.13) referent 0.79 0.40 
CG 107 0.51 (0.13) -0.00 (-0.04 to 0.03)   
CC 12 0.50 (0.10) -0.01 (-0.09 to 0.07)   
rs2248137 CC 97 0.52 (0.13) referent 0.63 0.73 
CG 144 0.52 (0.13) -0.00 (-0.04 to 0.03)   
GG 33 0.52 (0.12) -0.01 (-0.06 to 0.04)   
DBP rs16846876 AA 124 0.52 (0.13) referent 0.15 0.076 
AT 127 0.52 (0.13) 0.02 (-0.02 to 0.05)   
TT 24 0.54 (0.10) 0.04 (-0.02 to 0.10)   
rs7041 CC 65 0.51 (0.13) referent 0.094 0.74 
AC 148 0.51 (0.13) -0.00 (-0.04 to 0.04)   
AA 58 0.54 (0.13) 0.04 (-0.01 to 0.09)   
rs12512631 TT 114 0.53 (0.13) referent 0.47 0.19 
CT 131 0.51 (0.13) -0.02 (-0.05 to 0.01)   
CC 28 0.53 (0.13) -0.02 (-0.07 to 0.03)   
rs4588 GG 130 0.52 (0.13) referent 0.10 0.014 
GT 124 0.52 (0.13) 0.01 (-0.02 to 0.04)   
TT 24 0.53 (0.13) 0.05 (-0.01 to 0.11)   
rs2070741 TT 238 0.52 (0.12) referent 0.051 0.33 
TG 31 0.54 (0.14) 0.03 (-0.02 to 0.07)   
GG 3* 0.68 (0.05) -   
rs2298849 AA 182 0.51 (0.13) referent 0.28 0.92 
AG 88 0.53 (0.12) 0.02 (-0.01 to 0.06)   
GG 7 0.58 (0.12) 0.05 (-0.04 to 0.15)   
CYP27A1 rs17470271 AA 99 0.49 (0.14) referent 0.024 0.020 
AT 132 0.54 (0.11) 0.05 (0.01 to 0.08)   
TT 44 0.54 (0.13) 0.05 (0.01 to 0.09)   
CYP27B1 rs4646536 AA 112 0.54 (0.13) referent 0.91 0.86 
AG 129 0.50 (0.12) -0.03 (-0.07 to -0.00)   
GG 29 0.54 (0.13) -0.00 (-0.06 to 0.05)   
rs4646537 TT 254 0.52 (0.13) referent 0.031 0.91 
GT 21 0.57 (0.12) 0.07 (0.01 to 0.12)   
GG 0* - -   
CYP2R1 rs10500804 TT 96 0.54 (0.12) referent 0.85 0.29 
GT 132 0.50 (0.13) -0.05 (-0.08 to -0.01)   
GG 48 0.53 (0.12) -0.00 (-0.05 to 0.04)   
















AG 130 0.51 (0.13) -0.02 (-0.06 to 0.01)   
AA 49 0.53 (0.13) 0.02 (-0.03 to 0.06)   
rs10766197 GG 80 0.55 (0.11) referent 0.34 0.45 
AG 132 0.50 (0.13) -0.05 (-0.09 to -0.02)   
AA 58 0.53 (0.12) -0.02 (-0.06 to 0.02)   
LRP2 rs3755166 GG 92 0.52 (0.13) referent 0.26 0.96 
AG 126 0.52 (0.13) 0.01 (0.03 to 0.04)   
AA 57 0.54 (0.13) 0.02 (-0.02 to 0.07)   
DHCR7 rs12785878 TT 171 0.52 (0.13) referent 0.12 0.055 
GT 89 0.53 (0.13) 0.01 (-0.02 to 0.04)   
GG 15 0.50 (0.14) -0.06 (-0.14 to 0.02)   
rs3829251 GG 211 0.52 (0.13) referent 0.82 0.92 
AG 54 0.52 (0.13) -0.01 (-0.04 to 0.03)   
AA 7 0.51 (0.13) -0.01 (-0.11 to 0.09)   
VDR rs731236 AA 104 0.53 (0.12) referent 0.28 0.19 
AG 127 0.52 (0.13) -0.02 (-0.05 to 0.02)   
GG 43 0.51 (0.14) -0.03 (-0.07 to 0.02)   
rs4334089 GG 146 0.52 (0.13) referent 0.81 0.39 
AG 108 0.53 (0.13) -0.01 (-0.04 to 0.03)   
AA 21 0.51 (0.12) 0.01 (-0.05 to 0.07)   
rs10783219 AA 106 0.52 (0.12) referent 0.77 0.94 
AT 128 0.52 (0.13) -0.00 (-0.04 to 0.03)   
TT 33 0.50 (0.13) -0.01 (-0.06 to 0.04)   
rs4516035 TT 92 0.51 (0.12) referent 0.14 0.80 
CT 143 0.52 (0.13) 0.00 (-0.03 to 0.04)   
CC 31 0.55 (0.12) 0.04 (-0.01 to 0.09)   
rs11568820 CC 165 0.52 (0.13) referent 0.45 0.74 
CT 98 0.53 (0.13) 0.01 (-0.03 to 0.04)   
TT 11 0.47 (0.09) -0.03 (-0.11 to 0.05)   
rs7976091 CC 166 0.52 (0.13) referent 0.40 0.78 
CT 99 0.53 (0.13) 0.00 (-0.03 to 0.04)   
TT 12 0.48 (0.09) -0.03 (-0.11 to 0.04)   
rs2238136 CC 138 0.51 (0.12) referent 0.59 0.99 
CT 113 0.53 (0.13) 0.02 (-0.01 to 0.06)   
TT 19 0.53 (0.14) 0.02 (-0.04 to 0.08)   
rs1544410 CC 100 0.53 (0.12) referent 0.58 0.17 
CT 129 0.51 (0.13) -0.02 (-0.05 to 0.02)   
TT 46 0.52 (0.14) -0.01 (-0.06 to 0.03)   
rs2228570 GG 106 0.51 (0.13) referent 0.31 0.13 
AG 125 0.52 (0.13) 0.01 (-0.03 to 0.04)   
AA 41 0.53 (0.12) 0.02 (-0.02 to 0.07)   
rs2853559 GG 96 0.52 (0.13) referent 0.97 0.91 
AG 131 0.52 (0.12) -0.01 (-0.05 to 0.02)   
AA 44 0.53 (0.14) 0.00 (-0.05 to 0.05)   
rs7970314 AA 156 0.52 (0.13) referent 0.32 0.55 
AG 105 0.52 (0.13) 0.00 (-0.03 to 0.03)   
GG 14 0.49 (0.08) -0.04 (-0.11 to 0.04)   
rs7975232 AA 73 0.51 (0.14) referent 0.094 0.48 
AC 141 0.52 (0.12) 0.03 (-0.01 to 0.06)   
CC 55 0.54 (0.12) 0.04 (-0.01 to 0.08)   
[1] Adjusted for potential determinants of FEV1:FVC: Sex, age, ethnicity, body mass index, socio-economic position, smoking status, alcohol consumption, 
influenza vaccination, pneumococcal vaccination, and baseline vitamin D status. * Genotype could not be analysed due to <5 participants and/or too few 
events within this sub category. After correction for multiple comparisons testing, using Benjamini & Hochberg method with a false discovery rate of 5%, 
none of the p values for trend or interaction between baseline vitamin D status and genotype remain significant. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………. 
Abbreviations: 25(OH)D: 25-hydroxyvitamin D, SNP: Single nucleotide polymorphism, SD: Standard deviation, CI: Confidence interval, CYP-: Cytochrome P450 
enzyme, DBP: Vitamin D binding protein, DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also known as 
megalin), RXRA: Retanoid-X receptor-A, VDR: Vitamin D receptor, CUBN: Cubilin. 




Table 5.15. Genetic determinants of quadriceps strength (QS). 
 
Gene SNP Genotype N 1 Mean QS, kg 
(SD) 
Multivariable model: 








CYP3A4 rs2740574 AA 119 32.8 (11.9) referent 0.80 0.17 
AG 14 30.3 (15.7) -0.78 (-6.75 to 5.20)   
GG 0* - -   
CUBILIN rs3740165 TT 123 32.3 (12.6) referent 0.087 0.98 
TC 9 33.5 (6.4) 1.69 (-5.79 to 9.18)   
CC 1* - -   
RXRA rs7861779 GG 92 32.4 (11.6) referent 0.67 0.53 
GA 33 31.7 (13.3) -1.17 (-5.28 to 2.94)   
AA 3* 40.6 (8.3) -   
rs9409929 GG 58 30.6 (12.0) referent 0.42 0.64 
AG 61 33.9 (12.5) 2.27 (-1.77 to 6.31)   
AA 13 35.3 (12.4) 2.89 (-4.12 to 9.91)   
CYP24A1 rs6013897 TT 87 33.1 (12.0) referent 0.78 0.90 
AT 40 30.7 (12.8) -2.41 (-6.57 to 1.75)   
AA 6 35.9 (13.5) 1.36 (-8.25 to 10.95)   
rs2762934 GG 93 32.6 (11.7) referent 0.82 0.11 
AG 38 32.6 (13.9) 0.25 (-3.82 to 4.31)   
AA 3 31.1 (12.0) -1.43 (-13.95 to 11.09)   
rs2762939 GG 68 32.9 (12.8) referent 0.62 0.025 
CG 54 32.1 (12.4) -0.16 (-4.02 to 3.71)   
CC 10 34.5 (8.2) 1.85 (-5.44 to 9.14)   
rs2248137 CC 47 33.8 (11.8) referent 0.99 0.98 
CG 69 32.1 (12.7) -0.01 (-4.34 to 4.31)   
GG 17 31.9 (12.2) 0.04 (-6.30 to 6.38)   
DBP rs16846876 AA 60 34.6 (11.3) referent 0.56 0.12 
AT 63 29.8 (10.7) -2.80 (-6.78 to 1.19)   
TT 10 34.9 (20.4) 2.10 (-5.04 to 9.24)   
rs7041 CC 35 30.9 (10.8) referent 0.094 0.73 
AC 72 32.6 (13.3) 4.47 (-0.03 to 8.91)   
AA 23 34.3 (11.5) 5.05 (-0.87 to 10.98)   
rs12512631 TT 51 31.7 (12.9) referent 0.43 0.73 
CT 70 33.1 (11.9) -0.14 (-4.19 to 3.92)   
CC 13 33.0 (12.7) -2.69 (-9.49 to 4.11)   
rs4588 GG 63 32.9 (11.6) referent 0.38 0.63 
GT 59 32.5 (12.7) -0.03 (-3.96 to 3.89)   
TT 12 31.2 (14.4) 3.13 (-3.93 to 10.20)   
rs2070741 TT 120 32.8 (12.6) referent 0.82 0.59 
TG 12 28.9 (8.9) 0.48 (-5.79 to 6.75)   
GG 2* 39.8 (6.6) -   
rs2298849 AA 91 33.9 (11.8) referent 0.98 0.34 
AG 39 30.7 (13.0) -3.55 (-7.81 to 0.72)   
GG 4* 20.4 (4.7) -   
CYP27A1 rs17470271 AA 46 33.8 (11.8) referent 0.51 0.69 
AT 60 31.9 (13.3) -0.26 (-4.50 to 3.97)   
TT 27 32.3 (10.9) -1.74 (-6.95 to 3.47)   
CYP27B1 rs4646536 AA 57 33.2 (12.6) referent 0.26 0.62 
AG 58 31.6 (12.5) -0.19 (-4.26 to 3.88)   
GG 16 35.1 (11.2) 3.65 (-2.69 to 10.00)   
rs4646537 TT 122 32.6 (12.5) referent 0.50 0.56 
GT 12 32.5 (10.1) -2.32 (-9.06 to 4.43)   
GG 0* - -   
CYP2R1 rs10500804 TT 44 30.4 (13.5) referent 0.58 0.55 
GT 61 33.9 (13.2) 2.07 (-2.29 to 6.42)   
GG 28 32.8 (7.2) 1.49 (-3.81 to 6.79)   




Gene SNP Genotype N 1 Mean QS, kg 
(SD) 
Multivariable model: 








AG 63 33.9 (13.5) 0.90 (-3.29 to 5.09)   
AA 21 27.0 (10.2) -4.53 (-10.05 to 0.99)   
rs10766197 GG 37 30.8 (14.3) referent 0.40 0.17 
AG 63 33.2 (13.0) 1.16 (-3.43 to 5.75)   
AA 32 33.1 (7.9) 2.28 (-3.02 to 7.58)   
LRP2 rs3755166 GG 45 34.6 (13.4) referent 0.067 0.77 
AG 59 31.6 (11.6) -2.72 (-7.01 to 1.56)   
AA 30 31.4 (11.7) -4.59 (-9.50 to 0.33)   
DHCR7 rs12785878 TT 78 31.3 (12.1) referent 0.34 0.19 
GT 44 32.9 (13.2) 0.71 (-3.30 to 4.71)   
GG 11 39.9 (7.4) 3.73 (-3.92 to 11.38)   
rs3829251 GG 100 32.1 (12.1) referent 0.13 0.71 
AG 28 32.6 (13.2) 1.46 (-2.97 to 5.89)   
AA 5 40.1 (10.3) 7.36 (-2.25 to 16.97)   
VDR rs731236 AA 50 30.6 (12.6) referent 0.84 0.41 
AG 65 34.0 (11.9) 2.32 (-1.87 to 6.51)   
GG 19 32.7 (12.7) -0.60 (-6.48 to 5.28)   
rs4334089 GG 70 31.4 (13.3) referent 0.53 0.48 
AG 51 33.7 (11.5) 1.00 (-2.98 to 4.99)   
AA 13 34.4 (9.1) -2.05 (-8.58 to 4.48)   
rs10783219 AA 54 33.7 (10.7) referent 0.28 0.45 
AT 64 32.3 (13.4) 1.20 (-2.83 to 5.23)   
TT 15 29.9 (12.9) -3.36 (-9.45 to 2.74)   
rs4516035 TT 46 32.1 (11.2) referent 0.49 0.35 
CT 73 32.0 (13.2) 1.84 (-2.29 to 5.98)   
CC 13 35.8 (11.3) 2.45 (-4.52 to 9.42)   
rs11568820 CC 80 32.0 (13.4) referent 0.74 0.68 
CT 45 33.6 (10.9) 0.41 (-3.65 to 4.47)   
TT 9 32.5 (7.8) -1.22 (-8.56 to 6.13)   
rs7976091 CC 79 32.1 (13.4) referent 0.70 0.78 
CT 46 33.4 (10.9) -0.09 (-4.14 to 3.96)   
TT 9 32.5 (7.8) -1.42 (-8.79 to 5.95)   
rs2238136 CC 66 33.7 (10.5) referent 0.37 0.73 
CT 59 31.5 (14.0) 0.23 (-3.83 to 4.29)   
TT 8 32.6 (12.7) -4.16 (-13.22 to 4.91)   
rs1544410 CC 48 30.5 (12.6) referent 0.79 0.40 
CT 66 34.0 (11.9) 2.42 (-1.70 to 6.55)   
TT 20 32.8 (12.4) -0.79 (-6.49 to 4.92)   
rs2228570 GG 51 32.9 (12.0) referent 0.99 0.82 
AG 64 32.2 (12.4) 0.42 (-3.62 to 4.46)   
AA 18 32.6 (13.2) 0.03 (-5.92 to 5.98)   
rs2853559 GG 49 33.6 (10.9) referent 0.87 0.10 
AG 67 32.2 (13.2) 1.72 (-2.40 to 5.85)   
AA 17 31.8 (12.8) -0.50 (-6.56 to 5.55)   
rs7970314 AA 71 32.3 (13.5) referent 0.54 0.88 
AG 52 32.8 (11.4) -0.25 (-4.16 to 3.67)   
GG 10 32.4 (7.3) -2.21 (-9.43 to 5.00)   
rs7975232 AA 33 30.7 (11.6) referent 0.49 0.93 
AC 72 33.2 (12.6) 4.55 (0.01 to 9.09)   
CC 25 31.8 (12.7) 1.97 (-3.60 to 7.53)   
[1] Quadriceps strength measured in a subset of n=134. [2] Adjusted for potential determinants of quadriceps strength: Sex, age, body mass index, socio-
economic position, smoking status, alcohol consumption, and baseline vitamin D status. * Genotype could not be analysed due to <5 participants and/or too 
few events within this sub category. After correction for multiple comparisons testing, using Benjamini & Hochberg method with a false discovery rate of 5%, 
none of the p values for trend or interaction between baseline vitamin D status and genotype remain significant. 
……………………………………………………………………………………………………………………………………………………………………………………………………………... 
Abbreviations: 25(OH)D: 25-hydroxyvitamin D, SNP: Single nucleotide polymorphism, SD: Standard deviation, CI: Confidence interval, CYP-: Cytochrome P450 
enzyme, DBP: Vitamin D binding protein, DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also known as 
megalin), RXRA: Retanoid-X receptor-A, VDR: Vitamin D receptor, CUBN: Cubilin. 






To my knowledge this study represents the most comprehensive cross-sectional analysis of 
environmental and genetic determinants of serum 25(OH)D concentration, and clinical correlates of 
disease phenotype in a UK cohort of COPD patients. It is also the first to explore the influence of 
vitamin D deficiency on induced sputum biomarkers of disease severity in this patient group, and 
SNP in genes other than DBP and VDR.  
 
Vitamin D deficiency (defined by a serum 25[OH]D concentration <50 nmol/L) was present in the 
majority of participants (61.5%). Serum 25(OH)D concentration independently associated with BMI, 
SEP, vitamin D supplement consumption, quarter of sampling, and holidaying abroad, but not with 
any of the 15 investigated SNP which have been found to in healthy populations. Vitamin D showed 
an association with reduced lung function, as measured by % predicted FEV1 and % predicted FVC, 
but did not associate with the remaining investigated clinical correlates of COPD severity or control, 
namely: FEV1:FVC ratio, ICS requirement, health-related quality of life score, quadriceps strength, or 
% eosinophils or neutrophils in induced sputum. 
 
The findings I present on environmental determinants of vitamin D status are in agreement with 
previous findings in the healthy, UK population (298). With respect to our findings on genetic 
determinants of vitamin D status, before correcting for multiple comparison testing, two of our 
fifteen SNP (all of which have been shown to predict vitamin D status in healthy populations, 
summarised in (335)) independently associate with serum 25(OH)D concentration in our COPD 
cohort. TT genotype for one of these SNP – rs7041 in DBP – has previously been reported to associate 
with a 25% decrease in serum 25(OH)D concentration in COPD patients, compared to GG genotype 
(323); I found a 23.1% decrease in adjusted mean concentration for the same comparison, which 




respect to the null results of our analysis of potential genetic determinants of COPD phenotype: very 
few studies have investigated a potential association in this population, but one case-control study 
has reported an association between two DBP SNP (rs1155563 and rs17467825, that are tagged by 
a SNP in our panel [rs4588]) and % predicted FEV1, and FEV1/FVC. This team also replicated their 
finding in a second large cohort (336). Interestingly, I observed an interaction between rs4588 
genotype and baseline 25(OH)D concentration on the same outcomes of % predicted FEV1, and 
FEV1/FVC (P for interaction = 0.040 and 0.014, respectively), however these findings did not survive 
correction for multiple comparison testing. This may have been due to our relative lack of power to 
detect genotypic subgroup effects, or it may reflect type II error due to strict statistical correction for 
multiple comparisons, or it may be that vitamin D does not influence COPD phenotype and previous 
findings have arisen due to residual confounding. 
 
The associations I observed between vitamin D status and spiromteric indices, namely % predicted 
FEV1 and % predicted FVC, are consistent with previous reports (323, 324, 326-328). Further research 
is required to establish whether vitamin D deficiency is a cause or effect of this particular marker of 
COPD severity, or whether the association that I and others have observed is due to residual 
confounding. The lack of association I report between vitamin D status and % eosinophils and 
neutrophils in sputum is a novel finding. Limited intervention data report a reduction in asthmatic 
airway eosinophilia with vitamin D supplementation (337), thus one might expect to see an 
association in COPD patients – both being chronic respiratory diseases with certain 
immunopathological parallels. That I did not observe an association may be due to the relatively 
small subset (n=44) of participants I tested, or it may be that these cellular mediators of inflammation 
are not modulated by vitamin D. Our findings of no association between vitamin D status and 
FEV1:FVC, or quadriceps strength are supported by previous observational studies (324, 326, 330), 
whilst the lack of association between vitamin D status and ICS requirement I report is in contrast to 




serum 25(OH)D concentration in COPD cases using ICS vs. those who were not (P=0.05). However 
the analysis by Persson et al (328) was a univariate analysis, so factors which may confound the 
relationship between vitamin D status and ICS requirement were not controlled for. 
 
My analysis validated a number of other expected predictors of COPD phenotype, but also identified 
a few unexpected associations. Compared to the youngest COPD patients (1st quartile – 44 to 59 yrs) 
the oldest (4th quartile - 70 to 92 years) showed a slightly smaller drop in quadriceps strength than 
those in the 3rd quartile for age (65 to 70 years). This suggests the process of diminishing skeletal 
muscle in COPD may reach a plateau around 70 years of age. Alternatively, it may be that better 
disease management occurs in patients of more advanced age as a result of a greater impetus to 
participate in pulmonary rehabilitation classes. Another unexpected finding was the observation of 
better SGRQ score with increasing age. As there was an overall trend for worsening COPD control 
and severity with advancing age for most of our clinical correlates, one might expect to see poorer 
mean SGRQ scores in quartiles 2-4 of age, but the fact these data arise from self-report is most likely 
key – elderly participants may adopt a more modest attitude when describing the severity of their 
own illness, or lower expectations of QoL. 
 
6.3.1. Study strengths.  
 
My study has several strengths. I characterised participants in a considerable level of detail which 
allowed me to investigate a wide range of potential genetic and environmental determinants of 
vitamin D status; control for a wide range of potential factors which may confound the relationship 
between vitamin D status and COPD severity and control; and conduct a comprehensive analysis of 
potential determinants of COPD phenotype. Spirometry was performed using international 




MS/MS) in a laboratory that participated in the international vitamin D external quality assurance 
scheme (www.deqas.org/). The study population included COPD patients with a range of disease 
severity, whom were recruited and followed up in both community and hospital settings and across 
all four seasons – all of which are factors that enhance the generalisibility of my results. Finally, to 
our knowledge, this was the first study of COPD patients to investigate a cross-sectional relationship 
between vitamin D status and sputum biomarkers. 
 
6.3.2. Study limitations. 
 
This study is not without its limitations: due to the prevalence of vitamin D deficiency in the cohort 
only a little over 10% of participants had a serum 25(OH)D concentration >75 nmol/L, therefore I 
may have been underpowered to detect the influence of optimal vitamin D status on COPD 
phenotype. Type 2 error as a result of limited power may also have been an issue in our analysis of 
quadriceps strength, which was conducted in a subset of 134 patients, and sputum markers of COPD 
phenotype, which was conducted in a subset of 44 patients. 
 
5.7.  Conclusions. 
 
In conclusion, my findings highlight a high prevalence of vitamin D deficiency in a UK population of 
COPD patients. I found independent associations between low serum 25(OH)D concentrations and 
greater disease severity as indicated by reduced % predicted FEV1 and FVC; higher BMI, lower SEP, 
lack of vitamin D supplement consumption, sampling during winter/spring, and lack of holidaying 
abroad. I found no association between genotype and clinical correlates of COPD phenotype, either 
directly, or in interaction with vitamin D status which does not answer the question of possible 
reverse causation between vitamin D deficiency and severity of COPD phenotype. These findings will 




support the need to correct levels with an intervention that has now been shown to reduce risk of 








7. Genetic variants in the vitamin D pathway and susceptibility to 
acute respiratory infections in patients with asthma. 
 
 
This chapter presents the findings of an investigation into the relationship between single nucleotide 
polymorphisms in the vitamin D pathway and the risk of URI or disease exacerbation in patients with 
ICS-treated asthma, who participated in the ViDiAs trial (described in Methods, section 2.2.1). This 
will comprise analyses of SNP genotype association with URI / exacerbation directly (main effects), 





The potential role for vitamin D supplementation as a preventive treatment for acute respiratory 
infection (ARI) may be of particular significance to asthma sufferers in whom ARI commonly 
precipitate acute symptom exacerbations, for which there are limited interventions to prevent (39). 
Numerous observational studies have reported an association between vitamin D deficiency (defined 
by a serum 25-hydroxyvitamin D concentration <50 nmol/L) and increased risk of ARI (231) which is 
most significant in patients with asthma (338), and between vitamin D deficiency and markers of 
asthma severity such as poor lung function, lower asthma control test results, and increased 
requirement for inhaled corticosteroids (ICS) (245, 291-294). Results from clinical trials of vitamin D 
supplementation in the prevention of ARI and/or disease exacerbation in asthma cohorts are 
conflicting however: two trials conducted on children report significant protective effects (280, 299) 
whilst two conducted on adults report a null outcome, one of which is the ViDiAs trial (209, 300). The 
lack of effect in the latter two trials may be due to power issues, low prevalence of vitamin D 
deficiency at baseline, or sub-optimal dosing regimens. Another factor which could explain this 




ARI, either directly or by modifying the effects of vitamin D supplementation. I recently reviewed the 
literature surrounding variation in vitamin D genes and found reports of 55 single nucleotide 
polymorphisms (SNP) in genes encoding proteins involved in vitamin D metabolism, transportation, 
and signalling, that associate with circulating concentrations of 25-hydroxyvitamin D (25[OH]D), 
1,25-dihydroxyvitamin D (1,25[OH]2D), and/or non-skeletal health outcomes (335). Variation in the 
vitamin D binding protein (DBP) gene, a cytochrome P450 enzyme (CYP2R1) gene, and the 7-
dehydrocholesterol reductase (DHCR7) gene most commonly associate with vitamin D metabolite 
concentrations, whilst variation in the vitamin D receptor (VDR) gene associates with the majority of 
reports on non-skeletal health outcomes, of which infectious and autoimmune diseases were the 
most common groups (335). The VDR mutation, FokI (rs10735810/rs2228570) has been found to 
associate with risk of respiratory syncytial virus (RSV) infection and lower respiratory infection (LRI) 
in cohorts from the Netherlands (339), South Africa (340), and Canada (202). FokI has also been found 
to associate with markers of asthma phenotype: IgE concentration, spirometric lung function indices 
(forced expiratory volume in 1 second to forced vital capacity ratio [FEV1:FVC]), Th2 cytokine 
concentration, and overall risk of asthma (130, 195). The ApaI mutation in VDR (rs7975232) also 
associates with risk of asthma (196), and rs17470271 in CYP27A1 has been found to associate with 
another spirometric lung function index of asthma severity - FEV1 (297). Several reports have also 
been made of vitamin D pathway SNP modifying the effects of vitamin D supplementation on risk of 
disease outcomes: TaqI mutation (rs731236) in VDR has been shown to modify the effects of vitamin 
D supplementation on time to sputum culture conversion in patients receiving treatment for 
tuberculosis, in the UK (205); risk of advanced colorectal adenoma, in another UK clinical trial (341); 
and FokI mutation has been reported to modify the effect of vitamin D supplementation on 
treatment of Parkinson’s disease, in a clinical trial conducted in Japan (342). 
 
To my knowledge, an investigation of the effects of genetic variation on response to vitamin D 




conducted. I therefore conducted main effect and effect-modification analyses on my panel of 35 
SNP in 11 vitamin D pathway genes (described in Methods, section 2.3.2) and the previously 




























7.2. Results.  
 
 
7.2.1. Main effects: does vitamin D pathway genotype influence risk of URI or asthma 
exacerbation, independent of vitamin D supplementation? 
 
Results of the main effects analyses are presented in Table 7.1 and Table 7.2. Multivariable Cox 
regression analysis (described in Methods, section 2.4.2) identified the following SNP genotypes to 
associate with risk of URI: referent to GG genotype for rs2762934 (CYP24A1), AG genotype associates 
with a 21% lower risk, and AA genotype associates with a 65% lower risk (P value for trend = 0.022); 
referent to CC genotype for rs7041 (DBP), AC genotype associates with a 28% lower risk, and AA 
genotype associates with a 42% lower risk (P for trend = 0.012); referent to GG genotype for rs4588 
(DBP), GT genotype associates with a 22% lower risk, and TT genotype associates with a 57% lower 
risk (P for trend = 0.015); referent to TT genotype for rs16846876 (DBP), AT genotype associates with 
a 18% lower risk, and TT genotype associates with a 55% lower risk (P value for trend = 0.033). After 
correction for multiple comparison testing (Bejamini & Hochberg method with a false discovery rate 
of 5%) these associations did not remain significant. Multivariable Cox regression analysis did not 













Table 7.1. Main effects: Time to first URI. 
 
Gene SNP Genotype N Days at risk  
(IQR) 
Univariable  
Hazard Ratio  
(95% CI) 
P value Multivariable Hazard 
Ratio  
(95% CI) 1 
P value  
CUBN rs3740165 TT 221 121 (39 to UD) referent 0.82 referent 0.70 
TC 22 156 (97 to 229) 1.06 (0.65 to 1.73)  1.10 (0.67 to 1.81  
CC 0* - -  -  
CYP24A1 rs2762939 GG 135 110 (40 to 304) referent 0.28 referent 0.12 
CG 91 128 (36 to UD) 0.86 (0.62 to 1.18)  0.81 (0.58 to 1.12)  
CC 17 178 (46 to UD) 0.79 (0.42 to 1.47)  0.69 (0.37 to 1.31)  
rs2248137 CC 84 106 (41 to 344) referent 0.50 referent 0.51 
CG 110 144 (34 to 315) 1.00 (0.72 to 1.41)  0.95 (0.68 to 1.33)  
GG 49 138 (60 to UD) 0.85 (0.55 to 1.30)  0.83 (0.53 to 1.28)  
rs2762934 GG 175 112 (36 to 304) referent 0.042 referent 0.022 
AG 65 158 (53 to UD) 0.81 (0.57 to 1.14)  0.79 (0.55 to 1.11)  
AA 6 UD (178 to UD) 0.28 (0.07 to 1.15)  0.25 (0.06 to 1.01)  
rs6013897 TT 148 128 (38 to UD) referent 0.16 referent 0.12 
AT 82 138 (46 to 315) 1.10 (0.79 to 1.51)  1.11 (0.80 to 1.53)  
AA 13 90 (35 to 156) 1.70 (0.93 to 3.09)  1.87 (0.99 to 3.53)  
CYP27A1 rs17470271 AA 97 106 (36 to 339) referent 0.35 referent 0.54 
AT 113 128 (40 to UD) 0.88 (0.63 to 1.21)  0.89 (0.64 to 1.23)  
TT 37 165 (82 to UD) 0.83 (0.53 to 1.29)  0.90 (0.57 to 1.42)  
CYP27B1 rs4646537 TT 223 121 (41 to 339) referent 0.31 referent 0.35 
GT 22 180 (35 to UD) 0.75 (0.42 to 1.31  0.75 (0.41 to 1.36)  
GG 0* - -  -  
rs4646536 AA 114 130 (42 to UD) referent 0.23 referent 0.11 
AG 100 128 (38 to 328) 1.18 (0.85 to 1.62)  1.27 (0.91 to 1.78)  
GG 26 121 (41 to 250) 1.28 (0.77 to 2.12)  1.41 (0.83 to 2.39)  
CYP2R1 rs10500804 TT 84 121 (46 to UD) referent 1.00 referent 0.95 
GT 126 138 (40 to 346) 0.98 (0.71 to 1.36)  1.00 (0.71 to 1.40)  
GG 36 94 (33 to UD) 1.01 (0.64 to 1.60)  1.02 (0.63 to 1.64)  
rs2060793 GG 92 108 (41 to 344) referent 0.73 referent 0.83 
AG 112 138 (39 to UD) 0.95 (0.69 to 1.31)  0.97 (0.69 to 1.35)  
AA 33 130 (67 to UD) 0.93 (0.58 to 1.50)  0.96 (0.59 to 1.56)  
rs10766197 GG 72 128 (46 to UD) referent 0.40 referent 0.62 
AG 126 120 (38 to 344) 1.08 (0.77 to 1.53)  1.13 (0.80 to 1.61)  
AA 35 90 (40 to UD) 1.08 (0.67 to 1.75)  1.09 (0.66 to 1.81)  
CYP3A4 rs2740574 AA 213 134 (42 to UD) referent 0.010 referent 0.14 
AG 25 53 (32 to 180) 1.69 (1.05 to 2.69)  1.65 (1.02 to 2.69)  
GG 9 71 (19 to 138) 1.85 (0.91 to 3.78)  1.24 (0.55 to 2.80)  
DBP rs7041 CC 75 90 (36 to 287) referent 0.099 referent 0.012 
AC 113 165 (42 to UD) 0.79 (0.56 to 1.11)  0.72 (0.51 to 1.02)  
AA 54 166 (50 to UD) 0.71 (0.47 to 1.08)  0.58 (0.37 to 0.90)  
rs4588 GG 133 106 (39 to 285) referent 0.012 referent 0.015 
GT 97 180 (41 to UD) 0.77 (0.57 to 1.06)  0.78 (0.57 to 1.08)  
TT 15 335 (166 to UD) 0.43 (0.20 to 0.93)  0.43 (0.20 to 0.93)  
rs12512631 TT 95 158 (42 to UD) referent 0.14 referent 0.053 
CT 117 128 (53 to 328) 1.14 (0.82 to 1.58)  1.25 (0.89 to 1.74)  
CC 34 110 (30 to 309) 1.42 (0.90 to 2.23)  1.54 (0.97 to 2.45)  
rs2070741 TT 204 128 (42 to UD) referent 0.14 referent 0.13 
TG 39 62 (33 to 229) 1.35 (0.91 to 2.00)  1.36 (0.91 to 2.03)  
GG 0* - -  -  
rs2298849 AA 154 125 (39 to UD) referent 0.49 referent 0.92 
AG 83 106 (40 to 229) 1.27 (0.93 to 1.74)  1.25 (0.91 to 1.71)  
GG 8 204 (21 to UD) 0.74 (0.30 to 1.81)  0.45 (0.17 to 1.15)  
rs16846876 AA 116 110 (38 to 315) referent 0.097 referent 0.033 
AT 111 125 (43 to UD) 0.88 (0.65 to 1.20)  0.82 (0.59 to 1.13)  
TT 14 262 (166 to UD) 0.50 (0.23 to 1.09)  0.45 (0.21 to 0.99)  




Gene SNP Genotype N Days at risk  
(IQR) 
Univariable  
Hazard Ratio  
(95% CI) 
P value Multivariable Hazard 
Ratio  
(95% CI) 1 
P value  
AG 58 78 (36 to 206) 1.42 (1.01 to 2.00)  1.38 (0.97 to 1.97)  
AA 2* - -  -  
rs12785878 TT 131 144 (40 to UD) referent 0.35 referent 0.28 
GT 84 124 (43 to 309) 1.10 (0.79 to 1.52)  1.18 (0.84 to 1.65)  
GG 31 78 (17 to 346) 1.23 (0.78 to 1.94)  1.24 (0.76 to 2.04)  
LRP2 rs3755166 GG 84 144 (54 to UD) referent 0.57 referent 0.66 
AG 126 121 (36 to 285) 1.21 (0.87 to 1.68)  1.15 (0.82 to 1.61)  
AA 36 97 (33 to UD) 1.05 (0.65 to 1.70)  1.05 (0.64 to 1.72)  
RXRA rs7861779 GG 154 110 (35 to 346) referent 0.90 referent 0.80 
GA 75 178 (62 to UD) 0.84 (0.60 to 1.16)  0.83 (0.59 to 1.17)  
AA 15 75 (32 to 130) 1.57 (0.86 to 2.85)  1.25 (0.67 to 2.32)  
rs9409929 GG 106 108 (42 to 315) referent 0.53 referent 0.88 
AG 111 158 (38 to UD) 0.89 (0.65 to 1.22)  0.97 (0.70 to 1.34)  
AA 28 120 (36 to UD) 0.91 (0.55 to 1.48)  0.97 (0.59 to 1.61)  
VDR rs4334089 GG 124 112 (36 to UD) referent 0.49 referent 0.75 
AG 90 144 (50 to UD) 1.00 (0.72 to 1.38)  0.85 (0.61 to 1.19)  
AA 31 110 (39 to 269) 1.22 (0.78 to 1.92)  1.25 (0.79 to 1.98)  
rs10783219 AA 113 125 (41 to 285) referent 0.85 referent 0.92 
AT 100 134 (59 to UD) 0.77 (0.55 to 1.06)  0.75 (0.54 to 1.05)  
TT 31 84 (33 to 335) 1.18 (0.75 to 1.86)  1.22 (0.77 to 1.94)  
rs4516035 TT 99 86 (34 to 328) referent 0.28 referent 0.44 
CT 101 177 (63 to UD) 0.73 (0.52 to 1.02)  0.84 (0.59 to 1.19)  
CC 43 127 (41 to UD) 0.87 (0.57 to 1.33)  0.88 (0.56 to 1.36)  
rs11568820 CC 136 128 (41 to UD) referent 0.043 referent 0.11 
CT 71 166 (40 to UD) 1.00 (0.70 to 1.41)  0.96 (0.67 to 1.36)  
TT 32 71 (33 to 170) 1.76 (1.15 to 2.70)  1.68 (1.06 to 2.67)  
rs7976091 CC 138 128 (42 to UD) referent 0.081 referent 0.28 
CT 72 158 (40 to UD) 1.03 (0.73 to 1.45)  0.98 (0.69 to 1.39)  
TT 31 75 (34 to 170) 1.62 (1.04 to 2.50)  1.42 (0.89 to 2.26)  
rs2238136 CC 142 110 (40 to 309) referent 0.64 referent 0.83 
CT 85 165 (54 to UD) 0.79 (0.57 to 1.10)  0.81 (0.58 to 1.13)  
TT 19 67 (31 to 262) 1.17 (0.68 to 2.01)  1.27 (0.73 to 2.20)  
rs1544410 CC 85 170 (47 to UD) referent 0.17 referent 0.38 
CT 116 110 (34 to 315) 1.31 (0.93 to 1.84)  1.22 (0.86 to 1.75)  
TT 42 121 (42 to 299) 1.29 (0.84 to 2.00)  1.18 (0.75 to 1.86)  
rs2228570 GG 102 144 (47 to 346) referent 0.70 referent 0.57 
AG 111 106 (39 to UD) 1.07 (0.78 to 1.48)  1.04 (0.75 to 1.44)  
AA 34 128 (30 to 335) 1.07 (0.67 to 1.69)  1.15 (0.72 to 1.84)  
rs2853559 GG 103 130 (42 to UD) referent 0.77 referent 0.48 
AG 108 124 (39 to 328) 1.15 (0.83 to 1.58)  1.23 (0.89 to 1.71)  
AA 35 125 (40 to UD) 0.99 (0.62 to 1.59)  1.07 (0.66 to 1.75)  
rs7975232 AA 75 138 (53 to 346) referent 0.60 referent 0.81 
AC 111 106 (36 to UD) 1.06 (0.75 to 1.50)  0.98 (0.68 to 1.39)  
CC 51 128 (47 to UD) 0.87 (0.56 to 1.34)  0.95 (0.60 to 1.48)  
rs7970314 AA 138 127 (41 to UD) referent 0.18 referent 0.39 
AG 74 128 (39 to 344) 1.03 (0.74 to 1.44)  0.98 (0.70 to 1.38)  
GG 34 82 (34 to 210) 1.41 (0.92 to 2.17)  1.31 (0.83 to 2.08)  
rs731236 AA 95 120 (42 to UD) referent 0.63 referent 0.84 
AG 114 129 (34 to 309) 1.13 (0.81 to 1.56)  1.07 (0.76 to 1.50)  
GG 34 112 (53 to 346) 1.07 (0.67 to 1.70)  1.02 (0.63 to 1.67)  
[1] Adjusted for stratification factors i.e. British Thoracic Society treatment step (2/3 vs. 4/5) and inclusion in vs. exclusion from sputum induction sub-study; 
significant predictors of upper respiratory infection i.e. Body mass index (<30 kg/m2 vs. ≥30 kg/m2), exhaled nitric oxide level (<26 parts per billion vs. ≥26 parts 
per billion), and sex; and allocation to study intervention or placebo arm. After correction for multiple comparisons testing, using Benjamini & Hochberg method 
with a false discovery rate of 5%, none of the p values for interaction remain significant. 
* Genotype could not be analysed due to <5 participants and/or too few events within the sub category.  
…………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 
Abbreviations: SNP: Single nucleotide polymorphism, IQR: Inter-quartile range, UD: Undefined, CI: Confidence interval, CYP-: Cytochrome P450 enzyme, DBP: 
Vitamin D binding protein, DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also known as megalin), RXRA: 
Retanoid-X receptor-A, VDR: Vitamin D receptor. 




Table 7.2. Main effects: Time to first asthma exacerbation. 
  
Gene SNP Genotype N Days at risk  
(IQR) 
Univariable  
Hazard Ratio  
(95% CI) 
P value Multivariable Hazard 
Ratio  
(95% CI) 1 
P value  
CUBN rs3740165 TT 221 UD (151 to UD) referent 0.50 referent 0.76 
  TC 22 UD (98 to UD) 1.25 (0.65 to 2.41)  1.11 (0.57 to 2.14)  
  CC 0* - -  -  
CYP24A1 rs2762939 GG 135 UD (213 to UD) referent 0.96 referent 0.50 
  CG 91 UD (144 to UD) 1.04 (0.68 to 1.60)  0.89 (0.58 to 1.37)  
  CC 17 UD (63 to UD) 0.95 (0.41 to 2.21)  0.79 (0.33 to 1.89)  
 rs2248137 CC 84 UD (144 to UD) referent 0.74 referent 0.50 
  CG 110 UD (158 to UD) 1.07 (0.69 to 1.68)  1.01 (0.64 to 1.58)  
  GG 49 UD (192 to UD) 0.87 (0.49 to 1.57)  0.79 (0.44 to 1.43)  
 rs2762934 GG 175 UD (141 to UD) referent 0.52 referent 0.68 
  AG 65 UD (251 to UD) 0.78 (0.48 to 1.25)  0.82 (0.51 to 1.33)  
  AA 6 300 (43 to UD) 1.27 (0.40 to 4.02)  1.33 (0.41 to 4.35)  
 rs6013897 TT 148 UD (202 to UD) referent 0.12 referent 0.17 
  AT 82 UD (141 to UD) 1.09 (0.71 to 1.69)  1.09 (0.71 to 1.69)  
  AA 13 218 (37 to UD) 2.26 (1.07 to 4.75)  1.98 (0.94 to 4.21)  
CYP27A1 rs17470271 AA 97 UD (136 to UD) referent 0.42 referent 0.84 
  AT 113 UD (202 to UD) 0.86 (0.56 to 1.33)  0.91 (0.59 to 1.40)  
  TT 37 UD (155 to UD) 0.80 (0.43 to 1.50)  0.99 (0.53 to 1.88)  
CYP27B1 rs4646537 TT 223 UD (186 to UD) referent 0.26 referent 0.26 
  GT 22 301 (58 to UD) 1.44 (0.77 to 2.70)  1.46 (0.75 to 2.82)  
  GG 0* - -  -  
 rs4646536 AA 114 UD (216 to UD) referent 0.71 referent 0.81 
  AG 100 UD (114 to UD) 1.37 (0.90 to 2.09)  1.15 (0.75 to 1.77)  
  GG 26 UD (274 to UD) 0.80 (0.36 to 1.77)  0.92 (0.41 to 2.07)  
CYP2R1 rs10500804 TT 84 UD (117 to UD) referent 0.077 referent 0.058 
  GT 126 UD (155 to UD) 0.85 (0.56 to 1.30)  0.78 (0.50 to 1.19)  
  GG 36 UD (270 to UD) 0.52 (0.26 to 1.05)  0.52 (0.25 to 1.06)  
 rs2060793 GG 92 UD (231 to UD) referent 0.068 referent 0.057 
  AG 112 UD (105 to UD) 1.74 (1.10 to 2.74)  1.73 (1.09 to 2.74)  
  AA 33 UD (151 to UD) 1.50 (0.79 to 2.85)  1.58 (0.82 to 3.02)  
 rs10766197 GG 72 UD (117 to UD) referent 0.13 referent 0.11 
  AG 126 UD (155 to UD) 0.76 (0.49 to 1.19)  0.72 (0.46 to 1.12)  
  AA 35 UD (233 to UD) 0.63 (0.33 to 1.23)  0.63 (0.32 to 1.23)  
CYP3A4 rs2740574 AA 213 UD (155 to UD) referent 0.64 referent 0.26 
  AG 25 UD (63 to UD) 1.29 (0.69 to 2.42)  1.43 (0.75 to 2.74)  
  GG 9* - -  -  
DBP rs7041 CC 75 364 (119 to UD) referent 0.30 referent 0.13 
  AC 113 UD (221 to UD) 0.61 (0.38 to 0.97)  0.58 (0.36 to 0.92)  
  AA 54 UD (213 to UD) 0.80 (0.47 to 1.37)  0.70 (0.41 to 1.21)  
 rs4588 GG 133 UD (136 to UD) referent 0.66 referent 0.61 
  GT 97 UD (158 to UD) 0.96 (0.63 to 1.46)  0.87 (0.56 to 1.35)  
  TT 15 UD (274 to UD) 0.79 (0.32 to 1.98)  0.93 (0.37 to 2.36)  
 rs12512631 TT 95 UD (218 to UD) referent 0.34 referent 0.16 
  CT 117 UD (126 to UD) 1.34 (0.86 to 2.07)  1.43 (0.92 to 2.22)  
  CC 34 UD (151 to UD) 1.22 (0.65 to 2.27)  1.39 (0.74 to 2.61)  
 rs2070741 TT 204 UD (151 to UD) referent 0.85 referent 0.78 
  TG 39 UD (103 to UD) 1.05 (0.62 to 1.80)  1.08 (0.63 to 1.85)  
  GG 0* - -  -  
 rs2298849 AA 154 UD (158 to UD) referent 0.93 referent 0.89 
  AG 83 UD (133 to UD) 1.19 (0.78 to 1.81)  1.21 (0.79 to 1.87)  
  GG 8 UD (241 to UD) 0.53 (0.13 to 2.18)  0.53 (0.13 to 2.19)  
 rs16846876 AA 116 UD (135 to UD) referent 0.41 referent 0.38 
  AT 111 UD (155 to UD) 0.92 (0.61 to 1.39)  0.91 (0.60 to 1.37)  
  TT 14 UD (274 to UD) 0.63 (0.23 to 1.74)  0.62 (0.22 to 1.73)  




Gene SNP Genotype N Days at risk  
(IQR) 
Univariable  
Hazard Ratio  
(95% CI) 
P value Multivariable Hazard 
Ratio  
(95% CI) 1 
P value  
  AG 58 UD (155 to UD) 1.32 (0.84 to 2.07)  1.16 (0.72 to 1.85)  
  AA 2* - -  -  
 rs12785878 TT 131 UD (216 to UD) referent 0.54 referent 0.95 
  GT 84 UD (114 to UD) 1.28 (0.83 to 1.98)  1.25 (0.81 to 1.94)  
  GG 31 UD (203 to UD) 1.05 (0.54 to 2.02)  0.86 (0.43 to 1.69)  
LRP2 rs3755166 GG 84 UD (244 to UD) referent 0.20 referent 0.41 
  AG 126 353 (119 to UD) 1.90 (1.18 to 3.05)  1.64 (1.01 to 2.66)  
  AA 36 UD (218 to UD) 1.18 (0.58 to 2.41)  1.09 (0.53 to 2.25)  
RXRA rs7861779 GG 154 UD (151 to UD) referent 0.78 referent 0.90 
  GA 75 UD (118 to UD) 1.16 (0.75 to 1.78)   1.14 (0.73 to 1.77)  
  AA 15 UD (218 to UD) 0.90 (0.36 to 2.24)  0.72 (0.28 to 1.83)  
 rs9409929 GG 106 UD (136 to UD) referent 0.96 referent 0.90 
  AG 111 UD (202 to UD) 0.86 (0.56 to 1.32)  0.93 (0.60 to 1.43)  
  AA 28 UD (133 to UD) 1.16 (0.63 to 2.16)  1.12 (0.60 to 2.09)  
VDR rs4334089 GG 124 UD (106 to UD) referent 0.16 referent 0.11 
  AG 90 UD (202 to UD) 0.85 (0.55 to 1.30)  0.80 (0.52 to 1.24)  
  AA 31 UD (224 to UD) 0.63 (0.32 to 1.23)  0.60 (0.30 to 1.20)  
 rs10783219 AA 113 UD (202 to UD) referent 0.22 referent 0.19 
  AT 100 UD (213 to UD) 0.86 (0.55 to 1.34)  0.79 (0.50 to 1.24)  
  TT 31 270 (37 to UD) 1.77 (1.01 to 3.09)  2.01 (1.13 to 3.55)  
 rs4516035 TT 99 UD (128 to UD) referent 0.43 referent 0.54 
  CT 101 UD (155 to UD) 0.92 (0.59 to 1.43)  0.96 (0.61 to 1.50)  
  CC 43 UD (224 to UD) 0.78 (0.43 to 1.42)  0.82 (0.45 to 1.49)  
 rs11568820 CC 136 UD (144 to UD) referent 0.72 referent 0.47 
  CT 71 UD (128 to UD) 0.99 (0.63 to 1.57)  0.97 (0.61 to 1.55)  
  TT 32 UD (218 to UD) 0.87 (0.47 to 1.63)  0.76 (0.40 to 1.46)  
 rs7976091 CC 138 UD (136 to UD) referent 0.43 referent 0.26 
  CT 72 UD (128 to UD) 0.92 (0.58 to 1.44)  0.91 (0.57 to 1.44)  
  TT 31 UD (221 to UD) 0.77 (0.41 to 1.48)  0.67 (0.34 to 1.30)  
 rs2238136 CC 142 UD (135 to UD) referent 0.97 referent 0.74 
  CT 85 UD (220 to UD) 0.62 (0.39 to 1.00)  0.61 (0.38 to 0.99)  
  TT 19 274 (101 to UD) 1.65 (0.89 to 3.06)  1.43 (0.76 to 2.68)  
 rs1544410 CC 85 UD (155 to UD) referent 0.31 referent 0.55 
  CT 116 UD (192 to UD) 1.07 (0.67 to 1.70)  0.89 (0.56 to 1.44)  
  TT 42 UD (141 to UD) 1.37 (0.78 to 2.42)  1.25 (0.71 to 2.21)  
 rs2228570 GG 102 UD (216 to UD) referent 0.85 referent 0.28 
  AG 111 UD (119 to UD) 1.11 (0.73 to 1.71)  1.30 (0.84 to 2.01)  
  AA 34 UD (269 to UD) 1.00 (0.53 to 1.87)  1.29 (0.68 to 2.44)  
 rs2853559 GG 103 UD (126 to UD) referent 0.79 referent 0.77 
  AG 108 UD (229 to UD) 0.71 (0.46 to 1.10)  0.68 (0.43 to 1.06)  
  AA 35 UD (117 to UD) 1.12 (0.63 to 1.99)  1.16 (0.64 to 2.09)  
 rs7975232 AA 75 UD (151 to UD) referent 0.98 referent 0.94 
  AC 111 UD (216 to UD) 0.73 (0.45 to 1.16)  0.72 (0.44 to 1.17)  
  CC 51 UD (118 to UD) 1.05 (0.62 to 1.79)  1.08 (0.63 to 1.86)  
 rs7970314 AA 138 UD (144 to UD) referent 0.72 referent 0.55 
  AG 74 UD (128 to UD) 0.95 (0.61 to 1.49)  0.96 (0.61 to 1.52)  
  GG 34 UD (218 to UD) 0.90 (0.49 to 1.65)  0.81 (0.43 to 1.52)  
 rs731236 AA 95 UD (203 to UD) referent 0.47 referent 0.57 
  AG 114 UD (213 to UD) 1.00 (0.64 to 1.57)  0.93 (0.59 to 1.46)  
  GG 34 UD (141 to UD) 1.31 (0.72 to 2.36)  1.29 (0.71 to 2.35)  
[1] Adjusted for stratification factors i.e. British Thoracic Society treatment step (2/3 vs. 4/5) and inclusion in vs. exclusion from sputum induction sub-study; 
significant predictors of asthma exacerbation i.e. Baseline asthma control test score (<19 vs. ≥19), reversibility assessment (yes vs. no), and sex; and allocation 
to study intervention or placebo arm. After correction for multiple comparisons testing, using Benjamini & Hochberg method with a false discovery rate of 5%, 
none of the p values for interaction remain significant. * Genotype could not be analysed due to <5 participants and/or too few events within this sub category. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 
Abbreviations: SNP: Single nucleotide polymorphism, IQR: Inter-quartile range, CI: Confidence interval, UD: Undefined, CYP-: Cytochrome P450 enzyme, DBP: 
Vitamin D binding protein, DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also known as megalin), RXRA: 
Retanoid-X receptor-A, VDR: Vitamin D receptor. 




7.2.2. Interaction analysis: does vitamin D pathway genotype influence effect of vitamin D 
supplementation in prevention of URI or asthma exacerbation? 
 
 
Results of interaction analyses testing for effect modification are presented in Table 7.3 and Table 
7.4. Multivariable Cox regression analysis (described in Methods, section 2.4.3) identified 3 SNP in 
VDR which modify the effect of vitamin D supplementation on risk of URI. To illustrate this concept, 
Figure 7.1 shows Kaplan-Meier failure estimates for time to first URI, stratified by genotype for 
rs7975232: In participants with CC genotype for rs7975232, vitamin D supplementation offered 
protection from URI (adjusted hazard ratio [aHR] 0.23; 95% CI 0.10 to 0.51), but had no effect in 
those with AC genotype (aHR 1.21; 95% CI 0.77 to 1.91), or AA genotype (aHR 1.03; 95% CI 0.57 to 
1.84 - adjusted ratio of hazard ratios [aRHR] 0.58; 95% CI 0.37 to 0.91; P value for interaction = 0.017). 
In participants with CC genotype for rs1544410, vitamin D supplementation offered protection from 
URI (aHR 0.54; 95% CI 0.31 to 0.94), but had no effect in those with CT genotype (aHR 1.10; 95% CI 
0.71 to 1.71), or TT genotype (aHR 1.77; 95% CI 0.78 to 4.06 - aRHR 1.54; 95% CI 1.00 to 2.36; P for 
interaction = 0.049). Finally, in participants with AA genotype for rs731236, vitamin D 
supplementation offered protection from URI (aHR 0.51; 95% CI 0.31 to 0.85), but had no effect in 
those with AG genotype (aHR 1.23; 95% CI 0.79 to 1.92), or GG genotype (aHR 1.60; 95% CI 0.68 to 
3.76 - aRHR 1.68; 95% CI 1.08 to 2.61; P value for interaction = 0.022). 
 
Multivariable Cox regression analysis identified 1 SNP in DBP which modifies the effect of vitamin D 
supplementation on risk of asthma exacerbation. In participants with CC genotype for rs12512631, 
vitamin D supplementation offered protection from asthma exacerbation (aHR 0.47; 95% CI 0.15 to 
1.47), but had no effect in those with CT genotype (0.77; 95% CI 0.44 to 1.37), or TT genotype (aHR 





After correction for multiple comparisons testing (Bejamini & Hochberg method with a false 
discovery rate of 5%) none of the observed associations between SNP and the effects of vitamin D 



















Figure.7.1. Kaplan-Meier failure estimates from the effect modification analysis, illustrating the effect 
of allocation on number of days post randomisation to first URI event, stratified by genotype for the 
VDR SNP, rs7975232. Allocation to the treatment arm did not affect risk of URI for those with AA, or 
















N Median time to 
1st URI (IQR) : 
Control arm 
N Median time to 
1st URI (IQR) : 
Vitamin D arm 
Hazard ratio for effect 
of allocation within 
subgroup (95% CI) 1 
Hazard ratio for 
allocation*geno-
type interaction 
(95% CI) 1 
P value for 
interaction 1 
CUBN rs3740165 TT 109 110 (38 to 309) 112 130 (40 to UD) 0.84 (0.61 to 1.16) 0.84 (0.61 to 1.16) 0.29 
  TC 11 192 (82 to 315) 11 128 (106 to 229) 0.82 (0.23 to 2.94)   
  CC 0 - 0 - -   
CYP24A1 rs2762939 GG 68  97 (36 to 252) 67 121 (51 to UD) 0.66 (0.44 to 0.99) 0.73 (0.50 to 1.08) 0.18 
  CG 47 124 (50 to UD) 44 128 (31 to UD) 1.39 (0.81 to 2.39)   
  CC 6 156 (46 to 158) 11 287 (34 to UD) 0.48 (0.09 to 2.56)   
 rs2248137 CC 42 106 (41 to 304) 42 108 (47 to UD) 0.86 (0.51 to 1.44) 1.04 (0.68 to 1.59) 0.87 
  CG 58 114 (26 to 299) 59  166 (34 to UD) 0.91 (0.57 to 1.44)   
  GG 20 110 (59 to UD) 29 138 (80 to UD) 0.70 (0.31 to 1.55)   
 rs2762934 GG 83 90 (36 to 262) 92 128 (34 to 344) 0.83 (0.58 to 1.17) 1.12 (0.60 to 2.09) 0.72 
  AG 34 158 (75 to 309) 31 108 (42 to UD) 0.86 (0.45 to 1.64)   
  AA 4* - 2* - -   
 rs6013897 TT 73 110 (36 to UD) 75 134 (47 to UD) 0.84 (0.56 to 1.25) 0.86 (0.51 to 1.48) 0.60 
  AT 37 144 (59 to 315) 45 125 (42 to UD) 0.85 (0.47 to 1.52)   
  AA 11 90 (35 to 156) 2* - -   
CYP27A1 rs17470271 AA 48 106 (23 to UD) 49 103 (42 to 287) 1.17 (0.72 to 1.91) 0.79 (0.51 to 1.23) 0.30 
  AT 53 105 (41 to 285) 60 138 (34 to UD) 0.75 (0.47 to 1.18)   
  TT 22 165 (82 to 304) 15 125 (43 to UD) 0.91 (0.40 to 2.11)   
CYP27B1 rs4646537 TT 109 110 (40 to 299) 114 128 (42 to UD) 0.83 (0.61 to 1.13) 1.42 (0.43 to 4.73) 0.57 
  GT 12 165 (35 to UD) 10 180 (29 to UD) 0.66 (0.10 to 4.13)   
  GG 0 - 0 - -   
 rs4646536 AA 52 121 (41 to UD) 62 130 (42 to UD) 1.04 (0.64 to 1.67) 0.67 (0.41 to 1.08) 0.099 
  AG 50 129 (35 to 335) 50 128 (40 to 328) 0.91 (0.57 to 1.45)   
  GG 20 83 (27 to 211) 6 UD (121 to UD) 0.12 (0.02 to 0.70)   
CYP2R1 rs10500804 TT 36 97 (46 to 217) 48 130 (38 to UD) 0.99 (0.57 to 1.71) 0.79 (0.50 to 1.25) 0.31 
  GT 67 144 (38 to 339) 42 128 (42 to UD) 1.03 (0.67 to 1.58)   
  GG 20 75 (26 to 304) 16 110 (33 to UD) 0.53 (0.21 to 1.36)   
 rs2060793 GG 52 97 (40 to 335) 40 110 (42 to UD) 0.92 (0.57 to 1.51) 0.91 (0.58 to 1.43) 0.67 
  AG 53 114 (50 to 299) 59 138 (34 to UD) 0.87 (0.55 to 1.37)   
  AA 12 86 (6 to 190) 21 130 (71 to UD) 0.60 (0.23 to 1.57)   
 rs10766197 GG 32 97 (46 to UD) 40  130 (38 to UD) 0.96 (0.53 to 1.75) 0.76 (0.47 to 1.23) 0.27 
  AG 65 129 (38 to 309) 61  106 (40 to UD) 0.96 (0.63 to 1.47)   
  AA 21 82 (40 to 335) 14 108 (42 to UD) 0.52 (0.19 to 1.42)   
CYP3A4 rs2740574 AA 106 129 (56 to 346) 107 166 (42 to UD) 0.93 (0.67 to 1.29) 0.94 (0.52 to 1.69) 0.84 
  AG 12 35 (11 to 50) 13 128 (53 to UD) 0.35 (0.10 to 1.15)   
  GG 5 66 (12 to 204) 4* - -   
DBP rs7041 CC 37 86 (40 to 206) 38 106 (34 to 344) 0.76 (0.42 to 1.35) 1.24 (0.80 to 1.93) 0.34 
  AC 57 180 (38 to 346) 56 128 (47 to UD) 0.89 (0.56 to 1.42)   
  AA 28 105 (46 to UD) 26 166 (53 to UD) 0.88 (0.43 to 1.79)   
 rs4588 GG 62 90 (39 to 269) 71 108 (40 to 287) 0.87 (0.58 to 1.31) 0.98 (0.58 to 1.65) 0.95 
  GT 54 170 (38 to 339) 43 201 (43 to UD) 0.68 (0.41 to 1.13)   
  TT 6 335 (262 to UD) 9 UD (166 to UD) 0.53 (0.04 to 6.72)   
 rs12512631 TT 49 165 (50 to UD) 46 108 (40 to UD) 1.08 (0.65 to 1.80) 0.68 (0.44 to 1.07) 0.099 
  CT 57 112 (41 to 285) 60 130 (53 to UD) 0.83 (0.54 to 1.29)   
  CC 17 59 (26 to 213) 17 205 (34 to 328) 0.56 (0.21 to 1.52)   
 rs2070741 TT 105 112 (41 to 304) 99  138 (50 to UD) 0.78 (0.56 to 1.09) 0.71 (0.31 to 1.65) 0.43 
  TG 15 50 (11 to UD) 24 62 (34 to 211) 0.99 (0.44 to 2.24)   
  GG 0 - 0 - -   
 rs2298849 AA 72 121 (38 to 335) 82 128 (42 to UD) 0.81 (0.56 to 1.20) 1.49 (0.88 to 2.52) 0.14 
  AG 44 105 (36 to 208) 39 108 (40 to 285) 0.70 (0.42 to 1.18)   
  GG 6 269 (204 to UD) 2* - -   
 rs16846876 AA 54 110 (36 to 315) 62 120 (40 to 328) 0.79 (0.50 to 1.25) 0.94 (0.55 to 1.60) 0.82 
  AT 60 129 (46 to 335) 51 108 (34 to UD) 0.77 (0.49 to 1.23)   






N Median time to 
1st URI (IQR) : 
Control arm 
N Median time to 
1st URI (IQR) : 
Vitamin D arm 
Hazard ratio for effect 
of allocation within 
subgroup (95% CI) 1 
Hazard ratio for 
allocation*geno-
type interaction 
(95% CI) 1 
P value for 
interaction 1 
DHCR7 rs3829251 GG 92 144 (40 to 339) 94 166 (43 to UD) 0.85 (0.60 to 1.21) 1.31 (0.67 to 2.56) 0.44 
  AG 28 75 (19 to 192) 30 78 (42 to 328) 1.11 (0.58 to 2.11)   
  AA 1* - 1* - -   
 rs12785878 TT 72 112 (40 to 335) 59 178 (38 to UD) 0.74 (0.48 to 1.15) 1.06 (0.68 to 1.65) 0.81 
  GT 37 158 (69 to UD) 47 89 (42 to 287) 1.40 (0.80 to 2.44)   
  GG 13 46 (12 to 204) 18 121 (33 to UD) 0.50 (0.17 to 1.46)   
LRP2 rs3755166 GG 45 156 (60 to 315) 39  138 (42 to UD) 0.74 (0.43 to 1.28) 0.97 (0.62 to 1.52) 0.89 
  AG 60 110 (36 to 285) 66  130 (34 to 287) 0.92 (0.60 to 1.40)   
  AA 17 97 (18 to UD) 19 125 (53 to UD) 0.36 (0.13 to 1.01)   
RXRA rs7861779 GG 74 105 (35 to 269) 80 120 (34 to UD) 0.78 (0.53 to 1.14) 1.12 (0.67 to 1.87) 0.66 
  GA 37 180 (66 to UD) 38 177 (62 to UD) 1.03 (0.58 to 1.83)   
  AA 9 75 (36 to 110) 6 71 (32 to 138) 1.08 (0.27 to 4.36)   
 rs9409929 GG 53 110 (40 to 315) 53 106 (51 to UD) 0.97 (0.61 to 1.54) 0.87 (0.55 to 1.37) 0.54 
  AG 55 129 (41 to 285) 56 166 (34 to UD) 0.78 (0.49 to 1.24)   
  AA 14 89 (36 to UD) 14 130 (50 to UD) 0.44 (0.15 to 1.29)   
VDR rs4334089 GG 62 105 (35 to 315) 62 205 (42 to UD) 0.61 (0.38 to 0.98) 1.25 (0.79 to 1.96) 0.34 
  AG 42 190 (60 to UD) 48 120 (38 to 328) 1.28 (0.76 to 2.18)   
  AA 18 82 (41 to 269) 13 166 (33 to 229) 0.79 (0.32 to 1.92)   
 rs10783219 AA 54 94 (39 to 208) 59 166 (50 to UD) 0.67 (0.43 to 1.05) 1.11 (0.69 to 1.76) 0.67 
  AT 52 211 (63 to UD) 48 128 (34 to UD) 1.15 (0.69 to 1.91)   
  TT 16 84 (26 to 262) 15 67 (33 to UD) 0.58 (0.23 to 1.45)   
 rs4516035 TT 51 90 (36 to 335) 48 71 (32 to 328) 1.18 (0.74 to 1.88) 0.70 (0.46 to 1.07) 0.10 
  CT 47 165 (63 to UD) 54 177 (65 to UD) 0.88 (0.54 to 1.43)   
  CC 21 90 (18 to 190) 22 180 (53 to UD) 0.40 (0.17 to 0.95)   
 rs11568820 CC 69 110 (38 to 315) 67 178 (50 to UD) 0.71 (0.46 to 1.09) 1.22 (0.79 to 1.88) 0.37 
  CT 35 206 (40 to UD) 36 120 (40 to UD) 1.10 (0.62 to 1.95)   
  TT 15 75 (39 to 156) 17 71 (33 to 210) 0.94 (0.40 to 2.18)   
 rs7976091 CC 69 110 (38 to 315) 69 178 (53 to UD) 0.69 (0.45 to 1.06) 1.41 (0.92 to 2.17) 0.12 
  CT 38 206 (40 to UD) 34 110 (40 to 344) 1.17 (0.66 to 2.11)   
  TT 15 82 (46 to 170) 16 60 (32 to 138) 1.82 (0.73 to 4.53)   
 rs2238136 CC 70 127 (50 to 315) 72 101 (33 to 287) 1.03 (0.70 to 1.52) 0.67 (0.41 to 1.10) 0.11 
  CT 45 124 (36 to 339) 40 180 (87 to UD) 0.78 (0.45 to 1.37)   
  TT 7 35 (16 to 105) 12 106 (34 to UD) 0.36 (0.10 to 1.33)   
 rs1544410 CC 40 89 (40 to 269) 45 285 (89 to UD) 0.54 (0.31 to 0.94) 1.54 (1.00 to 2.36) 0.049 
  CT 59 124 (35 to 315) 57 106 (34 to 328) 1.10 (0.71 to 1.71)   
  TT 22 156 (75 to 335) 20 67 (34 to 238) 1.77 (0.78 to 4.06)   
 rs2228570 GG 51 144 (41 to 309) 51 166 (50 to UD) 0.80 (0.50 to 1.26) 0.99 (0.64 to 1.53) 0.95 
  AG 58 110 (41 to UD) 53 89 (34 to UD) 1.16 (0.73 to 1.83)   
  AA 14 81 (18 to 262) 20 128 (30 to UD) 0.80 (0.29 to 2.20)   
 rs2853559 GG 54 156 (46 to UD) 49 130 (42 to UD) 1.05 (0.65 to 1.70) 0.67 (0.43 to 1.03) 0.066 
  AG 50 121 (39 to 285) 58 128 (42 to UD) 0.82 (0.53 to 1.29)   
  AA 19 94 (27 to 208) 16 280 (40 to UD) 0.50 (0.19 to 1.28)   
 rs7975232 AA 40 165 (60 to 346) 35 125 (40 to 328) 1.03 (0.57 to 1.84) 0.58 (0.37 to 0.91) 0.017 
  AC 57 129 (40 to UD) 54 106 (32 to 344) 1.21 (0.77 to 1.91)   
  CC 20 86 (22 to 170) 31 328 (78 to UD) 0.23 (0.10 to 0.51)   
 rs7970314 AA 68 105 (35 to 309) 70 177 (53 to UD) 0.70 (0.46 to 1.06) 1.41 (0.93 to 2.15) 0.11 
  AG 38 192 (40 to UD) 36 108 (34 to 344) 1.13 (0.64 to 1.98)   
  GG 16 82 (46 to 204) 33 71 (33 to 210) 1.51 (0.65 to 3.51)   
 rs731236 AA 45 83 (36 to 250) 50 211 (78 to UD) 0.51 (0.31 to 0.85) 1.68 (1.08 to 2.61) 0.022 
  AG 61 158 (39 to 335) 53 106 (32 to 280) 1.23 (0.79 to 1.92)   
  GG 15 112 (75 to UD) 19 121 (34 to 238) 1.60 (0.68 to 3.76)   
[1] Adjusted for stratification factors i.e. British Thoracic Society treatment step (2/3 vs. 4/5) and inclusion in vs. exclusion from sputum induction sub-study; significant 
predictors of upper respiratory infection i.e. Body mass index (<30 kg/m2 vs. ≥30 kg/m2), exhaled nitric oxide level (<26 parts per billion vs. ≥26 parts per billion), and sex; 
and allocation to study intervention or placebo arm. After correction for multiple comparisons testing, using Benjamini & Hochberg method with a false discovery rate of 
5%, none of the p values for interaction remain significant. * Genotype could not be analysed due to <5 participants and/or too few events within this sub category. 
………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………. 
Abbreviations: SNP: Single nucleotide polymorphism, IQR: Inter-quartile range, CI: Confidence interval, UD: Undefined, CYP-: Cytochrome P450 enzyme, DBP: Vitamin D 
binding protein, DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also known as megalin), RXRA: Retanoid-X receptor-A, 
VDR: Vitamin D receptor, CUBN: Cubilin. 








N Median time to 
1st URI (IQR)  
: Control arm 
N Median time to 
1st URI (IQR)  
: Vitamin D arm 
Hazard ratio for 
effect of allocation 
within subgroup 
(95% CI) 1 
Hazard ratio for 
allocation*geno-
type interaction 
(95% CI) 1 
P value for 
interaction  
CUBN rs3740165 TT 109 UD (136 to UD) 112 UD (186 to UD) 1.14 (0.74 to 1.75) 0.49 (0.13 to 1.91) 0.31 
  TC 11 218 (76 to UD) 11 UD (216 to UD) 0.76 (0.15 to 3.81)   
  CC 0 - 0 - -   
CYP24A1 rs2762939 GG 68  UD (216 to UD) 67 UD (155 to UD) 1.19 (0.68 to 2.10) 0.92 (0.46 to 1.82) 0.81 
  CG 47 UD (111 to UD) 44 UD (158 to UD) 1.10 (0.55 to 2.18)   
  CC 6 UD (58 to UD) 11 UD (202 to UD) 0.31 (0.01 to 9.64)   
 rs2248137 CC 42 UD (117 to UD) 42 UD (186 to UD) 0.85 (0.41 to 1.76) 0.99 (0.56 to 1.75) 0.97 
  CG 58 UD (241 to UD) 59  353 (151 to UD) 1.80 (0.99 to 3.28)   
  GG 20 UD (117 to UD) 29 UD (203 to UD) 0.67 (0.24 to 1.88)   
 rs2762934 GG 83 UD (141 to UD) 92 UD (155 to UD) 1.23 (0.77 to 1.99) 0.42 (0.18 to 0.98) 0.046 
  AG 34 UD (119 to UD) 31 UD (328 to UD) 0.71 (0.29 to 1.77)   
  AA 4* - 2* - -   
 rs6013897 TT 73 UD (216 to UD) 75 UD (202 to UD) 1.23 (0.72 to 2.12) 0.63 (0.32 to 1.25) 0.19 
  AT 37 UD (126 to UD) 45 UD (151 to UD) 1.00 (0.48 to 2.08)   
  AA 11 136 (35 to 233) 2* - -   
CYP27A1 rs17470271 AA 48 UD (136 to UD) 49 UD (133 to UD) 1.25 (0.66 to 2.35) 0.76 (0.42 to 1.38) 0.36 
  AT 53 UD (144 to UD) 60 UD (202 to UD) 0.86 (0.46 to 1.60)   
  TT 22 UD (77 to UD) 15 UD (231 to UD) 1.00 (0.30 to 3.34)   
CYP27B1 rs4646537 TT 109 UD (136 to UD) 114 244 (38 to UD) 1.02 (0.66 to 1.57) 1.30 (0.36 to 4.70) 0.69 
  GT 12 UD (58 to UD) 10 UD (202 to UD) 1.80 (0.32 to 10.26)   
  GG 0 - 0 - -   
 rs4646536 AA 52 UD (241 to UD) 62 UD (202 to UD) 1.38 (0.69 to 2.75) 0.83 (0.42 to 1.64) 0.59 
  AG 50 300 (111 to UD) 50 UD (128 to UD) 0.79 (0.43 to 1.45)   
  GG 20 UD (29 to UD) 6 UD (274 to UD) 2.05 (0.15 to 28.22)   
CYP2R1 rs10500804 TT 36 UD (117 to UD) 48 UD (101 to UD) 1.06 (0.54 to 2.05) 1.17 (0.63 to 2.17) 0.61 
  GT 67 UD (111 to UD) 42 UD (203 to UD) 0.97 (0.55 to 1.70)   
  GG 20 UD (UD to UD) 16 UD (244 to UD) 2.89 (0.63 to 13.29)   
 rs2060793 GG 52 UD (229 to UD) 40 UD (231 to UD) 1.17 (0.53 to 2.59) 1.00 (0.56 to 1.80) 1.00 
  AG 53 342 (43 to UD) 59 UD (135 to UD) 0.77 (0.44 to 1.35)   
  AA 12 UD (269 to UD) 21 274 (133 to UD) 2.60 (0.71 to 9.58)   
 rs10766197 GG 32 UD (117 to UD) 40  UD (61 to UD) 1.18 (0.59 to 2.36) 1.15 (0.61 to 2.18) 0.66 
  AG 65 UD (111 to UD) 61  UD (216 to UD) 0.91 (0.51 to 1.63)   
  AA 21 UD (233 to UD) 14 328 (158 to UD) 2.37 (0.62 to 9.02)   
CYP3A4 rs2740574 AA 106 UD (141 to UD) 107 UD (186 to UD) 1.21 (0.78 to 1.86) 0.62 (0.26 to 1.50) 0.29 
  AG 12 105 (38 to UD) 13 UD (270 to UD) 0.50 (0.11 to 2.17)   
  GG 5 UD (UD to UD) 4* - -   
DBP rs7041 CC 37 288 (117 to UD) 38 UD (151 to UD) 0.67 (0.32 to 1.40) 1.48 (0.81 to 2.68) 0.20 
  AC 57 UD (269 to UD) 56 UD (220 to UD) 1.13 (0.57 to 2.26)   
  AA 28 UD (218 to UD) 26 UD (202 to UD) 1.63 (0.64 to 4.18)   
 rs4588 GG 62 UD (119 to UD) 71 UD (192 to UD) 0.81 (0.47 to 1.42) 1.59 (0.79 to 3.20) 0.19 
  GT 54 UD (218 to UD) 43 UD (155 to UD) 1.91 (0.95 to 3.83)   
  TT 6 UD (280 to UD) 9 UD (274 to UD) 1.78 (0.14 to 22.54)   
 rs12512631 TT 49 UD (280 to UD) 46 UD (213 to UD) 2.14 (1.03 to 4.45) 0.44 (0.24 to 0.78) 0.005 
  CT 57 UD (117 to UD) 60 UD (128 to UD) 0.77 (0.44 to 1.37)   
  CC 17 UD (36 to UD) 17 UD (317 to UD) 0.47 (0.15 to 1.47)   
 rs2070741 TT 105 UD (119 to UD) 99  UD (192 to UD) 0.87 (0.56 to 1.36) 0.31 (0.08 to 1.19) 0.088 
  TG 15 UD (UD to UD) 24 301 (98 to UD) 3.45 (0.90 to 13.29)   
  GG 0 - 0 - -   
 rs2298849 AA 72 UD (117 to UD) 82 UD (216 to UD) 0.92 (0.54 to 1.55) 1.50 (0.74 to 3.07) 0.26 
  AG 44 UD (119 to UD) 39 UD (135 to UD) 1.03 (0.51 to 2.05)   
  GG 6 UD (UD to UD) 2* - -   
 rs16846876 AA 54 UD (119 to UD) 62 UD (202 to UD) 0.83 (0.46 to 1.51) 1.39 (0.69 to 2.78) 0.36 
  AT 60 UD (144 to UD) 51 UD (155 to UD) 1.22 (0.65 to 2.26)   






N Median time to 
1st URI (IQR)  
: Control arm 
N Median time to 
1st URI (IQR)  
: Vitamin D arm 
Hazard ratio for 
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(95% CI) 1 
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(95% CI) 1 
P value for 
interaction  
DHCR7 rs3829251 GG 92 UD (136 to UD) 94 UD (192 to UD) 0.89 (0.55 to 1.45) 1.70 (0.71 to 4.08) 0.24 
  AG 28 UD (111 to UD) 30 317 (203 to UD) 1.51 (0.66 to 3.45)   
  AA 1* - 1* - -   
 rs12785878 TT 72 UD (229 to UD) 59 UD (213 to UD) 1.15 (0.65 to 2.04) 0.77 (0.44 to 1.36) 0.37 
  GT 37 UD (38 to UD) 47 UD (155 to UD) 0.75 (0.37 to 1.51)   
  GG 13 UD (58 to UD) 18 UD (266 to UD) 0.47 (0.13 to 1.74)   
LRP2 rs3755166 GG 45 UD (144 to UD) 39  UD (274 to UD) 0.82 (0.34 to 1.98) 1.68 (0.91 to 3.12) 0.10 
  AG 60 343 (66 to UD) 66  353 (155 to UD) 1.01 (0.60 to 1.69)   
  AA 17 UD (UD to UD) 19 UD (61 to UD) 2.57 (0.60 to 11.03)   
RXRA rs7861779 GG 74 UD (144 to UD) 80 UD (151 to UD) 1.45 (0.85 to 2.50) 0.57 (0.30 to 1.12) 0.10 
  GA 37 UD (58 to UD) 38 UD (220 to UD) 0.64 (0.31 to 1.33)   
  AA 9 UD (218 to UD) 6 UD (221 to UD) 0.38 (0.03 to 5.30)   
 rs9409929 GG 53 UD (126 to UD) 53 UD (151 to UD) 1.04 (0.57 to 1.91) 1.09 (0.60 to 1.98) 0.78 
  AG 55 UD (144 to UD) 56 UD (213 to UD) 1.29 (0.67 to 2.50)   
  AA 14 UD (58 to UD) 14 297 (155 to UD) 1.59 (0.48 to 5.22)   
VDR rs4334089 GG 62 UD (105 to UD) 62 UD (135 to UD) 1.00 (0.57 to 1.75) 1.40 (0.77 to 2.55) 0.27 
  AG 42 UD (126 to UD) 48 UD (203 to UD) 1.02 (0.51 to 2.06)   
  AA 18 UD (343 to UD) 13 UD (186 to UD) 2.04 (0.50 to 8.33)   
 rs10783219 AA 54 UD (241 to UD) 59 UD (133 to UD) 1.85 (0.98 to 3.46) 0.55 (0.30 to 1.02) 0.057 
  AT 52 UD (136 to UD) 48 UD (297 to UD) 0.60 (0.29 to 1.21)   
  TT 16 105 (35 to UD) 15 328 (151 to UD) 0.71 (0.23 to 2.21)   
 rs4516035 TT 51 UD (77 to UD) 48 UD (186 to UD) 0.93 (0.49 to 1.74) 1.11 (0.63 to 1.92) 0.72 
  CT 47 UD (144 to UD) 54 UD (192 to UD) 1.00 (0.52 to 1.93)   
  CC 21 UD (233 to UD) 22 UD (203 to UD) 1.39 (0.49 to 3.97)   
 rs11568820 CC 69 UD (111 to UD) 67 UD (213 to UD) 0.84 (0.48 to 1.47) 1.41 (0.79 to 2.50) 0.24 
  CT 35 UD (251 to UD) 36 UD (118 to UD) 1.22 (0.57 to 2.62)   
  TT 15 UD (241 to UD) 17 UD (202 to UD) 1.20 (0.37 to 3.94)   
 rs7976091 CC 69 UD (111 to UD) 69 UD (192 to UD) 0.98 (0.57 to 1.69) 1.23 (0.69 to 2.19) 0.49 
  CT 38 UD (251 to UD) 34 UD (128 to UD) 1.15 (0.54 to 2.45)   
  TT 15 UD (241 to UD) 16 UD (202 to UD) 1.07 (0.30 to 3.76)   
 rs2238136 CC 70 UD (141 to UD) 72 UD (128 to UD) 1.03 (0.62 to 1.72) 1.21 (0.64 to 2.30) 0.56 
  CT 45 UD (126 to UD) 40 UD (274 to UD) 0.92 (0.39 to 2.16)   
  TT 7 343 (37 to UD) 12 270 (101 to UD) 1.15 (0.19 to 7.05)   
 rs1544410 CC 40 UD (136 to UD) 45 UD (231 to UD) 1.06 (0.50 to 2.29) 1.16 (0.64 to 2.12) 0.63 
  CT 59 UD (105 to UD) 57 UD (213 to UD) 0.94 (0.50 to 1.74)   
  TT 22 UD (117 to UD) 20 274 (151 to UD) 1.46 (0.56 to 3.81)   
 rs2228570 GG 51 UD (241 to UD) 51 UD (186 to UD) 1.37 (0.71 to 2.61) 0.85 (0.48 to 1.52) 0.59 
  AG 58 UD (91 to UD) 53 UD (202 to UD) 0.71 (0.38 to 1.32)   
  AA 14 UD (269 to UD) 20 UD (135 to UD) 1.62 (0.42 to 6.28)   
 rs2853559 GG 54 UD (105 to UD) 49 UD (158 to UD) 1.35 (0.74 to 2.48) 0.77 (0.42 to 1.43) 0.41 
  AG 50 UD (216 to UD) 58 UD (244 to UD) 0.77 (0.39 to 1.52)   
  AA 19 UD (119 to UD) 16 UD (43 to UD) 1.23 (0.38 to 3.99)   
 rs7975232 AA 40 UD (141 to UD) 35 328 (151 to UD) 1.92 (0.92 to 3.99) 0.64 (0.35 to 1.16) 0.14 
  AC 57 UD (144 to UD) 54 UD (216 to UD) 0.91 (0.47 to 1.76)   
  CC 20 269 (58 to UD) 31 UD (155 to UD) 0.71 (0.27 to 1.89)   
 rs7970314 AA 68 UD (111 to UD) 70 UD (213 to UD) 0.86 (0.50 to 1.49) 1.46 (0.83 to 2.56) 0.18 
  AG 38 UD (251 to UD) 36 UD (118 to UD) 1.26 (0.60 to 2.65)   
  GG 16 UD (241 to UD) 33 364 (186 to UD) 1.45 (0.47 to 4.55)   
 rs731236 AA 45 UD (136 to UD) 50 UD (221 to UD) 0.95 (0.48 to 1.86) 1.23 (0.66 to 2.27) 0.52 
  AG 61 UD (216 to UD) 53 UD (192 to UD) 1.15 (0.62 to 2.15)   
  GG 15 UD (111 to UD) 19 353 (158 to UD) 1.61 (0.55 to 4.74)   
[1] Adjusted for stratification factors i.e. British Thoracic Society treatment step (2/3 vs. 4/5) and inclusion in vs. exclusion from sputum induction sub-study; significant 
predictors of asthma exacerbation i.e. Baseline asthma control test score (<19 vs. ≥19), reversibility assessment (yes vs. no), and sex; and allocation to study intervention 
or placebo arm. After correction for multiple comparisons testing, using Benjamini & Hochberg method with a false discovery rate of 5%, none of the p values for interaction 
remain significant. * Genotype could not be analysed due to <5 participants and/or too few events within this sub category.  
………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………. 
Abbreviations: SNP: Single nucleotide polymorphism, IQR: Inter-quartile range, UD: Undefined, CI: Confidence interval, CYP-: Cytochrome P450 enzyme, DBP: Vitamin D 
binding protein, DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also known as megalin), RXRA: Retanoid-X receptor-A, 
VDR: Vitamin D receptor, CUBN: Cubilin. 





In this chapter I have investigated the effect of known variants in common vitamin D pathway genes 
on the risk of URI or disease exacerbation in patients with asthma. Main effects and interaction 
analyses did not identify any SNP which directly associate with URI / exacerbation, or modify the 
effect of vitamin D supplementation in prevention of URI / exacerbation. 
 
The lack of association between vitamin D pathway SNP and risk of URI or asthma exacerbation I 
report in this adult study population chimes with null reports from two clinical trials of vitamin D 
supplementation conducted in adult participants (209) (300). If vitamin D supplementation is not an 
effective intervention for prevention of URI / exacerbation then an argument for the importance of 
variation in vitamin D related genes becomes harder to make. However, the disruption of genes 
which control concentrations of the active vitamin D metabolite (1,25[OH]2D) and those which 
govern vitamin D signalling could affect a change in vitamin D’s actions, without being largely 
dependent on circulating concentrations of 25(OH)D – which is often the sole measure of vitamin D’s 
potential in clinical trials. Interestingly, genetic studies have reported main effect associations 
between vitamin D pathway SNP and risk of respiratory infections in children (202, 340), while other 
studies have found vitamin D related SNP to associate with clinical markers of asthma phenotype in 
children: Pillai et al., and Nabih et al. report an association between rs10735810 (FokI mutation in 
VDR) and IgE concentration; FEV1/FVC spirometric volumes; and Th2 cytokine concentrations (130, 
195), and Leung et al. found rs17470271 (CYP27A1) to associate with FEV1 (297). Furthermore, two 
clinical trials have demonstrated a protective effect of vitamin D supplementation in asthmatic 
children (280, 299). A possible explanation for the contrasting findings between studies conducted 
in children and adults is that the developing airway may be more sensitive to the actions of vitamin 
D than that of adult asthma patients. Another possibility is that limitations of previous clinical trials 
conducted in adults were responsible for their null reports (e.g. large proportion of moderate asthma 




concentrations, within the physiological range), and that publication bias has resulted in the lack of 
null genetic study reports in children.   
 
To further investigate the potential of genetic variation in vitamin D related genes to influence risk 
of ARI / exacerbations, or influence the effects of vitamin D supplementation in prevention of these 
outcomes, large clinical trials are needed in severe asthma patients who are genotyped for the SNP 
I have investigated. 
 
 
7.3.1. Study strengths. 
To my knowledge, this is the first study to comprehensively investigate genetic variation in the 
vitamin D pathway on risk of upper respiratory infection and disease exacerbation in asthma patients 
participating in a clinical trial of vitamin D supplementation (209). My analysis utilised genotyping 
data from a panel of SNP which capture the current body of positive genetic association findings 
between vitamin D pathway variants and vitamin D metabolite / non-skeletal disease outcomes. 
Furthermore, my analysis was strengthened by the detailed information I collected on potential 
confounders of the relationship between vitamin D pathway SNP and risk of URI / asthma 
exacerbation.  25(OH)D concentrations were measured with the gold standard assay (LC-MS/MS) in 
a laboratory that participated in the international vitamin D external quality assurance scheme 
(www.deqas.org/). The study population included patients with mild, moderate and severe disease 
from both community and hospital settings, studied across all seasons: these features enhance 





7.3.2. Study limitations. 
One limitation of this study was power to detect modest effects of SNP on outcome measures: the 
clinical trial population was powered to detect the effects of vitamin D supplementation in the entire 
study population, rather than by SNP genotypes, which may have limited my ability to see a signal 
most for SNP with the smallest minor allele frequencies and opened the door to the potential for 
type II error. Another limitation was the way in which URI events were captured: URI were not 
laboratory-confirmed, however our method of event capture was validated against PCR in a previous 
study (222). One final possible limitation of this study may have been the use of an intermittent bolus 
vitamin D dosing regimen, rather than a daily or weekly regimen. Whilst intermittent bolus dosing 
generally offers better compliance, it has been speculated the sharp boost in vitamin D metabolite 
concentration which arises from bolus doses may cause dysregulation of the balance between 




Previous genetic studies have found vitamin D pathway SNP to associate with risk of ARI in healthy 
children, and clinical features of asthma phenotype in children. My analysis found no association 
between vitamin D pathway SNP and risk of ARI / exacerbation in adult asthma patients, nor did it 
find these SNP to influence vitamin D supplementation in prevention of ARI / exacerbations, which 
suggests vitamin D is not an effective intervention for this particular health outcome. However, type 
II error resulting from a lack of power cannot be discounted as a possible cause of my null results, 
therefore further investigation into the importance of genetic variation in the vitamin D pathway is 






8. Genetic variants in the vitamin D pathway and susceptibility to 
acute respiratory infections in older adults. 
 
 
In this chapter I will investigate the relationship between single nucleotide polymorphisms in the 
vitamin D pathway and risk of upper and lower respiratory infection in older adult, sheltered 
accommodation residents who participated in the ViDiFlu trial (described in Methods, section 2.2.1). 
This will comprise an investigation of main effects association between SNP and ARI outcomes, and 




Variation in genes along the vitamin D pathway may be of particular importance to healthy older 
adult populations, which are at high risk of ARI and vitamin D deficiency. Previous genetic studies 
have reported main effect associations between rs10735810 (FokI mutation) in VDR and risk of 
severe respiratory syncytial virus infection and lower respiratory infection in children (202, 340), but 
the effect of this variant has not been investigated in older adults, nor have other SNP in vitamin D 
pathway genes. These genes govern metabolism, transport, and signalling of the micronutrient. At 
least 55 SNP in 11 vitamin D related genes have shown main effect associations with vitamin D 
metabolite concentrations and/or a wide range of non-skeletal diseases (reviewed in (335)), and 
furthermore, the infectious and auto-immune diseases are among the most commonly reported 
outcomes. An investigation of genetic effect modification of vitamin D supplementation in the 
prevention of ARI in older adults has not been conducted, despite findings from clinical trials 
(presented in chapter 3) that show vitamin D is an effective intervention for this health outcome. 
Clinical studies specifically in older adults are conflicting however: Two cohort studies from Japan 




1,25(OH)2D and risk of febrile respiratory illness, or hospitalisation due to LRI (261) (262). Whilst 
clinical trials which have administered a vitamin D intervention for prevention of ARI in older adults 
have reported null/negative results (267, 273, 344). These results may have arisen due to study 
limitations e.g. the investigation of ARI as a secondary outcome or by post-hoc analysis, and the use 
of intermittent bolus dosing, which is of questionable efficacy (345). It is also possible that vitamin D 
may exert its effects on risk of ARI independent of serum 25(OH)D concentration. Or, it may be that 
previous positive observational findings have occurred due to uncontrolled confounding. 
 
To my knowledge a comprehensive investigation into the influence of genetic variation in the vitamin 
D pathway on risk of ARI in older adults has not been conducted. I therefore carried out a main effect 
analysis between 35 SNP in 11 vitamin D related genes and risk of ARI, and an interaction analysis 
between these SNP and allocation to vitamin D supplementation or placebo, for the prevention of 













8.2. Results.  
 
 
8.2.1. Main effects analysis: does vitamin D pathway genotype influence risk of ARI, 
independent of vitamin D supplementation? 
 
Results of main effects analyses are presented in Table 8.1 and Table 8.2. Multivariable Cox 
regression analysis (described in Methods, section 2.4.2) identified the following SNP genotypes to 
associate with risk of URI: referent to CC genotype rs2248137 (CYP24A1), CG genotype associates 
with a 19% higher risk, and GG genotype associates with a 80% higher risk (P value for trend = 0.026); 
referent to AA genotype for rs4646536 (CYP27B1), AG genotype associates with a 22% lower risk, 
and GG genotype associates with a 65% lower risk (P value for trend = 0.005).  
 
Multivariable Cox regression analysis also identified 1 SNP to associate with risk of LRI: referent to 
AA genotype for rs4646536 (CYP27B1), AG genotype associates with a 18% lower risk, and GG 
genotype associates with a 69% lower risk (P value for trend = 0.007).  
 
After correction for multiple comparisons testing (Bejamini & Hochberg method with a false 
discovery rate of 5%) none of the observed main effect associations between SNP and risk of URI or 









Table 8.1. Main effects: Time to first URI. 
 
Gene SNP Geno- 
type 
N Days at risk  
(IQR) 
Univariable  
Hazard Ratio  
(95% CI) 
P value Multivariable  
Hazard Ratio  
(95% CI) 1 
P value  
CUBN rs3740165 TT 207 300 (87 to UD) referent 0.52 referent 0.79 
  TC 20 UD (83 to UD) 0.92 (0.46 to 1.81)  1.07 (0.54 to 2.14)  
  CC 1* - -  -  
CYP24A1 rs2762939 GG 104 227 (85 to UD) referent 0.17 referent 0.14 
  CG 95 284 (80 to UD) 0.89 (0.61 to 1.29)  0.81 (0.55 to 1.19)  
  CC 32 UD (149 to UD) 0.64 (0.34 to 1.19)  0.67 (0.35 to 1.26)  
 rs2248137 CC 75 UD (75 to UD) referent 0.10 referent 0.026 
  CG 104 286 (82 to UD) 1.19 (0.78 to 1.82)  1.19 (0.78 to 1.82)  
  GG 54 210 (58 to UD) 1.50 (0.93 to 2.43)  1.80 (1.10 to 2.94)  
 rs2762934 GG 156 301 (89 to UD) referent 0.53 referent 0.47 
  AG 61 276 (75 to UD) 1.12 (0.74 to 1.69)  1.12 (0.02 to 1.34)  
  AA 10* - -  -  
 rs6013897 TT 141 286 (88 to UD) referent 0.72 referent 0.39 
  AT 79 301 (87 to UD) 1.01 (0.69 to 1.49)  1.14 (0.77 to 1.70)  
  AA 12 203 (41 to UD) 1.26 (0.55 to 2.89)  1.33 (0.57 to 3.08)  
CYP27A1 rs17470271 AA 92 339 (107 to UD) referent 0.85 referent 0.89 
  AT 102 227 (60 to UD) 1.35 (0.92 to 2.00)  1.29 (0.87 to 1.92)  
  TT 38 UD (126 to UD) 0.91 (0.53 to 1.58)  0.85 (0.48 to 1.49)  
CYP27B1 rs4646537 TT 202 301 (87 to UD) referent 0.78 referent 0.90 
  GT 24 220 (89 to UD) 1.09 (0.60 to 1.98)  1.04 (0.56 to 1.94)  
  GG 0* - -  -  
 rs4646536 AA 115 205 (63 to UD) referent 0.004 referent 0.005 
  AG 90 300 (130 to UD) 0.75 (0.51 to 1.09)  0.78 (0.53 to 1.15)  
  GG 30 UD (203 to UD) 0.36 (0.17 to 0.76)  0.35 (0.17 to 0.74)  
CYP2R1 rs10500804 TT 105  UD (117 to UD) referent 0.11 referent 0.18 
  GT 99 265 (83 to UD) 1.28 (0.87 to 1.88)  1.26 (0.85 to 1.86)  
  GG 32 141 (75 to UD) 1.46 (0.86 to 2.49)  1.37 (0.80 to 2.34)  
 rs2060793 GG 77 217 (76 to UD) referent 0.23 referent 0.33 
  AG 113 286 (96 to UD) 0.79 (0.53 to 1.18)  0.79 (0.47 to 1.32)  
  AA 45 329 (100 to UD) 0.75 (0.45 to 1.26)  0.84 (0.56 to 1.26)  
 rs10766197 GG 94 UD (118 to UD) referent 0.14 referent 0.19 
  AG 100 284 (83 to UD) 1.20 (0.80 to 1.80)  1.15 (0.77 to 1.73)  
  AA 32 141 (82 to UD) 1.50 (0.87 to 2.58)  1.45 (0.84 to 2.50)  
CYP3A4 rs2740574 AA 181 280 (83 to UD) referent 0.39 referent 0.47 
  AG 29 339 (125 to UD) 0.84 (0.48 to 1.48)  0.81 (0.46 to 1.46)  
  GG 24 UD (154 to UD) 0.79 (0.41 to 1.51)  0.83 (0.42 to 1.64)  
DBP rs7041 CC 60 304 (75 to UD) referent 0.48 referent 0.43 
  AC 105 300 (109 to UD) 0.94 (0.60 to 1.46)  0.96 (0.62 to 1.51)  
  AA 67 265 (75 to UD) 1.19 (0.73 to 1.92)  1.22 (0.74 to 2.00)  
 rs4588 GG 137 339 (87 to UD) referent 0.25 referent 0.41 
  GT 86 234 (85 to UD) 1.28 (0.89 to 1.86)  1.23 (0.85 to 1.79)  
  TT 13 159 (63 to UD) 1.17 (0.51 to 2.69)  1.05 (0.45 to 2.49)  
 rs12512631 TT 112 265 (75 to UD) referent 0.19 referent 0.17 
  CT 100 304 (96 to UD) 0.85 (0.58 to 1.24)  0.88 (0.60 to 1.28)  
  CC 23 UD (115 to UD) 0.67 (0.34 to 1.30)  0.63 (0.32 to 1.23)  
 rs2070741 TT 188 297 (88 to UD) referent 0.68 referent 0.90 
  TG 36 305 (59 to UD) 0.97 (0.58 to 1.62)  1.15 (0.68 to 1.95)  
  GG 3* - -  0.60 (0.08 to 4.35)  
 rs2298849 AA 132 234 (82 to UD) referent 0.38 referent 0.88 
  AG 75 UD (109 to UD) 0.73 (0.48 to 1.11)  0.81 (0.53 to 1.24)  
  GG 25 305 (52 to UD) 0.95 (0.53 to 1.71)  1.16 (0.63 to 2.13)  
 rs16846876 AA 116 339 (89 to UD) referent 0.22 referent 0.24 
  AT 103 234 (83 to UD) 1.23 (0.85 to 1.78)  1.25 (0.85 to 1.84)  
  TT 18 159 (86 to UD) 1.35 (0.69 to 2.64)  1.32 (0.66 to 2.63)  




Gene SNP Geno- 
type 
N Days at risk  
(IQR) 
Univariable  
Hazard Ratio  
(95% CI) 
P value Multivariable  
Hazard Ratio  
(95% CI) 1 
P value  
  AG 55 UD (107 to UD) 0.86 (0.55 to 1.33)  0.86 (0.55 to 1.34)  
  AA 8 117 (12 to UD) 1.36 (0.55 to 3.35)  1.37 (0.55 to 3.38)  
 rs12785878 TT 115 266 (86 to UD) referent 0.36 referent 0.28 
  GT 82 UD (126 to UD) 0.77 (0.51 to 1.16)  0.80 (0.53 to 1.21)  
  GG 38 132 (39 to UD) 1.51 (0.94 to 2.42)  1.63 (0.98 to 2.71)  
LRP2 rs3755166 GG 97 280 (88 to UD) referent 0.43 referent 0.43 
  AG 112 304 (80 to UD) 0.89 (0.61 to 1.30)  0.92 (0.63 to 1.35)  
  AA 28 UD (83 to UD) 0.81 (0.44 to 1.48)  0.78 (0.43 to 1.45)  
RXRA rs7861779 GG 139 286 (83 to UD) referent 0.89 referent 0.92 
  GA 61 300 (100 to UD) 1.06 (0.70 to 1.61)  1.04 (0.68 to 1.60)  
  AA 24 363 (76 to UD) 1.00 (0.53 to 1.89)  1.00 (0.52 to 1.92)  
 rs9409929 GG 123 304 (100 to UD) referent 0.88 referent 0.59 
  AG 88 262 (59 to UD) 1.20 (0.83 to 1.75)  1.07 (0.73 to 1.56)  
  AA 23 UD (89 to UD) 0.85 (0.44 to 1.66)  0.72 (0.36 to 1.43)  
VDR rs4334089 GG 116 234 (63 to UD) referent 0.36 referent 0.54 
  AG 79 UD (129 to UD) 0.74 (0.49 to 1.11)  0.81 (0.54 to 1.24)  
  AA 37 339 (59 to UD) 0.89 (0.53 to 1.49)  0.92 (0.54 to 1.57)  
 rs10783219 AA 109 301 (83 to UD) referent 0.57 referent 0.93 
  AT 87 286 (100 to UD) 0.99 (0.67 to 1.48)  0.94 (0.63 to 1.41)  
  TT 34 266 (85 to UD) 1.21 (0.72 to 2.04)  1.07 (0.62 to 1.82)  
 rs4516035 TT 107 266 (75 to UD) referent 0.25 referent 0.25 
  CT 88 284 (89 to UD) 0.98 (0.66 to 1.45)  1.01 (0.68 to 1.51)  
  CC 31 UD (159 to UD) 0.65 (0.35 to 1.21)  0.62 (0.32 to 1.18)  
 rs11568820 CC 135 284 (87 to UD) referent 0.93 referent 0.81 
  CT 59 328 (129 to UD) 0.81 (0.54 to 1.30)  0.89 (0.57 to 1.38)  
  TT  40 297 (75 to UD) 1.05 (0.65 to 1.71)  1.14 (0.69 to 1.88)  
 rs7976091 CC 135 286 (88 to UD) referent 0.88 referent 0.72 
  CT 57 328 (129 to UD) 0.85 (0.55 to 1.33)  0.89 (0.57 to 1.39)  
  TT 39 297 (75 to UD) 1.12 (0.69 to 1.83)  1.18 (0.71 to 1.95)  
 rs2238136 CC 146 301 (88 to UD) referent 0.55 referent 0.65 
  CT 78 329 (100 to UD) 0.95 (0.64 to 1.40)  0.94 (0.63 to 1.40)  
  TT 13 89 (30 to UD) 1.65 (0.79 to 3.42)  1.50 (0.72 to 3.14)  
 rs1544410 CC 84 231 (88 to UD) referent 0.19 referent 0.34 
  CT 110 284 (82 to UD) 1.00 (0.67 to 1.47)  1.04 (0.70 to 1.53)  
  TT 33 UD (118 to UD) 0.58 (0.30 to 1.12)  0.64 (0.33 to 1.25)  
 rs2228570 GG 106 304 (83 to UD) referent 0.65 referent 0.41 
  AG 99 284 (107 to UD) 1.10 (0.75 to 1.62)  1.16 (0.78 to 1.71)  
  AA 27 280 (82 to UD) 1.09 (0.61 to 1.97)  1.22 (0.67 to 2.22)  
 rs2853559 GG 98 266 (85 to UD) referent 0.59 referent 0.56 
  AG 111 328 (88 to UD) 0.92 (0.63 to 1.34)  0.89 (0.60 to 1.30)  
  AA 28 301 (75 to UD) 0.87 (0.48 to 1.57)  0.88 (0.49 to 1.61)  
 rs7975232 AA 71 UD (107 to UD) referent 0.20 referent 0.29 
  AC 121 266 (80 to UD) 1.33 (0.87 to 2.03)  1.26 (0.82 to 1.93)  
  CC 40 220 (89 to UD) 1.38 (0.80 to 2.39)  1.31 (0.76 to 2.28)  
 rs7970314 AA 126 286 (88 to UD) referent 0.96 referent 0.62 
  AG 63 280 (83 to UD) 0.99 (0.65 to 1.52)  1.06 (0.69 to 1.63)  
  GG 48 305 (75 to UD) 1.02 (0.64 to 1.62)  1.23 (0.69 to 1.84)  
 rs731236 AA 97 329 (96 to UD) referent 0.45 referent 0.57 
  AG 106 265 (80 to UD) 1.17 (0.80 to 1.70)  1.19 (0.82 to 1.75)  
  GG 31 UD (107 to UD) 0.61 (0.31 to 1.21)   0.64 (0.32 to 1.27)  
[1] Adjusted for study group (resident vs. carer); minimisation variables (level of care, size of scheme and season of randomisation); a significant 
predictor of upper respiratory infection i.e. baseline vitamin D status (<50 nmol/L vs. ≥50 nmol/L); and allocation to study intervention or placebo 
arm. After correction for multiple comparisons testing, using Benjamini & Hochberg method with a false discovery rate of 5%, none of the p values 
for interaction remain significant. * Genotype could not be analysed due to <5 participants and/or too few events within this sub category. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 
Abbreviations: SNP: Single nucleotide polymorphism, IQR: Inter-quartile range, UD: Undefined, CI: Confidence interval, CYP-: Cytochrome P450 
enzyme, DBP: Vitamin D binding protein, DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also 
known as megalin), RXRA: Retanoid-X receptor-A, VDR: Vitamin D receptor. 








N Days at risk  
(IQR) 
Univariable  
Hazard Ratio  
(95% CI) 
P value Multivariable  
Hazard Ratio 1 
(95% CI) 
P value  
CUBN rs3740165 TT 207 UD (127 to UD) referent 0.92 referent 0.62 
  TC 20 UD (86 to UD) 1.13 (0.57 to 2.23)  0.93 (0.43 to 1.99)  
  CC 1* - -  -  
CYP24A1 rs2762939 GG 104 UD (118 to UD) referent 0.71 referent 0.89 
  CG 95 361 (111 to UD) 1.24 (0.82 to 1.86)  1.14 (0.75 to 1.74)  
  CC 32 UD (151 to UD) 0.97 (0.51 to 1.84)  0.89 (0.41 to 1.93)  
 rs2248137 CC 75 UD (141 to UD) referent 0.66 referent 0.29 
  CG 104 UD (111 to UD) 1.14 (0.73 to 1.79)  1.21 (0.76 to 1.91)  
  GG 54 363 (125 to UD) 1.11 (0.66 to 1.88)  1.35 (0.75 to 2.44)  
 rs2762934 GG 156 UD (136 to UD) referent 0.66 referent 0.63 
  AG 61 284 (111 to UD) 1.40 (0.93 to 2.13)  1.39 (0.91 to 2.12)  
  AA 10* - -  -  
 rs6013897 TT 141 UD (117 to UD) referent 0.16 referent 0.24 
  AT 79 363 (126 to UD) 1.14 (0.75 to 1.72)  1.09 (0.71 to 1.68)  
  AA 12 203 (40 to UD) 1.96 (0.89 to 4.29)  1.88 (0.84 to 4.17)  
CYP27A1 rs17470271 AA 92 UD (109 to UD) referent 0.44 referent 0.65 
  AT 102 363 (88 to UD) 0.99 (0.65 to 1.50)  1.08 (0.68 to 1.71)  
  TT 38 UD (224 to UD) 0.77 (0.43 to 1.37)  0.83 (0.45 to 1.53)  
CYP27B1 rs4646537 TT 202 363 (117 to UD) referent 0.10 referent 0.12 
  GT 24 UD (306 to UD) 0.50 (0.22 to 1.14)  0.50 (0.21 to 1.18)  
  GG 0* - -  -  
 rs4646536 AA 115 361 (89 to UD) referent 0.066 referent 0.007 
  AG 90 UD (141 to UD) 0.86 (0.57 to 1.29)  0.82 (0.54 to 1.25)  
  GG 30 UD (203 to UD) 0.49 (0.23 to 1.03)  0.31 (0.14 to 0.70)  
CYP2R1 rs10500804 TT 105  UD (137 to UD) referent 0.51 referent 0.35 
  GT 99 362 (109 to UD) 1.25 (0.83 to 1.89)  1.28 (0.82 to 2.00)  
  GG 32 UD (119 to UD) 1.11 (0.62 to 2.00)  1.25 (0.67 to 2.33)  
 rs2060793 GG 77 361 (125 to UD) referent 0.71 referent 0.94 
  AG 113 UD (115 to UD) 0.89 (0.58 to 1.37)  0.91 (0.59 to 1.41)  
  AA 45 UD (117 to UD) 0.92 (0.54 to 1.59)  1.06 (0.61 to 1.85)  
 rs10766197 GG 94 UD (125 to UD) referent 0.84 referent 0.64 
  AG 100 363 (88 to UD) 1.11 (0.73 to 1.69)  1.10 (0.69 to 1.74)  
  AA 32 UD (119 to UD) 1.01 (0.56 to 1.83)  1.15 (0.61 to 2.16)  
CYP3A4 rs2740574 AA 181 UD (115 to UD) referent 0.96 referent 0.22 
  AG 29 UD (125 to UD) 1.04 (0.58 to 1.86)  0.65 (0.31 to 1.37)  
  GG 24 UD (154 to UD) 0.96 (0.50 to 1.86)  0.53 (0.17 to 1.68)  
DBP rs7041 CC 60 UD (115 to UD) referent 0.66 referent 0.93 
  AC 105 UD (137 to UD) 0.86 (0.53 to 1.38)  0.76 (0.47 to 1.25)  
  AA 67 339 (105 to UD) 1.12 (0.67 to 1.86)  1.07 (0.59 to 1.93)  
 rs4588 GG 137 UD (118 to UD) referent 0.96 referent 0.86 
  GT 86 UD (117 to UD) 1.03 (0.69 to 1.53)  0.99 (0.65 to 1.49)  
  TT 13 UD (109 to UD) 0.98 (0.39 to 2.43)  0.89 (0.34 to 2.38)  
 rs12512631 TT 112 346 (109 to UD) referent 0.18 referent 0.38 
  CT 100 UD (118 to UD) 0.87 (0.58 to 1.29)  0.91 (0.60 to 1.37)  
  CC 23 UD (138 to UD) 0.61 (0.29 to 1.28)  0.72 (0.34 to 1.53)  
 rs2070741 TT 188 UD (118 to UD) referent 0.74 referent 0.70 
  TG 36 UD (137 to UD) 0.95 (0.55 to 1.65)  0.92 (0.52 to 1.64)  
  GG 3* - -  -  
 rs2298849 AA 132 UD (115 to UD) referent 0.40 referent 0.29 
  AG 75 UD (126 to UD) 0.90 (0.58 to 1.39)  1.00 (0.64 to 1.58)  
  GG 25 273 (56 to UD) 1.50 (0.85 to 2.65)  1.50 (0.83 to 2.72)  
 rs16846876 AA 116 UD (136 to UD) referent 0.64 referent 0.60 
  AT 103 363 (109 to UD) 1.19 (0.80 to 1.77)  1.20 (0.79 to 1.83)  
  TT 18 UD (88 to UD) 0.97 (0.44 to 2.13)  1.01 (0.44 to 2.32)  






N Days at risk  
(IQR) 
Univariable  
Hazard Ratio  
(95% CI) 
P value Multivariable  
Hazard Ratio 1 
(95% CI) 
P value  
  AG 55 UD (148 to UD) 0.83 (0.52 to 1.32)  0.81 (0.51 to 1.31)  
  AA 8 117 (10 to UD) 1.67 (0.67 to 4.12)  1.46 (0.57 to 3.74)  
 rs12785878 TT 115 UD (138 to UD) referent 0.036 referent 0.18 
  GT 82 363 (137 to UD) 1.20 (0.78 to 1.84)  1.17 (0.74 to 1.84)  
  GG 38 232 (50 to UD) 1.79 (1.07 to 3.00)  1.60 (0.83 to 3.10)  
LRP2 rs3755166 GG 97 337 (132 to UD) referent 0.11 referent 0.081 
  AG 112 UD (114 to UD) 0.92 (0.62 to 1.37)  0.86 (0.57 to 1.30)  
  AA 28 UD (273 to UD) 0.50 (0.24 to 1.06)  0.49 (0.23 to 1.06)  
RXRA rs7861779 GG 139 UD (117 to UD) referent 0.41 referent 0.48 
  GA 61 306 (126 to UD) 1.31 (0.85 to 2.01)  1.32 (0.85 to 2.06)  
  AA 24 UD (105 to UD) 1.10 (0.56 to 2.16)  1.01 (0.44 to 2.32)  
 rs9409929 GG 123 UD (127 to UD) referent 0.55 referent 0.34 
  AG 88 363 (88 to UD) 1.15 (0.76 to 1.72)  1.26 (0.82 to 1.93)  
  AA 23 UD (119 to UD) 1.13 (0.59 to 2.16)  1.23 (0.63 to 2.40)  
VDR rs4334089 GG 116 UD (115 to UD) referent 0.75 referent 0.82 
  AG 79 UD (138 to UD) 0.88 (0.57 to 1.36)  0.92 (0.58 to 1.43)  
  AA 37 339 (60 to UD) 1.20 (0.70 to 2.04)  1.19 (0.62 to 2.29)  
 rs10783219 AA 109 346 (86 to UD) referent 0.42 referent 0.15 
  AT 87 UD (136 to UD) 0.87 (0.58 to 1.32)  0.76 (0.48 to 1.20)  
  TT 34 UD (109 to UD) 0.82 (0.45 to 1.47)  0.65 (0.34 to 1.24)  
 rs4516035 TT 107 UD (111 to UD) referent 0.57 referent 0.81 
  CT 88 363 (132 to UD) 0.97 (0.64 to 1.48)  1.21 (0.74 to 1.98)  
  CC 31 UD (137 to UD) 0.81 (0.43 to 1.52)  1.00 (0.50 to 2.01)  
 rs11568820 CC 135 UD (127 to UD) referent 0.45 referent 0.35 
  CT 59 UD (109 to UD) 1.12 (0.71 to 1.77)  1.12 (0.70 to 1.77)  
  TT  40 339 (105 to UD) 1.20 (0.71 to 2.01)  1.52 (0.67 to 3.45)  
 rs7976091 CC 135 UD (132 to UD) referent 0.36 referent 0.20 
  CT 57 UD (109 to UD) 1.14 (0.72 to 1.81)  1.12 (0.70 to 1.79)  
  TT 39 339 (60 to UD) 1.25 (0.75 to 2.11)  1.91 (0.83 to 4.36)  
 rs2238136 CC 146 UD (118 to UD) referent 0.41 referent 0.35 
  CT 78 UD (132 to UD) 0.94 (0.62 to 1.40)  0.89 (0.58 to 1.35)  
  TT 13 UD (89 to UD) 0.62 (0.23 to 1.70)  0.63 (0.23 to 1.76)  
 rs1544410 CC 84 UD (138 to UD) referent 0.66 referent 0.53 
  CT 110 313 (88 to UD) 1.39 (0.91 to 2.13)  1.49 (0.97 to 2.30)  
  TT 33 UD (137 to UD) 0.95 (0.49 to 1.84)  0.98 (0.50 to 1.93)  
 rs2228570 GG 106 UD (109 to UD) referent 0.64 referent 0.89 
  AG 99 UD (170 to UD) 0.86 (0.57 to 1.30)  0.90 (0.59 to 1.38)  
  AA 27 UD (89 to UD) 0.94 (0.50 to 1.77)  1.04 (0.54 to 1.98)  
 rs2853559 GG 98 302 (105 to UD) referent 0.077 referent 0.14 
  AG 111 UD (132 to UD) 0.66 (0.44 to 0.99)  0.65 (0.42 to 1.00)  
  AA 28 UD (118 to UD) 0.70 (0.36 to 1.34)  0.77 (0.39 to 1.53)  
 rs7975232 AA 71 UD (132 to UD) referent 0.44 referent 0.51 
  AC 121 313 (88 to UD) 1.40 (0.89 to 2.20)  1.36 (0.86 to 2.15)  
  CC 40 UD (126 to UD) 1.18 (0.65 to 2.14)  1.15 (0.63 to 2.12)  
 rs7970314 AA 126 UD (136 to UD) referent 0.21 referent 0.26 
  AG 63 346 (109 to UD) 1.30 (0.83 to 2.03)  1.24 (0.79 to 1.96)  
  GG 48 339 (60 to UD) 1.31 (0.80 to 2.14)  1.42 (0.65 to 3.13)  
 rs731236 AA 97 UD (136 to UD) referent 0.96 referent 0.97 
  AG 106 302 (88 to UD) 1.35 (0.90 to 2.02)  1.32 (0.87 to 2.01)  
  GG 31 UD (183 to UD) 0.78 (0.39 to 1.55)  0.79 (0.39 to 1.60)  
[1] Adjusted for study group (resident vs. carer); minimisation variables (level of care, size of scheme and season of randomisation); a significant predictor of 
lower respiratory infection i.e. ethnicity; and allocation to study intervention or placebo arm. After correction for multiple comparisons testing, using Benjamini 
& Hochberg method with a false discovery rate of 5%, none of the p values for interaction remain significant. * Genotype could not be analysed due to <5 
participants and/or too few events within this sub category. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 
Abbreviations: SNP: Single nucleotide polymorphism, IQR: Inter-quartile range, UD: Undefined, CI: Confidence interval, CYP-: Cytochrome P450 enzyme, DBP: 
Vitamin D binding protein, DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also known as megalin), RXRA: 
Retanoid-X receptor-A, VDR: Vitamin D receptor. 




8.2.2. Interaction analysis: does genotype influence effect of vitamin D supplementation in 
prevention of ARI? 
 
Results of interaction analyses testing for effect modification are presented in Table 8.3 and Table 
8.4. Multivariable Cox regression analysis (described in Methods, section 2.4.3) identified 2 SNP 
which modify the effect of vitamin D supplementation on risk of URI. Vitamin D supplementation 
conferred increased risk of URI to individuals with AA genotype for rs17470271 in CYP27A1 (aHR 
2.47; 95% CI 1.29 to 4.73), but had no effect of those with AT genotype (aHR 1.28; 95% CI 0.73 to 
2.24), or TT genotype (aHR 0.72; 95% CI 0.27 to 1.95 - aRHR 0.55; 95% CI 0.33 to 0.92; P value for 
interaction = 0.022). Vitamin D supplementation offered protection for URI to individuals with AA 
genotype for rs7975232 in VDR (aHR 0.85; 95% CI 0.40 to 1.79), and increased risk of URI to those 
with AC genotype (aHR 1.84; 95% CI 1.08 to 3.14), and CC genotype (aHR 3.21; 95% CI 1.03 to 10.02 
- aRHR 1.80; 95% CI 1.01 to 3.20; P value for interaction = 0.046). 
 
Multivariable Cox regression analysis also identified 1 SNP which modifies the effect of vitamin D 
supplementation on risk of LRI. Vitamin D supplementation conferred increased risk of LRI to 
individuals with GG genotype for rs10766197 in CYP2R1 (aHR 3.18; 95% CI 1.50 to 6.74), but had no 
effect on those with AG genotype (aHR 0.78; 95% CI 0.43 to 1.43), or AA genotype (aHR 0.91; 95% CI 
0.32 to 2.55 – aRHR 0.51; 95% CI 0.30 to 0.92; P value for interaction = 0.025).  
 
After correction for multiple comparisons testing (Bejamini & Hochberg method with a false 
discovery rate of 5%) none of the observed associations of modified effect of vitamin D 












N Median time to 
1st URI (IQR)           
: Control arm 
N Median time to 
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P value for 
interaction 1 
CUBN rs3740165 TT 85 UD (132 to UD) 122 231 (75 to UD) 1.70 (1.12 to 2.57) 0.61 (0.15 to 2.47) 0.49 
  TC 12 297 (83 to UD) 8 UD (33 to UD) 2.00 (0.36 to 11.12)   
  CC 1* - 0 - -   
CYP24A1 rs2762939 GG 45 286 (100 to UD) 59 220 (75 to UD) 1.31 (0.77 to 2.23) 1.49 (0.85 to 2.62) 0.17 
  CG 38 UD (83 to UD) 57 265 (60 to UD) 1.38 (0.74 to 2.57)   
  CC 19 UD (339 to UD) 13 149 (58 to UD) 4.90 (1.09 to 22.04)   
 rs2248137 CC 29 UD (134 to UD) 46  301 (126 to UD) 1.53 (0.74 to 3.20) 1.05 (0.63 to 1.74) 0.86 
  CG 44 UD (132 to UD) 60 220 (59 to UD) 1.59 (0.89 to 2.84)   
  GG 28 297 (100 to UD) 26 149 (47 to UD) 2.32 (1.05 to 5.12)   
 rs2762934 GG 67 UD (100 to UD) 89 265 (88 to UD) 1.41 (0.89 to 2.24) 1.77 (0.83 to 3.78) 0.14 
  AG 26 UD (132 to UD) 35 149 (41 to UD) 1.52 (0.72 to 3.23)   
  AA 5* - 5* - -   
 rs6013897 TT 58 286 (83 to UD) 83 305 (89 to UD) 1.07 (0.66 to 1.73) 2.42 (1.20 to 4.86) 0.013 
  AT 39 UD (171 to UD) 40 210 (48 to UD) 2.17 (1.11 to 4.26)   
  AA 4* - 8 58 (24 to 203) -   
CYP27A1 rs17470271 AA 42 UD (176 to UD) 50  172 (50 to UD) 2.47 (1.29 to 4.73) 0.55 (0.33 to 0.92) 0.022 
  AT 43 223 (63 to UD) 58 227 (58 to UD) 1.28 (0.73 to 2.24)   
  TT 14 300 (159 to UD) 24  UD (117 to UD) 0.72 (0.27 to 1.95)   
CYP27B1 rs4646537 TT 88 UD (132 to UD) 114 234 (75 to UD) 1.68 (1.11 to 2.54) 1.10 (0.31 to 3.98) 0.88 
  GT 9 UD (154 to UD) 15 220 (89 to UD) 0.99 (0.15 to 6.30)   
  GG 0 - 0 - -   
 rs4646536 AA 44 286 (76 to UD) 71 173 (59 to UD) 1.41 (0.83 to 2.40) 1.16 (0.65 to 2.08) 0.62 
  AG 46 UD (176 to UD) 44 265 (109 to UD) 1.57 (0.87 to 2.85)   
  GG 11 UD (UD to UD) 19 UD (75 to UD) 2.24 (0.42 to 11.78)   
CYP2R1 rs10500804 TT 49 UD (132 to UD) 56 304 (75 to UD) 1.34 (0.73 to 2.47) 0.78 (0.46 to 1.33) 0.36 
  GT 40 UD (83 to UD) 59 220 (58 to UD) 1.71 (0.95 to 3.08)   
  GG 12 107 (63 to UD) 20 141 (75 to UD) 0.76 (0.28 to 2.07)   
 rs2060793 GG 34 297 (83 to UD) 43  164 (60 to UD) 1.43 (0.76 to 2.69) 1.14 (0.67 to 1.94) 0.64 
  AG 49 UD (134 to UD) 64 227 (80 to UD) 1.67 (0.94 to 2.96)   
  AA 19 UD (132 to UD) 26 304 (50 to UD) 1.56 (0.61 to 4.00)   
 rs10766197 GG 46 UD (154 to UD) 48 262 (75 to UD) 1.78 (0.92 to 3.42) 0.67 (0.39 to 1.15) 0.15 
  AG 39 300 (100 to UD) 61 234 (75 to UD) 1.41 (0.79 to 2.54)   
  AA 16 107 (63 to UD) 16 141 (88 to UD) 1.00 (0.39 to 2.58)   
CYP3A4 rs2740574 AA 72 300 (83 to UD) 109 227 (75 to UD) 1.36 (0.89 to 2.07) 1.36 (0.74 to 2.51) 0.32 
  AG 13 UD (339 to UD) 16 173 (55 to UD) 2.38 (0.70 to 8.06)   
  GG 16 UD (176 to UD) 8 265 (42 to UD) 1.93 (0.43 to 8.72)   
DBP rs7041 CC 24 UD (125 to UD) 36 173 (42 to UD) 0.95 (0.45 to 2.03) 1.42 (0.84 to 2.38) 0.19 
  AC 44 UD (129 to UD) 61 247 (107 to UD) 1.32 (0.74 to 2.35)   
  AA 31 284 (59 to UD) 36 304 (75 to UD) 2.17 (1.05 to 4.48)   
 rs4588 GG 61 UD (118 to UD) 76 304 (60 to UD) 1.40 (0.84 to 2.32) 1.25 (0.67 to 2.33) 0.47 
  GT 35 UD (107 to UD) 51 227 (80 to UD) 1.59 (0.86 to 2.92)   
  TT 5 UD (159 to UD) 8 126 (55 to UD) 4.57 (0.31 to 66.68)   
 rs12512631 TT 45 UD (132 to UD) 67 149 (55 to UD) 2.25 (1.29 to 3.93) 0.62 (0.35 to 1.10) 0.10 
  CT 46 UD (100 to UD) 54 304 (96 to UD) 1.16 (0.64 to 2.10)   
  CC 9 UD (211 to UD) 14 UD (115 to UD) 0.45 (0.09 to 2.39)   
 rs2070741 TT 80 UD (125 to UD) 108 247 (75 to UD) 1.48 (0.97 to 2.27) 0.55 (0.20 to 1.52) 0.25 
  TG 17 UD (118 to UD) 19 205 (41 to UD) 3.17 (1.04 to 9.62)   
  GG 1* - 2* - -   
 rs2298849 AA 51 280 (83 to UD) 81 231 (60 to UD) 1.15 (0.71 to 1.86) 1.74 (0.96 to 3.16) 0.068 
  AG 39 UD (154 to UD) 36 118 (80 to UD) 2.78 (1.31 to 5.93)   
  GG 11 UD (76 to UD) 14 112 (41 to UD) 2.53 (0.62 to 10.29)   
 rs16846876 AA 49 UD (100 to UD) 67 329 (87 to UD) 1.13 (0.65 to 1.95) 1.66 (0.90 to 3.04) 0.10 
  AT 46 UD (132 (to UD) 57 203 (55 to UD) 2.16 (1.20 to 3.87)   
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1st URI (IQR)           
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N Median time to 
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P value for 
interaction 1 
DHCR7 rs3829251 GG 68 UD (134 to UD) 97 210 (60 to UD) 1.79 (1.12 to 2.86) 0.74 (0.35 to 1.55) 0.42 
  AG 27 UD (132 to UD) 28  305 (55 to UD) 1.52 (0.67 to 3.46)   
  AA 3* - 5 231 (117 to UD) -   
 rs12785878 TT 41 300 (100 to UD) 74 247 (85 to UD) 1.25 (0.73 to 2.15) 1.33 (0.78 to 2.29) 0.30 
  GT 40 UD (159 to UD) 42 265 (88 to UD) 1.70 (0.87 to 3.33)   
  GG 20 176 (39 to UD) 18 107 (24 to 305) 1.88 (0.73 to 4.83)   
LRP2 rs3755166 GG 46 297 (100 to UD) 51 266 (88 to UD) 1.18 (0.68 to 2.04) 1.12 (0.65 to 1.96) 0.68 
  AG 42 UD (216 to UD) 70 170 (47 to UD) 2.28 (1.23 to 4.21)   
  AA 14 284 (83 to UD) 14 UD (126 to UD) 0.96 (0.27 to 3.38)   
RXRA rs7861779 GG 55 UD (132 to UD) 84 220 (60 to UD) 1.77 (1.04 to 2.99) 1.03 (0.57 to 1.86) 0.94 
  GA 29 297 (118 to UD) 32 304 (87 to UD) 1.22 (0.59 to 2.53)   
  AA 11 UD (UD to UD) 13 173 (75 to UD) 3.83 (0.59 to 24.78)   
 rs9409929 GG 59 UD (118 to UD) 64 220 (85 to UD) 1.74 (1.01 to 2.98) 1.04 (0.60 to 1.83) 0.88 
  AG 32 UD (59 to UD) 56 227 (55 to UD) 1.48 (0.81 to 2.72)   
  AA 10 UD (154 to UD) 13 UD (89 to UD) 1.04 (0.24 to 4.47)   
VDR rs4334089 GG 41 UD (63 to UD) 75 220 (80 to UD) 1.68 (0.97 to 2.92) 1.03 (0.60 to 1.75) 0.92 
  AG 40 UD (134 to UD) 39 UD (75 to UD) 1.11 (0.56 to 2.20)   
  AA 20 UD (76 to UD) 17 173 (59 to UD) 1.67 (0.56 to 4.92)   
 rs10783219 AA 55 UD (125 to UD) 54 276 (59 to UD) 1.55 (0.87 to 2.76) 1.08 (0.60 to 1.92) 0.80 
  AT 36 UD (107 to UD) 51 205 (87 to UD) 2.14 (1.12 to 4.09)   
  TT 9 300 (42 to UD) 25 231 (88 to UD) 1.01 (0.30 to 3.41)   
 rs4516035 TT 45 UD (154 to UD) 62 170 (48 to UD) 2.30 (1.26 to 4.22) 0.59 (0.34 to 1.04) 0.066 
  CT 42 286 (100 to UD) 46 247 (89 to UD) 1.13 (0.62 to 2.05)   
  CC 11 UD (159 to UD) 20 UD (60 to UD) 1.74 (0.46 to 6.59)   
 rs11568820 CC 48 UD (100 to UD) 87 231 (80 to UD) 1.75 (1.04 to 2.95) 1.03 (0.62 to 1.69) 0.92 
  CT 30 UD (129 to UD) 29 328 (130 to UD) 1.14 (0.53 to 2.45)   
  TT 23 339 (125 to UD) 17 172 (58 to UD) 1.80 (0.67 to 4.80)   
 rs7976091 CC 48 UD (100 to UD) 87  234 (85 to UD) 1.71 (1.01 to 2.89) 0.99 (0.60 to 1.64) 0.98 
  CT 29 UD (107 to UD) 28 328 (130 to UD) 1.02 (0.47 to 2.20)   
  TT 22 339 (125 to UD) 17 172 (58 to UD) 1.46 (0.52 to 4.14)   
 rs2238136 CC 60 UD (129 to UD) 86 262 (75 to UD) 1.54 (0.93 to 2.55) 1.15 (0.59 to 2.24) 0.69 
  CT 38 UD (107 to UD) 40 329 (86 to UD) 1.53 (0.78 to 3.02)   
  TT 3* - 10 88 (30 to UD) -   
 rs1544410 CC 34 UD (100 to UD) 50 203 (87 to UD) 2.21 (1.09 to 4.49) 0.63 (0.36 to 1.13) 0.12 
  CT 46 UD (171 to UD) 64 234 (55 to UD) 1.84 (1.06 to 3.20)   
  TT 18 UD (118 to UD) 15 UD (UD to UD) 0.51 (0.13 to 1.98)   
 rs2228570 GG 45 UD (107 to UD) 61 262 (75 to UD) 1.51 (0.83 to 2.73) 1.13 (0.65 to 1.97) 0.67 
  AG 42 297 (176 to UD) 57 234 (87 to UD) 1.30 (0.73 to 2.29)   
  AA 13 UD (100 to UD) 14 89 (47 to UD) 3.51 (0.95 to 13.00)   
 rs2853559 GG 43 UD (154 to UD) 55 210 (50 to UD) 1.84 (1.02 to 3.32) 0.71 (0.40 to 1.26) 0.24 
  AG 48 UD (83 to UD) 63 276 (88 to UD) 1.36 (0.76 to 2.42)   
  AA 10 280 (171 to UD) 18 301 (60 to UD) 1.33 (0.34 to 5.18)   
 rs7975232 AA 37 284 (118 to UD) 34 UD (75 to UD 0.85 (0.40 to 1.79) 1.80 (1.01 to 3.20) 0.046 
  AC 49 UD (125 to UD) 72 194 (59 to UD) 1.84 (1.08 to 3.14)   
  CC 14 UD (217 to UD) 26 164 (87 to UD) 3.21 (1.03 to 10.02)   
 rs7970314 AA 43 UD (100 to UD) 83 247 (88 to UD) 1.51 (0.88 to 2.60) 1.17 (0.73 to 1.88) 0.52 
  AG 31 UD (129 to UD) 32 205 (24 to UD) 1.45 (0.71 to 2.97)   
  GG 28 UD (125 to UD) 20 172 (50 to UD) 2.36 (0.97 to 5.79)   
 rs731236 AA 39 UD (154 to UD) 58 220 (87 to UD) 2.10 (1.09 to 4.04) 0.63 (0.36 to 1.11) 0.11 
  AG 47 297 (129 to UD) 59 194 (59 to UD) 1.67 (0.98 to 2.83)   
  GG 14 UD (107 to UD) 17 UD (75 to UD) 0.63 (0.17 to 2.30)   
[1] Adjusted for study group (resident vs. carer); minimisation variables (level of care, size of scheme and season of randomisation); a significant predictor of upper 
respiratory infection i.e. baseline vitamin D status (<50 nmol/L vs. ≥50 nmol/L); and allocation to study intervention or placebo arm. After correction for multiple comparisons 
testing, using Benjamini & Hochberg method with a false discovery rate of 5%, none of the p values for interaction remain significant. * Genotype could not be analysed 
due to <5 participants and/or too few events within this sub category. 
………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………. 
Abbreviations: SNP: Single nucleotide polymorphism, IQR: Inter-quartile range, CI: Confidence interval, UD: Undefined, CYP-: Cytochrome P450 enzyme, DBP: Vitamin D 
binding protein, DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also known as megalin), RXRA: Retanoid-X receptor-A, 
VDR: Vitamin D receptor, CUBN: Cubilin. 
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P value for 
interaction 1 
CUBN rs3740165 TT 85 UD (138 to UD) 122 UD (117 to UD) 1.20 (0.78 to 1.85) 0.67 (0.16 to 2.76) 0.58 
  TC 12 337 (86 to UD) 8 UD (53 to UD) 0.50 (0.12 to 2.10)   
  CC 1* - 0 - -   
CYP24A1 rs2762939 GG 45 UD (137 to UD) 59  UD (105 to UD) 1.05 (0.56 to 1.96) 1.19 (0.67 to 2.11) 0.55 
  CG 38 362 (132 to UD) 57 361 (80 to UD) 1.28 (0.66 to 2.46)   
  CC 19 UD (183 to UD) 13 306 (115 to UD) 1.60 (0.43 to 5.95)   
 rs2248137 CC 29 362 (118 to UD) 46 UD (203 to UD) 0.77 (0.37 to 1.60) 1.38 (0.81 to 2.35) 0.23 
  CG 44 UD (138 to UD) 60 273 (60 to UD) 1.48 (0.81 to 2.70)   
  GG 28 UD (137 to UD) 26 313 (89 to UD) 1.56 (0.65 to 3.75)   
 rs2762934 GG 67 UD (148 to UD) 89 UD (126 to UD) 0.97 (0.58 to 1.61) 1.36 (0.65 to 2.84) 0.41 
  AG 26 346 (114 to UD) 35 273 (58 to UD) 1.46 (0.70 to 3.04)   
  AA 5* - 5* - -   
 rs6013897 TT 58 362 (109 to UD) 83 UD (127 to UD) 0.84 (0.50 to 1.43) 2.79 (1.38 to 5.63) 0.004 
  AT 39 UD (213 to UD) 40 276 (115 to UD) 1.93 (0.91 to 4.09)   
  AA 4* - 8 58 (24 to 273) -   
CYP27A1 rs17470271 AA 42 UD (167 to UD) 50 257 (56 to UD) 1.44 (0.76 to 2.73) 0.79 (0.46 to 1.36) 0.40 
  AT 43 362 (85 to UD) 59 UD (105 to UD) 0.80 (0.44 to 1.45)   
  TT 14 UD (227 to UD) 24 UD (170 to UD) 0.83 (0.30 to 2.31)   
CYP27B1 rs4646537 TT 88 UD (125 to UD) 114 363 (109 to UD) 1.18 (0.77 to 1.79) 1.33 (0.23 to 7.71) 0.75 
  GT 9 UD (UD to UD) 15 UD (306 to UD) 2.53 (0.15 to 41.03)   
  GG 0 - 0 - -   
 rs4646536 AA 44 UD (125 to UD) 71 306 (88 to UD) 1.52 (0.82 to 2.82) 0.78 (0.43 to 1.41) 0.41 
  AG 46 362 (148 to UD) 44 UD (141 to UD) 1.06 (0.56 to 2.00)   
  GG 11 UD (132 to UD) 19 UD (203 to UD) 0.91 (0.19 to 4.32)   
CYP2R1 rs10500804 TT 49 UD (183 to UD) 56 363 (89 to UD) 1.72 (0.87 to 3.38) 0.70 (0.40 to 1.22) 0.21 
  GT 40 294 (85 to UD) 59 UD (115 to UD) 0.89 (0.48 to 1.63)   
  GG 12 346 (138 to UD) 20 UD (88 to UD) 0.97 (0.33 to 2.88)   
 rs2060793 GG 34 346 (138 to UD) 43 361 (88 to UD) 1.05 (0.52 to 2.11) 0.99 (0.56 to 1.74) 0.98 
  AG 49 UD (137 to UD) 64 UD (109 to UD) 1.09 (0.60 to 1.97)   
  AA 19 UD (132 to UD) 26 363 (89 to UD) 1.72 (0.57 to 5.19)   
 rs10766197 GG 46 UD (154 to UD) 48 262 (80 to UD) 3.18 (1.50 to 6.74) 0.51 (0.30 to 0.92) 0.025 
  AG 39 284 (85 to UD) 61 UD (109 to UD) 0.78 (0.43 to 1.43)   
  AA 16 346 (111 to UD) 16 UD (119 to UD) 0.91 (0.32 to 2.55)   
CYP3A4 rs2740574 AA 72 UD (132 to UD) 109 UD (88 to UD) 1.24 (0.78 to 1.96) 0.99 (0.53 to 1.83) 0.97 
  AG 13 UD (137 to UD) 16 276 (109 to UD) 1.51 (0.46 to 4.94)   
  GG 16 UD (154 to UD) 8 306 (42 to UD) 1.35 (0.33 to 5.45)   
DBP rs7041 AA 31 UD (234 to UD) 36 224 (52 to UD) 2.85 (1.21 to 6.71) 2.03 (1.16 to 3.56) 0.014 
  AC 44 UD (118 to UD) 61 UD (165 to UD) 0.97 (0.51 to 1.84)   
  CC 24* - 36 UD (115 to UD) -   
 rs4588 GG 61 362 (137 to UD) 76 UD (89 to UD) 1.02 (0.61 to 1.71) 1.35 (0.69 to 2.66) 0.38 
  GT 35 UD (132 to UD) 51 363 (117 to UD) 1.66 (0.82 to 3.35)   
  TT 5 UD (162 to UD) 8 UD (109 to UD) 0.48 (0.04 to 6.42)   
 rs12512631 TT 45 362 (132 to UD) 67 313 (88 to UD) 1.38 (0.77 to 2.45) 0.83 (0.45 to 1.55) 0.57 
  CT 46 UD (125 to UD) 54 363 (105 to UD) 1.60 (0.82 to 3.12)   
  CC 9 UD (138 to UD) 14 UD (271 to UD) 0.09 (0.01 to 1.22)   
 rs2070741 TT 80 UD (125 to UD) 108 UD (117 to UD) 1.00 (0.64 to 1.58) 0.50 (0.17 to 1.49) 0.22 
  TG 17 UD (346 to UD) 19 306 (59 to UD) 2.23 (0.70 to 7.05)   
  GG 1 - 2 -  -   
 rs2298849 AA 51 UD (109 to UD) 81 363 (115 to UD) 1.12 (0.65 to 1.94) 1.06 (0.60 to 1.86) 0.84 
  AG 39 UD (154 to UD) 36 UD (88 to UD) 1.15 (0.54 to 2.43)   
  GG 11 339 (114 to UD) 14 151 (40 to UD) 1.41 (0.45 to 4.43)   
 rs16846876 AA 49 339 (118 to UD) 67 UD (165 to UD) 0.61 (0.34 to 1.08) 2.57 (1.32 to 5.02) 0.006 
  AT 46 UD (167 to UD) 57 234 (85 to UD) 2.42 (1.26 to 4.66)   






N Median time to 1st 
URI (IQR)                  
: Control arm 
N Median time to 
1st URI (IQR)          
: Vitamin D arm 
Hazard ratio for effect 
of allocation within 
subgroup (95% CI) 




P value for 
interaction 1 
DHCR7 rs3829251 GG 68 UD (138 to UD) 97 361 (85 to UD) 1.45 (0.88 to 2.38) 0.54 (0.25 to 1.16) 0.11 
  AG 27 UD (137 to UD) 28 UD (234 to UD) 0.82 (0.33 to 2.03)   
  AA 3 - 5 232 (117 to UD) -   
 rs12785878 TT 41 UD (167 to UD) 74 UD (136 to UD) 1.00 (0.54 to 1.85) 1.01 (0.58 to 1.73) 0.98 
  GT 40 UD (162 to UD) 42 273 (56 to UD) 1.67 (0.87 to 3.20)   
  GG 20 234 (39 to UD) 18 232 (50 to UD) 0.69 (0.26 to 1.82)   
LRP2 rs3755166 GG 46 337 (132 to UD) 51 363 (136 to UD) 0.97 (0.54 to 1.74) 1.21 (0.66 to 2.23) 0.53 
  AG 42 UD (167 to UD) 70 361 (85 to UD) 1.39 (0.75 to 2.57)   
  AA 14 UD (284 to UD) 14 UD (273 to UD) 0.36 (0.08 to 1.69)   
RXRA rs7861779 GG 55 UD (148 to UD) 84 UD (109 to UD) 1.20 (0.69 to 2.08) 0.92 (0.52 to 1.62) 0.76 
  GA 29 284 (118 to UD) 32 363 (136 to UD) 0.72 (0.35 to 1.45)   
  AA 11 UD (234 to UD) 13 363 (105 to UD) 3.26 (0.66 to 16.22)   
 rs9409929 GG 59 UD (125 to UD) 64 UD (127 to UD) 0.96 (0.54 to 1.71) 1.15 (0.65 to 2.05) 0.63 
  AG 32 UD (280 to UD) 56 262 (53 to UD) 2.34 (1.13 to 4.88)   
  AA 10 167 (65 to UD) 13 UD (210 to UD) 0.66 (0.10 to 4.54)   
VDR rs4334089 GG 41 UD (162 to UD) 75 363 (89 to UD) 1.66 (0.91 to 3.01) 0.82 (0.47 to 1.42) 0.47 
  AG 40 337 (132 to UD) 39 UD (170 to UD) 0.63 (0.30 to 1.34)   
  AA 20 346 (125 to UD) 17 273 (59 to UD) 1.31 (0.43 to 3.96)   
 rs10783219 AA 55 UD (118 to UD) 54 306 (59 to UD) 1.23 (0.67 to 2.26) 1.08 (0.58 to 2.01) 0.81 
  AT 36 UD (167 to UD) 51 363 (126 to UD) 1.38 (0.71 to 2.67)   
  TT 9 UD (302 to UD) 25 UD (109 to UD) 0.80 (0.20 to 3.16)   
 rs4516035 TT 45 UD (154 to UD) 62 313 (85 to UD) 1.43 (0.78 to 2.63) 0.64 (0.36 to 1.14) 0.13 
  CT 42 UD (132 to UD) 46 363 (127 to UD) 1.05 (0.54 to 2.03)   
  CC 11 162 (118 to UD) 20  UD (262 to UD) 0.68 (0.20 to 2.31)   
 rs11568820 CC 48 UD (148 to UD) 87 UD (117 to UD) 1.31 (0.76 to 2.27) 0.99 (0.59 to 1.66) 0.97 
  CT 30 UD (109 to UD) 29 276 (165 to UD) 1.01 (0.45 to 2.25)   
  TT 23 UD (125 to UD) 17 306 (60 to UD) 1.69 (0.57 to 5.05)   
 rs7976091 CC 48 UD (148 to UD) 87 UD (119 to UD) 1.28 (0.74 to 2.22) 1.04 (0.62 to 1.76) 0.88 
  CT 29 346 (86 to UD) 28 UD (165 to UD) 0.88 (0.40 to 1.98)   
  TT 22 UD (154 to UD) 17 273 (58 to UD) 1.66 (0.59 to 4.70)   
 rs2238136 CC 60 UD (137 to UD) 86 313 (105 to UD) 1.30 (0.77 to 2.20) 0.84 (0.41 to 1.71) 0.63 
  CT 38 UD (138 to UD) 40 UD (117 to UD) 0.96 (0.48 to 1.91)   
  TT 3* - 10 UD (89 to UD) -   
 rs1544410 CC 34 UD (162 to UD) 50 UD (126 to UD) 1.40 (0.66 to 2.95) 0.79 (0.44 to 1.40) 0.41 
  CT 46 337 (111 to UD) 64 313 (85 to UD) 1.11 (0.63 to 1.93)   
  TT 18 UD (137 to UD) 15 UD (273 to UD) 0.83 (0.22 to 3.04)   
 rs2228570 GG 45 UD (111 to UD) 61 313 (88 to UD) 1.50 (0.81 to 2.79) 0.71 (0.39 to 1.31) 0.27 
  AG 42 UD (213 to UD) 57 UD (141 to UD) 1.03 (0.54 to 1.98)   
  AA 13 280 (118 to UD) 14 UD (58 to UD) 1.39 (0.34 to 5.61)   
 rs2853559 GG 43 346 (154 to UD) 55 271 (85 to UD) 1.44 (0.80 to 2.59) 0.68 (0.36 to 1.28) 0.23 
  AG 48 UD (137 to UD) 63 UD (126 to UD) 1.09 (0.57 to 2.07)   
  AA 10 280 (118 to UD) 18 UD (141 to UD) 0.52 (0.14 to 1.99)   
 rs7975232 AA 37 UD (132 to UD) 34  UD (273 to UD) 0.64 (0.29 to 1.45) 1.73 (0.97 to 3.10) 0.065 
  AC 49 362 (114 to UD) 72 306 (88 to UD) 1.26 (0.72 to 2.19)   
  CC 14 UD (UD to UD) 26 232 (89 to UD) 3.87 (1.08 to 13.88)   
 rs7970314 AA 43 UD (148 to UD) 83 UD (126 to UD) 1.15 (0.64 to 2.07) 1.19 (0.72 to 1.94) 0.50 
  AG 31 294 (111 to UD) 32 363 (59 to UD) 0.90 (0.43 to 1.88)   
  GG 28 UD (125 to UD) 20 257 (50 to UD) 1.33 (0.55 to 3.23)   
 rs731236 AA 39 UD (154 to UD) 58 UD (119 to UD) 1.58 (0.77 to 3.22) 0.68 (0.38 to 1.23) 0.21 
  AG 47 302 (111 to UD) 59 306 (85 to UD) 1.18 (0.67 to 2.09)   
  GG 14 UD (137 to UD) 17 UD (273 to UD) 0.82 (0.21 to 3.21)   
[1] Adjusted for stratification factors i.e. Percent predicted forced expiratory volume in 1 second (<50% vs. ≥50%) and inclusion in vs. exclusion from sputum induction sub-study; significant 
predictors of upper respiratory infection i.e. Age (<70 years vs. ≥70 years), and smoking status (current vs. non-current); and allocation to study intervention or placebo arm. After 
correction for multiple comparisons testing, using Benjamini & Hochberg method with a false discovery rate of 5%, none of the p values for interaction remain significant. 
* Genotype could not be analysed due to <5 participants and/or too few events within this sub category.  
……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………. 
Abbreviations: SNP: Single nucleotide polymorphism, IQR: Inter-quartile range, CI: Confidence interval, UD: Undefined, CYP-: Cytochrome P450 enzyme, DBP: Vitamin D binding protein, 
DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also known as megalin), RXRA: Retanoid-X receptor-A, VDR: Vitamin D receptor, CUBN: 
Cubilin. 
 






In this chapter I have investigated a link between known variants in common vitamin D pathway 
genes and risk of URI and LRI in older adults, both independently and via modification of vitamin D 
supplementation effect. My panel of 35 SNP did not predict risk of these outcomes after correction 
for multiple comparisons testing.  
 
Previous studies have yet to investigate whether variation in vitamin D related genes affect risk of 
ARI in older adults, though two groups have reported a main effect association between FokI 
mutation and risk of severe RSV infection and LRI, in children (202, 340). In both cases the mutant 
allele (f) associated with increased risk. The number of studies which have reported an association 
between vitamin D related SNP and various infectious disease outcomes make a strong case for the 
importance of genetic variation in the vitamin D pathway on risk of ARI.  These include associations 
with: Tuberculosis risk, or resolution of inflammation during adjunctive vitamin D therapy (FokI 
[rs10735810/rs2228570], BsmI [rs1544410] and TaqI [rs731236] in VDR, and rs7041/rs4588 in DBP) 
(184, 203, 205, 346, 347); risk of hepatitis C (ApaI [rs7975232] in VDR, rs10877012 in CYP27B1) (133, 
348); risk of HIV infection (rs4516035 in VDR) (349); risk of rubella (Cdx2 [rs11568820] and rs7970314 
in VDR) (350); and risk of Periodontitis (BsmI [rs1544410], ApaI [rs7975232] and TaqI [rs731236] in 
VDR) (351) (352). However, none of these studies have focused specifically on older adult 
populations. Further investigation of the effects of vitamin D supplementation in prevention of ARI 
in older adults is clearly needed, and is something we will address in our current IPD meta-analysis, 
but there are a range of proposed factors surrounding age-related immune system decline which 
may be responsible for the lack of effect I have seen in this study. These include age-related 
impairment of neutrophil chemotaxis and antigen presentation by macrophages (91, 92) (93); the 
progressive increase in production of pro-inflammatory cytokines (“inflammaging”) (94); attenuation 
of adaptive immune responses via reduced dendritic cell-mediated stimulation of T and B cells (95); 




naïve lymphocytes populations due to thymic involution (98); decreased progenitor B cell production 
in bone marrow (99); and accumulation of anergic effector memory CD8+ T cells (100). All of these 
factors could potentially affect the mechanisms by which vitamin D modulates immune responses to 
respiratory pathogens, and dampen its ability to offer protection against ARI in older adults, which 
may explain null reports from previous clinical trials in this study population (273) (267) (344) and 
the non-significant effect of genetic variants I report in this study. 
 
8.3.1. Study strengths. 
To my knowledge, this is the first study to comprehensively investigate genetic variation in the 
vitamin D pathway on risk of URI and LRI in the older adult population. The majority of participants 
were vitamin D deficient at baseline and using intermittent bolus dosing a high level of compliance 
was achieved, which translated to a good average level of repletion in the active arm. Participants 
were well characterised for possible environmental determinants of ARI and vitamin D status, which 
allowed wide control for factors which might confound the association between genetic variation 
and my investigated outcomes. Another strength of this study was the comprehensive panel of SNP 
which capture the current body of positive genetic association findings between vitamin D pathway 
variants and vitamin D metabolite / non-skeletal disease outcomes. Finally, 25(OH)D concentrations 
were measured with the gold standard assay (LC-MS/MS) in a laboratory that participated in the 
international vitamin D external quality assurance scheme (www.deqas.org/). 
 
8.3.2. Study limitations. 
One limitation of this study arises from the use of data from a clinical trial which was powered to 
detect respiratory outcomes in the study population as a whole, but was not powered to detect the 
same outcomes across ranging frequencies of SNP genotypes. This may have resulted in type II error, 




which may have limited the potential to find associations in this study was the use of an intermittent 
monthly bolus dosing regimen of vitamin D supplementation in addition to a small daily dose, which 
may have caused a sharp enough spike in vitamin D levels to upregulate synthesis of CYP24A1 
enzyme, which is responsible for breaking down both 25(OH)D and 1,25(OH)2D (343). This may have 
resulted in lower extra-renal concentrations of the active metabolite in the active arm than the 
control arm, as the control arm received only the small daily dose of vitamin D.   
 
8.4. Conclusions. 
In this study, none of the 35 SNP in 11 vitamin D related genes showed a significant main effects 
association with ARI in older adults, nor did they modify the effects of vitamin D supplementation 
for the prevention of ARI, which suggests vitamin D status does not impact risk of ARI in this 
population. Whilst the analysis was well controlled for potential cofounding factors, a lack of 
statistical power, or type II error from strict multiple comparisons testing may also be responsible 
for these null results, as may the use of an intermittent bolus dosing regimen of vitamin D which 
could have resulted in lower than optimal concentrations of localised 1,25(OH)2D in pulmonary 
tissue. Future research should be conducted to investigate the impact of genetic variants in this 










9. Genetic variants in the vitamin D pathway and susceptibility to 
acute respiratory infections in patients with COPD. 
  
In this chapter I present findings of an investigation into the relationship between single nucleotide 
polymorphisms in the vitamin D pathway and the risk of upper respiratory infection and acute 
exacerbation in patients with COPD who participated in the ViDiCO trial (described in Methods, 
section 2.2.1). This comprises an investigation of main effects association between SNP and risk of 
URI / exacerbation, and an investigation of effect modification of SNP on vitamin D supplementation 
in prevention of these outcomes. 
 
9.1. Introduction. 
There is a high prevalence of vitamin D deficiency in chronic obstructive pulmonary disease (COPD) 
patients who are at higher than normal risk for upper respiratory infections (URI) (323). URI 
commonly lead to life-threatening acute symptom exacerbations in COPD patients and there are 
currently no interventions to treat them (353). Two clinical trials of vitamin D supplementation in the 
prevention of URI and COPD exacerbation have been conducted to date and both found no 
protective effect of supplementation in the study group as a whole, but did report reduced risk of 
moderate to severe disease exacerbation in subgroups who were profoundly vitamin D deficient at 
baseline (210, 272). Another potential subgroup effect which has not been comprehensively 
explored is that of genotype as a determinant of outcome risk, either directly or as modifier of the 
effects of vitamin D supplementation. Polymorphic genes have been identified within pathways of 
vitamin D metabolism, transport, and signalling which associate with variation in vitamin D status, 
and with a striking array of disease outcomes. Variation in vitamin D binding protein (DBP) is the 
most widely reported determinant of vitamin D status, whilst variation in vitamin D receptor protein 
(VDR) has been highlighted as the major determinant of disease outcomes (335). A limited number 




conducted in Belgium found rs7041 to associate with risk of vitamin D deficiency and risk of COPD 
(323), whilst a Norwegian case-control study reported an association (which they replicated in a 
second study population) between rs1155563 / rs17467825 and clinical markers of COPD severity, 
namely lung function tests: percent predicted forced expiratory volume in 1 second (% FEV1) and 
FEV1 to forced vital capacity (FVC) ratio (336). Research investigating variation in VDR in association 
with COPD is lacking, however several findings relating to respiratory infection and disease have been 
made: FokI mutation (rs10735810/rs2228570) has been found to associate with risk of respiratory 
syncytial virus (RSV) infection and acute lower respiratory infection (LRI) in child cohorts from the 
Netherlands (339), South Africa (340), and Canada (202); and with risk of tuberculosis in Gujarati 
Asians residing in London (346), Chinese Hans (203), and North Central Indian Castes (347). 
Furthermore, BsmI mutation (rs1544410) has been found to associate with risk of smear-positive, 
multi-drug-resistant tuberculosis in three Central Indian populations (347). Besides these main effect 
associations, findings of genetic effect modification have also been reported: TaqI mutation 
(rs731236) in VDR has been shown to modify the effects of vitamin D supplementation on time to 
sputum culture conversion in patients receiving treatment for tuberculosis, in the UK (205); risk of 
advanced colorectal adenoma, in a UK clinical trial (341); and FokI mutation has been reported to 
modify the effect of vitamin D supplementation on treatment of Parkinson’s disease, in a clinical trial 
conducted in Japan (342). 
 
The possible mechanisms by which polymorphic vitamin D pathway genes may influence risk of ARI 
and exacerbations of COPD are numerous, and not restricted to DBP and VDR. The investigation of 
genetic determinants of health outcomes in COPD patients is lacking. Therefore in this chapter I will 
present results of an analysis of 35 SNP in 11 vitamin D pathway genes which have previously been 
linked to vitamin D status and/or risk of non-skeletal disease, for a main effects association with URI 








9.2.1. Main effects: does vitamin D pathway genotype influence risk of URI or COPD 
exacerbation, independent of vitamin D supplementation? 
 
Results of main effects analyses are presented in Table 9.1 and Table 9.2. Multivariable Cox 
regression analysis (described in Methods, section 2.4.2) identified the following SNP genotypes to 
associate with risk of URI: referent to GG genotype for rs4334089 (VDR), AG genotype associated 
with a 41% higher risk, and AA genotype associated with a 77% higher risk (P value for trend = 0.015); 
referent to CC genotype for rs11568820 (VDR), CT genotype associated with a 41% higher risk, and 
TT genotype associated with a 112% higher risk (P value for trend = 0.013); referent to CC genotype 
for rs7976091 (VDR), CT genotype associated with a 38% higher risk, and TT genotype associated 
with a 124% higher risk (P value for trend = 0.011); finally, referent to AA genotype for rs7970314 
(VDR), AG genotype associated with a 34% higher risk, and GG genotype associated with a 92% higher 
risk (P value for trend = 0.024).  
 
Multivariable Cox regression analysis also identified one SNP to show an association with risk of 
COPD exacerbation: referent to CC genotype for rs2238136 (VDR), CT genotype associated with a 
26% lower risk, and TT genotype associated with a 60% lower risk (P value for trend = 0.026) (Table 
9.2). However, after correction for multiple comparisons testing (Bejamini & Hochberg method with 








Table 9.1. Main effects: Time to first URI. 
 
Gene SNP Genotype N Days at risk  
(IQR) 
Univariable 
Hazard Ratio (95% 
CI) 
P value Multivariable 
Hazard Ratio  
(95% CI) 
P value 1 
CUBN rs3740165 TT 223 176 (28 to UD) referent 0.26 referent 0.38 
  TC 12 156 (54 to UD) 0.79 (0.37 to 1.69)  0.87 (0.40 to 1.88)  
  CC 1* - -  -  
CYP24A1 rs2762939 GG 133 217 (26 to UD) referent 0.15 referent 0.20 
  CG 93 137 (33 to 372) 1.24 (0.89 to 1.74)  1.29 (0.92 to 1.82)  
  CC 11 120 (61 to 344) 1.40 (0.70 to 2.80)  1.19 (0.59 to 2.42)  
 rs2248137 CC 86 217 (27 to 374) referent 0.41 referent 0.79 
  CG 121 136 (35 to UD) 1.15 (0.82 to 1.63)  1.24 (0.88 to 1.76)  
  GG 30 UD (33 to UD) 0.65 (0.36 to 1.17)  0.74 (0.41 to 1.33)  
 rs2762934 GG 167 203 (27 to UD) referent 0.46 referent 0.25 
  AG 65 144 (33 to 374) 1.20 (0.84 to 1.70)  1.22 (0.85 to 1.75)  
  AA 6 62 (42 to UD) 0.96 (0.35 to 2.62)  1.30 (0.47 to 3.62)  
 rs6013897 TT 156 178 (27 to UD) referent 0.91 referent 0.83 
  AT 67 202 (32 to UD) 0.88 (0.61 to 1.29)  0.89 (0.61 to 1.32)  
  AA 12 92 (54 to 239) 1.31 (0.68 to 2.51)  1.34 (0.69 to 2.59)  
CYP27A1 rs17470271 AA 90 200 (50 to 374) referent 0.82 referent 0.64 
  AT 108 171 (26 to UD) 0.99 (0.70 to 1.41)  1.14 (0.79 to 1.63)  
  TT 40 152 (27 to UD) 1.07 (0.67 to 1.70)  1.08 (0.68 to 1.72)  
CYP27B1 rs4646537 TT 220 176 (32 to UD) referent 0.71 referent 0.87 
  GT 17 88 (26 to UD) 1.12 (0.61 to 2.07)  1.05 (0.57 to 1.96)  
  GG 0* - -  -  
 rs4646536 AA 95 159 (26 to UD) referent 0.55 referent 0.35 
  AG 113 176 (35 to UD) 1.05 (0.74 to 1.49)  1.12 (0.79 to 1.59)  
  GG 25 147 (18 to UD) 1.20 (0.70 to 2.06)  1.28 (0.74 to 2.20)  
CYP2R1 rs10500804 TT 80 137 (28 to UD) referent 0.21 referent 0.57 
  GT 115 202 (32 to UD) 0.88 (0.62 to 1.26)  0.99 (0.69 to 1.43)  
  GG 42 261 (43 to UD) 0.74 (0.46 to 1.20)  0.85 (0.51 to 1.40)  
 rs2060793 GG 80 197 (28 to UD) referent 0.35 referent 0.91 
  AG 115 203 (32 to UD) 1.11 (0.77 to 1.59)  0.96 (0.66 to 1.40)  
  AA 42 117 (26 to UD) 1.25 (0.78 to 1.99)  1.04 (0.65 to 1.68)  
 rs10766197 GG 67 198 (45 to UD) referent 0.86 referent 0.66 
  AG 116 159 (27 to UD) 1.18 (0.81 to 1.72)  1.34 (0.91 to 1.98)  
  AA 51 261 (35 to UD) 0.93 (0.58 to 1.49)  1.05 (0.64 to 1.73)  
CYP3A4 rs2740574 AA 214 171 (31 to UD) referent 0.49 referent 0.30 
  AG 23 212 (58 to UD) 0.82 (0.46 to 1.45)  0.73 (0.41 to 1.31)  
  GG 0* - -  -  
DBP rs7041 CC 57 203 (44 to UD) referent 0.89 referent 0.45 
  AC 125 178 (26 to UD) 1.14 (0.77 to 1.70)  1.21 (0.81 to 1.81)  
  AA 52 144 (53 to UD) 1.03 (0.64 to 1.65)  1.19 (0.73 to 1.93)  
 rs4588 GG 112 216 (44 to UD) referent 0.17 referent 0.13 
  GT 107 171 (22 to UD) 1.18 (0.84 to 1.65)  1.26 (0.9 to 1.78)  
  TT 20 119 (53 to 176) 1.42 (0.81 to 2.49)  1.39 (0.79 to 2.46)  
 rs12512631 TT 98 144 (47 to 374) referent 0.58 referent 0.22 
  CT 114 212 (25 to UD) 0.89 (0.63 to 1.25)  0.81 (0.58 to 1.15)  
  CC 23 203 (64 to UD) 0.92 (0.53 to 1.59)  0.76 (0.44 to 1.33)  
 rs2070741 TT 205 173 (28 to UD) referent 0.46 referent 0.091 
  TG 27 197 (47 to UD) 0.86 (0.51 to 1.48)  1.09 (0.63 to 1.89)  
  GG 3* - -  -  
 rs2298849 AA 159 203 (33 to UD) referent 0.14 referent 0.067 
  AG 73 178 (27 to UD) 1.08 (0.76 to 1.53)  1.13 (0.79 to 1.62)  
  GG 7 64 (27 to 144) 2.56 (1.18 to 5.54)  3.01 (1.37 to 6.60)  
 rs16846876 AA 108 202 (28 to UD) referent 0.58 Referent 0.41 
  AT 109 197 (35 to UD) 1.02 (0.72 to 1.43)  1.13 (0.80 to 1.59)  
  TT 20 144 (32 to 374) 1.23 (0.70 to 2.15)  1.21 (0.68 to 2.13)  




Gene SNP Genotype N Days at risk  
(IQR) 
Univariable 
Hazard Ratio (95% 
CI) 
P value Multivariable 
Hazard Ratio  
(95% CI) 
P value 1 
  AG 49 117 (26 to UD) 1.30 (0.88 to 1.90)  1.33 (0.91 to 1.96)  
  AA 6 27 (22 to 123) 1.65 (0.61 to 4.49)  1.88 (0.68 to 5.24)  
 rs12785878 TT 148 198 (35 to UD) referent 0.46 referent 0.80 
  GT 75 171 (28 to UD) 1.09 (0.77 to 1.54)  1.00 (0.70 to 1.42)  
  GG 14 54 (25 to UD) 1.26 (0.64 to 2.50)  1.15 (0.58 to 2.31)  
LRP2 rs3755166 GG 82 178 (28 to UD) referent 0.84 referent 0.93 
  AG 108 171 (33 to 374) 1.07 (0.75 to 1.54)  1.04 (0.72 to 1.50)  
  AA 48 198 (32 to UD) 0.93 (0.59 to 1.47)  0.97 (0.61 to 1.54)  
RXRA rs7861779 GG 171 173 (31 to UD) referent 0.98 referent 0.61 
  GA 54 197 (26 to UD) 0.95 (0.65 to 1.41)  0.85 (0.58 to 1.27)  
  AA 5 136 (92 to 159) 1.23 (0.45 to 3.33)  1.13 (0.41 to 3.14)  
 rs9409929 GG 98 197 (58 to UD) referent 0.054 referent 0.10 
  AG 120 171 (26 to UD) 1.25 (0.89 to 1.76)  1.32 (0.93 to 1.87)  
  AA 18 77 (21 to 300) 1.74 (0.97 to 3.14)  1.43 (0.78 to 2.60)  
VDR rs4334089 GG 121 239 (62 to UD) referent 0.013 referent 0.015 
  AG 97 123 (21 to UD) 1.46 (1.04 to 2.04)  1.41 (0.99 to 2.00)  
  AA 20 47 (15 to 374) 1.68 (0.96 to 2.94)  1.77 (1.00 to 3.13)  
 rs10783219 AA 98 137 (22 to UD) referent 0.22 referent 0.13 
  AT 111 217 (43 to UD) 0.83 (0.59 to 1.17)  0.80 (0.57 to 1.13)  
  TT 24 212 (50 to UD) 0.75 (0.41 to 1.35)  0.70 (0.38 to 1.28)  
 rs4516035 TT 79 200 (33 to UD) referent 0.97 referent 0.80 
  CT 127 143 (25 to 374) 1.19 (0.84 to 1.70)  1.13 (0.79 to 1.61)  
  CC 30 226 (57 to UD) 0.85 (0.47 to 1.51)  0.82 (0.46 to 1.46)  
 rs11568820 CC 138 216 (53 to UD) referent 0.050 referent 0.013 
  CT 877 137 (22 to UD) 1.26 (0.90 to 1.77)  1.41 (0.99 to 2.00)  
  TT 11 27 (15 to UD) 1.92 (0.93 to 3.98)  2.12 (1.01 to 4.45)  
 rs7976091 CC 139 217 (53 to UD) referent 0.042 referent 0.011 
  CT 88 143 (22 to UD) 1.25 (0.90 to 1.75)  1.38 (0.97 to 1.95)  
  TT 12 27 (15 to 152) 1.99 (1.00 to 3.96)  2.24 (1.11 to 4.51)  
 rs2238136 CC 121 154 (23 to UD) referent 0.53 referent 0.40 
  CT 95 217 (59 to 374) 0.92 (0.66 to 1.29)  0.88 (0.63 to 1.23)  
  TT 16 156 (18 to UD) 0.84 (0.40 to 1.74)  0.82 (0.39 to 1.71)  
 rs1544410 CC 85 217 (35 to UD) referent 0.17 referent 0.19 
  CT 114 154 (41 to 374) 1.18 (0.82 to 1.69)  1.15 (0.80 to 1.66)  
  TT 39 143 (19 to 348) 1.37 (0.86 to 2.19)  1.38 (0.86 to 2.22)  
 rs2228570 GG 94 216 (58 to UD) referent 0.22 referent 0.24 
  AG 108 143 (27 to 374) 1.25 (0.88 to 1.78)  1.24 (0.87 to 1.77)  
  AA 35 137 (20 to UD) 1.28 (0.78 to 2.10)  1.26 (0.77 to 2.08)  
 rs2853559 GG 79 171 (27 to 374) referent 0.51 referent 0.37 
  AG 115 159 (28 to UD) 1.08 (0.75 to 1.54)  1.02 (0.71 to 1.46)  
  AA 39 231 (57 to UD) 0.79 (0.47 to 1.31)  0.76 (0.45 to 1.26)  
 rs7975232 AA 65 143 (32 to UD) referent 0.26 referent 0.26 
  AC 117 176 (28 to UD) 0.90 (0.62 to 1.30)  0.93 (0.64 to 1.36)  
  CC 50 217 (42 to UD) 0.76 (0.48 to 1.22)  0.75 (0.47 to 1.21)  
 rs7970314 AA 130 216 (51 to UD) referent 0.10 referent 0.024 
  AG 93 147 (26 to 374) 1.19 (0.85 to 1.66)  1.34 (0.95 to 1.90)  
  GG 14 27 (15 to UD) 1.72 (0.89 to 3.33)  1.92 (0.98 to 3.78)  
 rs731236 AA 89 217 (42 to UD) referent 0.35 referent 0.50 
  AG 114 154 (31 to 374) 1.20 (0.84 to 1.72)  1.14 (0.80 to 1.64)  
  GG 35 171 (23 to UD) 1.20 (0.74 to 1.96)  1.14 (0.70 to 1.87)  
[1] Adjusted for stratification factors i.e. Percent predicted forced expiratory volume in 1 second (<50% vs. ≥50%) and inclusion in vs. exclusion 
from sputum induction sub-study; significant predictors of upper respiratory infection i.e. Age (<70 years vs. ≥70 years), and smoking status (current 
vs. non-current); and allocation to study intervention or placebo arm.  After correction for multiple comparisons testing, using Benjamini & 
Hochberg method with a false discovery rate of 5%, none of the p values for interaction remain significant. * Genotype could not be analysed due 
to <5 participants and/or too few events within this sub category. 
………………………………………………………………………………………………………………………………………………………………………………………………………………………… 
Abbreviations: SNP: Single nucleotide polymorphism, IQR: Inter-quartile range, CI: Confidence interval, UD: Undefined, CYP-: Cytochrome P450 
enzyme, DBP: Vitamin D binding protein, DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also 
known as megalin), RXRA: Retanoid-X receptor-A, VDR: Vitamin D receptor, CUBN: Cubilin. 




Table 9.2. Main effects: Time to first exacerbation COPD exacerbation. 
 
Gene SNP Genotype N Days at risk (IQR) Univariable Hazard 
Ratio  
(95% CI) 
P value Multivariable Hazard 
Ratio  
(95% CI) 
P value 1  
CUBN rs3740165 TT 223 UD (151 to UD) referent 0.60 referent 0.55 
  TC 12 UD (98 to UD) 1.01 (0.44 to 2.29)  1.04 (0.45 to 2.38)  
  CC 1* - -  -  
CYP24A1 rs2762939 GG 133 345 (68 to UD) referent 0.55 referent 0.34 
  CG 93 329 (103 to UD) 1.01 (0.69 to 1.47)  0.94 (0.64 to 1.38)  
  CC 11 UD (180 to UD) 0.60 (0.22 to 1.64)  0.54 (0.20 to 1.51)  
 rs2248137 CC 86 UD (89 to UD) referent 0.15 referent 0.22 
  CG 121 329 (111 to UD) 1.19 (0.79 to 1.78)  1.12 (0.74 to 1.68)  
  GG 30 153 (30 to UD) 1.53 (0.86 to 2.71)  1.48 (0.83 to 2.64)  
 rs2762934 GG 167 371 (87 to UD) referent 0.41 referent 0.44 
  AG 65 329 (87 to UD) 1.17 (0.78 to 1.74)  1.16 (0.77 to 1.73)  
  AA 6 261 (163 to UD) 1.24 (0.46 to 3.40)  1.23 (0.44 to 3.41)  
 rs6013897 TT 156 342 (90 to UD) referent 0.93 referent 0.77 
  AT 67 369 (67 to UD) 1.00 (0.66 to 1.52)  1.05 (0.69 to 1.62)  
  AA 12 224 (89 to UD) 0.95 (0.41 to 2.18)  1.09 (0.47 to 2.51)  
CYP27A1 rs17470271 AA 90 251 (72 to UD) referent 0.096 referent 0.21 
  AT 108 369 (120 to UD) 0.74 (0.50 to 1.10)  0.78 (0.52 to 1.16)  
  TT 40 UD (87 to UD) 0.67 (0.39 to 1.17)  0.75 (0.43 to 1.31)  
CYP27B1 rs4646537 TT 220 342 (89 to UD) referent 0.78 referent 0.89 
  GT 17 261 (123 to UD) 0.90 (0.44 to 1.85)  0.95 (0.46 to 1.96)  
  GG 0* - -  -  
 rs4646536 AA 95 369 (95 to UD) referent 0.86 referent 0.94 
  AG 113 263 (67 to UD) 1.33 (0.90 to 1.97)  1.29 (0.87 to 1.91)  
  GG 25 371 (187 to UD) 0.80 (0.40 to 1.59)  0.74 (0.37 to 1.49)  
CYP2R1 rs10500804 TT 80 329 (69 to UD) referent 0.81 referent 0.59 
  GT 115 350 (77 to UD) 1.03 (0.68 to 1.55)  1.14 (0.68 to 1.91)  
  GG 42 315 (125 to UD) 0.92 (0.53 to 1.57)  1.18 (0.68 to 2.02)  
 rs2060793 GG 80 368 (125 to UD) referent 0.78 referent 0.69 
  AG 115 263 (67 to UD) 1.29 (0.85 to 1.95)  1.09 (0.64 to 1.87)  
  AA 42 UD (85 to UD) 0.99 (0.56 to 1.74)  0.94 (0.53 to 1.66)  
 rs10766197 GG 67 329 (89 to UD) referent 0.76 referent 0.53 
  AG 116 350 (68 to UD) 1.08 (0.70 to 1.66)  1.07 (0.69 to 1.66)  
  AA 51 315 (137 to UD) 0.91 (0.54 to 1.54)  0.83 (0.49 to 1.41)  
CYP3A4 rs2740574 AA 214 351 (89 to UD) referent 0.37 referent 0.41 
  AG 23 274 (44 to UD) 1.30 (0.73 to 2.32)  1.28 (0.71 to 2.30)  
  GG 0* - -  -  
DBP rs7041 CC 57 304 (69 to UD) referent 0.97 referent 0.96 
  AC 125 369 (89 to UD) 0.84 (0.54 to 1.30)  0.91 (0.58 to 1.42)  
  AA 52 252 (103 to UD) 1.00 (0.60 to 1.67)  1.02 (0.61 to 1.71)  
 rs4588 GG 112 329 (85 to UD) referent 0.85 referent 0.68 
  GT 107 369 (73 to UD) 0.97 (0.66 to 1.42)  1.05 (0.72 to 1.55)  
  TT 20 194 (111 to UD) 1.14 (0.60 to 2.18)  1.13 (0.59 to 2.17)  
 rs12512631 TT 98 371 (123 to UD) referent 0.056 referent 0.14 
  CT 114 329 (54 to UD) 1.35 (0.90 to 2.00)  1.32 (0.89 to 1.97)  
  CC 23 180 (77 to UD) 1.66 (0.92 to 3.00)  1.42 (0.78 to 2.58)  
 rs2070741 TT 205 329 (85 to UD) referent 0.39 referent 0.34 
  TG 27 UD (120 to UD) 0.87 (0.48 to 1.58)  0.89 (0.49 to 1.65)  
  GG 3* - -  -  
 rs2298849 AA 159 304 (85 to UD) referent 0.59 referent 0.97 
  AG 73 371 (120 to UD) 0.83 (0.55 to 1.24)  0.95 (0.63 to 1.45)  
  GG 7 274 (20 to UD) 1.21 (0.44 to 3.29)  1.24 (0.45 to 3.43)  
 rs16846876 AA 108 304 (62 to UD) referent 0.20 referent 0.28 
  AT 109 351 (111 to UD) 0.85 (0.59 to 1.25)  0.88 (0.61 to 1.29)  
  TT 20 UD (129 to UD) 0.64 (0.30 to 1.34)  0.68 (0.32 to 1.43)  




Gene SNP Genotype N Days at risk (IQR) Univariable Hazard 
Ratio  
(95% CI) 
P value Multivariable Hazard 
Ratio  
(95% CI) 
P value 1  
  AG 49 201 (89 to UD) 1.04 (0.67 to 1.62)  1.12 (0.72 to 1.75)  
  AA 6 UD (233 to UD) 0.64 (0.16 to 2.60)  0.56 (0.14 to 2.29)  
 rs12785878 TT 148 304 (67 to UD) referent 0.47 referent 0.48 
  GT 75 369 (125 to UD) 0.78 (0.52 to 1.17)  0.79 (0.52 to 1.18)  
  GG 14 233 (28 to UD) 1.05 (0.48 to 2.27)  1.05 (0.48 to 2.30)  
LRP2 rs3755166 GG 82 350 (108 to UD) referent 0.99 referent 0.94 
  AG 108 304 (64 to UD) 1.16 (0.77 to 1.75)  1.16 (0.77 to 1.75)  
  AA 48 UD (89 to UD) 0.96 (0.57 to 1.63)  0.98 (0.58 to 1.66)  
RXRA rs7861779 GG 171 329 (90 to UD) referent 0.70 referent 0.58 
  GA 54 345 (89 to UD) 1.00 (0.64 to 1.55)  1.07 (0.69 to 1.67)  
  AA 5 133 (20 to UD) 1.60 (0.50 to 5.06)  1.41 (0.44 to 4.55)  
 rs9409929 GG 98 371 (123 to UD) referent 0.58 referent 0.91 
  AG 120 252 (56 to UD) 1.40 (0.95 to 2.06)  1.35 (0.91 to 2.00)  
  AA 18 UD (187 to UD) 0.78 (0.35 to 1.74)  0.67 (0.30 to 1.50)  
VDR rs4334089 GG 121 UD (103 to UD) referent 0.16 referent 0.24 
  AG 97 261 (68 to UD) 1.33 (0.91 to 1.95)  1.28 (0.87 to 1.88)  
  AA 20 329 (57 to 369) 1.33 (0.71 to 2.49)  1.27 (0.68 to 2.40)  
 rs10783219 AA 98 368 (87 to UD) referent 0.67 referent 0.83 
  AT 111 329 (111 to UD) 1.02 (0.69 to 1.49)  0.97 (0.66 to 1.43)  
  TT 24 UD (89 to UD) 0.79 (0.39 to 1.61)  0.94 (0.46 to 1.92)  
 rs4516035 TT 79 371 (67 to UD) referent 0.80 referent 0.78 
  CT 127 301 (90 to UD) 1.13 (0.76 to 1.70)  1.05 (0.70 to 1.57)  
  CC 30 UD (49 to UD) 0.99 (0.52 to 1.90)  1.08 (0.56 to 2.08)  
 rs11568820 CC 138 329 (89 to UD) referent 0.73 referent 0.83 
  CT 877 342 (89 to UD) 1.12 (0.77 to 1.63)  1.13 (0.77 to 1.64)  
  TT 11 UD (57 to UD) 0.94 (0.38 to 2.33)  0.84 (0.33 to 2.12)  
 rs7976091 CC 139 329 (89 to UD) referent 0.52 referent 0.60 
  CT 88 345 (87 to UD) 1.14 (0.78 to 1.65)  1.15 (0.79 to 1.68)  
  TT 12 278 (21 to UD) 1.13 (0.49 to 2.61)  1.01 (0.43 to 2.37)  
 rs2238136 CC 121 278 (57 to UD) referent 0.052 referent 0.026 
  CT 95 368 (111 to UD) 0.81 (0.55 to 1.19)  0.74 (0.50 to 1.08)  
  TT 16 UD (240 to UD) 0.39 (0.14 to 1.07)  0.40 (0.14 to 1.10)  
 rs1544410 CC 85 263 (95 to UD) referent 0.91 referent 0.85 
  CT 114 371 (77 to UD) 0.90 (0.60 to 1.35)  0.91 (0.60 to 1.37)  
  TT 39 263 (95 to UD) 1.08 (0.64 to 1.81)  0.98 (0.58 to 1.67)  
 rs2228570 GG 94 342 (87 to UD) referent 0.32 referent 0.42 
  AG 108 UD (103 to UD) 0.85 (0.57 to 1.27)  0.87 (0.58 to 1.30)  
  AA 35 132 (45 to UD) 1.52 (0.91 to 2.52)  1.39 (0.83 to 2.32)  
 rs2853559 GG 79 369 (72 to UD) referent 0.21 referent 0.17 
  AG 115 350 (111 to UD) 0.98 (0.64 to 1.48)  0.90 (0.59 to 1.37)  
  AA 39 153 (45 to UD) 1.51 (0.90 to 2.54)  1.65 (0.97 to 2.79)  
 rs7975232 AA 65 345 (89 to UD) referent 0.71 referent 0.97 
  AC 117 368 (69 to UD) 0.96 (0.62 to 1.48)  1.04 (0.68 to 1.62)  
  CC 50 369 (123 to UD) 0.90 (0.53 to 1.54)  0.98 (0.57 to 1.68)  
 rs7970314 AA 130 329 (89 to UD) referent 0.90 referent 0.96 
  AG 93 345 (89 to UD) 1.10 (0.76 to 1.61)  1.10 (0.75 to 1.61)  
  GG 14 UD (57 to UD) 0.87 (0.37 to 2.01)  0.83 (0.35 to 1.94)  
 rs731236 AA 89 301 (108 to UD) referent 0.77 referent 0.93 
  AG 114 368 (77 to UD) 0.96 (0.64 to 1.43)  0.93 (0.62 to 1.39)  
  GG 35 329 (73 to UD) 1.13 (0.66 to 1.92)  1.00 (0.58 to 1.73)  
[1] Adjusted for stratification factors i.e. Percent predicted forced expiratory volume in 1 second (<50% vs. ≥50%) and inclusion in vs. exclusion from 
sputum induction sub-study; a significant predictor of COPD exacerbation i.e. use of inhaled corticosteroids (yes vs. no); and allocation to study 
intervention or placebo arm. After correction for multiple comparisons testing, using Benjamini & Hochberg method with a false discovery rate of 
5%, none of the p values for interaction remain significant. * Genotype could not be analysed due to <5 participants and/or too few events within 
this sub category. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 
Abbreviations: SNP: Single nucleotide polymorphism, IQR: Inter-quartile range, CI: Confidence interval, UD: Undefined, CYP-: Cytochrome P450 
enzyme, DBP: Vitamin D binding protein, DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also 
known as megalin), RXRA: Retanoid-X receptor A, VDR: Vitamin D receptor, CUBN: Cubilin. 




9.2.2. Interaction analysis: does genotype influence effect of vitamin D supplementation in 
prevention of URI or COPD exacerbation? 
 
Results of interaction analyses testing for effect modification are presented in Table 9.3 and Table 
9.4. Multivariable Cox regression analysis (described in Methods, section 2.4.3) identified 5 SNP in 
VDR which modify the effect of vitamin D supplementation on risk of URI: Vitamin D supplementation 
conferred increased risk of URI to individuals with GG genotype for rs4334089 (aHR 1.65; 95% CI 1.00 
to 2.70); offered protection from URI to individuals with AG genotype (aHR 0.45; 95% CI 0.27 to 0.76); 
and had no effect on individuals with AA genotype (aHR 0.90; 95% CI 0.13 to 6.21 – aRHR 0.36; 95% 
CI 0.22 to 0.60; P value for interaction <0.001). Vitamin D supplementation conferred increased risk 
of URI to individuals with TT genotype for rs10783219 (aHR 6.09; 95% CI 1.24 to 30.01); had no effect 
on individuals with AT genotype (aHR 1.32; 95% CI 0.81 to 2.17), and offered protection to individuals 
with AA genotype (aHR 0.49; 95% CI 0.29 to 0.85 – aRHR 0.42; 95% CI 0.29 to 0.85; P value for 
interaction = 0.001). Vitamin D supplementation offered protection from URI to individuals with CT 
genotype for rs11568820 (aHR 0.51; 95% CI 0.29 to 0.89), but not to individuals with CC genotype 
(aHR 1.36; 95% CI 0.87 to 2.13 – aRHR 0.35; 95% CI 0.20 to 0.61; P value for interaction <0.001). 
Vitamin D supplementation offered protection from URI to individuals with CT genotype for 
rs7976091 (aHR 0.49; 95% CI 0.28 to 0.86), but not to individuals with CC genotype (aHR 1.33; 95% 
CI 0.85 to 2.08 – aRHR 0.35; 95% CI 0.20 to 0.61; P value for interaction <0.001). Finally, vitamin D 
supplementation offered protection from URI to individuals with AG genotype for rs7970314 (aHR 
0.43; 95% CI 0.25 to 0.74), but not to individuals with AA genotype (aHR 1.27; 95% CI 0.80 to 2.00), 
or individuals with GG genotype (aHR 0.96; 95% CI 0.14 to 6.65 – aRHR 0.45; 95% CI 0.26 to 0.76; P 
value for interaction = 0.003). 
 
Multivariable Cox regression analysis also identified 1 SNP which modifies the effect of vitamin D 
supplementation on risk of COPD exacerbation: Vitamin D supplementation offered protection from 




0.72), but not to individuals with CG genotype (aHR 1.03; 95% CI 0.61 to 1.73), or individuals with CC 


























N Median time to 
1st URI (IQR) : 
Control arm 
N Median time to 
1st URI (IQR) : 
Vitamin D arm 
Hazard ratio for 
effect of allocation 
within sub-group 
(95% CI) 1 
Ratio of hazard 
ratios for 
allocation*genotype 
interaction (95% CI) 1 
P value for 
interaction  
CUBN rs3740165 TT 113 154 (27 to UD) 110 203 (33 to UD) 0.93 (0.66 to 1.31) 0.70 (0.18 to 2.77) 0.61 
  TC 3* - 9 226 (147 to UD) -   
  CC 1* - 0 - -   
CYP24A1 rs2762939 GG 61 159 (22 to UD) 72 282 (44 to UD) 0.56 (0.35 to 0.91) 1.73 (1.02 to 2.95) 0.042 
  CG 52 143 (32 to 374) 41 123 (33 to 348) 1.40 (0.83 to 2.35)   
  CC 4* - 7 120 (62 to 344) -   
 rs2248137 CC 40 176 (26 to 374) 46  226 (27 to 372) 0.94 (0.51 to 1.71) 0.76 (0.46 to 1.23) 0.26 
  CG 64 110 (21 to UD) 57 198 (59 to UD) 0.79 (0.50 to 1.25)   
  GG 13 263 (32 to UD) 17 UD (92 to UD) 0.40 (0.12 to 1.35)   
 rs2762934 GG 78 152 (21 to UD) 89 231 (45 to UD) 0.77 (0.51 to 1.15) 1.31 (0.71 to 2.40) 0.38 
  AG 39 144 (33 to 374) 26 123 (33 to 300) 1.38 (0.72 to 2.64)   
  AA 1* - 5 62 (42 to UD) -   
 rs6013897 TT 73 137 (21 to UD) 83  244 (45 to UD) 0.69 (0.46 to 1.03) 1.59 (0.91 to 2.81) 0.11 
  AT 39 217 (41 to UD) 28 147 (27 to UD) 1.62 (0.82 to 3.22)   
  AA 4* - 8 92 (51 to 239) -   
CYP27A1 rs17470271 AA 47 156 (33 to 374) 43 217 (54 to UD) 0.74 (0.41 to 1.33) 1.11 (0.71 to 1.74) 0.64 
  AT 54 171 (23 to UD) 54 173 (33 to 372) 0.75 (0.45 to 1.23)   
  TT 17 136 (15 to UD) 23 198 (44 to 344) 1.36 (0.57 to 3.21)   
CYP27B1 rs4646537 TT 111 152 (23 to UD) 109 83 (21 to UD) 0.79 (0.56 to 1.18) 2.80 (0.77 to 10.17) 0.12 
  GT 7 261 (62 to UD) 10 261 (45 to UD) 2.82 (0.60 to 13.30)   
  GG 0 - 0 - -   
 rs4646536 AA 48 143 (17 to UD) 47  231 (28 to UD) 0.89 (0.51 to 1.57) 0.97 (0.58 to 1.62) 0.92 
  AG 56 152 (27 to 374) 57 203 (50 to UD) 0.79 (0.49 to 1.28)   
  GG 10 144 (9 to UD) 15 147 (18 to UD) 0.86 (0.25 to 2.93)   
CYP2R1 rs10500804 TT 36 108 (27 to UD) 44 147 (31 to 362) 0.97 (0.55 to 1.71) 1.02 (0.65 to 1.61) 0.93 
  GT 62 136 (17 to UD) 53 217 (55 to 372) 0.80 (0.48 to 1.34)   
  GG 18 261 (64 to UD) 24 282 (19 to UD) 0.75 (0.30 to 1.89)   
 rs2060793 GG 39 156 (22 to UD) 41 231 (83 to UD) 0.58 (0.32 to 1.07) 1.46 ( 0.91 to 2.35) 0.12 
  AG 58 152 (27 to UD) 45 226 (45 to UD) 0.93 (0.57 to 1.53)   
  AA 20 143 (53 to UD) 22 109 (22 to 327) 2.27 (0.91 to 5.67)   
 rs10766197 GG 31 261 (43 to UD) 36 239 (51 to UD) 1.07 (0.56 to 2.03) 1.03 (0.66 to 1.61) 0.90 
  AG 61 110 (21 to UD) 55 216 (50 to 372) 0.78 (0.48 to 1.27)   
  AA 25 261 (43 to UD) 26 178 (27 to UD) 0.91 (0.41 to 2.03)   
CYP3A4 rs2740574 AA 107 154 (23 to UD) 107 200 (42 to UD) 0.86 (0.61 to 1.22) 0.64 (0.20 to 2.02) 0.45 
  AG 10 64 (58 to UD) 13 231 (118 to UD) 0.48 (0.14 to 1.65)   
  GG 0 - 0 - -   
DBP rs7041 CC 28 202 (23 to UD) 29 226 (50 to 372) 0.99 (0.50 to 1.95) 0.72 (0.45 to 1.16) 0.18 
  AC 58 152 (21 to UD) 67 212 (27 to UD) 0.94 (0.59 to 1.48)   
  AA 29 136 (53 to 374) 23  282 (83 to UD) 0.48 (0.21 to 1.08)   
 rs4588 GG 59 197 (41 to UD) 53 244 (50 to UD) 1.04 (0.63 to 1.70) 0.81 (0.49 to 1.31) 0.39 
  GT 47 95 (16 to UD) 60 198 (27 to UD) 0.78 (0.48 to 1.29)   
  TT 12 137 (53 to 176) 8 118 (51 to UD) 0.56 (0.13 to 2.45)   
 rs12512631 TT 55 242 (64 to UD) 43 173 (50 to UD) 0.82 (0.48 to 1.38) 1.15 (0.70 to 1.90) 0.58 
  CT 51 154 (15 to UD) 63 226 (27 to UD) 0.94 (0.57 to 1.54)   
  CC 11 137 (35 to 374) 12 118 (45 to 344) 1.23 (0.38 to 3.91)   
 rs2070741 TT 99 154 (26 to UD) 106 216 (42 to UD) 0.84 (0.59 to 1.20) 1.08 (0.43 to 2.75) 0.86 
  TG 16 108 (43 to UD) 11 198 (54 to UD) 1 .12 (0.31 to 3.99)   
  GG 2* - 1* - -   
 rs2298849 AA 73 159 (28 to UD) 86 231 (44 to UD) 0.80 (0.53 to 1.22) 0.98 (0.54 to 1.78) 0.94 
  AG 41 108 (22 to UD) 32 200 (50 to 365) 0.74 (0.41 to 1.36)   
  GG 4* - 3* - -   
 rs16846876 AA 55 156 (27 to UD) 53 226 (34 to UD) 0.98 (0.60 to 1.62) 0.72 (0.44 to 1.18) 0.20 
  AT 53 171 (22 to UD) 56 198 (50 to UD) 0.87 (0.53 to 1.42)   






N Median time to 
1st URI (IQR) : 
Control arm 
N Median time to 
1st URI (IQR) : 
Vitamin D arm 
Hazard ratio for 
effect of allocation 
within sub-group 
(95% CI) 1 
Ratio of hazard 
ratios for 
allocation*genotype 
interaction (95% CI) 1 
P value for 
interaction  
DHCR7 rs3829251 GG 90 144 (27 to UD) 91 239 (57 to UD) 0.80 (0.55 to 1.18) 1.42 (0.74 to 2.74) 0.30 
  AG 22 171 (32 to UD) 27 54 (19 to UD) 1.13 (0.52 to 2.42)   
  AA 5 27 (22 to UD) 1* - -   
 rs12785878 TT 71 144 (33 to UD) 77 217 (44 to UD) 0.91 (0.60 to 1.38) 0.88 (0.51 to 1.52) 0.65 
  GT 38 154 (22 to UD) 37 216 (51 to 372) 0.78 (0.43 to 1.41)   
  GG 7 64 (22 to UD) 7 54 (25 to UD) 1.20 (0.17 to 8.32)   
LRP2 rs3755166 GG 39 64 (17 to UD) 43 231 (92 to UD) 0.64 (0.36 to 1.14) 1.47 (0.94 to 2.31) 0.091 
  AG 54 171 (27 to 374) 54 212 (42 to 372) 0.92 (0.56 to 1.49)   
  AA 24 242 (32 to UD) 24 118 (27 to UD) 1.28 (0.58 to 2.82)   
RXRA rs7861779 GG 84 156 (27 to UD) 87 198 (31 to 372) 1.03 (0.70 to 1.51) 0.51 (0.25 to 1.04) 0.063 
  GA 29 83 (21 to 346) 25 UD (62 to UD) 0.54 (0.25 to 1.16)   
  AA 4* - 1* - -   
 rs9409929 GG 47 176 (32 to UD) 51 244 (62 to UD) 0.89 (0.51 to 1.56) 1.03 (0.62 to 1.71) 0.92 
  AG 58 137 (26 to UD) 62 200 (27 to UD) 0.83 (0.52 to 1.31)   
  AA 12 53 (7 to 242) 6 117 (27 to 300) 0.35 (0.06 to 1.86)   
VDR rs4334089 GG 64 346 (90 to UD) 57 212 (45 to 365) 1.65 (1.00 to 2.70) 0.36 (0.22 to 0.60) <0.001† 
  AG 42 41 (14 to 154) 55 226 (34 to UD) 0.45 (0.27 to 0.76)   
  AA 12 26 (15 to 171) 8 70 (10 to UD) 0.90 (0.13 to 6.21)   
 rs10783219 TT 16 217 (89 to UD) 8 50 (26 to 212) 6.09 (1.24 to 30.01) 0.42 (0.24 to 0.71) 0.001† 
  AT 50 242 (54 to UD) 61 200 (42 to 365) 1.32 (0.81 to 2.17)   
  AA 51 62 (17 to 261) 47 226 (54 to UD) 0.49 (0.29 to 0.85)   
 rs4516035 TT 40 136 (26 to UD) 39 327 (50 to UD) 0.60 (0.33 to 1.11) 1.10 (0.67 to 1.83) 0.70 
  CT 62 171 (27 to UD) 65 118 (25 to 372) 1.09 (0.70 to 1.70)   
  CC 14 154 (35 to UD) 16 226 (57 to UD) 0.46 (0.14 to 1.45)   
 rs11568820 CC 70 261 (64 to UD) 68 198 (44 to 372) 1.36 (0.87 to 2.13) 0.35 (0.20 to 0.61) <0.001† 
  CT 39 62 (11 to 374) 48 244 (33 to UD) 0.51 (0.29 to 0.89)   
  TT 7 26 (15 to 47) 4* - -   
 rs7976091 CC 71 250 (64 to UD) 68 198 (44 to 372) 1.33 (0.85 to 2.08) 0.35 (0.20 to 0.61) <0.001† 
  CT 39 62 (11 to 374) 49 244 (34 to UD) 0.49 (0.28 to 0.86)   
  TT 8 26 (15 to 47) 4* - -   
 rs2238136 CC 63 137 (20 to UD) 58 226 (27 to UD) 0.71 (0.44 to 1.14) 1.23 (0.71 to 2.14) 0.46 
  CT 42 242 (58 to UD) 53 198 (83 to 362) 1.27 (0.75 to 2.16)   
  TT 10 89 (17 to UD) 6 UD (25 to UD) 0.37 (0.05 to 2.76)   
 rs1544410 CC 38 159 (28 to UD) 47 231 (42 to UD) 0.65 (0.35 to 1.21) 1.11 (0.69 to 1.79) 0.68 
  CT 55 152 (27 to 374) 59 173 (50 to 372) 1.02 (0.63 to 1.63)   
  TT 25 90 (17 to 346) 14 282 (33 to 348) 0.80 (0.34 to 1.88)   
 rs2228570 GG 50 202 (43 to UD) 44 231 (62 to UD) 0.91 (0.52 to 1.58) 1.01 (0.63 to 1.61) 0.97 
  AG 48 119 (16 to 374) 60 200 (44 to 372) 0.79 (0.48 to 1.30)   
  AA 19 137 (21 to UD) 16 45 (10 to UD) 0.89 (0.37 to 2.15)   
 rs2853559 GG 42 136 (23 to 374) 37 348 (70 to UD) 0.52 (0.29 to 0.93) 1.26 (0.79 to 2.01) 0.34 
  AG 51 209 (28 to UD) 64 120 (28 to 344) 1.32 (0.81 to 2.14)   
  AA 23 176 (47 to UD) 16 231 (57 to UD) 0.59 (0.29 to 1.53)   
 rs7975232 AA 33 143 (27 to UD) 32 120 (33 to UD) 0.87 (0.48 to 1.58) 1.02 (0.64 to 1.63) 0.92 
  AC 57 144 (22 to 374) 60 212 (51 to UD) 0.75 (0.46 to 1.21)   
  CC 23 217 (62 to UD) 27 226 (25 to UD) 0.88 (0.38 to 2.05)   
 rs7970314 AA 66 242 (61 to UD) 64 198 (42 to UD) 1.27 (0.80 to 2.00) 0.45 (0.26 to 0.76) 0.003† 
  AG 41 95 (14 to 263) 52 244 (44 to UD) 0.43 (0.25 to 0.74)   
  GG 9 27 (23 to 64) 5 UD (5 to UD) 0.96 (0.14 to 6.65)   
 rs731236 AA 40 110 (28 to UD) 49 231 (44 to UD) 0.62 (0.34 to 1.13) 1.18 (0.73 to 1.90) 0.49 
  AG 56 154 (22 to 374) 58 173 (34 to 372) 1.05 (0.66 to 1.68)   
  GG 22 90 (23 to UD) 13 344 (45 to UD) 0.78 (0.30 to 1.99)   
[1] Adjusted for stratification factors i.e. Percent predicted forced expiratory volume in 1 second (<50% vs. ≥50%) and inclusion in vs. exclusion from sputum induction sub-
study; significant predictors of upper respiratory infection i.e. Age (<70 years vs. ≥70 years), and smoking status (current vs. non-current); and allocation to study 
intervention or placebo arm. † Remains significant after correction for multiple comparisons testing, using Benjamini & Hochberg method with a false discovery rate of 5%. 
* Genotype could not be analysed due to <5 participants and/or too few events within this sub category.  
………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………. 
Abbreviations: SNP: Single nucleotide polymorphism, IQR: Inter-quartile range, CI: Confidence interval, UD: Undefined, CYP-: Cytochrome P450 enzyme, DBP: Vitamin D 
binding protein, DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also known as megalin), RXRA: Retanoid-X receptor-A, 
VDR: Vitamin D receptor, CUBN: Cubilin. 




Table 9.4. Interaction analysis: Time to first exacerbation. 
Gene SNP Geno-
type 
N Median time to 
1st URI (IQR) : 
Control arm 
N Median time to 
1st URI (IQR) : 
Vitamin D arm 
Hazard ratio for 
effect of allocation 
within sub-group 
(95% CI) 1 
Ratio of hazard  
ratios for 
allocation*genotype 
interaction (95% CI) 1 
P value for 
interaction 
CUBN rs3740165 TT 113 278 (89 to UD) 110 UD (85 to UD) 0.86 (0.58 to 1.26) 1.69 (0.35 to 8.15) 0.51 
  TC 3* - 9 UD (89 to UD) -   
  CC 1* - 0 - -   
CYP24A1 rs2762939 GG 61 304 (58 to UD) 72 350 (68 to UD) 0.82 (0.49 to 1.38) 0.77 (0.41 to 1.46) 0.42 
  CG 52 274 (120 to UD) 41 UD (87 to UD) 0.95 (0.51 to 1.79)   
  CC 4* - 7 UD (263 to UD) -   
 rs2248137 CC 40 368 (112 to UD) 46  UD (67 to UD) 1.04 (0.47 to 2.30) 0.51 (0.29 to 0.91) 0.023 
  CG 64 342 (120 to UD) 57 329 (108 to UD) 1.03 (0.61 to 1.73)   
  GG 13 64 (22 to 153) 17 UD (72 to UD) 0.24 (0.08 to 0.72)   
 rs2762934 GG 78 371 (89 to UD) 89 350 (87 to UD) 1.02 (0.64 to 1.61) 0.68 (0.35 to 1.34) 0.27 
  AG 39 189 (103 to UD) 26 UD (87 to UD) 0.64 (0.29 to 1.39)   
  AA 1* - 5 263 (163 to UD) -   
 rs6013897 TT 73 342 (112 to UD) 83  350 (87 to UD) 1.02 (0.65 to 1.60) 0.75 (0.39 to 1.43) 0.38 
  AT 39 228 (69 to UD) 28 UD (44 to UD) 0.69 (0.30 to 1.61)   
  AA 4* - 8 224 (89 to UD) -   
CYP27A1 rs17470271 AA 47 278 (77 to UD) 43 224 (67 to UD) 1.27 (0.68 to 2.35) 0.69 (0.40 to 1.18) 0.18 
  AT 54 261 (112 to UD) 54 UD (177 to UD) 0.55 (0.30 to 0.99)   
  TT 17 UD (90 to UD) 23 UD (87 to UD) 1.30 (0.41 to 4.07)   
CYP27B1 rs4646537 TT 111 329 (89 to UD) 109 351 (87 to UD) 0.91 (0.62 to 1.34) 0.42 (0.09 to 1.86) 0.25 
  GT 7 228 (77 to 261) 10 UD (137 to UD) 0.52 (0.10 to 2.78)   
  GG 0 - 0 - -   
 rs4646536 AA 48 304 (64 to UD) 47  UD (137 to UD) 0.84 (0.44 to 1.58) 1.03 (0.59 to 1.78) 0.93 
  AG 56 252 (77 to UD) 57 263 (59 to UD) 0.93 (0.55 to 1.55)   
  GG 10 371 (240 to UD) 15 UD (39 to UD) 0.69 (0.20 to 2.42)   
CYP2R1 rs10500804 TT 36 274 (69 to UD) 44 UD (67 to UD) 0.95 (0.48 to 1.86) 1.05 (0.62 to 1.77) 0.85 
  GT 62 278 (77 to UD) 53 UD (87 to UD) 0.72 (0.41 to 1.26)   
  GG 18 368 (228 to UD) 24 315 (118 to UD) 1.46 (0.50 to 4.27)   
 rs2060793 GG 39 304 (112 to UD) 41 UD (137 to UD) 0.71 (0.36 to 1.42) 1.07 (0.64 to 1.79) 0.81 
  AG 58 261 (103 to UD) 45 263 (45 to UD) 1.04 (0.60 to 1.81)   
  AA 20 274 (22 to UD) 22 UD (108 to UD) 0.80 (0.27 to 2.34)   
 rs10766197 GG 31 274 (90 to UD) 36 UD (87 to UD) 0.87 (0.41 to 1.84) 1.13 (0.68 to 1.89) 0.64 
  AG 61 278 (62 to UD) 55 UD (72 to UD) 0.74 (0.43 to 1.27)   
  AA 25 368 (228 to UD) 26 315 (125 to UD) 1.27 (0.53 to 3.04)   
CYP3A4 rs2740574 AA 107 304 (90 to UD) 107 UD (87 to UD) 0.86 (0.57 to 1.28) 1.41 (0.43 to 4.57) 0.57 
  AG 10 274 (58 to UD) 13 301 (44 to UD) 1.84 (0.50 to 6.74)   
  GG 0 - 0 -    
DBP rs7041 CC 28 252 (129 to UD) 29 315 (85 to UD) 0.99 (0.47 to 2.10) 0.92 (0.53 to 1.60) 0.78 
  AC 58 342 (89 to UD) 67 UD (89 to UD) 0.87 (0.51 to 1.47)   
  AA 29 304 (64 to UD) 23  UD (87 to UD) 0.87 (0.37 to 2.01)   
 rs4588 GG 59 329 (90 to UD) 53 350 (67 to UD) 1.08 (0.62 to 1.90) 0.85 (0.47 to 1.52) 0.57 
  GT 47 252 (56 to UD) 60 UD (95 to UD) 0.68 (0.39 to 1.19)   
  TT 12 274 (129 to 368) 8 194 (97 to UD) 2.69 (0.41 to 17.39)   
 rs12512631 TT 55 274 (120 to UD) 43 UD (187 to UD) 0.58 (0.30 to 1.13) 1.38 (0.80 to 2.41) 0.25 
  CT 51 342 (38 to UD) 63 301 (67 to UD) 1.08 (0.64 to 1.83)   
  CC 11 201 (77 to UD) 12 163 (45 to UD) 0.93 (0.30 to 2.88)   
 rs2070741 TT 99 274 (64 to UD) 106 UD (90 to UD) 0.81 (0.54 to 1.20) 0.62 (0.22 to 1.74) 0.37 
  TG 16 UD (153 to UD) 11 UD (32 to UD) 9.91 (1.38 to 71.36)   
  GG 2* - 1* - -   
 rs2298849 AA 73 304 (77 to UD) 86 315 (87 to UD) 0.95 (0.60 to 1.49) 1.01 (0.65 to 1.58) 0.20 
  AG 41 345 (123 to UD) 32 UD (89 to UD) 0.70 (0.34 to 1.47)   
  GG 4* - 3* - -   
 rs16846876 AA 55 251 (56 to UD) 53 UD (72 to UD) 0.68 (0.39 to 1.19) 0.94 (0.52 to 1.70) 0.85 
  AT 53 369 (144 to UD) 56 301 (87 to UD) 1.28 (0.73 to 2.17)   
  TT 10 132 (103 to UD) 10 UD (UD to UD) 0.95 (0.03 to 28.64)   






N Median time to 
1st URI (IQR) : 
Control arm 
N Median time to 
1st URI (IQR) : 
Vitamin D arm 
Hazard ratio for 
effect of allocation 
within sub-group 
(95% CI) 1 
Ratio of hazard  
ratios for 
allocation*genotype 
interaction (95% CI) 1 
P value for 
interaction 
  AG 22 153 (103 to UD) 27 301 (87 to UD) 0.66 (0.26 to 1.66)   
  AA 5 UD (UD to UD) 1* - -   
 rs12785878 TT 71 274 (89 to UD) 77 351 (67 to UD) 0.90 (0.57 to 1.42) 1.08 (0.57 to 2.05) 0.82 
  GT 38 261 (90 to UD) 37 UD (177 to UD) 0.55 (0.26 to 1.16)   
  GG 7 UD (21 to UD) 7 89 (28 to UD) 21.73 (1.32 to 356.45)   
LRP2 rs3755166 GG 39 371 (140 to UD) 43 301 (87 to UD) 1.39 (0.72 to 2.69) 0.84 (0.50 to 1.40) 0.50 
  AG 54 201 (57 to UD) 54 UD (87 to UD) 0.59 (0.34 to 1.03)   
  AA 24 278 (123 to UD) 24 UD (85 to UD) 0.96 (0.34 to 2.73)   
RXRA rs7861779 GG 84 369 (112 to UD) 87 315 (87 to UD) 1.08 (0.70 to 1.67) 0.40 (0.17 to 0.94) 0.035 
  GA 29 252 (89 to UD) 25 UD (95 to UD) 0.54 (0.21 to 1.37)   
  AA 4* - 1* - -   
 rs9409929 GG 47 371 (112 (to UD) 51 UD (145 to UD) 0.91 (0.48 to 1.71) 0.93 (0.53 to 1.61) 0.94 
  AG 58 240 (57 to UD) 62 UD (45 to UD) 0.81 (0.49 to 1.33)   
  AA 12 UD (278 to UD) 6 UD (187 to UD) 0.23 (0.02 to 2.29)   
VDR rs4334089 GG 64 278 (64 to 369) 57 UD (108 to UD) 0.82 (0.47 to 1.45) 1.16 (0.66 to 2.06) 0.60 
  AG 42 228 (49 to UD) 55 315 (72 to UD) 0.82 (0.46 to 1.47)   
  AA 12 371 (103 to UD) 8 329 (22 to UD) 1.94 (0.36 to 10.38)   
 rs10783219 AA 51 219 (49 to UD) 47 UD (90 to UD) 0.64 (0.35 to 1.20) 1.14 (0.63 to 2.08) 0.67 
  AT 50 329 (129 to UD) 61 315 (73 to UD) 1.14 (0.66 to 1.95)   
  TT 16 252 (62 to UD) 8 UD (108 to UD) 0.52 (0.07 to 4.21)   
 rs4516035 TT 40 345 (62 to UD) 39 UD (67 to UD) 0.83 (0.40 to 1.69) 0.73 (0.40 to 1.32) 0.30 
  CT 62 342 (129 to UD) 65 224 (85 to UD) 1.23 (0.75 to 2.01)   
  CC 14 77 (23 to UD) 16 UD ( UD to UD) 0.20 (0.05 to 0.80)   
 rs11568820 CC 70 252 (89 to UD) 68 UD (87 to UD) 0.78 (0.47 to 1.30) 1.29 (0.69 to 2.41) 0.43 
  CT 39 345 (123 to UD) 48 315 (85 to UD) 1.07 (0.58 to 1.95)   
  TT 7 278 (57 to UD) 4* - -   
 rs7976091 CC 71 252 (89 to UD) 68 UD (87 to UD) 0.80 (0.48 to 1.34) 1.14 (0.61 to 2.12) 0.68 
  CT 39 345 (112 to UD) 49 329 (87 to UD) 1.04 (0.57 to 1.92)   
  TT 8 120 (21 to UD) 4* - -   
 rs2238136 CC 63 228 (49 to UD) 58 UD (67 to UD) 0.72 (0.43 to 1.19) 1.28 (0.69 to 2.41) 0.44 
  CT 42 368 (133 to UD) 53 UD (90 to UD) 1.13 (0.60 to 2.12)   
  TT 10 UD (240 to UD) 6 UD (UD to UD) 0.46 (0.04 to 5.41)   
 rs1544410 CC 38 261 (123 to UD) 47 263 (90 to UD) 0.98 (0.52 to 1.87) 1.23 (0.71 to 2.13) 0.47 
  CT 55 274 (64 to UD) 59 UD (87 to UD) 0.67 (0.38 to 1.17)   
  TT 25 345 (89 to UD) 14 187 (45 to 351) 2.51 (0.96 to 6.58)   
 rs2228570 GG 50 252 (64 to UD) 44 UD (87 to UD) 0.64 (0.35 to 1.18) 1.39 (0.81 to 2.41) 0.23 
  AG 48 368 (103 to UD) 60 UD(95 to UD) 0.99 (0.55 to 1.80)   
  AA 19 189 (120 to UD) 16 111 (39 to UD) 1.13 (0.43 to 2.99)   
 rs2853559 GG 42 345 (64 to UD) 37 UD (108 to UD) 0.61 (0.31 to 1.21) 1.12 (0.64 to 1.96) 0.68 
  AG 51 342 (123 to UD) 64 UD (111 to UD) 1.06 (0.60 to 1.88)   
  AA 23 129 (77 to UD) 16 301 (44 to UD) 0.63 (0.26 to 1.50)   
 rs7975232 AA 33 345 (89 to UD) 32 351 (73 to UD) 0.92 (0.45 to 1.86) 0.95 (0.55 to 1.62) 0.84 
  AC 57 278 (69 to UD) 60 UD (67 to UD) 0.76 (0.43 to 1.35)   
  CC 23 369 (132 to UD) 27 UD (108 to UD) 1.03 (0.42 to 2.49)   
 rs7970314 AA 66 261 (89 to UD) 64 UD (87 to UD) 0.84 (0.50 to 1.42) 1.05 (0.57 to 1.94) 0.88 
  AG 41 345 (123 to UD) 52 329 (85 to UD) 1.02 (0.56 to 1.85)   
  GG 9 278 (57 to UD) 5 UD (UD to UD) 0.34 (0.02 to 4.70)   
 rs731236 AA 40 261 (123 to UD) 49 301 (90 to UD) 0.88 (0.47 to 1.64) 1.38 (0.79 to 2.42) 0.26 
  AG 56 278 (64 to UD) 58 UD (87 to UD) 0.70 (0.40 to 1.24)   
  GG 22 342 (89 to UD) 13 187 (45 to 351) 3.69 (1.31 to 10.38)   
[1] Adjusted for stratification factors i.e. Percent predicted forced expiratory volume in 1 second (<50% vs. ≥50%) and inclusion in vs. exclusion from sputum induction sub-study; a 
significant predictor of COPD exacerbation i.e. use of inhaled corticosteroids (yes vs. no); and allocation to study intervention or placebo arm. After correction for multiple comparisons 
testing, using Benjamini & Hochberg method with a false discovery rate of 5%, none of the p values for interaction remain significant. * Genotype could not be analysed due to <5 
participants and/or too few events within this sub category.  
…………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 
Abbreviations: SNP: Single nucleotide polymorphism, IQR: Inter-quartile range, CI: Confidence interval, UD: Undefined, CYP-: Cytochrome P450 enzyme, DBP: Vitamin D binding protein, 
DHCR7: 7-dehydrocholesterol reductase enzyme, LRP2: Low density lipoprotein-related protein 2 (also known as megalin), RXRA: Retanoid-X receptor-A, VDR: Vitamin D receptor, CUBN: 
Cubilin. 




In summary, main effects analysis identified five SNP in the VDR gene which show an association with 
clinical outcomes, independent of vitamin D supplementation: four associate with risk of URI 
(rs4334089, rs11568820, rs7976091, and rs7970314), and one associates with risk of COPD 
exacerbation (rs2238136). Interaction analysis identified five SNP in VDR which associate with the 
effect of vitamin D supplementation on risk of URI: rs4334089, rs11568820, rs7976091, rs7970314, 
rs10783219, and one SNP which associates with the effect of vitamin D supplementation on risk of 
COPD exacerbation: rs2248137 in CYP24A1. 
 
After correction for multiple comparisons testing (Bejamini & Hochberg method with a false 
discovery rate of 5%) only the interaction analysis findings for rs4334089; rs11568820; rs7976091; 
rs7970314; rs10783219 and effect of vitamin D supplementation on risk of URI remain significant. 
Figure 9.1 displays a panel of Kaplan-Meier failure estimates for the effect of allocation on time to 












Figure 9.1: Kaplan-Meier failure estimates from the effect modification analysis, illustrating the effect 
of allocation on number of days post randomisation to first URI event, stratified by genotype for five 












































9.2.3. SNP haplotype analysis. 
Further investigation of the 5 putative effect modifying VDR SNP highlighted a high level of linkage 
between these variants. Figure 9.2 is a linkage disequilibrium (LD) map generated from the HapMap 
database (CEU dataset, release #27) which shows that rs4334089 is in perfect LD (R2 = 1.00) with 
rs10783219, which in turn is in perfect LD with rs11568820 and rs7970314. LD data were not 
available in the HapMap database for one SNP (rs7976091) but were available in the 1000 genomes 
database (integrated phase 1, version 3 [March 2012]), which reported rs7976091 to be tightly linked 
with rs7970314 (R2 = 0.90), shown in Table 9.4. Due to this linkage pattern it is reasonable to assign 
haplotypes which may more closely associate with the effect of vitamin D supplementation on risk 
of URI than individual variant genotypes do. 




Figure 9.2: A linkage disequilibrium map of 4 of the 5 putative effect modifying SNP in VDR gene. Values 
presented within cells are R2 measurements of linkage disequilibrium – a value of 1.0 represents perfect 
linkage, which is represented as red cells. One SNP (rs7976091) was not contained in the HapMap 






Table 9.5: Linkage disequilibrium between variants rs7976091 and rs7970314. 
 
Variant 1 Variant 2 R2 D D prime Variant 1 (rs#) Variant 2 (rs#) 
chr12:48308174 chr12:48304552 0.902 0.171 0.992 rs7976091 rs7970314 
 
Data retrieved from the 1000 genomes database (integrated phase 1, version 3 [March 2012]). 
 
Using the National Institutes of Health’s LDlink tool (http://analysistools.nci.nih.gov) and phased 
genotype data from the 1000 genomes dataset (Phase 1, version 3 - Utah residents with Northern 
and Western European ancestry from the CEPH collection [CEU]) six haplotypes were inferred for our 
5 VDR SNP of interest (presented in Figure 9.3). Manually assigning haplotypes using Clark’s method 
(354) I identified 5 of the 6 most frequent haplotypes in the 1000 genomes dataset to be the most 
frequently occurring in our participants (GACCA in 75%; GTCCA in 42.9%; AACCA in 40.8%; AATTG in 




Figure 9.3: Inferred Haplotypes generated by NIH’s LDlink online tools, using 1000 genomes SNP data 




Results of the interaction analysis between haplotype and study intervention are presented in Table 
9.6 and Figure 9.4. Multivariable Cox regression identified significant independent associations 
between haplotypes GTCCA, AACCA, and AATTG and the effect of vitamin D supplementation on time 
to first URI. The strongest protective effect of supplementation was seen in participants with 
haplotype AACCA (aRHR 0.39; 95% CI 0.23 to 0.67; P=0.001); a milder protective effect was shown in 
participants with haplotype AATTG (aRHR 0.42; 95% CI 0.21 to 0.84; P=0.013), whilst supplemented 











Table 9.6. Haplotype-allocation interaction analysis: Time to first URI. 
 
Haplotype Positive N Median time to 
1st URI (IQR) : 
Control arm 
N Median time to 
1st URI (IQR) : 
Vitamin D arm 
Hazard ratio for effect 
of allocation within 
sub-group (95% CI) 1 




(95% CI) 1 
P value for 
interaction  
GACCA 1 85 143 (22 to UD) 96 203 (44 to UD) 1.24 (0.51 to 3.03) 1.19 (0.50 to 2.84) 0.69 
 0 27 136 (26 to 374) 18 109 (26 to UD) 0.85 (0.58 to 1.23)   
GTCCA 1 54 356 (89 to UD) 49 118 (28 to 282) 2.00 (1.17 to 3.41) 4.77 (2.41 to 9.44) <0.001 
 0 58 47 (15 to 171) 65 279 (55 to UD) 0.43 (0.27 to 0.68)   
AACCA 1 43 41 (11 to 154) 55 203 (34 to UD) 0.39 (0.23 to 0.67) 0.31 (0.16 to 0.62) 0.001 
 0 69 242 (61 to UD) 59 178 (42 to 372) 1.32 (0.83 to 2.09)   
AATTG 1 30 26 (14 to 143) 27 173 (21 to UD) 0.42 (0.21 to 0.84) 0.34 (0.16 to 0.72) 0.004 
 0 82 226 (54 to UD) 87 212 (45 to UD) 1.14 (0.76 to 1.70)   
GATTG 1 22 27 (14 to 152) 23 173 (21 to UD) 0.46 (0.21 to 1.01) 0.58 (0.26 to 1.29) 0.18 
 0 90 176 (33 to UD) 91 212 (44 to UD) 0.97 (0.67 to 1.42)   
 
[1] Adjusted for stratification factors i.e. Percent predicted forced expiratory volume in 1 second (<50% vs. ≥50%) and inclusion  in vs. 
exclusion from sputum induction sub-study; significant predictors of upper respiratory infection i.e. Age (<70 years vs. ≥70 years), and 
smoking status (current vs. non-current); and allocation to study intervention or placebo arm. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 


























Figure 9.4: Kaplan-Meier failure estimates illustrating the effect of allocation on number of days post 












9.2.4. Immune profile analysis. 
Based on the strongest signal of effect-modification, I classified participants as genetically defined 
‘responders’ and ‘non-responders’ to vitamin D supplementation depending on whether they were 
positive or negative for haplotype AACCA (A allele for rs4334089; A allele for rs10783219; C allele for 
rs11568820; C allele for rs7976091; A allele for rs7970314). In a subset of n=60 participants I 
investigated an association between the effects of clinical trial allocation on their inflammatory 
profile, stratified by the ACCAA haplotype. Participants’ inflammatory profile was characterised by 
measuring the concentration of 30 inflammatory markers (described in methods - chapter.2, section 
3.4), in supernatants of whole blood stimulated ex-vivo with 5 toll-like receptor (TLR) ligands 
(lipopolysaccharide [LPS], PAM2, Polyinosinic:polycytidylic acid [Poly I:C], R848, and serum) 
 
Results of the multiple linear regression analysis are presented in Table 9.7. Two trends appeared in 
these data: lower relative concentrations of Granulocyte-colony stimulating factor (GCSF) were 
observed for individuals positive for haplotype AACCA receiving vitamin D supplementation, 
compared to individuals negative for haplotype AACCA receiving vitamin D supplementation, under 
stimulation with: LPS (GMR 0.79; 95 % CI 0.66 - 0.95; P=0.014 vs. GMR 1.20; 95% CI 1.02 – 1.40; 
P=0.028. P value for interaction = 0.004); Pam2 (GMR 0.88; 95% CI 0.77 – 1.00; P=0.058 vs. GMR 1.08; 
95% CI 0.94 – 1.23; P=0.26. P value for interaction = 0.029); and R848 (GMR 0.88; 95% CI 0.76 – 1.01; 
P=0.059 vs. GMR 1.04; 95% CI 0.92 – 1.18; P=0.50. P value for interaction = 0.050). Lower relative 
concentration of Monokine induced by gamma interferon (MIG) were observed for individuals 
positive for haplotype AACCA receiving vitamin D supplementation, compared to individuals negative 
for haplotype AACCA receiving vitamin D supplementation, under stimulation with: LPS (GMR 0.98; 
95% CI 0.83 - 1.15; P=0.77 vs. GMR 1.30; 95% CI 1.05 – 1.62; P=0.021. P value for interaction = 0.018); 
Pam2 (GMR 0.96; 95% CI 0.81 – 1.14; P=0.64 vs. GMR 1.35; 95% CI 1.04 – 1.76; P=0.028. P value for 




P=0.039. P value for trend = 0.038); and R848 (GMR 0.89; 95% CI 0.64 – 1.23; P=0.46 vs. GMR 1.67; 
95% CI 0.17 – 2.37; P=0.006. P value for trend = 0.006). 
 
After correction for multiple comparisons testing (Bejamini & Hochberg method with a false 




















Table 9.7. TLR ligand-stimulated inflammatory cytokine release from PBMCs, stratified by AACCA haplotype (subgroup of n=60). 
 
 Lipopolysaccharide (LPS) Pam2 Polyinosinic:polycytidylic acid (Poly I:C) 
 effect of allocation : 
AACCA positive 
effect of allocation : 
AACCA negative 
P value for 
Interaction 
effect of allocation : AACCA 
positive 
effect of allocation : AACCA 
negative 
P value for 
Interaction 
effect of allocation : 
AACCA positive 
effect of allocation : AACCA 
negative 
P value for 
Interaction 
Analyte GMR (95% CI) P GMR (95% CI) P  GMR (95% CI) P GMR (95% CI) P  GMR (95% CI) P GMR (95% CI) P  
FGF Basic 0.99 (0.86 - 1.15) 0.93 1.10 (0.88 – 1.38) 0.40 0.58 0.96 (0.62 – 1.49) 0.87 1.00 (0.63 – 1.58) 1.00 0.94 0.82 (0.54 – 1.25) 0.34 0.87 (0.52 – 1.45) 0.58 0.87 
IL-1β 0.74 (0.49 - 1.12) 0.15 1.34 (0.79 – 2.27) 0.27 0.074 0.69 (0.51 – 0.92) 0.015 0.96 (0.63 – 1.47) 0.86 0.31 0.82 (0.40 – 1.67) 0.57 1.36 (0.81 – 2.28) 0.23 0.41 
G-CSF 0.79 (0.66 - 0.95) 0.014 1.20 (1.02 – 1.40) 0.028 0.004 0.88 (0.77 – 1.00) 0.058 1.08 (0.94 – 1.23) 0.26 0.029 0.97 (0.77 – 1.21) 0.77 1.13 (0.92 – 1.40) 0.24 0.33 
IL-10 0.61 (0.40 - 0.92) 0.021 0.97 (0.60 – 1.57) 0.90 0.17 0.53 (0.32 – 0.90) 0.020 0.87 (0.59 – 1.30) 0.49 0.23 1.07 (0.57 – 1.99) 0.84 1.08 (0.81 – 1.45) 0.60 0.73 
IL-13 0.87 (0.75 - 1.03) 0.10 1.07 (0.94 – 1.22) 0.27 0.092 0.84 (0.69 – 1.02) 0.081 1.02 (0.85 – 1.23) 0.80 0.15 0.75 (0.59 – 0.96) 0.023 1.07 (0.87 – 1.33) 0.50 0.088 
IL-6 - - - - - 0.56 (0.34 – 0.92) 0.024 1.09 (0.56 – 2.14) 0.79 0.11 0.39 (0.16 – 0.94) 0.036 1.00 (0.49 – 2.04) 1.00 0.12 
IL-12 0.58 (0.33 - 1.03) 0.062 1.21 (0.70 – 2.11) 0.49 0.079 0.89 (0.78 – 1.01) 0.064 0.92 (0.82 – 1.04) 0.19 0.35 1.22 (0.73 – 2.04) 0.44 0.88 (0.74 – 1.04) 0.12 0.51 
RANTES - - 0.59 (0.11 – 3.11) 0.49 - 0.96 (0.42 – 2.17) 0.91 0.46 (0.12 – 1.70) 0.23 0.42 1.20 (0.43 – 3.34) 0.71 0.78 (0.49 – 1.24) 0.28 0.42 
Eotaxin/CCL11 0.76 (0.53 - 1.10) 0.14 0.89 (0.75 – 1.07) 0.20 0.43 0.82 (0.56 – 1.23) 0.34 1.03 (0.81 – 1.32) 0.80 0.40 1.10 (0.80 – 1.51) 0.53 1.12 (0.89 – 1.40) 0.32 0.95 
IL-17 0.99 (0.85 - 1.16) 0.92 1.04 (0.96 – 1.13) 0.33 0.89 0.96 (0.83 – 1.11) 0.58 0.98 (0.83 – 1.16) 0.81 0.49 0.94 (0.76 – 1.17) 0.58 1.00 (0.79 – 1.26) 1.00 0.77 
MIP-1α 0.63 (0.33 - 1.18) 0.14 1.28 (0.72 – 2.29) 0.38 0.096 0.57 (0.38 – 0.86) 0.010 0.80 (0.42 – 1.55) 0.50 0.39 0.66 (0.28 – 1.58) 0.34 1.36 (0.62 – 2.99) 0.43 0.27 
GM-CSF 0.86 (0.67 - 1.10) 0.22 1.01 (0.91 – 1.11) 0.90 0.68 0.89 (0.70 – 1.13) 0.32 0.86 (0.61 – 1.20) 0.37 0.48 0.93 (0.69 – 1.26) 0.63 1.02 (0.92 – 1.13) 0.74 0.46 
MIP-1β/CCL4 0.68 (0.36 - 1.30) 0.23 0.95 (0.52 – 1.74) 0.87 0.56 0.70 (0.48 – 1.04) 0.077 0.98 (0.60 – 1.60) 0.92 0.33 0.57 (0.26 – 1.23) 0.14 1.29 (0.73 – 2.28) 0.36 0.076 
MCP-1/CCL2 0.79 (0.56 - 1.12) 0.17 1.21 (0.85 – 1.73) 0.27 0.073 0.71 (0.38 – 1.32) 0.27 1.32 (0.79 – 2.23) 0.28 0.12 0.99 (0.44 – 2.23) 0.98 1.28 (0.644 – 2.53) 0.47 0.49 
IL-15 0.88 (0.71 - 1.10) 0.25 1.20 (0.98 – 1.47) 0.075 0.15 0.85 (0.69 – 1.05) 0.12 1.24 (0.84 – 1.84) 0.27 0.092 0.60 (0.32 – 1.11) 0.099 1.33 (0.72 – 2.43) 0.35 0.071 
EGF 0.89 (0.69 - 1.15) 0.37 0.94 (0.81 – 1.09) 0.39 0.93 0.98 (0.67 – 1.44) 0.92 0.80 (0.65 – 1.00) 0.046 0.31 0.86 (0.66 – 1.13) 0.26 0.93 (0.78 – 1.12) 0.44 0.93 
IL-5 0.95 (0.87 - 1.04) 0.26 1.07 (0.96 – 1.19) 0.21 0.17 0.95 (0.87 – 1.05) 0.33 1.07 (0.96 – 1.19) 0.19 0.18 0.99 (0.89 – 1.10) 0.85 1.03 (0.92 – 1.15) 0.63 0.53 
HGF 0.91 (0.83 - 1.01) 0.063 1.09 (0.96 – 1.22) 0.17 0.021 0.91 (0.77 – 1.06) 0.21 0.98 (0.83 – 1.16) 0.83 0.43 0.91 (0.75 – 1.11) 0.34 1.03 (0.86 – 1.25) 0.72 0.35 
VEGF 0.96 (0.83 - 1.10) 0.52 1.18 (0.99 – 1.41) 0.068 0.17 0.80 (0.67 – 0.95) 0.015 0.97 (0.77 – 1.22) 0.81 0.18 0.77 (0.51 – 1.16) 0.20 1.12 (0.84 – 1.49) 0.44 0.13 
IFN-γ 0.91 (0.60 - 1.38) 0.66 1.36 (1.03 – 1.78) 0.029 0.083 1.02 (0.93 – 1.12) 0.65 1.05 (0.97 – 1.14) 0.24 0.64 0.98 (0.69 – 1.38) 0.89 0.89 (0.57 – 1.40) 0.61 0.76 
IFN-α 0.91 (0.82 - 1.00) 0.052 1.06 (0.98 – 1.15) 0.15 0.033 0.85 (0.70 – 1.04) 0.11 0.96 (0.78 – 1.18) 0.69 0.34 0.95 (0.68 – 1.32) 0.75 0.93 (0.73 – 1.19) 0.56 0.67 
IL-1RA 0.84 (0.55 - 1.29) 0.41 1.23 (0.91 – 1.65) 0.17 0.25 0.77 (0.54 – 1.08) 0.13 0.86 (0.56 – 1.32) 0.47 0.75 0.78 (0.51 – 1.19) 0.23 0.85 (0.52 – 1.40) 0.51 0.73 
TNF-α 0.76 (0.47 - 1.23) 0.25 1.52 (0.92 – 2.51) 0.10 0.045 0.77 (0.61 – 0.97) 0.028 0.98 (0.56 – 1.70) 0.94 0.42 0.91 (0.54 – 1.56) 0.73 1.29 (0.95 – 1.75) 0.097 0.19 
IL-2 0.86 (0.65 - 1.14) 0.29 0.92 (0.73 – 1.16) 0.47 0.87 - - - - - - - - - - 
IL-7 0.96 (0.86 - 1.07) 0.44 1.15 (1.01 – 1.32) 0.035 0.13 0.86 (0.66 – 1.13) 0.27 0.89 (0.65 – 1.21) 0.43 0.96 0.61 (0.40 – 0.93) 0.025 1.29 (0.77 – 2.16) 0.33 0.018 
IP-10 1.09 (0.57 - 2.10) 0.78 2.77 (1.47 – 5.23) 0.003 0.032 0.95 (0.71 – 1.28) 0.75 1.27 (0.89 – 1.80) 0.18 0.25 1.32 (0.47 – 3.72) 0.58 1.19 (0.41 – 3.46) 0.74 0.94 
IL-2R 0.97 (0.87 - 1.08) 0.57 1.17 (1.01 – 1.36) 0.035 0.040 0.97 (0.81 – 1.17) 0.77 1.10 (0.94 – 1.29) 0.24 0.32 1.01 (0.82 – 1.25) 0.92 1.05 (0.84 – 1.32) 0.63 0.73 
MIG/CXCL9 0.98 (0.83 - 1.15) 0.77 1.30 (1.05 – 1.62) 0.021 0.018 0.96 (0.81 – 1.14) 0.64 1.35 (1.04 – 1.76) 0.028 0.026 0.89 (0.65 – 1.21) 0.43 1.33 (1.02 – 1.75) 0.039 0.038 
IL-4 0.94 (0.81 - 1.09) 0.40 1.09 (0.99 – 1.21) 0.072 0.079 0.90 (0.74 – 1.11) 0.31 0.95 (0.82 – 1.10) 0.45 0.69 0.84 (0.62 – 1.13) 0.23 0.99 (0.85 – 1.15) 0.89 0.30 


























* None of the p values were significant after correcting for multiple 
comparison testing using the Benjamini & Hochberg method with a false 
discovery rate of 5%.  
** A small constant (0.05) was added to each analytes’ median 
concentration before log transforming for the regression analysis, to 
avoid taking logs of 0. 
…………………………………………………………………………………………………………….. 
Abbreviations: GMR: Geometric mean ratio. FGF Basic: Fibroblast 
growth factor basic; GCSF: Granulocyte-colony stimulating factor; IL-n: 
Interleukin-n; RANTES: Regulated on Activation, Normal T Cell Expressed 
and Secreted; MIP-1α: Macrophage inflammatory protein 1 alpha; 
GMCSF: Granulocyte macrophage colony-stimulating factor; MIP-1β: 
Macrophage inflammatory protein 1 beta; Monocyte chemoattractant 
protein 1; EFG: epidermal growth factor; HPG: Hepatocyte growth 
factor; VEGF: Vascular endothelial growth factor; IFN-γ: Interferon 
gamma; IFN-α: Interferon alpha; IL-1RA: Interleukin-1 receptor 
antagonist; TNF-α: Tumour necrosis factor alpha; IP-10: IFN-γ-Inducible 
protein 10; IL-2R: Interleukin-2 receptor; MIG: Monokine induced by 
gamma interferon.
 R848 Serum 
 effect of allocation : AACCA 
positive 
effect of allocation : AACCA 
negative 
P value for 
Interaction 
effect of allocation : AACCA 
positive 
effect of allocation : AACCA 
negative 
P value for 
Interaction 
Analyte GMR (95% CI) P GMR (95% CI) P  GMR (95% CI) P GMR (95% CI) P  
FGF Basic 0.98 (0.81 – 1.18) 0.81 1.10 (0.92 – 1.31) 0.28 0.37 - - - - - 
IL-1β 0.81 (0.53 – 1.25) 0.33 1.27 (0.89 – 1.82) 0.18 0.11 - - - - - 
G-CSF 0.88 (0.76 – 1.01) 0.059 1.04 (0.92 – 1.18) 0.50 0.050 1.11 (0.79 – 1.57) 0.53 0.97 (0.77 – 1.22) 0.78 0.55 
IL-10 0.79 (0.51 – 1.23) 0.28 1.03 (0.76 – 1.40) 0.82 0.20 1.13 (0.70 – 1.82) 0.59 1.16 (0.95 – 1.42) 0.15 0.56 
IL-13 0.90 (0.79 – 1.04) 0.14 1.05 (0.91 – 1.22) 0.48 0.15 0.93 (0.56 – 1.56) 0.79 0.98 (0.65 – 1.47) 0.91 0.94 
IL-6 - - - - - 1.18 (0.84 – 1.66) 0.32 1.08 (0.82 – 1.43) 0.55 0.15 
IL-12 0.61 (0.37 – 1.00) 0.049 1.14 (0.71 – 1.82) 0.59 0.080 1.02 (0.89 – 1.18) 0.75 1.02 (0.87 – 1.19) 0.81 0.89 
RANTES 1.23 (0.52 – 2.87) 0.60 0.47 (0.09 – 2.50) 0.34 0.29 0.92 (0.43 – 1.99) 0.82 0.75 (0.45 – 1.26) 0.26 0.66 
Eotaxin/CCL11 1.02 (0.84 – 1.25) 0.83 0.97 (0.81 – 1.15) 0.68 0.66 1.03 (0.79 – 1.34) 0.84 1.06 (0.83 – 1.35) 0.63 0.82 
IL-17 0.93 (0.85 – 1.01) 0.071 1.04 (0.94 – 1.14) 0.43 0.062 - - - - - 
MIP-1α 1.22 (0.56 – 2.63) 0.60 1.60 (1.01 – 2.53) 0.048 0.54 1.20 (0.86 – 1.67) 0.27 1.20 (0.97 – 1.47) 0.085 0.29 
GM-CSF 0.85 (0.67 – 1.07) 0.16 1.08 (0.91 – 1.27) 0.36 0.81 0.91 (0.70 – 1.19) 0.48 1.13 (0.98 – 1.31) 0.085 0.81 
MIP-1β/CCL4 1.68 (0.82 – 3.41) 0.14 1.65 (0.89 – 3.05) 0.10 0.93 1.32 (0.96 – 1.81) 0.089 1.14 (0.88 – 1.47) 0.31 0.19 
MCP-1/CCL2 1.06 (0.72 – 1.56) 0.75 1.19 (0.95 – 1.49) 0.12 0.59 1.12 (0.85 – 1.47) 0.41 1.22 (0.94 – 1.58) 0.13 0.70 
IL-15 0.97 (0.72 – 1.30) 0.82 1.04 (0.94 – 1.16) 0.44 0.58 - - - - - 
EGF 0.88 (0.72 – 1.06) 0.17 0.97 (0.87 – 1.08) 0.58 0.48 1.65 (0.95 – 2.88) 0.073 0.79 (0.43 – 1.46) 0.44 0.10 
IL-5 0.99 (0.92 – 1.08) 0.86 1.03 (0.92 – 1.15) 0.59 0.67 1.11 (1.01 – 1.21) 0.025 1.06 (0.96 – 1.18) 0.22 0.59 
HGF 0.94 (0.83 – 1.07) 0.37 1.06 (0.93 – 1.20) 0.36 0.19 1.51 (1.13 – 2.01) 0.007 1.06 (0.88 – 1.27) 0.53 0.019 
VEGF 0.99 (0.80 – 1.23) 0.93 1.06 (0.87 – 1.29) 0.54 0.60 - - - - - 
IFN-γ 0.66 (0.26 – 1.66) 0.37 2.30 (1.21 – 4.39) 0.013 0.016 1.01 (0.96 – 1.06) 0.77 1.06 (1.00 – 1.12) 0.036 0.16 
IFN-α 0.70 (0.50 – 0.96) 0.030 0.93 (0.66 – 1.30) 0.64 0.16 1.06 (0.92 – 1.23) 0.42 1.09 (0.95 – 1.25) 0.21 1.00 
IL-1RA 0.80 (0.53 – 1.22) 0.29 0.77 (0.42 – 1.43) 0.40 0.98 1.17 (0.84 – 1.63) 0.33 1.34 (0.98 – 1.83) 0.065 0.58 
TNF-α 0.66 (0.38 – 1.15) 0.13 1.67 (1.06 – 2.61) 0.027 0.012 1.27 (0.88 – 1.83) 0.20 1.08 (0.77 – 1.51) 0.65 0.45 
IL-2 0.92 (0.78 – 1.08) 0.28 1.04 (0.91 – 1.20) 0.54 0.30 - - - - - 
IL-7 0.94 (0.82 – 1.08) 0.37 1.09 (0.93 – 1.27) 0.27 0.34 - - - - - 
IP-10 - - - - - 1.03 (0.85 – 1.24) 0.76 1.13 (0.91 – 1.41) 0.26 0.50 
IL-2R 1.02 (0.87 – 1.19) 0.84 1.11 (0.98 – 1.26) 0.086 0.33 1.18 (0.94 – 1.48) 0.15 1.15 (0.95 – 1.39) 0.14 0.86 
MIG/CXCL9 0.89 (0.64 – 1.23) 0.46 1.67 (0.17 – 2.37) 0.006 0.006 1.17 (0.93 – 1.48) 0.17 1.41 (1.02 – 1.94) 0.037 0.37 
IL-4 0.97 (0.85 – 1.11) 0.67 1.05 (0.95 – 1.17) 0.32 0.34 1.03 (0.87 – 1.21) 0.75 1.12 (0.93 – 1.34) 0.22 0.46 
IL-8 0.66 (0.41 – 1.06) 0.085 0.79 (0.45 – 1.39) 0.40 0.69 0.95 (0.46 – 1.97) 0.88 1.03 (0.54 – 1.96) 0.93 0.82 




9.2.5. VDR expression analysis. 
The enhanced response to vitamin D supplementation I observed in AACCA positive individuals could 
be mediated by VDR expression i.e. higher expression would result in more receptor available to ligate 
1,25(OH)2D. One of the 5 putative effect modifying VDR SNP, rs11568820, is a binding site for a 
transcription factor (caudal-type homeobox protein 2 [cdx2]) which has been reported to affect VDR 
expression level (355). To investigate an association between all AACCA haplotype SNP and VDR gene 
expression level, I carried out reverse transcription-quantitative polymerase chain reaction (RT-qPCR, 
as described in methods – chapter 2, section 3.3) on whole blood samples in a subgroup of 55 
participants. Relative quantification of VDR messenger-RNA (mRNA) was calculated using the 
comparative 2-ΔΔCT method (356). Results of this analysis are presented in Table 9.8. Relative to the 
housekeeping gene (Glyceraldehyde-3-Phosphate Dehydrogenase [GAPDH]), the ratio of VDR 
expression did not significantly differ between individuals with the common genotype vs. 
heterozygous/uncommon genotypes for any of the 5 SNP comprising the AACCA haplotype. 
 
Table 9.8. RT-qPCR: VDR mRNA expression levels stratified by VDR SNP (subgroup of n=55). 
 
SNP Average ΔCt 1 :  
Common genotype 




ΔΔCt Fold change in 
VDR expression 
(2-ΔΔCt) 
P value 2 
rs10783219 5.31 5.16 -0.15 1.11 0.79 
rs4334089 4.97 5.42 0.45 0.73 0.46 
rs11568820 4.90 5.51 0.61 0.66 0.27 
rs7976091 4.83 5.56 0.73 0.60 0.17 
rs7970314 4.98 5.41 0.44 0.74 0.34 
 
[1] VDR mRNA cycle threshold (Ct) values were normalised to housekeeping gene (Glyceraldehyde-3-Phosphate Dehydrogenase [GAPDH]) Ct 
values. [2] Significance of expression fold change was obtained by Mann-Whitney U test of (VDR-Ct)-(GAPDH-Ct) values for those with the 
common genotype vs. those with heterozygous/uncommon genotype. 
…………………………………………………………………………………………………………………………………………………………………………………………………………………….. 








9.3. Discussion.  
In this chapter I have investigated the effect of known variants in common vitamin D pathway genes 
on the risk of URI or disease exacerbation in patients with COPD. By main effects analysis these variants 
do not significantly associate with either outcome, independent of the effect of vitamin D 
supplementation. However, I did observe a signal of effect modification in haplotypes of 5 SNP in the 
vitamin D receptor gene (rs4334089; rs10783219; rs11568820; rs7976091; and rs7970314), the 
clearest of which was in participants positive for the assigned haplotype AACCA (98/226; 43.4%), in 
whom vitamin D supplementation conferred a 61% lower risk of URI as compared to those receiving 
placebo (aHR 0.39; 95% CI 0.23 to 0.67), but in individuals who were negative for AACCA, the 
intervention had no effect (aHR 1.32; 95% CI 0.83 to 2.09 – aRHR 0.31; 95% CI 0.16 to 0.62; P value for 
interaction = 0.001). 
 
Several findings relating to non-skeletal disease outcomes have been reported for some of the AACCA 
haplotype SNP, all of which share an inflammatory basis: rs11568820 and rs7976091 have been linked 
to risk of late-onset Alzheimer’s disease (357); rs11568820 has been found to associate with risk of 
gout (358); rs7970314 and rs4334089 have been reported to associate with risk of Parkinson’s disease 
(359, 360); finally, rs11568820 and rs7970314 have been linked to TNF-α levels post-rubella 
vaccination (350). Interestingly, I observed an association between AACCA haplotype and TNF-α 
concentration released from PBMCs stimulated by LPS and R848 (Table 9.7), though this was prior to 
correction for multiple comparison testing thus they may be due to type I error.  
 
Quantitative PCR did not reveal a significantly different mean concentration of VDR mRNA by genotype 
for our five VDR SNP of interest. This suggests these variants do not effect gene expression, which is 
supported by the lack of previous functional findings for the intronic SNP: rs7976091, rs4334089, 
rs10783219, or rs7970314. However, rs11568820 is a promoter region SNP located in the binding site 




experiments have been conducted which show the A allele confers 30% higher VDR promoter 
transcriptional activity, compared to the G allele (324). If one or more SNP within AACCA haplotype do 
have a causal effect on vitamin D supplementation in prevention of URI, rs11568820 would seem the 
most likely candidate, but considering the high degree of linkage between these and neighbouring 
variants it is not possible to say whether this is the causal allele, without conducting gene sequencing 
experiments.  
 
The immunological data presented in this chapter do suggest a mechanism by which variation in VDR 
may influence the effect of vitamin D supplementation on risk of URI. Prior to correction for multiple 
comparison testing, results for AACCA-positive individuals who received vitamin D supplementation 
display a trend for decreased release of G-CSF (granulocyte colony stimulating factor) and MIG 
(Monokine induced by γ-interferon/CXCL9) under stimulation from LPS, Pam2, Poly I:C, and R848 in 
response to supplementation. G-CSF is a growth factor which has been shown to stimulate a rise in 
monocyte, lymphocyte and neutrophil levels in peripheral blood (361), and has been linked to the 
exacerbation of inflammatory conditions in patients with rheumatoid arthritis (362, 363), whilst MIG 
is a chemoattractant chemokine which has been reported to increase T cell and monocyte recruitment 
to the lung of COPD and tuberculosis patients (364, 365). A common histopathological feature of COPD 
is elevated neutrophil levels that become further elevated in the face of microbial infection and can 
result in hyper-inflammatory airway conditions; tissue necrosis, degranulation and lung destruction 
(94), but a certain level of airway inflammation is required for an effective immune response, thus a 
reduction in pro-inflammatory leukocyte chemotaxis mediated by a vitamin D-driven reduction in the 
activation of inflammatory mediators may be responsible for the enhanced protection I have seen in 






9.3.1. Study strengths. 
To my knowledge, this is the first study to comprehensively investigate genetic variation in the vitamin 
D pathway on risk of upper respiratory infection and disease exacerbation in COPD patients 
participating in a clinical trial of vitamin D supplementation (210). The study population comprised 
patients with a wide range of disease severity, who were recruited from different hospital and 
community settings, making them generalisable to larger populations. The majority of participants 
were deficient at baseline and with intermittent bolus dosing a high level of compliance was achieved, 
which translated to a good level of repletion in the active arm. Participants were well characterised for 
possible environmental determinants of ARI, disease exacerbations, and vitamin D status, which 
allowed for comprehensive control of factors which might confound the association between genetic 
variation on the outcomes investigated. One final strength, was the use of multiplex ELISA and RT-
qPCR to elucidate a mechanism which may explain the findings of genetic association. 
 
9.3.2. Study Limitations. 
This study was not without limitation. The overall study population size was powered for the effect of 
intervention on clinical end-point in all-comers, rather than to detect a signal between genotype and 
COPD health outcomes, which likely affected the chance of detecting an association between SNP with 
small minor allele frequencies and COPD exacerbations the most as they were less frequent than URI, 
but type II error may have been an issue for the more common alleles and outcomes also. However, 
despite this limitation the investigation did highlight a strong signal between a group of VDR SNP and 
the effects of supplementation on risk of URI, which survived correction for multiple comparison 
testing, using a strict false discovery rate of 5%. Furthermore, it was only possible to carry out multiplex 
ELISA and RT-qPCR on a subset of participants, which gave me a relatively small window of observation 
into the relationship between AACCA haplotype and the effects of supplementation on URI risk. Also 
it may be that using peripheral blood samples for RT-qPCR was not informative as changes in VDR 





Current clinical trials of vitamin D supplementation in the prevention of URI and exacerbations of COPD 
(210, 272) have not demonstrated a protective effect from this intervention in their study populations 
as a whole. However, this analysis has identified a haplotype of 5 VDR SNP, possession of which 
associates with enhanced response to vitamin D supplementation and significantly reduced risk of 
upper respiratory infection. As URI are a major precipitant of life-threatening exacerbations for this 
disease that by 2010 had become the 3rd most common cause of death worldwide (366), I believe 
further investigation of this haplotype is warranted, specifically with a view to elucidating a causal 











10. Concluding remarks and future directions for research. 
 
My thesis has reviewed previous clinical studies which have investigated the potential of vitamin D as 
an intervention for prevention of ARI; it has investigated the environmental and genetic determinants 
of vitamin D status in 3 distinct study populations in whom ARI takes a high toll; it has investigated an 
association between vitamin D deficiency and the clinical features of asthma and COPD, including an 
investigation of the role of genetic variation; and finally, it has covered the effect of genetic variation 
on risk of ARI and disease exacerbations, which included an investigation of genetic effect modification 
of vitamin D supplementation. 
 
Does vitamin D offer protection against ARI? 
Chapter 2 presents a systematic review I conducted in the area of vitamin D supplementation in 
prevention of ARI, which covered clinical studies conducted up until late 2012. The overarching 
message was of a ‘disconnect’ that exists between observational studies which consistently report an 
inverse association between vitamin D metabolite concentrations and risk of ARI, and clinical trials 
which report highly conflicting outcomes – only half of the 14 published trials at that time reported 
protective effects from a vitamin D intervention. Since 2012, 13 new trials have been published and a 
further 2 have completed and are pending publication (these are presented in Table 10.1). ARI was the 
primary or co-primary outcome in 12 of the 13 published trials, while one investigated a measure of 
asthma treatment failure (300). Six trials report that vitamin D supplementation offers protection from 
ARI – 3 in the whole study population (367-369), 1 in a subgroup with profound vitamin D deficiency 
at baseline (370), one in only the low-dose intervention group (371), and one reports protection only 
at the mid-point of follow-up (372). One trial reports vitamin D supplementation offered protection 
from COPD exacerbations in a subgroup of profoundly deficient participants (210). Five trials report 
null effects of vitamin D supplementation on all respiratory outcomes investigated (209, 300, 373-375), 




of positive reports is comparable to the 14 clinical trials reviewed in Chapter 3 – vitamin D offers 
protection against ARI in roughly half of the studies. The possible cause of this heterogeneity is less 
obvious in these more recent trials however because their reports do not align with the major 
limitations which aligned with the null/negative outcomes in the previous trials i.e. inadequate dosing 
regimens to attain sustained repletion of serum 25(OH)D concentration in the intervention arm; 
possible type I or type II error from post-hoc analysis, or prospective analysis of ARI as secondary 
outcome; and small proportions of vitamin D deficient participants at baseline. Two trends do present 
themselves however: the majority of positive findings come from trials which administered a daily or 
weekly dosing regimen (6 of the 7 positive reports (367-372)), whilst only 1 of the 4 trials which 
administered a monthly bolus dosing regimen reported a positive finding, and this came from a pre-
specified analysis of those who were vitamin D deficient (<50 nmol/L) at baseline (210). This trend 
lends support to the theory that large intermittent bolus doses of vitamin D cause a sharp increase in 
metabolite concentrations which may trigger a strong negative feedback response with abnormally 
low 1α-hydroxylase activity and abnormally high 24-hydroxylase activity resulting in lowered extra-
renal 1,25(OH)2D concentrations (345). To add further credence to this observation, the preliminary 
results of our currently unpublished IPD meta-analysis - which includes data from all but one of the 
trials presented in Table 10.1 (300); the two as yet unpublished trials from Mezawa et al. and Ginde et 
al.; and 10 of the trials I review in Chapter 3 (268, 269, 271, 272, 274-276, 278-280) – also indicate a 
significant trial-level effect for protection from ARI in those who received a daily or weekly dosing 
regimen, but not those who received a monthly or two-monthly bolus dosing regimen. This is a finding 
that has been previously highlighted in the meta-analysis of some of these trials, albeit with limitations 
of possible publication bias and a large degree of study heterogeneity (376). Another trend which 
appears in the trials presented in Table 10.1, and those reviewed in Chapter 3, are signs of greater 
protection in deficient participants at baseline. Several studies have found no effect of intervention in 
the entire study group, but have reported protection in subgroups with baseline 25(OH)D levels <25 




setting that has very few dietary sources of vitamin D and is at a latitude that receives little effective 
UVR exposure to stimulate cutaneous vitamin D synthesis (377). As a result, their intervention arm had 
a median baseline 25(OH)D status of just 17.5 nmol/L, and they reported a large reduction in ARI rates 
(RR 0.50; 95% CI 0.28 – 0.88) from a modest dosing regimen (300 IU/day, for 7 weeks). More trials 
which report protection from administering effective dosing regimens to deficient study populations 
are needed before vitamin D can be said to be effective in preventing ARI, but conducting such trials 
are difficult owed to the ethical issue of randomising deficient participants to the placebo arm. At least 
one trial has registered to address this need (PRECOVID trial - NCT02122627). The group plans to give 
a 16,000 IU/week regimen to adult COPD patients with a 25(OH)D concentration between 15-50 
nmol/L. IPD meta-analysis of existing trials is the next best thing as it affords us greater statistical 
power when combining deficient participants across multiple trials. Our IPD meta-analysis supports 
previous findings: our preliminary analysis shows vitamin D offered a 44% reduction in risk of ARI in 
those with a baseline vitamin D status of <25 nmol/L (OR 0.56; 95% CI 0.41 to 0.77; P<0.001), compared 
to a non-significant effect in those with a baseline vitamin D status ≥25 nmol/L (OR 0.90; 0.76 to 1.05; 
P=0.17 – P value for interaction = 0.004).  
 
The determinants of vitamin D deficiency and features of asthma/COPD phenotype. 
Given that evidence from clinical studies highlights populations with serum 25(OH)D concentrations 
<50 nmol/L as a key target to receive daily dosing regimens of vitamin D for prevention of ARI, the 
characterisation of factors responsible for vitamin D deficiency in those which suffer the greatest 
consequences of ARI is all the more imperative. In Chapters Four, Five, and Six I identified a range of 
classical environmental factors - known to impact vitamin D status in healthy populations - which 
operate in our ‘at-risk’ study populations. Use of these findings could lead to a low-cost and highly 
effective method of correcting vitamin D deficiency in specific patient groups. If these findings are 
accurate, their impact on vitamin D status is significant. To use the asthma cohort as an example: an 




supplement, is unemployed, has not recently taken a sunny holiday abroad, and has a BMI of 25 kg/m2 
or more, would be expected to have a serum 25(OH)D concentration approximately 70 nmol/L lower 
than if they visited during summer and are taking a daily vitamin D supplement, have a professional 
occupation, had recently been on a sunny holiday abroad, and have a BMI less than 25 kg/m2. 
Considering the mean tested baseline 25(OH)D concentration in our study population of asthma 
patients was only 45.7 nmol/L, the potential impact of just 5 environmental factors could be enough 
to sway levels from profound deficiency to complete repletion, or vice versa. Future studies to replicate 
our findings could lead to the development of a cheap screening tool for vitamin D deficiency in 
asthma, COPD, or older adult patient groups, which could guide general practitioners in prescribing 
supplements of appropriate doses in a personalised fashion, and reduce the significant cost of blanket 
testing vitamin D levels.  
 
In contrast to the range of environmental factors which predict vitamin D status in our study, genetic 
factors show no strong association despite having been reported to do so in healthy populations; 
reaching GWAS level significance in some SNP (reviewed in (335)). The most obvious reason for my 
lack of significant findings is insufficient power to detect a signal due to our relatively small clinical trial 
cohorts which were powered to detect an effect of intervention on the study population. However, 
other studies have identified associations between vitamin D pathway SNP and 25(OH)D 
concentrations in similarly sized cohorts (130, 169, 378, 379), though they did only investigate several 
SNP and therefore any correction for multiple comparison testing they may have carried out would 
have had less of an impact than it did for my panel of SNP.  
 
My analysis did not find the associations between vitamin D status and clinical features of asthma 
phenotype that have been shown to operate in children with asthma (245, 291-294). The cohort 
comprised adults with relatively well controlled asthma compared to these participants, which may 




supplementation in children but not in adults. Previous trials which have investigated asthma 
exacerbation risk with vitamin D interventions have found a reduction in children (270, 299), but not 
in adults (209, 300), which would support the theory. My analysis did however highlight an association 
between vitamin D deficiency and increased COPD severity, determined by decreased spirometric 
volumes: % predicted FEV1 (ppFEV1) and % predicted FVC (ppFVC) (Tables 5.4 and 5.5). These findings 
have been reported previously (323-328), though questions of reverse causality and/or residual 
confounding have been suggested. My analysis controlled for a range of factors which may potentially 
confound the association between vitamin D status and ppFEV1/ppFVC, such as age, sex, BMI, SEP, and 
smoking status, which reduces the likelihood of this finding being due to residual confounding. That 
my analysis did not find a signal between genetic variants previously shown to associate with vitamin 
D status, or a signal to suggest the association between vitamin D status and ppFEV1/ppFVC are 
modified by genetic variants (Tables 5.12 and 5.13) would suggest that vitamin D deficiency does not 
cause reduced ppFEV1/ppFVC, however due the limitations of lacking power and/or the stringent 
statistical correction discussed above, I cannot exclude the possibility that genetic variants do predict 
vitamin D status in COPD patients and I simply failed to detect this signal. Further studies should be 
conducted to investigate the association between vitamin D deficiency and reduced spirometric 
volume in COPD patients, in a study population powered to detect the influence of genetic variation 
in vitamin D status and give conclusive results on the direction of effect. If we can establish that this it 
is forward causation, recommendations to use vitamin D supplementation to improve COPD severity 
can be made.  
 
The effect of genetic variation on efficacy of vitamin D supplementation. 
The major finding I present in this thesis is evidence of a haplotype of 5 VDR SNP which modify the 
effects of vitamin D supplementation on prevention of URI in COPD patients. Presence of the AACCA 
haplotype (Figure 9.4) independently associates with a 61% reduction in URI risk in intervention arm 




interaction = 0.001) (210). This finding was not replicated in the asthma and older adult trials, however. 
Given the level of significance of the finding in COPD patients, and that the 5 individual genetic variants, 
in high LD with each other, independently modified the effect of vitamin D supplementation after 
correction for multiple comparison testing, the likelihood of this being a chance finding is low. So why 
would this haplotype of SNP affect response to vitamin D supplementation in COPD patients, but not 
in asthma patients or older adults? Unlike results from COPD clinical trials (210, 272), trials in adults 
with asthma and older adults have not offered evidence that vitamin D supplementation is an effective 
intervention in prevention of ARI and/or exacerbations: two adult asthma trials report null results for 
protection against asthma treatment failure rates, risk of first URI, and risk of severe exacerbation 
(209, 300), whilst three older adult trials report null results for outcomes of self-reported ARI or 
antibiotic use, risk of hospital readmission due to LRI, and risk of first ARI (273) (267) (344). These trials 
do have limitations which might be responsible for their lack of positive findings (discussed in Chapters 
3, 7, and 8) thus null results from further trials which don’t suffer from the same limitations will be 
required to show these patient groups are non-responsive to the actions of vitamin D, and genetic 
variation in the vitamin D pathway is irrelevant to risk of ARI. 
 
Whilst my investigation of variation in genes along the vitamin D pathway did highlight a haplotype in 
VDR as an effect modifier of vitamin D supplementation, it did not offer a solid explanation of the 
mechanism by which this haplotype affects differential risk of URI in COPD patients. Several of the 
AACCA haplotype SNP have been found to associate with a range of inflammatory disease outcomes 
(discussed in Chapter 9), and one of them (rs11568820 [cdx2]) has been reported to be functional by 
affecting affinity of a binding site on VDR for the positive transcription factor protein, cdx2, making it 
the most likely causal variant. RT-qPCR failed to show a significant difference in VDR mRNA expression 
level in whole blood, though I was grossly under-powered to test this in my subset of 55 participants 
for whom samples were available. Positive immunological analysis results were also tempered by 




the intervention arm showed decreased release of pro-inflammatory mediators, G-CSF and 
MIG/CXCL9, in response to stimulation with TLR ligands, which hints towards a mechanism by which 
vitamin D supplementation in AACCA positive individuals might result in a dampening of the hyper-
inflammatory airway conditions seen in COPD patients, that lead to tissue necrosis, degranulation and 
lung destruction.  
 
Further work to validate the importance of AACCA haplotype in COPD patients, and elucidate the 
mechanism by which possession of these variants offer a drastic reduction in risk of URI, may lead to 




Table 10.1. Clinical trials of vitamin D supplementation in the prevention of ARI outcomes, conducted since spring, 2012. 
Author Bergman et al. (367) Rees et al. (373) Marchisio et al. (368) Tran et al. (374)  Grant et al. (371) Goodall et al. (369) Urashima et al. (372) Simpson et al. (370) 
Publication Year 2012 2013 2013 2013 2014 2014 2014 2015 
Location Sweden USA Italy Australia New Zealand Canada Japan Australia 
Journal BMJ Open Clin Infect Dis Pediatr Infect Dis J AJCN Acta Paediatrica BMC Infecious 
Diseases 
Food & Fnctn BMC Nut 




NCT01158560 UMIN000002532 ACTRN12612000054819 
Participants Adults with antibody 
deficiency or 
recurrent ARI 
Adults aged 45-75 
with baseline 
25(OH)D >12 ng/ml 
Children aged 1-5 yr 
with recurrent acute 
otitis media 
Healthy adults aged 
60-84 at recruitment, 
mean age 72 years 
Pregnant women and 
their offspring 
Healthy students, age 
17 and older at 
enrollment with at 
least 1 housemate 
High school students 
aged 15-18 years 
Healthy adults, mean 
age ~32yrs 
Participants (n) 140           
Intervention = 70      
Control = 70 
759                    
Intervention = 399    
Control = 360 
116              
Intervention = 58   
Control = 58 
644                 
Intervention = 430  
Control = 214 
260                 
Intervention = 173  
Control = 87 
600                           
Intervention = 300  
Control = 300 
247             
Intervention = 148  
Control = 99 
34                                              
Intervention = 18                                      
Control = 16 
Mean / median 25(OH)D, 
baseline (nmol/L) 
51.4 62.4  64.9 41.9 54.9 (maternal) not measured not measured 67.9  
Dose vit D Intervention (IU) 4,000 IU 1,000 IU +/- 1200 
mg calcium 





10,000 IU  2,000 IU 20,000 IU 
Study Duration 1 year 13 months average 6 months 12 months 18 months 8 weeks 2 months 17 weeks 
Frequency vit D 
Intervention 
daily daily daily monthly daily weekly daily weekly 
Attained mean 25(OH)D 
(nmol/L) 
Intervention = 133.2 
Control = 66.6 
Intervention = 83.1 
Control = 62.6 
Intervention = 91.9  
Control = 46.7 
Intervention = 70.9 
Control = 41.9 
Intervention = ~92 
Control = ~77 
(at 6 months) 
not measured not measured Intervention = 76.4 
Control = 60.4 
Type of Randomisation  individual individual / 2x2 
Factorial  
individual individual individual individual / 2x2 
Factorial  
individual individual 
Investigated Outcome ARI URI Acute otitis media 
(AOM) 
URI ARI URI (primary) and lab 
confirmed URI 
(secondary) 
Influenza A ARI 
Major Finding(s) Reduced infectious 
score in vit D arm 
(202 points vs. 249 
points in control arm) 
adjusted relative 
score 0.77 (95% CI 
0.60 – 0.99, P=0.04) 
No significant 
difference in winter 
URI rate (RR 0.93; 
95% CI 0.79 – 1.09); 
colds rate (RR 0.93; 
95% CI 0.78 – 1.10); 
or ILI (RR 0.95; 95% 
CI 0.62 – 1.46) 
between arms 
Reduced number 
experiencing ≥1 AOM 
in intervention vs. 
control group (26 vs. 
38; P=0.03) 
No significant 
difference in number 
of prescribed 
antibiotics for ARI 
between arms (RR 
0.72; 95% CI 0.48 – 
1.07) 
Significant reduction 
in  proportion of ARI 
visits for high dose 
group vs. placebo 
(84% vs. 99%, 
P=0.004); non-
significant reduction 
for low dose group vs. 
placebo (95% vs. 99%, 
P=0.17) 
Significant reduction 
in lab confirmed URI 
in intervention arm 
(RR 0.54; 95% CI 0.34 
– 0.84; P=0.007) No 
significant difference 
in reported URI 
between intervention 








in influenza A in 
intervention arm 
after 1 month in post-
hoc analysis (RR 0.17; 
95% CI 0.04 – 0.77; 
P=0.009)  
No significant 
difference in risk of ARI 
between intervention 
and control groups (HR 
0.83; 95% CI 0.53 – 
1.31); significant 
reduction in risk in 
subgroup analysis of 
those vit D deficient at 
baseline (HR 0.27; 95% 


















Author Dubnov-Raz et al. (375) Martineau et al. 
(209) 
Martineau et al. 
(210) 
Martineau et al. 
(313) 
Castro et al. (300) Mezawa et al. Ginde et al. 
Publication Year 2015 2015 2015 2015 2015 unpublished unpublished 
Location NR UK UK UK USA Japan USA 
Journal Pediatr Exerc Sci Thorax Lancet Resp Thorax Am J Respir Crit Care 
Med 
-- -- 
Trial Registration ID NCT01158560 NCT00978315 NCT00977873 NCT01069874 NCT01248065 UMIN000004161 NCT01102374 
Participants Adolescent swimmers Adults with asthma Adults with COPD Older adults and 
their carers 
Adults with asthma 
and 25(OH)D < 75 
nmol/L 
Children with 




home or assisted 
living) age >=60 
years 
Participants (n) 55                                                        
Intervention = 27                                    
Control = 27 
250     
Intervention = 125   
Control = 125 
240           
Intervention = 122    
Control = 118 
240           
Intervention = 137    
Control = 103 
408 
Intervention = 201 
Control = 207 
89                         
Intervention = 54 
Control = 35 
107              
Intervention = 55 
Control = 52 
Mean / median 25(OH)D, 
baseline (nmol/L) 
60.4 50.4 45.7 42.4 47.2 71.8  57.4 
Dose vit D Intervention (IU) 2,000 IU/day 6 x 120,000 IU 
boluses  
6 x 120,000 IU 
boluses 
6 x 120,000 IU 
boluses  
10,000 IU loading 
dose; 4,000 IU/day 
800 IU 100,000 IU 
Study Duration 12 weeks 1 year 1 year 1 year 6 months 2 months 12 months 
Frequency vit D 
Intervention 
daily 2 monthly 2 monthly 2 monthly daily daily monthly 
Attained mean 25(OH)D 
(nmol/L) 
Intervention = 73.9 
Control = 50.7 
Intervention = 70.4 
Control = 46.4 
Intervention = 67.4 
Control = 47.1 
Intervention = 85.3 
Control = 59.1 
Intervention = 104.3 
Control = 49.9  
(at 28 weeks) 
Intervention = 87.4 
Control = 70.1 
-- 
Type of Randomisation  individual individual individual cluster individual individual individual 
Investigated Outcome URI URI and asthma 
exacerbation 
URI and COPD 
exacerbation 





Major Finding(s) No significant 
difference between 
frequency, severity, or 
duration of URI 
between intervention 
and control groups.  
No significant 
difference in time to 
first severe 
exacerbation (aHR 
1.02; 95% CI 0.69 – 
1.53; P=0.91) or first 
URI (aHR 0.87; 95% CI 
0.64 – 1.16; P=0.34) 
between study arms. 
No significant 
difference in time to 
first exacerbation 
(aHR 0.86; 95% CI 
0.60 – 1.24; P=0.42) 
or URI (aHR 0.95; 95% 
CI 0.69 – 1.31; 
P=0.75) between 
arms; significant 
difference in time to 
first exacerbation in 
those vit D deficient 
at baseline (aHR 0.57; 
95% CI 0.35 – 0.92, 
P=0.021) 
No significant 
difference in time 
to first ARI between 
arms (aHR 1.18; 
95% CI 0.80 – 1.74; 
P=0.42); 
significantly greater 
risk of URI (aHR 
1.48; 95% CI 1.02 – 
2.16; P=0.039) and 
duration of URI 
symptoms (7 vs 5 




difference in asthma 
treatment failure rate 
between study arms 
(aHR 0.90; 95% CI 
0.60 – 1.30) 
-- -- 






1. Denny FW, Jr. The clinical impact of human respiratory virus infections. American Journal of 
Respiratory and Critical Care Medicine. 1995;152(4 Pt 2):S4-12. 
2. Baron S, Peake RC, Schuenke S. Medical microbiology. 4th ed / associate editor Rhonda C. 
Peake / scientific illustrator Steve Schuenke. ed. Galveston, Tex.: University of Texas Medical Branch 
at Galveston; 1996. 
3. Korppi M. Mixed microbial aetiology of community-acquired pneumonia in children. APMIS : 
Acta Pathologica, Microbiologica, et Immunologica Scandinavica. 2002;110(7-8):515-22. 
4. Whitley RJ, Monto AS. Seasonal and pandemic influenza preparedness: a global threat. The 
Journal of Infectious Diseases. 2006;194 Suppl 2:S65-9. 
5. Fishman AP, Elias JA. Fishman's pulmonary diseases and disorders. 4th ed. / co-editors, Jack 
A. Elias ... [et al.]. ed. New York ; London: McGraw-Hill Medical; 2008. 
6. Smith SM, Fahey T, Smucny J, Becker LA. Antibiotics for acute bronchitis. The Cochrane 
Database of Systematic Reviews. 2014;3:CD000245. 
7. Marguet C, Lubrano M, Gueudin M, Le Roux P, Deschildre A, Forget C, et al. In very young 
infants severity of acute bronchiolitis depends on carried viruses. PLoS One. 2009;4(2):e4596. 
8. WHO. Pneumonia : Fact sheet N°331 Updated November 2014 [Available from: 
http://www.who.int/mediacentre/factsheets/fs331/en/. 
9. Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J. Etiology of community-
acquired pneumonia: increased microbiological yield with new diagnostic methods. Clinical Infectious 
Diseases. 2010;50(2):202-9. 
10. Smith JA, Kauffman CA. Pulmonary fungal infections. Respirology. 2012;17(6):913-26. 
11. Richardson MD. Changing patterns and trends in systemic fungal infections. The Journal of 
Antimicrobial Chemotherapy. 2005;56 Suppl 1:i5-i11. 
12. Bowers RM, Sullivan AP, Costello EK, Collett JL, Jr., Knight R, Fierer N. Sources of bacteria in 
outdoor air across cities in the midwestern United States. Applied and Environmental Microbiology. 
2011;77(18):6350-6. 
13. Finlay BB, McFadden G. Anti-immunology: evasion of the host immune system by bacterial 
and viral pathogens. Cell. 2006;124(4):767-82. 
14. Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus 
pathogenesis. Journal of Virology. 2008;82(5):2040-55. 
15. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. Respiratory syncytial virus infection 
of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious 
cytopathology. Journal of Virology. 2002;76(11):5654-66. 
16. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, et al. Pattern recognition 
receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nature Immunology. 
2000;1(5):398-401. 
17. Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: 
balancing virus clearance and immunopathology. Seminars in Immunopathology. 2016. 
18. Mortality GBD, Causes of Death C. Global, regional, and national age-sex specific all-cause 
and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global 
Burden of Disease Study 2013. Lancet. 2014. 
19. NICE. Respiratory tract infections – antibiotic prescribing: Prescribing of antibiotics for self-
limiting respiratory tract infections in adults and children in primary care (Clinical Guideline 69) 2008 
[Available from: http://www.nice.org.uk/guidance/cg69  
20. Davey PG, Bax RP, Newey J, Reeves D, Rutherford D, Slack R, et al. Growth in the use of 
antibiotics in the community in England and Scotland in 1980-93. BMJ. 1996;312(7031):613. 
21. F T. Presentation d'une methodologie permettant de mesurer en quantite et de comparer les 




22. Fleming DM, Ross AM, Cross KW, Kendall H. The reducing incidence of respiratory tract 
infection and its relation to antibiotic prescribing. British Journal of General Practice. 
2003;53(495):778-83. 
23. Gulliford MC, Dregan A, Moore MV, Ashworth M, Staa T, McCann G, et al. Continued high 
rates of antibiotic prescribing to adults with respiratory tract infection: survey of 568 UK general 
practices. BMJ open. 2014;4(10):e006245. 
24. Lindbaek M. Prescribing antibiotics to patients with acute cough and otitis media. British 
Journal of General Practice. 2006;56(524):164-6. 
25. Office for National Statistics: 131 million working days lost to sickness in 2011 - but it’s falling 
2012 [Available from: http://www.ons.gov.uk/ons/rel/mro/news-release/131-million-working-days-
lost-to-sickness-in-2011---but-it-s-falling/sanr0512.html. 
26. Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute respiratory 
infections in the United States. Clinical Infectious Diseases. 2001;33(6):757-62. 
27. Adams PF, Hendershot GE, Marano MA, Centers for Disease C, Prevention/National Center 
for Health S. Current estimates from the National Health Interview Survey, 1996. Vital and health 
statistics Series 10, Data from the National Health Survey. 1999(200):1-203. 
28. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clinical 
Infectious Diseases. 1992;15(1):77-83. 
29. Adam D. Global antibiotic resistance in Streptococcus pneumoniae. The Journal of 
Antimicrobial Chemotherapy. 2002;50 Suppl:1-5. 
30. Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance among Streptococcus 
pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Annals of Clinical Microbiology 
and Antimicrobials. 2008;7:1. 
31. Linares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes and 
genotypes in Streptococcus pneumoniae over a 30-year period. Clinical Microbiology and Infection. 
2010;16(5):402-10. 
32. Currie CJ, Berni E, Jenkins-Jones S, Poole CD, Ouwens M, Driessen S, et al. Antibiotic 
treatment failure in four common infections in UK primary care 1991-2012: longitudinal analysis. 
BMJ. 2014;349:g5493. 
33. Bryce J, Boschi-Pinto C, Shibuya K, Black RE, Group WHOCHER. WHO estimates of the causes 
of death in children. Lancet. 2005;365(9465):1147-52. 
34. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease 
caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 
2009;374(9693):893-902. 
35. Sasaki S, Sullivan M, Narvaez CF, Holmes TH, Furman D, Zheng N-Y, et al. Limited efficacy of 
inactivated influenza vaccine in elderly individuals is associated with decreased production of 
vaccine-specific antibodies. Journal of Clinical Investigation. 2011;121(8):3109-19. 
36. Vila-Corcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodriguez T, et al. Protective 
effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 
study. Clinical Infectious Diseases. 2006;43(7):860-8. 
37. Valenzuela MT, Altuzarra RH, Trucco OA, Villegas RR, Inostroza JS, Granata PS, et al. 
Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in elderly residents of a long-
term care facility. The Brazilian journal of infectious diseases : an official publication of the Brazilian 
Society of Infectious Diseases. 2007;11(3):322-6. 
38. Commission E. Health statistics. Atlas on mortality in the European Union. Luxembourg: 
Office for Official Publications of the European Communities,. 2008. 
39. Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and 
prevention. Journal of Allergy and Clinical Immunology. 2011;128(6):1165-74. 
40. Bousquet J, Khaltaev NG. Global surveillance, prevention and control of chronic respiratory 
diseases : a comprehensive approach. Geneva: World Health Organization; 2007. 





42. UK A. Where Do We Stand? : Asthma in the UK today 2004 [Available from: available from: 
http://www.asmabronquica.com.br/medical/wheredowestand%5B1%5D.pdf?id=92. 
43. WHO. Chronic obstructive pulmonary disease (COPD): Fact sheet N°315 Updated January 
2015 [Available from: http://www.who.int/mediacentre/factsheets/fs315/en/. 
44. Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical 
and absenteeism costs of COPD among adults aged >/= 18 years in the United States for 2010 and 
projections through 2020. Chest. 2015;147(1):31-45. 
45. Wedzicha JA. Role of viruses in exacerbations of chronic obstructive pulmonary disease. 
Proceedings of the American Thoracic Society. 2004;1(2):115-20. 
46. Rajakumar K. Vitamin D, cod-liver oil, sunlight, and rickets: a historical perspective. 
Pediatrics. 2003;112(2):e132-5. 
47. MuCollum EV DM. Observations on the isolation of the substance in butter fat which exerts a 
stimulating effect on growth. The Journal of Biological Chemistry. 1914;19:245-50. 
48. McCollum EV SN, Becker JE, Shipley PG. Studies on experimental rickets. XXI. An 
experimental demonstration of the existence of a vitamin which promotes calcium deposition. The 
Journal of Biological Chemistry. 1922(53):293-312. 
49. Holick MF. Vitamin D deficiency. The New England Journal of Medicine. 2007;357(3):266-81. 
50. Holick MF. The cutaneous photosynthesis of previtamin D3: a unique photoendocrine 
system. Journal of Investigative Dermatology. 1981;77(1):51-8. 
51. Woodward R.B HR. Stereochemistry of Electrocyclic Reactions. Journal of the American 
Chemical Society. 1965;2(87):395–7. 
52. Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW. Genetic evidence that the human 
CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proceedings of the National Academy of Sciences 
of the United States. 2004;101(20):7711-5. 
53. Gupta RP, He YA, Patrick KS, Halpert JR, Bell NH. CYP3A4 is a vitamin D-24- and 25-
hydroxylase: analysis of structure function by site-directed mutagenesis. The Journal of Clinical 
Endocrinology and Metabolism. 2005;90(2):1210-9. 
54. Jones G. Pharmacokinetics of vitamin D toxicity. The American Journal of Clinical Nutrition. 
2008;88(2):582S-6S. 
55. DeLuca HF. Overview of general physiologic features and functions of vitamin D. The 
American Journal of Clinical Nutrition. 2004;80(6 Suppl):1689S-96S. 
56. Murayama A, Takeyama K, Kitanaka S, Kodera Y, Hosoya T, Kato S. The promoter of the 
human 25-hydroxyvitamin D3 1 alpha-hydroxylase gene confers positive and negative responsiveness 
to PTH, calcitonin, and 1 alpha,25(OH)2D3. Biochemical and Biophysical Research Communications. 
1998;249(1):11-6. 
57. Kong XF, Zhu XH, Pei YL, Jackson DM, Holick MF. Molecular cloning, characterization, and 
promoter analysis of the human 25-hydroxyvitamin D3-1alpha-hydroxylase gene. Proceedings of the 
National Academy of Sciences of the United States. 1999;96(12):6988-93. 
58. Omdahl JL, Morris HA, May BK. Hydroxylase enzymes of the vitamin D pathway: expression, 
function, and regulation. Annual Review of Nutrition. 2002;22:139-66. 
59. Allen SH, Shah JH. Calcinosis and metastatic calcification due to vitamin D intoxication. A case 
report and review. Hormone Research. 1992;37(1-2):68-77. 
60. Marins TA, Galvao Tde F, Korkes F, Malerbi DA, Ganc AJ, Korn D, et al. Vitamin D intoxication: 
case report. Einstein (Sao Paulo). 2014;12(2):242-4. 
61. Koul PA, Ahmad SH, Ahmad F, Jan RA, Shah SU, Khan UH. Vitamin d toxicity in adults: a case 
series from an area with endemic hypovitaminosis d. Oman Medical Journal. 2011;26(3):201-4. 
62. Maji D. Vitamin D toxicity. Indian Journal of Endocrinology and Metabolism. 2012;16(2):295-
6. 
63. Vieth R. The mechanisms of vitamin D toxicity. Journal of Bone and Mineral Research. 
1990;11(3):267-72. 
64. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. The 




65. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on 
dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians 
need to know. The Journal of Clinical Endocrinology and Metabolism. 2011;96(1):53-8. 
66. Grzybowski A, Pietrzak K. From patient to discoverer--Niels Ryberg Finsen (1860-1904) --the 
founder of phototherapy in dermatology. Clinics in Dermatology. 2012;30(4):451-5. 
67. Hope-Simpson RE. The role of season in the epidemiology of influenza. The Journal of 
hygiene. 1981;86(1):35-47. 
68. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) 
gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-
dihydroxyvitamin D3. FASEB JOURNAL. 2005;19(9):1067-77. 
69. Komatsuzawa H, Ouhara K, Yamada S, Fujiwara T, Sayama K, Hashimoto K, et al. Innate 
defences against methicillin-resistant Staphylococcus aureus (MRSA) infection. The Journal of 
Pathology. 2006;208(2):249-60. 
70. Klotman ME, Chang TL. Defensins in innate antiviral immunity. Nature Reviews Immunology. 
2006;6(6):447-56. 
71. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting edge: 1,25-
dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. The Journal of 
Immunology. 2004;173(5):2909-12. 
72. Cohen MS, Mesler DE, Snipes RG, Gray TK. 1,25-Dihydroxyvitamin D3 activates secretion of 
hydrogen peroxide by human monocytes. The Journal of Immunology. 1986;136(3):1049-53. 
73. Rockett KA, Brookes R, Udalova I, Vidal V, Hill AV, Kwiatkowski D. 1,25-Dihydroxyvitamin D3 
induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human 
macrophage-like cell line. Infection and Immunity. 1998;66(11):5314-21. 
74. Sly LM, Lopez M, Nauseef WM, Reiner NE. 1alpha,25-Dihydroxyvitamin D3-induced 
monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by 
the NADPH-dependent phagocyte oxidase. The Journal of Biological Chemistry. 2001;276(38):35482-
93. 
75. Nijnik A, Hancock RE. The roles of cathelicidin LL-37 in immune defences and novel clinical 
applications. Current Opinion in Hematology. 2009;16(1):41-7. 
76. Clairmont A, Tessman D, Stock A, Nicolai S, Stahl W, Sies H. Induction of gap junctional 
intercellular communication by vitamin D in human skin fibroblasts is dependent on the nuclear 
Induction of gap junctional intercellular communication by vitamin D in human skin fibroblasts is 
dependent on the nuclear vitamin D receptor. Carcinogenesis. 1996;17(6):1389-91. 
77. Gniadecki R, Gajkowska B, Hansen M. 1,25-dihydroxyvitamin D3 stimulates the assembly of 
adherens junctions in keratinocytes: involvement of protein kinase C. Endocrinology. 
1997;138(6):2241-8. 
78. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, et al. Vitamin D(3) 
promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the 
inhibition of beta-catenin signaling. The Journal of Cell Biology. 2001;154(2):369-87. 
79. Piemonti L, Monti P, Sironi M, Fraticelli P, Leone BE, Dal Cin E, et al. Vitamin D3 affects 
differentiation, maturation, and function of human monocyte-derived dendritic cells. The Journal of 
Immunology. 2000;164(9):4443-51. 
80. Szeles L, Keresztes G, Torocsik D, Balajthy Z, Krenacs L, Poliska S, et al. 1,25-dihydroxyvitamin 
D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell 
phenotype. The Journal of Immunology. 2009;182(4):2074-83. 
81. Kushwah R, Hu J. Role of dendritic cells in the induction of regulatory T cells. Cell & 
Bioscience. 2011;1(1):20. 
82. von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odum N, Geisler C. Vitamin D controls T 
cell antigen receptor signaling and activation of human T cells. Nature immunology. 2010;11(4):344-
9. 
83. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts.The 




84. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D 
supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, 
randomized, placebo-controlled trial. The American Journal of Clinical Nutrition. 2006;83(4):754-9. 
85. Corberand J, Ngyen F, Laharrague P, Fontanilles AM, Gleyzes B, Gyrard E, et al. 
Polymorphonuclear functions and aging in humans. Journal of the American Geriatrics Society. 
1981;29(9):391-7. 
86. Davila DR, Edwards CK, 3rd, Arkins S, Simon J, Kelley KW. Interferon-gamma-induced priming 
for secretion of superoxide anion and tumor necrosis factor-alpha declines in macrophages from 
aged rats. FASEB Journal. 1990;4(11):2906-11. 
87. Ding A, Hwang S, Schwab R. Effect of aging on murine macrophages. Diminished response to 
IFN-gamma for enhanced oxidative metabolism. The Journal of Immunology. 1994;153(5):2146-52. 
88. Fu YK, Arkins S, Li YM, Dantzer R, Kelley KW. Reduction in superoxide anion secretion and 
bactericidal activity of neutrophils from aged rats: reversal by the combination of gamma interferon 
and growth hormone. Infection and Immunity. 1994;62(1):1-8. 
89. Lu Q, Ceddia MA, Price EA, Ye SM, Woods JA. Chronic exercise increases macrophage-
mediated tumor cytolysis in young and old mice. Am J Physiol. 1999;276(2 Pt 2):R482-9. 
90. Gomez CR, Nomellini V, Faunce DE, Kovacs EJ. Innate immunity and aging. Experimental 
Gerontology. 2008;43(8):718-28. 
91. Fortin CF, Lesur O, Fulop T, Jr. Effects of aging on triggering receptor expressed on myeloid 
cells (TREM)-1-induced PMN functions. FEBS Letters. 2007;581(6):1173-8. 
92. Fulop T, Larbi A, Douziech N, Fortin C, Guerard KP, Lesur O, et al. Signal transduction and 
functional changes in neutrophils with aging. Aging Cell. 2004;3(4):217-26. 
93. Plowden J, Renshaw-Hoelscher M, Engleman C, Katz J, Sambhara S. Innate immunity in aging: 
impact on macrophage function. Aging Cell. 2004;3(4):161-7. 
94. Franceschi C. Inflammaging as a major characteristic of old people: can it be prevented or 
cured? Nutrition Reviews. 2007;65(12 Pt 2):S173-6. 
95. Plackett TP, Boehmer ED, Faunce DE, Kovacs EJ. Aging and innate immune cells. Journal of 
Leukocyte Biology. 2004;76(2):291-9. 
96. Nel AE, Slaughter N. T-cell activation through the antigen receptor. Part 2: role of signaling 
cascades in T-cell differentiation, anergy, immune senescence, and development of immunotherapy. 
Journal of Allergy and Clinical Immunology. 2002;109(6):901-15. 
97. Larbi A, Dupuis G, Khalil A, Douziech N, Fortin C, Fulop T, Jr. Differential role of lipid rafts in 
the functions of CD4+ and CD8+ human T lymphocytes with aging. Cell Signal. 2006;18(7):1017-30. 
98. Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. 
Nature immunology. 2004;5(2):133-9. 
99. Allman D, Miller JP. B cell development and receptor diversity during aging. Current Opinion 
in Immunology. 2005;17(5):463-7. 
100. Pawelec G, Akbar A, Caruso C, Solana R, Grubeck-Loebenstein B, Wikby A. Human 
immunosenescence: is it infectious? Immunological Reviews. 2005;205:257-68. 
101. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: 
a quantitative review. Vaccine. 2006;24(8):1159-69. 
102. Barnes PJ. Th2 cytokines and asthma: an introduction. Respiratory Research. 2001;2(2):64-5. 
103. Wills-Karp M, Santeliz J, Karp CL. The germless theory of allergic disease: revisiting the 
hygiene hypothesis. Nature Reviews Immunology. 2001;1(1):69-75. 
104. Vasiliou JE, Lui S, Walker SA, Chohan V, Xystrakis E, Bush A, et al. Vitamin D deficiency 
induces Th2 skewing and eosinophilia in neonatal allergic airways disease. Allergy. 2014;69(10):1380-
9. 
105. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of 
T cell-mediated tissue damage. Nature Medicine. 2007;13(2):139-45. 
106. Cosmi L, Liotta F, Maggi E, Romagnani S, Annunziato F. Th17 cells: new players in asthma 




107. Hamzaoui A, Berraies A, Hamdi B, Kaabachi W, Ammar J, Hamzaoui K. Vitamin D reduces the 
differentiation and expansion of Th17 cells in young asthmatic children. Immunobiology. 
2014;219(11):873-9. 
108. Hoenderdos K, Condliffe A. The neutrophil in chronic obstructive pulmonary disease. 
American Journal of Respiratory Cell and Molecular Biology. 2013;48(5):531-9. 
109. Hiemstra PS. Altered macrophage function in chronic obstructive pulmonary disease. Annals 
of the American Thoracic Society. 2013;10 Suppl:S180-5. 
110. Yoshikawa T, Dent G, Ward J, Angco G, Nong G, Nomura N, et al. Impaired neutrophil 
chemotaxis in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical 
Care Medicine. 2007;175(5):473-9. 
111. Rytila P, Plataki M, Bucchieri F, Uddin M, Nong G, Kinnula VL, et al. Airway neutrophilia in 
COPD is not associated with increased neutrophil survival. The European Respiratory Journal. 
2006;28(6):1163-9. 
112. Sajjan US. Susceptibility to viral infections in chronic obstructive pulmonary disease: role of 
epithelial cells. Current Opinion in Pulmonary Medicine. 2013;19(2):125-32. 
113. Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. Respiratory 
epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. The 
Journal of Immunology. 2008;181(10):7090-9. 
114. Monkawa T, Yoshida T, Hayashi M, Saruta T. Identification of 25-hydroxyvitamin D3 1alpha-
hydroxylase gene expression in macrophages. Kidney International. 2000;58(2):559-68. 
115. Takahashi K, Nakayama Y, Horiuchi H, Ohta T, Komoriya K, Ohmori H, et al. Human 
neutrophils express messenger RNA of vitamin D receptor and respond to 1alpha,25-
dihydroxyvitamin D3. Immunopharmacology and Immunotoxicology. 2002;24(3):335-47. 
116. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a 
vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770-3. 
117. Zou L, Porter TD. Rapid suppression of 7-dehydrocholesterol reductase activity in 
keratinocytes by vitamin D. The Journal of Steroid Biochemistry and Molecular Biology. 2015;148:64-
71. 
118. Witsch-Baumgartner M, Ciara E, Loffler J, Menzel HJ, Seedorf U, Burn J, et al. Frequency 
gradients of DHCR7 mutations in patients with Smith-Lemli-Opitz syndrome in Europe: evidence for 
different origins of common mutations. European Journal of Human Genetics : EJHG. 2001;9(1):45-
50. 
119. Salen G, Shefer S, Batta AK, Tint GS, Xu G, Honda A, et al. Abnormal cholesterol biosynthesis 
in the Smith-Lemli-Opitz syndrome. Journal of Lipid Research. 1996;37(6):1169-80. 
120. Ryan AK, Bartlett K, Clayton P, Eaton S, Mills L, Donnai D, et al. Smith-Lemli-Opitz syndrome: 
a variable clinical and biochemical phenotype. Journal of Medical Genetics. 1998;35(7):558-65. 
121. Cunniff C, Kratz LE, Moser A, Natowicz MR, Kelley RI. Clinical and biochemical spectrum of 
patients with RSH/Smith-Lemli-Opitz syndrome and abnormal cholesterol metabolism. American 
Journal of Medical Genetics. 1997;68(3):263-9. 
122. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, et al. Common genetic 
determinants of vitamin D insufficiency: a genome-wide association study. Lancet. 
2010;376(9736):180-8. 
123. Grunhage F, Hochrath K, Krawczyk M, Hoblinger A, Obermayer-Pietsch B, Geisel J, et al. 
Common genetic variation in vitamin D metabolism is associated with liver stiffness. Hepatology. 
2012;56(5):1883-91. 
124. Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, et al. Genome-
wide association study of circulating vitamin D levels. Human Molecular Genetics. 2010;19(13):2739-
45. 
125. Kuan V, Martineau AR, Griffiths CJ, Hypponen E, Walton R. DHCR7 mutations linked to higher 





126. Cheng JB, Motola DL, Mangelsdorf DJ, Russell DW. De-orphanization of cytochrome P450 
2R1: a microsomal vitamin D 25-hydroxilase. The Journal of Biological Chemistry. 
2003;278(39):38084-93. 
127. Gupta RP, Hollis BW, Patel SB, Patrick KS, Bell NH. CYP3A4 is a human microsomal vitamin D 
25-hydroxylase. Journal of Bone and Mineral Research. 2004;19(4):680-8. 
128. Yamasaki T, Izumi S, Ide H, Ohyama Y. Identification of a novel rat microsomal vitamin D3 25-
hydroxylase. The Journal of Biological Chemistry. 2004;279(22):22848-56. 
129. Ramos-Lopez E, Bruck P, Jansen T, Herwig J, Badenhoop K. CYP2R1 (vitamin D 25-
hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in 
Germans. Diabetes/Metabolism Research and Reviews. 2007;23(8):631-6. 
130. Pillai DK, Iqbal SF, Benton AS, Lerner J, Wiles A, Foerster M, et al. Associations between 
genetic variants in vitamin D metabolism and asthma characteristics in young African Americans: a 
pilot study. Journal of Investigative Medicine. 2011;59(6):938-46. 
131. Wjst M, Altmuller J, Faus-Kessler T, Braig C, Bahnweg M, Andre E. Asthma families show 
transmission disequilibrium of gene variants in the vitamin D metabolism and signalling pathway. 
Respiratory Research. 2006;7:60. 
132. Barchetta I, Carotti S, Labbadia G, Gentilucci UV, Muda AO, Angelico F, et al. Liver vitamin D 
receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in 
patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology. 2012;56(6):2180-7. 
133. Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermehren J, et al. Vitamin 
D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C 
and poor response to interferon-alfa based therapy. Hepatology. 2011;54(5):887-93. 
134. Garcia-Alvarez M, Pineda-Tenor D, Jimenez-Sousa MA, Fernandez-Rodriguez A, Guzman-
Fulgencio M, Resino S. Relationship of vitamin D status with advanced liver fibrosis and response to 
hepatitis C virus therapy: a meta-analysis. Hepatology. 2014;60(5):1541-50. 
135. Nie S, Chen G, Cao X, Zhang Y. Cerebrotendinous xanthomatosis: a comprehensive review of 
pathogenesis, clinical manifestations, diagnosis, and management. Orphanet Journal of Rare 
Diseases. 2014;9(1):179. 
136. Appelbaum PC, Bhamjee A, Scragg JN, Hallett AF, Bowen AJ, Cooper RC. Streptococcus 
pneumoniae resistant to penicillin and chloramphenicol. Lancet. 1977;2(8046):995-7. 
137. Repa JJ, Lund EG, Horton JD, Leitersdorf E, Russell DW, Dietschy JM, et al. Disruption of the 
sterol 27-hydroxylase gene in mice results in hepatomegaly and hypertriglyceridemia. Reversal by 
cholic acid feeding. The Journal of Biological Chemistry. 2000;275(50):39685-92. 
138. Kliewer SA. The nuclear pregnane X receptor regulates xenobiotic detoxification. Journal of 
Nutrition. 2003;133(7 Suppl):2444S-7S. 
139. Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ. Expression of CYP3A4, CYP2B6, and 
CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. The Journal 
of Biological Chemistry. 2002;277(28):25125-32. 
140. Xu Y, Iwanaga K, Zhou C, Cheesman MJ, Farin F, Thummel KE. Selective induction of intestinal 
CYP3A23 by 1alpha,25-dihydroxyvitamin D3 in rats. Biochemical Pharmacology. 2006;72(3):385-92. 
141. Khan AA, Dragt BS, Porte RJ, Groothuis GM. Regulation of VDR expression in rat and human 
intestine and liver--consequences for CYP3A expression. Toxicology in vitro : an international journal 
published in association with BIBRA. 2010;24(3):822-9. 
142. Thummel KE, Brimer C, Yasuda K, Thottassery J, Senn T, Lin Y, et al. Transcriptional control of 
intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Molecular Pharmacology. 
2001;60(6):1399-406. 
143. Thompson PD, Jurutka PW, Whitfield GK, Myskowski SM, Eichhorst KR, Dominguez CE, et al. 
Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D 
responsive elements. Biochemical and Biophysical Research Communications. 2002;299(5):730-8. 
144. Pavek P, Pospechova K, Svecova L, Syrova Z, Stejskalova L, Blazkova J, et al. Intestinal cell-





145. Xu Y, Hashizume T, Shuhart MC, Davis CL, Nelson WL, Sakaki T, et al. Intestinal and hepatic 
CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced 
osteomalacia. Molecular Pharmacology. 2006;69(1):56-65. 
146. Fraser DR, Kodicek E. Unique biosynthesis by kidney of a biological active vitamin D 
metabolite. Nature. 1970;228(5273):764-6. 
147. Kreutz M, Andreesen R, Krause SW, Szabo A, Ritz E, Reichel H. 1,25-dihydroxyvitamin D3 
production and vitamin D3 receptor expression are developmentally regulated during differentiation 
of human monocytes into macrophages. Blood. 1993;82(4):1300-7. 
148. Adams JS, Gacad MA, Singer FR, Sharma OP. Production of 1,25-dihydroxyvitamin D3 by 
pulmonary alveolar macrophages from patients with sarcoidosis. Annals of the New York Academy of 
Sciences. 1986;465:587-94. 
149. Sigmundsdottir H, Pan J, Debes GF, Alt C, Habtezion A, Soler D, et al. DCs metabolize sunlight-
induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nature 
immunology. 2007;8(3):285-93. 
150. Lopez ER, Zwermann O, Segni M, Meyer G, Reincke M, Seissler J, et al. A promoter 
polymorphism of the CYP27B1 gene is associated with Addison's disease, Hashimoto's thyroiditis, 
Graves' disease and type 1 diabetes mellitus in Germans. European Journal of Endocrinology / 
European Federation of Endocrine Societies. 2004;151(2):193-7. 
151. Australia, New Zealand Multiple Sclerosis Genetics C, Bahlo M, Booth DR, Broadley SA, Brown 
MA, et al. Genome-wide association study identifies new multiple sclerosis susceptibility loci on 
chromosomes 12 and 20. Nature Genetics. 2009;41(7):824-8. 
152. Sundqvist E, Baarnhielm M, Alfredsson L, Hillert J, Olsson T, Kockum I. Confirmation of 
association between multiple sclerosis and CYP27B1. European Journal of Human Genetics : EJHG. 
2010;18(12):1349-52. 
153. Jones G, Prosser DE, Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its 
important role in the degradation of vitamin D. Archives of Biochemistry and Biophysics. 
2012;523(1):9-18. 
154. Tashiro K, Abe T, Oue N, Yasui W, Ryoji M. Characterization of vitamin D-mediated induction 
of the CYP 24 transcription. Molecular and Cellular Endocrinology. 2004;226(1-2):27-32. 
155. Masuda S, Byford V, Arabian A, Sakai Y, Demay MB, St-Arnaud R, et al. Altered 
pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and 
tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. Endocrinology. 
2005;146(2):825-34. 
156. Ren S, Nguyen L, Wu S, Encinas C, Adams JS, Hewison M. Alternative splicing of vitamin D-24-
hydroxylase: a novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis. 
The Journal of Biological Chemistry. 2005;280(21):20604-11. 
157. Dinour D, Beckerman P, Ganon L, Tordjman K, Eisenstein Z, Holtzman EJ. Loss-of-function 
mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric 
nephrolithiasis and nephrocalcinosis. The Journal of Urology. 2013;190(2):552-7. 
158. Kantarci S, Ragge NK, Thomas NS, Robinson DO, Noonan KM, Russell MK, et al. Donnai-
Barrow syndrome (DBS/FOAR) in a child with a homozygous LRP2 mutation due to complete 
chromosome 2 paternal isodisomy. American Journal of Medical Genetics Part A. 
2008;146A(14):1842-7. 
159. Willnow TE, Goldstein JL, Orth K, Brown MS, Herz J. Low density lipoprotein receptor-related 
protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and 
lactoferrin, an inhibitor of chylomicron remnant clearance. The Journal of Biological Chemistry. 
1992;267(36):26172-80. 
160. Stefansson S, Kounnas MZ, Henkin J, Mallampalli RK, Chappell DA, Strickland DK, et al. gp330 
on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen 
activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex. Journal of Cell 




161. Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J, et al. An endocytic pathway 
essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell. 1999;96(4):507-15. 
162. Nykjaer A, Fyfe JC, Kozyraki R, Leheste JR, Jacobsen C, Nielsen MS, et al. Cubilin dysfunction 
causes abnormal metabolism of the steroid hormone 25(OH) vitamin D(3). Proceedings of the 
National Academy of Sciences of the United States. 2001;98(24):13895-900. 
163. Grasbeck R. Imerslund-Grasbeck syndrome (selective vitamin B(12) malabsorption with 
proteinuria). Orphanet Journal of Rare Diseases. 2006;1:17. 
164. Norman AW, Ishizuka S, Okamura WH. Ligands for the vitamin D endocrine system: different 
shapes function as agonists and antagonists for genomic and rapid response receptors or as a ligand 
for the plasma vitamin D binding protein. The Journal of Steroid Biochemistry and Molecular Biology. 
2001;76(1-5):49-59. 
165. Berg JP. Vitamin D-binding protein prevents vitamin D deficiency and presents vitamin D for 
its renal activation. European Journal of Endocrinology / European Federation of Endocrine Societies. 
1999;141(4):321-2. 
166. Cleve H, Constans J. The mutants of the vitamin-D-binding protein: more than 120 variants of 
the GC/DBP system. Vox Sanguinis. 1988;54(4):215-25. 
167. Arnaud J, Constans J. Affinity differences for vitamin D metabolites associated with the 
genetic isoforms of the human serum carrier protein (DBP). Human Genetics. 1993;92(2):183-8. 
168. Wood AM, Bassford C, Webster D, Newby P, Rajesh P, Stockley RA, et al. Vitamin D-binding 
protein contributes to COPD by activation of alveolar macrophages. Thorax. 2011;66(3):205-10. 
169. Signorello LB, Shi J, Cai Q, Zheng W, Williams SM, Long J, et al. Common variation in vitamin 
D pathway genes predicts circulating 25-hydroxyvitamin D Levels among African Americans. PLoS 
One. 2011;6(12):e28623. 
170. Hibler EA, Hu C, Jurutka PW, Martinez ME, Jacobs ET. Polymorphic variation in the GC and 
CASR genes and associations with vitamin D metabolite concentration and metachronous colorectal 
neoplasia. Cancer epidemiology, biomarkers & prevention : a publication of the American Association 
for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2012;21(2):368-
75. 
171. Lauridsen AL, Vestergaard P, Hermann AP, Brot C, Heickendorff L, Mosekilde L, et al. Plasma 
concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype 
of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. 
Calcified Tissue International. 2005;77(1):15-22. 
172. Engelman CD, Fingerlin TE, Langefeld CD, Hicks PJ, Rich SS, Wagenknecht LE, et al. Genetic 
and environmental determinants of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels in 
Hispanic and African Americans. The Journal of Clinical Endocrinology and Metabolism. 
2008;93(9):3381-8. 
173. Powe CE, Ricciardi C, Berg AH, Erdenesanaa D, Collerone G, Ankers E, et al. Vitamin D-binding 
protein modifies the vitamin D-bone mineral density relationship. Journal of Bone and Mineral 
Research. 2011;26(7):1609-16. 
174. Chun RF, Peercy BE, Orwoll ES, Nielson CM, Adams JS, Hewison M. Vitamin D and DBP: the 
free hormone hypothesis revisited. The Journal of Steroid Biochemistry and Molecular Biology. 
2014;144 Pt A:132-7. 
175. Yamamoto N, Homma S. Vitamin D3 binding protein (group-specific component) is a 
precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated 
lymphocytes. Proceedings of the National Academy of Sciences of the United States. 
1991;88(19):8539-43. 
176. Viau M, Constans J, Debray H, Montreuil J. Isolation and characterization of the O-glycan 
chain of the human vitamin-D binding protein. Biochemical and Biophysical Research 
Communications. 1983;117(1):324-31. 
177. Kueppers F, Miller RD, Gordon H, Hepper NG, Offord K. Familial prevalence of chronic 





178. Horne SL, Cockcroft DW, Dosman JA. Possible protective effect against chronic obstructive 
airways disease by the GC2 allele. Human Heredity. 1990;40(3):173-6. 
179. Schellenberg D, Pare PD, Weir TD, Spinelli JJ, Walker BA, Sandford AJ. Vitamin D binding 
protein variants and the risk of COPD. American Journal of Respiratory and Critical Care Medicine. 
1998;157(3 Pt 1):957-61. 
180. Ishii T, Keicho N, Teramoto S, Azuma A, Kudoh S, Fukuchi Y, et al. Association of Gc-globulin 
variation with susceptibility to COPD and diffuse panbronchiolitis. The European Respiratory Journal. 
2001;18(5):753-7. 
181. Xie X, Zhang Y, Ke R, Wang G, Wang S, Hussain T, et al. Vitamin D-binding protein gene 
polymorphisms and chronic obstructive pulmonary disease susceptibility: A meta-analysis. 
Biomedical Reports. 2015;3(2):183-8. 
182. Li F, Jiang L, Willis-Owen SA, Zhang Y, Gao J. Vitamin D binding protein variants associate with 
asthma susceptibility in the Chinese Han population. BMC Medical Genetics. 2011;12:103. 
183. Bahr GM, Eales LJ, Nye KE, Majeed HA, Yousof AM, Behbehani K, et al. An association 
between Gc (vitamin D-binding protein) alleles and susceptibility to rheumatic fever. Immunology. 
1989;67(1):126-8. 
184. Martineau AR, Leandro ACCS, Anderson ST, Newton SM, Wilkinson KA, Nicol MP, et al. 
Association between Gc genotype and susceptibility to TB is dependent on vitamin D status. The 
European Respiratory Journal. 2010;35(5):1106-12. 
185. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. Anatomical profiling of 
nuclear receptor expression reveals a hierarchical transcriptional network. Cell. 2006;126(4):789-99. 
186. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system 
essential for good health. The American Journal of Clinical Nutrition. 2008;88(2):491S-9S. 
187. Carlberg C. Genome-wide (over)view on the actions of vitamin D. Frontiers in Physiology. 
2014;5:167. 
188. Zmuda JM, Cauley JA, Ferrell RE. Molecular epidemiology of vitamin D receptor gene 
variants. Epidemiologic Reviews. 2000;22(2):203-17. 
189. Baker AR, McDonnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, et al. Cloning 
and expression of full-length cDNA encoding human vitamin D receptor. Proceedings of the National 
Academy of Sciences of the United States. 1988;85(10):3294-8. 
190. Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HT, et al. Functionally relevant 
polymorphisms in the human nuclear vitamin D receptor gene. Molecular and Cellular Endocrinology. 
2001;177(1-2):145-59. 
191. Gross C, Eccleshall TR, Malloy PJ, Villa ML, Marcus R, Feldman D. The presence of a 
polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low 
bone mineral density in postmenopausal Mexican-American women. Journal of Bone and Mineral 
Research. 1996;11(12):1850-5. 
192. Ingles SA, Haile RW, Henderson BE, Kolonel LN, Nakaichi G, Shi CY, et al. Strength of linkage 
disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for 
association studies. Cancer epidemiology, biomarkers & prevention : a publication of the American 
Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 
1997;6(2):93-8. 
193. Ross J. Control of messenger RNA stability in higher eukaryotes. Trends in Genetics : TIG. 
1996;12(5):171-5. 
194. Wittke A, Weaver V, Mahon BD, August A, Cantorna MT. Vitamin D receptor-deficient mice 
fail to develop experimental allergic asthma. The Journal of Immunology. 2004;173(5):3432-6. 
195. Samir Nabih E BKT. Association between vitamin D receptor gene FokI polymorphism and 
atopic childhood bronchial asthma Egyptian Journal of Chest Diseases and Tuberculosis. 
2014;63(3):547-52. 
196. Saadi A, Gao G, Li H, Wei C, Gong Y, Liu Q. Association study between vitamin D receptor 





197. Poon AH, Laprise C, Lemire M, Montpetit A, Sinnett D, Schurr E, et al. Association of vitamin 
D receptor genetic variants with susceptibility to asthma and atopy. American Journal of Respiratory 
and Critical Care Medicine. 2004;170(9):967-73. 
198. Raby BA, Lazarus R, Silverman EK, Lake S, Lange C, Wjst M, et al. Association of vitamin D 
receptor gene polymorphisms with childhood and adult asthma. American Journal of Respiratory and 
Critical Care Medicine. 2004;170(10):1057-65. 
199. Iordanidou M, Paraskakis E, Giannakopoulou E, Tavridou A, Gentile G, Borro M, et al. Vitamin 
D receptor ApaI a allele is associated with better childhood asthma control and improvement in 
ability for daily activities. Omics : a Journal of Integrative Biology. 2014;18(11):673-81. 
200. Hopkinson NS, Li KW, Kehoe A, Humphries SE, Roughton M, Moxham J, et al. Vitamin D 
receptor genotypes influence quadriceps strength in chronic obstructive pulmonary disease. The 
American Journal of Clinical Nutrition. 2008;87(2):385-90. 
201. Quint JK, Donaldson GC, Wassef N, Hurst JR, Thomas M, Wedzicha JA. 25-hydroxyvitamin D 
deficiency, exacerbation frequency and human rhinovirus exacerbations in chronic obstructive 
pulmonary disease. BMC Pulmonary Medicine. 2012;12:28. 
202. Roth DE, Jones AB, Prosser C, Robinson JL, Vohra S. Vitamin D receptor polymorphisms and 
the risk of acute lower respiratory tract infection in early childhood. The Journal of Infectious 
Diseases. 2008;197(5):676-80. 
203. Zhang H-Q, Deng A, Guo C-F, Wang Y-X, Chen L-Q, Wang Y-F, et al. Association between FokI 
polymorphism in vitamin D receptor gene and susceptibility to spinal tuberculosis in Chinese Han 
population. Archives of Medical Research. 2010;41(1):46-9. 
204. Bornman L, Campbell SJ, Fielding K, Bah B, Sillah J, Gustafson P, et al. Vitamin D receptor 
polymorphisms and susceptibility to tuberculosis in West Africa: a case-control and family study. The 
Journal of Infectious Diseases. 2004;190(9):1631-41. 
205. Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, et al. High-dose 
vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-
blind randomised controlled trial. Lancet. 2011;377(9761):242-50. 
206. Hibler EA, Jurutka PW, Egan JB, Hu C, LeRoy EC, Martinez ME, et al. Association between 
polymorphic variation in VDR and RXRA and circulating levels of vitamin D metabolites. The Journal 
of Steroid Biochemistry and Molecular Biology. 2010;121(1-2):438-41. 
207. Nunez V, Alameda D, Rico D, Mota R, Gonzalo P, Cedenilla M, et al. Retinoid X receptor alpha 
controls innate inflammatory responses through the up-regulation of chemokine expression. 
Proceedings of the National Academy of Sciences of the United States. 2010;107(23):10626-31. 
208. Martineau AR. Old wine in new bottles: vitamin D in the treatment and prevention of 
tuberculosis. The Proceedings of the Nutrition Society. 2012;71(1):84-9. 
209. Martineau AR, MacLaughlin BD, Hooper RL, Barnes NC, Jolliffe DA, Greiller CL, et al. Double-
blind randomised placebo-controlled trial of bolus-dose vitamin D3 supplementation in adults with 
asthma (ViDiAs). Thorax. 2015;70(5):451-7. 
210. Martineau AR, James WY, Hooper RL, Barnes NC, Jolliffe DA, Greiller CL, et al. Vitamin D3 
supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, 
double-blind, randomised controlled trial. The Lancet Respiratory Medicine. 2015;3(2):120-30. 
211. Society BT. BTS/SIGN Asthma Guideline. 2011. 
212. Fitzpatrick T.B. Fitzpatrick skin type chart. 1975. 
213. Office for National Statistics. The National Statistics Socioeconomic Classification user 
manual. Palgrave Macmillan; 2005. 
214. Norwood OT. Male pattern baldness: classification and incidence. Southern Medical Journal. 
1975;68(11):1359-65. 
215. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring 
in the female sex. The British Journal of Dermatology. 1977;97(3):247-54. 
216. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of 




217. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the 
asthma control test: a survey for assessing asthma control. Journal of Allergy and Clinical 
Immunology. 2004;113(1):59-65. 
218. American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for 
standardized procedures for the online and offline measurement of exhaled lower respiratory nitric 
oxide and nasal nitric oxide, 2005. American Journal of Respiratory and Critical Care Medicine. 
2005;171(8):912-30. 
219. Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM, Squillace D, et al. Indices of 
airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase 
measurements. American Journal of Respiratory and Critical Care Medicine. 1996;154(2 Pt 1):308-17. 
220. Jackson GG, Dowling HF, Spiesman IG, Boand AV. Transmission of the common cold to 
volunteers under controlled conditions. I. The common cold as a clinical entity. AMA Archives of 
Internal Medicine. 1958;101(2):267-78. 
221. Payne L, Kuhlmann-Berenzon S, Ekdahl K, Giesecke J, Hogberg L, Penttinen P. 'Did you have 
flu last week?' A telephone survey to estimate a point prevalence of influenza in the Swedish 
population. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European 
Communicable Disease Bulletin. 2005;10(12):241-4. 
222. Martineau AR HY, Hooper RL, et al. Increased risk of upper respiratory infection with addition 
of intermittent bolus-dose vitamin D supplementation to a daily low-dose regimen. Thorax 2013; 68 
(suppl 3): A64. 
223. Macfarlane J, Holmes W, Gard P, Macfarlane R, Rose D, Weston V, et al. Prospective study of 
the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. 
Thorax. 2001;56(2):109-14. 
224. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. 
Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized 
trial. American Journal of Respiratory and Critical Care Medicine. 2001;164(8 Pt 1):1392-7. 
225. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and 
recovery of exacerbations in patients with chronic obstructive pulmonary disease. American Journal 
of Respiratory and Critical Care Medicine. 2000;161(5):1608-13. 
226. Maunsell Z, Wright DJ, Rainbow SJ. Routine isotope-dilution liquid chromatography-tandem 
mass spectrometry assay for simultaneous measurement of the 25-hydroxy metabolites of vitamins 
D2 and D3. Clinical Chemistry. 2005;51(9):1683-90. 
227. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in 
genetic association studies. Nature Genetics. 2005;37(11):1217-23. 
228. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype 
maps. Bioinformatics. 2005;21(2):263-5. 
229. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from 
human nucleated cells. Nucleic Acids Research. 1988;16(3):1215. 
230. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical and Powerful 
Approach to Multiple Testing. Journal of Royal Statistics Society Series-B Statistical Methodology. 
1995;57(1):289-300. 
231. Jolliffe DA, Griffiths CJ, Martineau AR. Vitamin D in the prevention of acute respiratory 
infection: systematic review of clinical studies. The Journal of Steroid Biochemistry and Molecular 
Biology. 2013;136:321-9. 
232. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Krstic G, Wetterslev J, et al. Vitamin D 
supplementation for prevention of cancer in adults. The Cochrane Database of Systematic Reviews. 
2014;6:CD007469. 
233. James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan SV. The effect of vitamin D-
related interventions on multiple sclerosis relapses: a meta-analysis. Multiple Sclerosis. 
2013;19(12):1571-9. 
234. Shen L, Ji H-F. Vitamin D deficiency is associated with increased risk of Alzheimer’s disease 




235. Brondum-Jacobsen P, Benn M, Jensen GB, Nordestgaard BG. 25-hydroxyvitamin d levels and 
risk of ischemic heart disease, myocardial infarction, and early death: population-based study and 
meta-analyses of 18 and 17 studies. Arteriosclerosis Thrombosis and Vascular Biology. 
2012;32(11):2794-802. 
236. Burgaz A, Orsini N, Larsson SC, Wolk A. Blood 25-hydroxyvitamin D concentration and 
hypertension: a meta-analysis. Journal of Hypertension. 2011;29(4):636-45. 
237. Mitri J, Muraru MD, Pittas AG. Vitamin D and type 2 diabetes: a systematic review. European 
journal of clinical nutrition. 2011;65(9):1005-15. 
238. Anglin RE, Samaan Z, Walter SD, McDonald SD. Vitamin D deficiency and depression in adults: 
systematic review and meta-analysis. The British Journal of Psychiatry : the Journal of Mental 
Science. 2013;202:100-7. 
239. Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: a systematic review and 
meta-analysis. International Journal of Epidemiology. 2008;37(1):113-9. 
240. Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, Madronich S, et al. Epidemic influenza 
and vitamin D. Epidemiology and Infection. 2006;134(6):1129-40. 
241. Hewison M. Antibacterial effects of vitamin D. Nature Reviews Endocrinology. 2011;7(6):337-
45. 
242. Ginde AA, Mansbach JM, Camargo CA, Jr. Association between serum 25-hydroxyvitamin D 
level and upper respiratory tract infection in the Third National Health and Nutrition Examination 
Survey. Archives of Internal Medicine. 2009;169(4):384-90. 
243. Jartti T, Ruuskanen O, Mansbach JM, Vuorinen T, Camargo CA, Jr. Low serum 25-
hydroxyvitamin D levels are associated with increased risk of viral coinfections in wheezing children. 
Journal of Allergy and Clinical Immunology. 2010;126(5):1074-6, 6 e1-4. 
244. Berry DJ, Hesketh K, Power C, Hypponen E. Vitamin D status has a linear association with 
seasonal infections and lung function in British adults. British Journal of Nutrition. 2011;106(9):1433-
40. 
245. Brehm JM, Acosta-Perez E, Klei L, Roeder K, Barmada M, Boutaoui N, et al. Vitamin D 
insufficiency and severe asthma exacerbations in Puerto Rican children. American Journal of 
Respiratory Critical Care Medicine. 2012;186(2):140-6. 
246. Muhe L, Lulseged S, Mason KE, Simoes EA. Case-control study of the role of nutritional rickets 
in the risk of developing pneumonia in Ethiopian children. Lancet. 1997;349(9068):1801-4. 
247. Najada AS, Habashneh MS, Khader M. The frequency of nutritional rickets among 
hospitalized infants and its relation to respiratory diseases. Journal of Tropical Pediatrics. 
2004;50(6):364-8. 
248. Wayse V, Yousafzai A, Mogale K, Filteau S. Association of subclinical vitamin D deficiency with 
severe acute lower respiratory infection in Indian children under 5 y. European Journal of Clinical 
Nutrition. 2004;58(4):563-7. 
249. Karatekin G, Kaya A, Salihoglu O, Balci H, Nuhoglu A. Association of subclinical vitamin D 
deficiency in newborns with acute lower respiratory infection and their mothers. European Journal of 
Clinical Nutrition. 2009;63(4):473-7. 
250. Roth DE, Shah R, Black RE, Baqui AH. Vitamin D status and acute lower respiratory infection 
in early childhood in Sylhet, Bangladesh. Acta Paediatrica. 2010;99(3):389-93. 
251. Leis KS, McNally JD, Montgomery MR, Sankaran K, Karunanayake C, Rosenberg AM. [Vitamin 
D intake in young children with acute lower respiratory infection]. Chinese Journal of Contemporary 
Pediatrics. 2012;14(1):1-6. 
252. Roth DE, Jones AB, Prosser C, Robinson JL, Vohra S. Vitamin D status is not associated with 
the risk of hospitalization for acute bronchiolitis in early childhood. Eur Journal of Clinical Nutrition. 
2009;63(2):297-9. 
253. McNally JD, Leis K, Matheson LA, Karuananyake C, Sankaran K, Rosenberg AM. Vitamin D 





254. Laaksi I, Ruohola JP, Tuohimaa P, Auvinen A, Haataja R, Pihlajamaki H, et al. An association of 
serum vitamin D concentrations < 40 nmol/L with acute respiratory tract infection in young Finnish 
men. American Journal of Clinical Nutrition. 2007;86(3):714-7. 
255. Sabetta JR, DePetrillo P, Cipriani RJ, Smardin J, Burns LA, Landry ML. Serum 25-
hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. PLoS 
One. 2010;5(6):e11088. 
256. Camargo CA, Jr., Ingham T, Wickens K, Thadhani R, Silvers KM, Epton MJ, et al. Cord-blood 
25-hydroxyvitamin D levels and risk of respiratory infection, wheezing, and asthma. Pediatrics. 
2011;127(1):e180-7. 
257. Belderbos ME, Houben ML, Wilbrink B, Lentjes E, Bloemen EM, Kimpen JL, et al. Cord blood 
vitamin D deficiency is associated with respiratory syncytial virus bronchiolitis. Pediatrics. 
2011;127(6):e1513-20. 
258. Morales E, Romieu I, Guerra S, Ballester F, Rebagliato M, Vioque J, et al. Maternal vitamin D 
status in pregnancy and risk of lower respiratory tract infections, wheezing, and asthma in offspring. 
Epidemiology. 2012;23(1):64-71. 
259. Mohamed WA, Al-Shehri MA. Cord Blood 25-Hydroxyvitamin D Levels and the Risk of Acute 
Lower Respiratory Tract Infection in Early Childhood. Journal of Tropical Pediatrics. 2012. 
260. Brehm JM, Schuemann B, Fuhlbrigge AL, Hollis BW, Strunk RC, Zeiger RS, et al. Serum vitamin 
D levels and severe asthma exacerbations in the Childhood Asthma Management Program study. 
Journal of Allergy and Clinical Immunology. 2010;126(1):52-8 e5. 
261. Asamura T, Ohrui T, Nakayama K, He M, Yamasaki M, Ebihara T, et al. Low serum 1,25-
dihydroxyvitamin D level and risk of respiratory infections in institutionalized older people. 
Gerontology. 2010;56(6):542-3. 
262. Tsujimoto Y, Tahara H, Shoji T, Emoto M, Koyama H, Ishimura E, et al. Active vitamin D and 
acute respiratory infections in dialysis patients. Clinical Journal of the American Society of 
Nephrology. 2011;6(6):1361-7. 
263. Porojnicu AC, Moroti-Constantinescu R, Laslau A, Lagunova Z, Dahlback A, Hristea A, et al. 
Vitamin D status in healthy Romanian caregivers and risk of respiratory infections. Public Health 
Nutrition. 2012:1-6. 
264. Kunisaki KM, Niewoehner DE, Connett JE. Vitamin D levels and risk of acute exacerbations of 
chronic obstructive pulmonary disease: a prospective cohort study. American Journal of Respiratory 
Critical Care Medicine. 2012;185(3):286-90. 
265. Gale CR, Robinson SM, Harvey NC, Javaid MK, Jiang B, Martyn CN, et al. Maternal vitamin D 
status during pregnancy and child outcomes. European Journal of Clinical Nutrition. 2008;62(1):68-
77. 
266. Aloia JF, Li-Ng M. Epidemic influenza and vitamin D. Epidemiology and Infection. 2007:1-4. 
267. Bischoff-Ferrari HA, Dawson-Hughes B, Platz A, Orav EJ, Stahelin HB, Willett WC, et al. Effect 
of high-dosage cholecalciferol and extended physiotherapy on complications after hip fracture: a 
randomized controlled trial. Archives of Internal Medicine. 2010;170(9):813-20. 
268. Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D 
supplementation to prevent seasonal influenza A in schoolchildren. The American Journal of Clinical 
Nutrition. 2010;91(5):1255-60. 
269. Manaseki-Holland S, Qader G, Isaq Masher M, Bruce J, Zulf Mughal M, Chandramohan D, et 
al. Effects of vitamin D supplementation to children diagnosed with pneumonia in Kabul: a 
randomised controlled trial. Tropical Medicine & International Health : TM & IH. 2010;15(10):1148-
55. 
270. Majak P, Olszowiec-Chlebna M, Smejda K, Stelmach I. Vitamin D supplementation in children 
may prevent asthma exacerbation triggered by acute respiratory infection. Journal of Allergy and 
Clinical Immunology. 2011;127(5):1294-6. 
271. Camargo CA, Jr., Ganmaa D, Frazier AL, Kirchberg FF, Stuart JJ, Kleinman K, et al. Randomized 





272. Lehouck A, Mathieu C, Carremans C, Baeke F, Verhaegen J, Van Eldere J, et al. High doses of 
vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. 
Annals of Internal Medicine. 2012;156(2):105-14. 
273. Avenell A, Cook JA, Maclennan GS, Macpherson GC. Vitamin D supplementation to prevent 
infections: a sub-study of a randomised placebo-controlled trial in older people (RECORD trial, 
ISRCTN 51647438). Age Ageing. 2007. 
274. Li-Ng M, Aloia JF, Pollack S, Cunha BA, Mikhail M, Yeh J, et al. A randomized controlled trial of 
vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. 
Epidemiology and Infection. 2009:1-9. 
275. Laaksi I, Ruohola JP, Mattila V, Auvinen A, Ylikomi T, Pihlajamaki H. Vitamin D 
supplementation for the prevention of acute respiratory tract infection: a randomized, double-
blinded trial among young Finnish men. The Journal of Infectious Diseases. 2010;202(5):809-14. 
276. Kumar GT, Sachdev HS, Chellani H, Rehman AM, Singh V, Arora H, et al. Effect of weekly 
vitamin D supplements on mortality, morbidity, and growth of low birthweight term infants in India 
up to age 6 months: randomised controlled trial. BMJ. 2011;342:d2975. 
277. Jorde R, Witham M, Janssens W, Rolighed L, Borchhardt K, de Boer IH, et al. Vitamin D 
supplementation did not prevent influenza-like illness as diagnosed retrospectively by questionnaires 
in subjects participating in randomized clinical trials. Scandinavian Journal of Infectious Diseases. 
2012;44(2):126-32. 
278. Murdoch DR, Slow S, Chambers ST, Jennings LC, Stewart AW, Priest PC, et al. Effect of vitamin 
D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized 
controlled trial. JAMA. 2012;308(13):1333-9. 
279. Manaseki-Holland S, Maroof Z, Bruce J, Mughal MZ, Masher MI, Bhutta ZA, et al. Effect on 
the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in 
Kabul: a randomised controlled superiority trial. Lancet. 2012;379(9824):1419-27. 
280. Majak P, Olszowiec-Chlebna M, Smejda K, Stelmach I. Vitamin D supplementation in children 
may prevent asthma exacerbation triggered by acute respiratory infection. Journal of Allergy and 
Clinical Immunology. 2011;127(5):1294-6. 
281. Tomkins A. Assessing micronutrient status in the presence of inflammation. Journal of 
Nutrition. 2003;133(5 Suppl 2):1649S-55S. 
282. Thacher TD, Fischer PR, Strand MA, Pettifor JM. Nutritional rickets around the world: causes 
and future directions. Annals of Tropical Paediatrics. 2006;26(1):1-16. 
283. Zerwekh JE. Blood biomarkers of vitamin D status. The American Journal of Clinical Nutrition. 
2008;87(4):1087S-91S. 
284. Ilahi M, Armas LA, Heaney RP. Pharmacokinetics of a single, large dose of cholecalciferol. 
American Journal of Clinical Nutrition. 2008;87(3):688-91. 
285. Nielsen NO, Skifte T, Andersson M, Wohlfahrt J, Soborg B, Koch A, et al. Both high and low 
serum vitamin D concentrations are associated with tuberculosis: a case-control study in Greenland. 
British Journal of Nutrition. 2010;104:1487-91. 
286. Martineau AR, Wilkinson KA, Newton SM, Floto RA, Norman AW, Skolimowska K, et al. IFN-- 
and TNF-Independent Vitamin D-Inducible Human Suppression of Mycobacteria: The Role of 
Cathelicidin LL-37. The The Journal of Immunology. 2007;178(11):7190-8. 
287. Vieth R. How to optimize vitamin D supplementation to prevent cancer, based on cellular 
adaptation and hydroxylase enzymology. Anticancer Research. 2009;29(9):3675-84. 
288. Martineau AR. Bolus-dose vitamin D and prevention of childhood pneumonia. Lancet. 
2012;379(9824):1373-5. 
289. Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, et al. High-dose 
vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind 
randomised controlled trial. Lancet. 2011;377(9761):242-50. 
290. Martineau AR, Leandro AC, Anderson ST, Newton SM, Wilkinson KA, Nicol MP, et al. 
Association between Gc genotype and susceptibility to TB is dependent on vitamin D status. 




291. Brehm JM, Celedon JC, Soto-Quiros ME, Avila L, Hunninghake GM, Forno E, et al. Serum 
vitamin D levels and markers of severity of childhood asthma in Costa Rica. American Journal of 
Respiratory and Critical Care Medicine. 2009;179(9):765-71. 
292. Brehm JM, Schuemann B, Fuhlbrigge AL, Hollis BW, Strunk RC, Zeiger RS, et al. Serum vitamin 
D levels and severe asthma exacerbations in the Childhood Asthma Management Program study. 
Journal of Allergy and Clinical Immunology. 2010;126(1):52-8.e5. 
293. Searing DA, Zhang Y, Murphy JR, Hauk PJ, Goleva E, Leung DYM. Decreased serum vitamin D 
levels in children with asthma are associated with increased corticosteroid use. Journal of Allergy and 
Clinical Immunology. 2010;125(5):995-1000. 
294. Gupta A, Sjoukes A, Richards D, Banya W, Hawrylowicz C, Bush A, et al. Relationship between 
serum vitamin D, disease severity, and airway remodeling in children with asthma. American Journal 
of Respiratory and Critical Care Medicine. 2011;184(12):1342-9. 
295. Simon KC, Munger KL, Xing Y, Ascherio A. Polymorphisms in vitamin D metabolism related 
genes and risk of multiple sclerosis. Multiple Sclerosis. 2010;16(2):133-8. 
296. Ismail MF, Elnady HG, Fouda EM. Genetic variants in vitamin D pathway in Egyptian 
asthmatic children: a pilot study. Human Immunology. 2013;74(12):1659-64. 
297. Leung TF, Wang SS, Tang MF, Kong AP, Sy HY, Hon KL, et al. Childhood asthma and 
spirometric indices are associated with polymorphic markers of two vitamin D 25-hydroxylase genes. 
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy 
and Immunology. 2015;26(4):375-82. 
298. Hypponen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort 
study of dietary and lifestyle predictors. The American Journal of Clinical Nutrition. 2007;85(3):860-8. 
299. Yadav M, Mittal K. Effect of vitamin D supplementation on moderate to severe bronchial 
asthma. Indian Journal of Pediatrics. 2014;81(7):650-4. 
300. Castro M, King TS, Kunselman SJ, Cabana MD, Denlinger L, Holguin F, et al. Effect of vitamin 
D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the 
VIDA randomized clinical trial. JAMA. 2014;311(20):2083-91. 
301. Gilthorpe MS, Lay-Yee R, Wilson RC, Walters S, Griffiths RK, Bedi R. Variations in 
hospitalization rates for asthma among black and minority ethnic communities. Respiratory 
Medicine. 1998;92(4):642-8. 
302. Moudgil H, Honeybourne D. Differences in asthma management between white European 
and Indian subcontinent ethnic groups living in socioeconomically deprived areas in the Birmingham 
(UK) conurbation. Thorax. 1998;53(6):490-4. 
303. MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. 
Journal of Clinical Investigation. 1985;76(4):1536-8. 
304. Weinstein JR, Anderson S. The aging kidney: physiological changes. Advances in Chronic 
Kidney Disease. 2010;17(4):302-7. 
305. Webb AR, Pilbeam C, Hanafin N, Holick MF. An evaluation of the relative contributions of 
exposure to sunlight and of diet to the circulating concentrations of 25-hydroxyvitamin D in an 
elderly nursing home population in Boston. The American Journal of Clinical Nutrition. 
1990;51(6):1075-81. 
306. Gloth FM, 3rd, Gundberg CM, Hollis BW, Haddad JG, Jr., Tobin JD. Vitamin D deficiency in 
homebound elderly persons. JAMA. 1995;274(21):1683-6. 
307. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of 
mortality in the general population. Archives of Internal Medicine. 2008;168(15):1629-37. 
308. Cheng S, Massaro JM, Fox CS, Larson MG, Keyes MJ, McCabe EL, et al. Adiposity, 
cardiometabolic risk, and vitamin D status: the Framingham Heart Study. Diabetes. 2010;59(1):242-8. 
309. Vimaleswaran KS, Berry DJ, Lu C, Tikkanen E, Pilz S, Hiraki LT, et al. Causal relationship 
between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple 
cohorts. PLoS Medicine. 2013;10(2):e1001383. 
310. Shoenfeld N, Amital H, Shoenfeld Y. The effect of melanism and vitamin D synthesis on the 




311. Bischoff-Ferrari HA, Willett WC, Orav EJ, Oray EJ, Lips P, Meunier PJ, et al. A pooled analysis 
of vitamin D dose requirements for fracture prevention. The New England Journal of Medicine. 
2012;367(1):40-9. 
312. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, et 
al. Effect of Vitamin D on falls: a meta-analysis. JAMA. 2004;291(16):1999-2006. 
313. Martineau AR, Hanifa Y, Witt KD, Barnes NC, Hooper RL, Patel M, et al. Double-blind 
randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory 
infection in older adults and their carers (ViDiFlu). Thorax. 2015. 
314. England PH. National Diet and Nutrition Survey. Results from Years 1-4 (combined) of the 
Rolling Programme (2008/2009 – 2011/12). 2012. 
315. Brock K, Wilkinson M, Cook R, Lee S, Bermingham M. Associations with Vitamin D deficiency 
in "at risk" Australians. The Journal of Steroid Biochemistry and Molecular Biology. 2004;89-90(1-
5):581-8. 
316. Semba RD, Garrett E, Johnson BA, Guralnik JM, Fried LP. Vitamin D deficiency among older 
women with and without disability. The American Journal of Clinical Nutrition. 2000;72(6):1529-34. 
317. Solanki T, Hyatt RH, Kemm JR, Hughes EA, Cowan RA. Are elderly Asians in Britain at a high 
risk of vitamin D deficiency and osteomalacia? Age Ageing. 1995;24(2):103-7. 
318. van Dam RM, Snijder MB, Dekker JM, Stehouwer CD, Bouter LM, Heine RJ, et al. Potentially 
modifiable determinants of vitamin D status in an older population in the Netherlands: the Hoorn 
Study. The American Journal of Clinical Nutrition. 2007;85(3):755-61. 
319. Smith M. Seasonal, ethnic and gender variations in serum vitamin D3 levels in the local 
population of Peterborough Bioscience Horizons 2010;3(2):124-31. 
320. Glickman ME, Rao SR, Schultz MR. False discovery rate control is a recommended alternative 
to Bonferroni-type adjustments in health studies. Journal of Clinical Epidemiology. 2014;67(8):850-7. 
321. Forli L, Halse J, Haug E, Bjortuft O, Vatn M, Kofstad J, et al. Vitamin D deficiency, bone 
mineral density and weight in patients with advanced pulmonary disease. Journal of Internal 
Medicine. 2004;256(1):56-62. 
322. Jorgensen NR, Schwarz P, Holme I, Henriksen BM, Petersen LJ, Backer V. The prevalence of 
osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. 
Respiratory Medicine. 2007;101(1):177-85. 
323. Janssens W, Bouillon R, Claes B, Carremans C, Lehouck A, Buysschaert I, et al. Vitamin D 
deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. 
Thorax. 2010;65(3):215-20. 
324. Mekov E, Slavova Y, Tsakova A, Genova M, Kostadinov D, Minchev D, et al. Vitamin D 
Deficiency and Insufficiency in Hospitalized COPD Patients. PLoS One. 2015;10(6):e0129080. 
325. Persson LJP, Aanerud M, Hiemstra PS, Hardie JA, Bakke PS, Eagan TML. Chronic obstructive 
pulmonary disease is associated with low levels of vitamin D. PLoS One. 2012;7(6):e38934. 
326. Romme EAPM, Rutten EPA, Smeenk FWJM, Spruit MA, Menheere PPCA, Wouters EFM. 
Vitamin D status is associated with bone mineral density and functional exercise capacity in patients 
with chronic obstructive pulmonary disease. Annals of Medicine. 2013;45(1):91-6. 
327. Kocabas A, Ozyilmaz E, Ocak M, Seydaoglu G. The effect of Vitamin D deficiency on lung 
function in current smoker COPD patients. European Respiratory Journal. 2014;44(Suppl 58). 
328. Persson LJ, Aanerud M, Hiemstra PS, Hardie JA, Bakke PS, Eagan TM. Chronic obstructive 
pulmonary disease is associated with low levels of vitamin D. PLoS One. 2012;7(6):e38934. 
329. Hornikx M, Van Remoortel H, Lehouck A, Mathieu C, Maes K, Gayan-Ramirez G, et al. Vitamin 
D supplementation during rehabilitation in COPD: a secondary analysis of a randomized trial. 
Respiratory Research. 2012;13:84. 
330. Jackson AS, Shrikrishna D, Kelly JL, Kemp SV, Hart N, Moxham J, et al. Vitamin D and skeletal 
muscle strength and endurance in COPD. The European Respiratory Journal. 2013;41(2):309-16. 
331. Liesker JJ, Bathoorn E, Postma DS, Vonk JM, Timens W, Kerstjens HA. Sputum inflammation 





332. Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. International Journal of 
Chronic Obstructive Pulmonary Disease. 2006;1(1):39-47. 
333. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacological Reviews. 
2004;56(4):515-48. 
334. Touvier M, Deschasaux M, Montourcy M, Sutton A, Charnaux N, Kesse-Guyot E, et al. 
Determinants of vitamin D status in Caucasian adults: influence of sun exposure, dietary intake, 
sociodemographic, lifestyle, anthropometric, and genetic factors. Journal of Investigative 
Dermatology. 2015;135(2):378-88. 
335. Jolliffe DA, Walton RT, Griffiths CJ, Martineau AR. Single nucleotide polymorphisms in the 
vitamin D pathway associating with circulating concentrations of vitamin D metabolites and non-
skeletal health outcomes: review of genetic association studies. The Journal of Steroid Biochemistry 
and Molecular Biology. 2015. 
336. Bakke PS, Zhu G, Gulsvik A, Kong X, Agusti AG, Calverley PM, et al. Candidate genes for COPD 
in two large data sets. The European Respiratory Journal. 2011;37(2):255-63. 
337. de Groot JC, van Roon EN, Storm H, Veeger NJ, Zwinderman AH, Hiemstra PS, et al. Vitamin D 
reduces eosinophilic airway inflammation in nonatopic asthma. Journal of Allergy and Clinical 
Immunology. 2015;135(3):670-5 e3. 
338. Ginde AA, Mansbach JM, Camargo CA, Jr. Association between serum 25-hydroxyvitamin D 
level and upper respiratory tract infection in the Third National Health and Nutrition Examination 
Survey. Archives of Internal Medicine. 2009;169(4):384-90. 
339. Janssen R, Bont L, Siezen CLE, Hodemaekers HM, Ermers MJ, Doornbos G, et al. Genetic 
susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate 
immune genes. The Journal of Infectious Diseases. 2007;196(6):826-34. 
340. Kresfelder TL, Janssen R, Bont L, Pretorius M, Venter M. Confirmation of an association 
between single nucleotide polymorphisms in the VDR gene with respiratory syncytial virus related 
disease in South African children. Journal of Medical Virology. 2011;83(10):1834-40. 
341. Barry EL, Mott LA, Rees JR, Ahnen DJ, Bostick RM, Bresalier RS, et al. Abstract 4584: VDR 
genotype modifies vitamin D efficacy for colorectal adenoma prevention in a randomized controlled 
trial. Cancer Research. 2015;75(15 Supplement):4584. 
342. Suzuki M, Yoshioka M, Hashimoto M, Murakami M, Noya M, Takahashi D, et al. Randomized, 
double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. The 
American Journal of Clinical Nutrition. 2013;97(5):1004-13. 
343. Hollis BW, Wagner CL. Clinical review: The role of the parent compound vitamin D with 
respect to metabolism and function: Why clinical dose intervals can affect clinical outcomes. The 
Journal of Clinical Endocrinology and Metabolism. 2013;98(12):4619-28. 
344. Martineau AR, Hanifa Y, Witt KD, Barnes NC, Hooper RL, Patel M, et al. Double-blind 
randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory 
infection in older adults and their carers (ViDiFlu). Thorax. 2015;70(10):953-60. 
345. Vieth R. How to optimize vitamin D supplementation to prevent cancer, based on cellular 
adaptation and hydroxylase enzymology. Anticancer Research. 2009;29(9):3675-84. 
346. Wilkinson RJ, Llewelyn M, Toossi Z, Patel P, Pasvol G, Lalvani A, et al. Influence of vitamin D 
deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west 
London: a case-control study. Lancet. 2000;355(9204):618-21. 
347. Sharma PR, Singh S, Jena M, Mishra G, Prakash R, Das PK, et al. Coding and non-coding 
polymorphisms in VDR gene and susceptibility to pulmonary tuberculosis in tribes, castes and 
Muslims of Central India. Infection, genetics and evolution : Journal of Molecular Epidemiology and 
Evolutionary Genetics in Infectious Diseases. 2011;11(6):1456-61. 
348. Baur K, Mertens JC, Schmitt J, Iwata R, Stieger B, Eloranta JJ, et al. Combined effect of 25-OH 
vitamin D plasma levels and genetic vitamin D receptor (NR 1I1) variants on fibrosis progression rate 
in HCV patients. Liver international : official Journal of the International Association for the Study of 




349. Torres C, Sanchez de la Torre M, Garcia-Moruja C, Carrero AJ, Trujillo MdM, Fibla J, et al. 
Immunophenotype of vitamin D receptor polymorphism associated to risk of HIV-1 infection and rate 
of disease progression. Current HIV Research. 2010;8(6):487-92. 
350. Ovsyannikova IG, Dhiman N, Haralambieva IH, Vierkant RA, O'Byrne MM, Jacobson RM, et al. 
Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-
like, vitamin A and D receptors, and innate immune response genes. Human Genetics. 
2010;127(2):207-21. 
351. Deng H, Liu F, Pan Y, Jin X, Wang H, Cao J. BsmI, TaqI, ApaI, and FokI polymorphisms in the 
vitamin D receptor gene and periodontitis: a meta-analysis of 15 studies including 1338 cases and 
1302 controls. Journal of Clinical Periodontology. 2011;38(3):199-207. 
352. Tanaka K, Miyake Y, Hanioka T, Arakawa M. VDR gene polymorphisms, interaction with 
smoking and risk of periodontal disease in Japanese women: the Kyushu Okinawa maternal and child 
health study. Scandinavian The Journal of Immunology. 2013;78(4):371-7. 
353. Sapey E, Stockley RA. COPD exacerbations . 2: aetiology. Thorax. 2006;61(3):250-8. 
354. Clark AG. Inference of haplotypes from PCR-amplified samples of diploid populations. 
Molecular Biology and Evolution. 1990;7(2):111-22. 
355. Arai H, Miyamoto KI, Yoshida M, Yamamoto H, Taketani Y, Morita K, et al. The polymorphism 
in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor 
gene. Journal of Bone and Mineral Research. 2001;16(7):1256-64. 
356. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative 
PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8. 
357. Wang L, Hara K, Van Baaren JM, Price JC, Beecham GW, Gallins PJ, et al. Vitamin D receptor 
and Alzheimer's disease: a genetic and functional study. Neurobiology of Aging. 2012;33(8):1844 e1-
9. 
358. Liu SG, Li YY, Sun RX, Wang JL, Li XD, Han L, et al. Polymorphisms in the vitamin D receptor 
and risk of gout in Chinese Han male population. Rheumatology International. 2015;35(6):963-71. 
359. Gao Z, Fu HJ, Xue JJ, Wu ZX, Zhao LB. Genetic polymorphisms in VDR, ESR1 and ESR2 genes 
may contribute to susceptibility to Parkinson's disease: a meta-analysis. Molecular Biology Reports. 
2014;41(7):4463-74. 
360. Butler MW, Burt A, Edwards TL, Zuchner S, Scott WK, Martin ER, et al. Vitamin D receptor 
gene as a candidate gene for Parkinson disease. Annals of Human Genetics. 2011;75(2):201-10. 
361. Reyes E, Garcia-Castro I, Esquivel F, Hornedo J, Cortes-Funes H, Solovera J, et al. Granulocyte 
colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative 
response. British Journal of Cancer. 1999;80(1-2):229-35. 
362. Eyles JL, Hickey MJ, Norman MU, Croker BA, Roberts AW, Drake SF, et al. A key role for G-
CSF-induced neutrophil production and trafficking during inflammatory arthritis. Blood. 
2008;112(13):5193-201. 
363. Lawlor KE, Campbell IK, Metcalf D, O'Donnell K, van Nieuwenhuijze A, Roberts AW, et al. 
Critical role for granulocyte colony-stimulating factor in inflammatory arthritis. Proceedings of the 
National Academy of Sciences of the United States. 2004;101(31):11398-403. 
364. Costa CHd, Rufino R, Lapa E Silva JR. [Inflammatory cells and their mediators in COPD 
pathogenesis]. Celulas inflamatorias e seus mediadores na patogenese da DPOC. Revista da 
Associação Médica Brasileira. 2009;55(3):347-54. 
365. Abramo C, Meijgaarden KE, Garcia D, Franken KL, Klein MR, Kolk AJ, et al. Monokine induced 
by interferon gamma and IFN-gamma response to a fusion protein of Mycobacterium tuberculosis 
ESAT-6 and CFP-10 in Brazilian tuberculosis patients. Microbes and Infection / Institut Pasteur. 
2006;8(1):45-51. 
366. Burney PG, Patel J, Newson R, Minelli C, Naghavi M. Global and regional trends in COPD 
mortality, 1990-2010. The European Respiratory Journal. 2015;45(5):1239-47. 
367. Bergman P, Norlin AC, Hansen S, Rekha RS, Agerberth B, Bjorkhem-Bergman L, et al. Vitamin 
D3 supplementation in patients with frequent respiratory tract infections: a randomised and double-




368. Marchisio P, Consonni D, Baggi E, Zampiero A, Bianchini S, Terranova L, et al. Vitamin D 
supplementation reduces the risk of acute otitis media in otitis-prone children. The Pediatric 
Infectious Disease Journal. 2013;32(10):1055-60. 
369. Goodall EC, Granados AC, Luinstra K, Pullenayegum E, Coleman BL, Loeb M, et al. Vitamin D3 
and gargling for the prevention of upper respiratory tract infections: a randomized controlled trial. 
BMC Infectious Diseases. 2014;14:273. 
370. Simpson S, van der Mei I, Stewart N, Blizzard L, Tettey P, Taylor B. Weekly cholecalciferol 
supplementation results in significant reductions in infection risk among the vitamin D deficient: 
results from the CIPRIS pilot RCT. BMC Nutrition. 2015;1(1):7. 
371. Grant CC, Kaur S, Waymouth E, Mitchell EA, Scragg R, Ekeroma A, et al. Reduced primary care 
respiratory infection visits following pregnancy and infancy vitamin D supplementation: a 
randomised controlled trial. Acta Paediatrica. 2015;104(4):396-404. 
372. Urashima M, Mezawa H, Noya M, Camargo CA, Jr. Effects of vitamin D supplements on 
influenza A illness during the 2009 H1N1 pandemic: a randomized controlled trial. Food & Function. 
2014;5(9):2365-70. 
373. Rees JR, Hendricks K, Barry EL, Peacock JL, Mott LA, Sandler RS, et al. Vitamin D3 
supplementation and upper respiratory tract infections in a randomized, controlled trial. Clinical 
Infectious Diseases. 2013;57(10):1384-92. 
374. Tran B, Armstrong BK, Ebeling PR, English DR, Kimlin MG, van der Pols JC, et al. Effect of 
vitamin D supplementation on antibiotic use: a randomized controlled trial. The American Journal of 
Clinical Nutrition. 2014;99(1):156-61. 
375. Dubnov-Raz G, Rinat B, Hemila H, Choleva L, Cohen AH, Constantini NW. Vitamin D 
supplementation and upper respiratory tract infections in adolescent swimmers: a randomized 
controlled trial. Pediatric Exercise Science. 2015;27(1):113-9. 
376. Bergman P, Lindh AU, Bjorkhem-Bergman L, Lindh JD. Vitamin D and Respiratory Tract 
Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One. 
2013;8(6):e65835. 
377. Ganmaa D, Holick MF, Rich-Edwards JW, Frazier LA, Davaalkham D, Ninjin B, et al. Vitamin D 
deficiency in reproductive age Mongolian women: a cross sectional study. The Journal of Steroid 
Biochemistry and Molecular Biology. 2014;139:1-6. 
378. Hassanein SI, Abu El Maaty MA, Sleem HM, Gad MZ. Triangular relationship between single 
nucleotide polymorphisms in the CYP2R1 gene (rs10741657 and rs12794714), 25-hydroxyvitamin d 
levels, and coronary artery disease incidence. Biomarkers. 2014;19(6):488-92. 
379. Orton SM, Morris AP, Herrera BM, Ramagopalan SV, Lincoln MR, Chao MJ, et al. Evidence for 
genetic regulation of vitamin D status in twins with multiple sclerosis. The American Journal of 






































































































































































































My supervisors, Professor Adrian Martineau, Professor Robert Walton, and Professor Chris Griffiths. 
Special thanks to Adrian Martineau for being a great supervisor, boss, and friend over the past 5 and a 
half years; for teaching me an immeasurable amount of skills; for endless support and patience; and 
for trusting me with the responsibility to coordinate a range of exciting projects outside of my studies. 
Particular thanks to Robert Walton for the excellent advice on all matters genetically related. A big 
thanks to Chris Griffiths for signing off on my project and lending financial support to my studies. 
The study teams of ViDiCO, ViDiAs, and ViDiFlu trials. Special thanks to Mr Kamrul Islam, Dr Karolina 
Witt, Ms Wai Yee James, Ms Beverly Maclaughlin, Mrs Kate Kilpin, Mrs Mital Patel, Mr Gareth Fletcher, 
Mr Deanen Perumal, and Dr Yasmeen Hanifa for their tireless work in conducting the studies from 
where my data arose. 
Dr Claire Greiller, for teaching me immunoassay techniques and for being a great drinking partner! 
Dr Mimoza Hoti, and Dr Charles Mein of Queen Mary University’s Genome Centre, for hosting and 
teaching me genotyping techniques. 
Dr Jennifer Roe, for assistance with PCR and kindly hosting me at UCL. 
Dr Richard Hooper for advice on statistical analyses relating to this project. 
My good friend, Liisa, for all her WhatsApp messages of encouragement and distraction. 
Finally, my family for all their love and support: my Nephew, Jacob (who’s the coolest dude on the 
planet); my Sister, Sheena (best Sis’ that ever lived); and my Mother, Sandy, for always selflessly 
supporting me in any endeavour. 
 
